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I.	Abstract		Survival	outcomes	for	traditional	Human	papillomavirus	(HPV)-negative	squamous	cell	carcinoma	of	the	head	and	neck	(SCCHN)	have	not	improved	significantly	over	the	last	20-30	years.	In	contrast,	HPV-positive	oropharyngeal	SCC	is	associated	with	favourable	survival	outcomes,	but	patients	often	suffer	long-term	functional	ramifications	from	the	toxicity	of	their	treatment.	Therefore,	 in	the	context	of	HPV-negative	SCCHN	there	is	a	need	 to	 improve	 treatment	 efficacy	 to	 enhance	 survival	 outcomes,	 while	 for	 HPV-positive	oropharyngeal	 SCC	 there	 is	 a	need	 to	minimise	 treatment-associated	 toxicity.	Fundamental	 to	 this	 is	 to	 identify	novel	radiosensitising	therapeutic	approaches	given	that	radiotherapy	(RT)	remains	a	mainstay	of	treatment	for	all	SCCHN	patients.	Cancer	cell	metabolism	is	an	attractive	putative	target	in	this	regard,	yet	has	received	relatively	little	 attention	 in	 the	 context	 of	 SCCHN.	 p53	 is	 known	 to	 be	 a	 potentially	 important	metabolic	 mediator,	 while	 TP53	 mutation	 is	 central	 to	 SCCHN	 oncogenesis	 and	 is	associated	with	poorer	 clinical	 outcomes.	Consequently,	 the	primary	of	 aims	of	 thesis	these	were	to	examine	the	metabolic	phenotype	exhibited	by	SCCHNs,	whether	this	was	related	 to	 TP53	 status,	 and	 to	 determine	 whether	 tailored	 anti-metabolic	 treatment	might	have	potential	therapeutic	value,	specifically	in	enhancing	the	effects	of	 ionising	radiation	 (IR).	 Secondary	 aims	were	 to	 explore	 the	mechanistic	 basis	 underlying	 any	metabolic	alterations	and	any	observed	anti-metabolic	therapeutic	effects.	
	Microplate-based	 extra-cellular	 flux	 analysis	 revealed	 that	 mutant	 TP53	 SCCHN	 cell	lines	exhibited	a	distinct	metabolic	phenotype	to	that	of	wild-type	TP53	cell	lines.	Wild-type	 TP53	 cells	 maintained	 metabolic	 diversity,	 while	 mutant	 TP53	 cells	 exhibited	 a	specific	 survival	 dependence	 on	 glycolysis.	 This	 correlated	 with	 radiation	 response	following	 glycolytic	 inhibition	 with	 2-deoxy-D-glucose	 (2-DG),	 which	 potentiated	 IR	effects	in	mutant	TP53	cells	only.	In	line	with	their	more	diverse	metabolic	phenotype,	in	wild-type	TP53	 cells	 (HPV-positive	 SCCHN	 cells	 included)	 a	 broader	 anti-metabolic	approach,	 comprising	 both	 2-DG	 and	 metformin	 (inhibitor	 of	 mitochondrial	respiration),	was	required	to	achieve	a	similar	effect.			The	potentiating	effects	of	glycolytic	inhibition	on	IR	in	mutant	TP53	SCCHN	cells	were	reversed	 by	 the	 addition	 of	N-acetylcysteine	 (free	 radical	 scavenger).	 Consistent	with	this,	flow	cytometry	demonstrated	a	marked	increase	in	reactive	oxygen	species	(ROS)	following	IR	+	2-DG,	and	also	increased	levels	of	apoptosis,	implicating	oxidative	stress-
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mediated	 activation	 of	 apoptotic	 signalling	 as	 the	 mechanism	 underlying	 the	radiosensitising	 effects	 of	 2-DG.	 That	 oxidative	 stress	 was	 centrally	 involved	 in	 the	mechanism	underlying	glycolytic	 inhibition	 in	SCCHN	also	 suggested	 that	 the	 impetus	driving	 mutant	 TP53	 SCCHN	 cells	 towards	 glycolysis	 was	 at	 least	 partly	 to	 regulate	cellular	 redox	 status	 and	 evade	 excessive	ROS	 accumulation.	 In	 accordance	with	 this,	pentose	phosphate	pathway	(PPP)	enzyme	expression	and	intracellular	NADPH/NADP	ratios	were	greater	 in	mutant	TP53	SCCHN	cells,	 indicative	of	 increased	PPP	flux.	This	appeared	to	be	mediated	by	de-regulated	TIGAR	overexpression	in	those	cells	with	loss	of	p53	function.	Therapeutically,	the	addition	of	the	PPP	inhibitor	6-aminonicotinamide	further	potentiated	IR	effects	in	mutant	TP53	cells	over	and	above	glycolytic	inhibition.		Ultimately,	 the	 findings	 described	 in	 this	 thesis	 present	 the	 opportunity	 for	 a	 novel,	tailored	 anti-metabolic	 therapeutic	 approach	 in	 SCCHN,	 which	 not	 only	 carries	 a	selective	 therapeutic	 index,	 but	 is	 also	 informed	 by	 TP53	 status	 as	 a	 predictive	biomarker.	 Specifically,	we	 propose	 that	 in	mutant	TP53	SCCHNs	 glycolytic	 inhibition	with	2-DG,	possibly	 in	combination	with	6-AN-induced	PPP	 inhibition,	would	result	 in	significant	radiosensitisation.	This	strategy	would	be	applicable	in	upwards	of	60-85%	of	 SCCHN	 tumours	 and	 would	 be	 preferentially	 effective	 in	 targeting	 the	 treatment-resistant	disease	typically	associated	with	TP53	mutation.	For	SCCHNs	harbouring	wild-type	TP53	 (HPV-positive	 disease	 included)	we	 suggest	 the	 combination	 of	 2-DG	with	metformin.	This	strategy	may	also	provide	an	attractive	platform	for	the	treatment	de-intensification	of	carefully	selected	HPV-positive	cases	by	facilitating	RT	dose	reduction	to	minimise	 the	 impact	of	 treatment	on	 long-term	 function.	The	efficacy	and	safety	of	these	strategies	will	require	further	validation	in	pre-clinical	models	prior	to	translation	into	the	clinical	setting,	and	future	work	will	be	directed	in	this	regard.		 	
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1.	Introduction	
	
1.1.	Squamous	cell	carcinoma	of	the	head	and	neck	
	
1.1.1.	Definition	and	regional	anatomy	The	broad	terms	“head	and	neck	cancer”	and	“squamous	cell	carcinoma	of	the	head	and	neck”	 (SCCHN)	 are	 used	 interchangeably	 to	 describe	 collectively	 malignant	 tumours	arising	 from	 the	 epithelial	 lining	 of	 the	 upper	 aerodigestive	 tract,	which	 encompasses	the	 oral	 cavity,	 pharynx,	 and	 larynx(1,	 2).	 Although	 cancers	 of	 other	 histopathological	types	may	arise	from	this	anatomical	region,	squamous	cell	carcinomas	account	for	the	overwhelming	majority	(>90%)(1,	2),	and	are	thus	the	exclusive	focus	of	this	thesis.	It	is	also	important	to	note	that	other	cancers	occurring	in	the	head	and	neck	region,	such	as	salivary	gland,	thyroid,	intra-cranial,	and	cutaneous	malignancies	are	excluded	from	this	definition.		Although	 SCCHN	 is	 often	 considered	 as	 one	 disease,	 tumours	 can	 be	 stratified	 on	 the	basis	 of	 their	 anatomical	 subsite	 of	 origin	 (figure	 1.1.1.1),	 which	 influences	 biological	behaviour	 and	 from	 a	 clinical	 perspective	 has	 implications	 for	 diagnosis,	 staging,	treatment,	and	prognosis(1,	3,	4).	The	 four	common	subsites	of	SCCHN	are	as	 follows:	oral	 cavity,	 oropharynx,	 larynx,	 and	 hypopharynx,	 with	 oral	 cavity	 being	 the	 most	common	 site	 of	 origin	 (≈40%)(5).	 Although	 the	 nasopharynx	 is	 also	 technically	 an	SCCHN	 subsite,	 nasopharygeal	 carcinoma	 is	 generally	 regarded	 as	 a	 separate	clinicopathological	entity	given	its	distinct	clinical	behaviour(1,	6)	and	is	not	considered	further	 here.	 The	 oral	 cavity	 extends	 from	 the	 lips	 anteriorly	 to	 the	 junction	 of	 the	anterior	 2/3	 and	 posterior	 1/3	 of	 the	 tongue	 posteriorly,	 the	 palatoglossal	 arch	posterolaterally,	 and	 the	 hard	 palate	 superiorly(5).	 Posteriorly,	 the	 oral	 cavity	 then	communicates	with	the	oropharynx,	which	is	bounded	by	the	soft	palate	superiorly,	the	base	of	the	tongue	(posterior	1/3	of	the	tongue)	to	the	level	of	the	epiglottis	inferiorly,	the	 palatoglossal	 and	 palatopharyngeal	 arches	 laterally,	 and	 the	 posterior	 pharyngeal	wall	 posteriorly(5).	 Particularly	 important	 constituent	 parts	 of	 the	 oropharynx	 in	relation	 to	 Human	 papillomavirus	 (HPV)-positive	 SCCHN	 (discussed	 in	 section	 1.1.2.)	are	 the	 collections	 of	 lymphoid	 tissue	 at	 the	 base	 of	 tongue	 and	 on	 either	 side	 of	 the	oropharynx	 in	 the	 cleft	 between	 the	 palatoglossal	 and	 palatopharyngeal	 arches	 –	 the	lingual	and	palatine	tonsils	respectively(5).	These	areas,	particularly	the	palatine	tonsils,	seem	to	be	disproportionally	affected	by	HPV-related	disease,	although	the	reasons	for	
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this	 remain	 to	 be	 fully	 elucidated.	 Inferior	 to	 the	 oropharynx	 lies	 the	 larynx,	 which	communicates	with	 the	 pharynx	 through	 the	 laryngeal	 inlet.	 The	 larynx	 extends	 from	the	 laryngeal	 surface	 of	 the	 epiglottis	 superiorly	 to	 the	 inferior	 edge	 of	 the	 cricoid	cartilage	 inferiorly,	 is	 bounded	 anteriorly	 by	 the	 thyrohyoid	 membrane	 and	 anterior	laryngeal	cartilages,	and	posterolaterally	by	the	aryepiglottic	folds,	the	arytenoid	region,	and	the	posterior	aspect	of	the	cricoid	cartilage(5).	The	remainder	of	the	pharynx,	which	surrounds	 the	 larynx	posteriorly	and	 laterally,	extends	 inferiorly	 from	the	oropharynx	(specifically	from	the	level	of	the	superior	aspect	of	the	hyoid	bone)	to	the	level	of	the	inferior	border	the	cricoid	cartilage	and	constitutes	the	hypopharynx(5).		
	
Figure	1.1.1.1:	Anatomical	sub-sites	of	the	head	and	neck.	A	diagrammatic	representation	of	the	 different	 anatomical	 sub-sites	 of	 the	 head	 and	neck	 relevant	 to	 SCCHN	 including	pertinent	regional	anatomy. Figure	adapted	from	(7).		As	would	be	 expected	on	 the	basis	 of	 regional	 anatomy,	 the	upper	 aerodigestive	 tract	plays	 critical	 functional	 roles	 in	 mastication,	 speech,	 voice,	 and	 swallowing.	 Clinical	presentation	often	reflects	 this	and	significant	 functional	ramifications	can	result	 from	both	the	tumour	itself	and	subsequent	cancer	treatment.	In	general,	for	tumours	of	the	oral	cavity	and	oropharynx	more	anterior	 lesions	tend	to	alter	speech	and	mastication	to	 a	 larger	 extent,	 while	 more	 posterior	 lesions	 result	 in	 greater	 swallowing	impairment(8,	 9).	 More	 distal	 tumours	 affecting	 the	 larynx	 and	 hypopharynx	 tend	 to	carry	both	voice	and	swallowing	functional	morbidity(1,	2).	
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1.1.2.	Epidemiology	and	risk	factors	SCCHN	 is	 the	 sixth	 most	 common	 cancer	 globally	 and	 represents	 around	 6%	 of	 all	cancer	 cases,	 with	 an	 estimated	 incidence	 of	 800,000	 cases	 per	 year,	 approximately	11,000	of	which	arise	in	the	United	Kingdom	(UK)(10,	11).	Although	subtle	differences	exist	between	SCCHN	subsites,	the	incidence	of	SCCHN	is	strongly	and	directly	related	to	age:	the	median	age	at	diagnosis	is	over	60	years	old,	and	98%	and	50%	of	patients	in	Europe	 are	 over	 40	 and	 60	 years	 old	 at	 diagnosis	 respectively(12).	 There	 is	 also	 a	significant	 male	 preponderance,	 particularly	 for	 laryngeal	 cancer,	 with	 a	 male:female	gender	ratio	of	approximately	10:1	in	developed	countries(10,	11).	These	demographic	patterns	are	depicted	clearly	in	the	context	of	the	UK	population	in	figure	1.1.2.1.			
	
Figure	1.1.2.1:	Age-specific	incidence	rates	of	SCCHN	in	the	UK.	Graphs	illustrating	both	the	average	number	of	new	cases/year,	and	the	age-specific	incidence	rates	in	the	UK	in	2012-2014	for	SCCHN.	There	is	a	clear	increase	in	incidence	from	the	age	around	40	with	a	peak	in	the	sixth	decade,	 and	 a	marked	male	 preponderance	 in	 this	 age	 group.	 Figure	 reproduced	 from	 Cancer	Research	UK	website(11).		The	incidence	of	SCCHN	varies	quite	considerably	around	the	world(10,	12),	 indicative	of	 a	 strong	 environmental	 component	 to	 disease	 pathogenesis	 and	 geographical	differences	in	the	prevalence	of	risk	factors.	With	respect	to	oral	cavity	cancer,	high-risk	areas	 include	 Melanesia	 (a	 sub-region	 of	 Oceania,	 northeast	 of	 Australia)	 and	 south-central	 Asia,	 western	 and	 southern	 Europe,	 and	 southern	 Africa.	 In	 contrast,	 for	
Head & Neck Cancer (C00-C14, C30-C32): 2012-2014
Average Number of New Cases Per Year and Age-Specific Incidence Rates per 100,000 Population, UK
Age Range Male Cases
Female 
Cases Male Rates
Female 
Rates
0 to 04 1 2 0.0 0.1
05 to 09 4 4 0.2 0.2
10 to 14 5 5 0.3 0.3
15 to 19 10 9 0.5 0.5
20 to 24 15 15 0.7 0.7
25 to 29 26 33 1.2 1.5
30 to 34 54 39 2.5 1.8
35 to 39 84 56 4.2 2.8
40 to 44 221 119 10.0 5.2
45 to 49 516 199 22.3 8.4
50 to 54 811 316 37.7 14.4
55 to 59 1,105 402 59.5 21.1
60 to 64 1,258 466 72.2 25.7
65 to 69 1,289 487 76.5 27.3
70 to 74 969 415 80.3 30.9
75 to 79 696 367 73.0 32.2
80 to 84 451 281 69.3 31.2
85 to 89 267 199 77.4 33.6
90+ 116 139 77.6 36.4
All Ages 7,897 3,552 25.0 10.9
Source: cruk.org/cancerstats
You are welcome to reuse this Cancer Research UK statistics content for your own work. 
Credit us as authors by referencing Cancer Research UK as the primary source. 
Suggested style: Cancer Research UK, full URL of the page, Accessed [month] [year].
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laryngeal	cancer,	prevalence	is	highest	in	southern	and	eastern	Europe,	South	America,	and	western	Asia(10,	12).	However,	it	is	also	important	to	note	that	this	may	also	partly	reflect	varying	data	quality	worldwide.		The	major	 risk	 factors	 in	 the	 development	 of	 SCCHN	 are	 consumption	 of	 tobacco	 and	alcohol,	 which	 have	 a	 synergistic	 effect	 and	 together	 are	 implicated	 in	 75%	 of	 all	SCCHNs(13).	Both	tobacco	and	alcohol	increase	the	risk	of	developing	SCCHN	in	a	dose-dependent	manner,	 and	 the	 combination	 of	 tobacco	 and	 alcohol	 confers	 an	 estimated	relative	 risk	 (RR)	 of	 22	 (95%	 confidence	 interval	 [CI]:	 12.9-37.8)(14).	 The	 fact	 that	many	 tobacco	 and	 alcohol	 users	 tend	 to	 consume	 both	 substances	 has	 made	distinguishing	 the	 independent	 associations	 of	 these	 individual	 agents	 challenging.	Nonetheless,	 tobacco	 smoking	 has	 been	 reported	 to	 increase	 the	 risk	 of	 SCCHN	 at	 all	anatomical	subsites	with	a	RR	of	8.4	for	current	smokers	(95%	confidence	interval	[CI]:	5.8-12.2)(15),	while	the	risk	decreases	gradually	after	stopping	smoking,	with	no	excess	risk	 after	more	 than	20	 years	 of	 cessation(15).	 Similarly,	 smokeless	 forms	 of	 tobacco,	such	 as	 oral	 snuff	 or	 the	 chewing	 of	 betel	 quid	 (a	 preparation	 of	 various	 ingredients,	including	tobacco	and	the	seeds	of	the	betel	palm	wrapped	in	a	betel	leaf),	also	carry	an	increased	 risk	 of	 SCCHN,	 specifically	 oral	 cavity	 cancer,	 which	 has	 been	 estimated	 as	high	 as	 a	 RR	 of	 2.6	 (95%	 CI:	 1.3-5.2)(reviewed	 in(16)).	 In	 relation	 to	 alcohol	consumption,	 a	 pooled	 analysis	 of	 15	 case-control	 studies	 revealed	 that	 non-smokers	who	consume	three	or	more	alcoholic	drinks	a	day	have	approximately	double	the	risk	of	 developing	 SCCHN	 compared	 with	 non-drinkers	 (odds	 ratio	 [OR]	 =	 2.04,	 95%	 CI:	1.29-3.21)(17),	with	the	relative	effect	being	strongest	for	pharyngeal	cancers,	reported	to	be	as	high	as	8.5	(95%	CI:	4.0-18.2)	in	an	individual	study(15).		Interestingly,	 selected	 genetic	 polymorphisms	 in	 genes	 encoding	 enzymes	 involved	 in	the	metabolism	of	 tobacco	 and	 alcohol	 can	 influence	 individual	 susceptibility	 to	 these	risk	factors.	For	instance,	the	gene	that	encodes	the	alcohol	metabolising	enzyme	alcohol	dehydrogenase	 1B	 (ADH1B)	 (involved	 in	 oxidation	 of	 ethanol	 to	 acetaldehyde	 in	 the	liver)	 has	 a	 polymorphism	 that	 enhances	 alcohol-oxidising	 capability,	 known	 as	 allele	ADH1B*2,	which	has	been	reported	to	confer	a	significant	protective	effect	in	the	risk	of	SCCHN	development	in	moderate	and	heavy	drinkers	(ORs	of	0.57	[95%	CI:	0.36-0.91]	and	0.36	[95%	CI:	0.17-0.77]	respectively)(18).	In	contrast,	a	polymorphism	in	the	gene	encoding	aldehyde	dehydrogenase	2,	the	major	enzyme	that	converts	acetaldehyde	into	acetate,	 results	 in	 inactivation	 of	 the	 enzyme	 and	 increased	 accumulation	 of	acetaldehyde,	 which	 significantly	 heightens	 the	 risk	 of	 SCCHN	 development	 in	 the	
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context	of	alcohol	consumption(19).	Similarly,	in	relation	to	tobacco,	a	polymorphism	in	the	 gene	encoding	glutathione-S-transferase,	which	 is	 involved	 in	 the	detoxification	of	carcinogenic	metabolites,	 is	 associated	with	 a	 1.23	 fold	 (95%	CI:	 1.06-1.42)	 increased	risk	of	developing	SCCHN(13).		Whilst	tobacco	and	alcohol	consumption	are	the	traditional	risk	factors,	there	is	now	a	considerable	 body	 of	 evidence	 implicating	 HPV	 as	 a	 cause	 of	 SCCHN,	 in	 particular	 of	oropharyngeal	 SCC	 affecting	 the	 base	 of	 tongue	 and	 tonsils,	 which according	 to	 the	International	 Agency	 for	 Research	 on	 Cancer	 monograph	 fulfils	 the	 criteria	 for	causality(20).	More	than	170	different	HPV	types	have	been	identified	to	date,	of	which	types	16,	18,	31,	33,	35,	39,	45,	51,	52,	56,	58,	59,	68,	73,	and	82	are	considered	“high-risk”	 and	 carcinogenic(21).	 Such	 oncogenic	 HPVs	 have	 long	 been	 recognised	 as	 the	major	cause	of	cervical	cancer(21),	and	nearly	30	years	ago	 it	was	 first	suggested	that	certain	 high-risk	 HPVs	 may	 also	 be	 involved	 in	 the	 pathogenesis	 of	 SCCHN(22).	Numerous	 observational	 case-series	 published	 throughout	 the	 1990s	 and	 early	 2000s	evaluated	 the	 point	 prevalence	 of	 HPV	 infection	 in	 SCCHN	 with	 varying	 results.	 This	culminated	 in	a	 large-scale	systematic	review	in	2005	of	over	5,000	SCCHN	specimens	from	60	studies,	which	concluded	 that	overall	prevalence	of	HPV	 infection	was	25.9%	(95%	CI:	 24.7-27.2%),	with	 the	overwhelming	majority	 (86.7%	of	 oropharyngeal	 SCC,	95%	 CI:	 82.6-90.1%)	 being	 associated	 with	 HPV-16(23).	 Type	 18	 was	 also	 found	 to	account	 for	 a	 significant	 minority	 (2.8%	 of	 oropharyngeal	 SCC,	 95%	 CI:	 82.6-90.1%),	while	 other	 HPV	 types	 were	 rarely	 implicated(23).	 A	 further	 prominent	 finding	 from	this	 study	 was	 the	 propensity	 for	 HPV	 infection	 to	 affect	 tumours	 arising	 in	 the	oropharynx,	with	 over	 one	 third	 (35.6%,	 95%	CI:	 32.6-38.7%)	 of	 oropharyngeal	 SCCs	containing	HPV	DNA	 (87%	of	which	were	HPV-16)(23).	 Similarly,	 a	 subsequent	meta-analysis	 demonstrated	 a	 strong	 association	 between	 HPV-16	 and	 tonsillar	 SCC	specifically	 (OR	 =	 15.1,	 95%	 CI:	 6.8-33.7),	 a	 moderate	 association	 with	 other	oropharyngeal	SCCs	(OR	=	4.3,	95%	CI:	2.1-8.9),	and	weak	association	for	oral	cavity	and	laryngeal	 SCCs	 (OR	 =	 2.0,	 95%	 CI:	 1.2-3.4;	 and	 OR	 =	 2.0,	 95%	 CI:	 1.0-4.2	respectively)(24).	Consistent	with	this,	a	more	recent	meta-analysis	from	2013	seeking	primarily	 to	 determine	 the	 chronology	 of	 HPV	 prevalence	 in	 SCCHN	 reported	 a	prevalence	of	72.2%	 (95%	CI:	 52.9–85.7%)	 in	oropharyngeal	 SCCs	between	2005	and	2009,	while	only	6.1%	(95%	CI:	0.7-39.0%)	of	SCCHNs	outside	of	the	oropharynx	were	found	 to	 be	 attributable	 to	 HPV-16	 infection	 during	 the	 same	 time	 period(25).	 In	addition	to	viral	DNA	presence,	several	studies	have	corroborated	a	causal	relationship	in	 these	 tumours,	demonstrating	 localisation	of	HPV	DNA	to	 the	cell	nucleus(26),	viral	
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DNA	 integration(26,	 27),	 elevated	 viral	 copy	 number	 in	 malignancy(28),	 and	 most	importantly	 evidence	 of	 viral	 oncogene	 expression(29).	 Such	 supporting	 evidence	 for	causality	 remains	 lacking	 for	 SCCHNs	 outwith	 the	 oropharynx.	 The	 biological	 reasons	underlying	 these	 anatomical	 subsite	 differences	 remain	 unclear.	 Interestingly,	 HPV-related	 SCCHN	 also	 tends	 to	 affect	 younger	 patients	 often	 in	 the	 absence	 of	 the	traditional	risk	factors	of	tobacco	and	alcohol	consumption,	another	demographic	aspect	of	the	disease	that	is	poorly	understood(30).		Although	 contentious,	 HPV-positive	 SCCHN	 is	 increasingly	 considered	 as	 sexually	transmitted.	 A	 relatively	 recent	 pooled	 analysis	 of	 eight	 multi-national	 observational	studies	 demonstrated	 that	 the	 risk	 of	 developing	 oropharyngeal	 SCC	 was	 associated	with	 a	 history	 of	 six	 or	more	 lifetime	 sexual	 partners	 (OR	=	 1.25,	 95%	CI:	 1.01-1.54),	four	or	more	lifetime	oral	sex	partners	(OR	=	3.36,	95%	CI:	1.32-8.53),	and	for	men	an	earlier	age	at	sexual	debut	(OR	=	2.36,	95%	CI:	1.37-5.05)(31).			In	 addition	 to	 the	 major	 risk	 factors	 of	 tobacco,	 alcohol,	 and	 HPV	 infection,	epidemiological	 studies	 have	 also	 identified	more	minor	 risk	 factors.	 Consumption	 of	fruits	 and	 vegetables,	 particularly	 carotene-rich	 vegetables,	 has	 been	 consistently	associated	with	a	reduced	risk	of	SCCHN(32),	while	several	other	dietary	factors	such	as	salted	meat	and	fish	and	charcoal-grilled	or	deep-fried	foods	have	been	linked	with	an	elevated	 risk(33).	 Factors	 relating	 to	 oral	 hygiene	 have	 also	 been	 associated	 with	increased	 risk	 of	 SCCHN,	 specifically	 frequent	 gum	 bleeding,	 no	 dental	 check-ups,	 no	tooth	 brushing,	 and	 frequent	 use	 of	 mouthwash(34).	 Occupational	 factors	 are	 also	implicated,	with	approximately	4-10%	of	all	 SCCHN	 in	western	countries	estimated	 to	result	 from	 occupational	 exposures(35).	 Asbestos	 exposure	 has	 been	 reported	 to	increase	the	risk	of	laryngeal	cancer	in	a	dose-dependent	manner,	exposure	to	welding	fumes	has	been	 linked	with	an	elevated	 risk	of	pharyngeal	 and	 laryngeal	 cancers,	 and	exposure	to	wood	dust	has	been	associated	with	a	strongly	increased	risk	of	SCCHN	of	all	anatomical	subsites(36).			The	 patterns	 of	 SCCHN	 incidence	 over	 time	 and	 by	 geography	 are	 intriguing,	 carry	important	public	health	implications,	and	reflect	closely	the	changing	prevalence	of	the	aforementioned	 major	 risk	 factors.	 Although	 rates	 of	 oral	 and	 laryngeal	 cancers	 are	stable	or	decreasing	slightly	 in	developed	countries	(figure	1.1.2.2.),	primarily	because	the	population	is	smoking	less,	the	worst	of	the	tobacco	epidemic	has	yet	to	manifest	in	developing	 countries	 because	 of	 the	 ≈40	 year	 temporal	 gap	 between	 changes	 in	
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population	tobacco	use	and	resulting	epidemiological	effects(12).	Indeed,	World	Health	Organisation	projections	estimate	that	whilst	mortality	in	Europe	is	expected	to	remain	stable,	figures	are	projected	to	rise	markedly	in	South	East	Asia,	with	modest	rises	also	predicted	in	Africa,	the	Americas,	and	the	Middle	East(37).	In	contrast,	there	has	been	a	dramatic	 upsurge	 in	 the	 incidence	of	 oropharyngeal	 cancer	 in	 the	developed	world	 in	recent	years.	In	the	United	States	(US),	the	incidence	of	oropharyngeal	SCC	increased	by	22%	between	1999	and	2006,	after	no	change	between	1975	and	1999(38),	and	the	UK	has	seen	a	doubling	in	incidence	from	1/100,000	population	to	2.3/100,000	in	just	over	a	 decade	 (figure	 1.1.2.2.)(39).	 This	 rapid	 increase	 has	 been	 widely	 attributed	 to	 an	exponential	 rise	 in	 the	 incidence	of	HPV-related	disease,	 a	 consensus	 corroborated	by	several	 prevalence	 studies.	 Scandinavian	 data	 showed	 a	 progressive	 proportional	increase	in	HPV	detection	in	oropharyngeal	SCCs,	specifically	of	the	tonsil,	over	the	past	three	decades:	23%	in	the	1970s,	29%	in	1980s,	57%	in	1990s,	68%	between	2000	and	2002,	77%	between	2003	and	2005,	and	93%	between	2006	and	2007(40).	 Similarly,	the	2013	meta-analysis	of	HPV	prevalence	mentioned	above	demonstrated	an	increase	in	HPV	point	prevalence	 in	oropharyngeal	 SCCs	 in	Europe	 from	35.3%	(95%	CI:	28.7-42.5%)	before	2000	to	73.1%	(95%	CI:	39.4-91.9%)	between	2005-2009,	and	in	the	US	from	50.7%	(95%	CI:	42.6-58.7%)	to	69.7%	(95%	CI:	46.8-85.7%)	during	the	same	time	periods(25).	 Interestingly,	 however,	 a	 recent	UK	 study	 showed	 that	 the	 prevalence	 of	HPV-positive	 oropharyngeal	 SCC	 has	 been	 stable	 at	 51.8%	 (95%	 CI:	 49.3–54.4%)	between	2002	and	2011	despite	an	increase	in	incidence,	suggesting	an	increase	in	both	HPV-positive	and	HPV-negative	disease(41).	The	reasons	for	this	parallel	increase	as	yet	remain	unclear.		
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PROFILE OF HEAD AND NECK CANCERS IN ENGLAND: INCIDENCE, MORTALITY AND SURVIVAL10
1. Incidence 
Oral cavity cancer excluding inner part of lip and hard palate  
(ICD-10 C02, C03, C04 and C06) 
Trends in the 
incidence of oral 
cavity cancer 
in England, 
1990–2006
Year
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Incidence of oral cavity cancer by SHA, 2002–2006
 Total 
cases 
Cases per 
Year ASIR*
95% CI
Lower Upper
England 8834 1766.8 3.02 2.95 3.08
Q30 North East 524 104.8 3.43 3.13 3.73
Q31 North West 1316 263.2 3.33 3.15 3.52
Q32 Yorkshire and The Humber 869 173.8 2.94 2.73 3.14
Q33 East Midlands 797 159.4 3.10 2.88 3.33
Q34 West Midlands 949 189.8 3.05 2.85 3.25
Q35 East of England 854 170.8 2.48 2.31 2.65
Q36 London 1240 248.0 3.64 3.43 3.85
Q37 South East Coast 728 145.6 2.70 2.49 2.91
Q38 South Central 623 124.6 2.70 2.48 2.92
Q39 South West 934 186.8 2.79 2.60 2.98
*ASIR is (directly) age-standardised rate per 100,000 population
Source: National Cancer Information Service
B 
PROFILE OF HEAD AND NECK CANCERS IN ENGLAND: INCIDENCE, MORTALITY AND SURVIVAL16
Oropharynx cancer excluding soft palate (ICD-10 C01, C09 and C10)
Trends in the 
incidence of 
oropharynx 
cancer in England, 
1990–2006
Year
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Incidence of oropharynx cancer by SHA, 2002–2006
 Total 
cases 
Cases per 
Year ASIR*
95% CI
Lower Upper
England 5330 1066 2.00 1.95 2.05
Q30 North East 327 65.4 2.32 2.06 2.58
Q31 North West 895 179.0 2.42 2.25 2.58
Q32 Yorkshire and The Humber 520 104.0 1.92 1.75 2.09
Q33 East Midlands 411 82.2 1.74 1.57 1.91
Q34 West Midlands 581 116.2 2.02 1.85 2.18
Q35 East of England 546 109.2 1.81 1.66 1.97
Q36 London 718 143.6 2.27 2.10 2.43
Q37 South East Coast 419 83.8 1.75 1.58 1.92
Q38 South Central 358 71.6 1.76 1.58 1.94
Q39 South West 555 111.0 1.91 1.75 2.07
*ASIR is (directly) age-standardised rate per 100,000 population
Source: National Cancer Information Service
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Larynx c ncer (ICD-10 C32)
Trends in the 
incidence of 
larynx cancer 
in England, 
1990–2006
Year
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Incidence of larynx cancer by SHA, 2002–2006
 Total 
cases 
Cases per 
Year ASIR*
95% CI
Lower Upper
England 8645 1729 3.01 2.94 3.07
Q30 North East 674 134.8 4.39 4.05 4.73
Q31 North West 1560 312.0 3.96 3.76 4.16
Q32 Yorkshire and The Humber 1004 200.8 3.46 3.24 3.68
Q33 East Midlands 708 141.6 2.78 2.57 2.99
Q34 West Midlands 901 180.2 2.91 2.72 3.10
Q35 East of England 806 161.2 2.40 2.23 2.57
Q36 London 1057 211.4 3.26 3.06 3.46
Q37 South East Coast 595 119.0 2.21 2.03 2.39
Q38 South Central 531 106.2 2.41 2.20 2.62
Q39 South West 809 161.8 2.44 2.27 2.62
*ASIR is (directly) age-standardised rate per 100,000 population
Source: National Cancer Information Service
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Figure	1.1.2.2:	Trends	in	incidence	rates	of	SCCHNs	in	the	England	from	1990-2006.	Graphs	illustrating	 incidence	 rates	 in	 England	 year	 by	 year	 from	 1990-2006	 for	 oral	 cavity	 (A),	oropharyngeal	 (B),	 laryngeal	 (C),	 and	hypopharyngeal	 (D)	 SCCs.	There	 is	 a	marked	 increase	 in	incidence	of	oropharyngeal	 SCCs	with	a	doubling	of	 incidence	on	 just	over	a	decade,	while	 the	incidence	rates	 for	 the	other	subsites	have	remained	relatively	unchanged.	Figures	reproduced	from	the	National	Cancer	Intelligence	Network	website(39).		
1.1.3.	Molecular	carcinogenesis	As	with	most	 types	 of	 human	 cancer,	 SCCHN	arises	 as	 a	 result	 of	 the	 accumulation	 of	numerous	 genomic	 changes,	 secondary	 to	 exposure	 to	 the	 carcinogenic	 risk	 factors	detailed	 in	 the	previous	 section(42).	 Such	 accumulation	of	 genomic	 alterations,	which	provide	a	selective	advantage,	results	in	the	acquisition	of	characteristic	cancer-related	phenotypes,	 termed	 the	 hallmarks	 of	 cancer	 by	Hanahan	 and	Weinberg(43),	 and	 thus	malignant	transformation	of	normal	cells.	These	hallmarks	were	originally	described	as	limitless	 replicative	 potential,	 self-sufficiency	 in	 growth	 signals,	 insensitivity	 to	 anti-growth	 signals,	 ability	 to	 evade	 apoptosis,	 invasion	 and	 metastasis,	 and	 sustained	angiogenesis(43),	 but	 more	 recently	 the	 additional	 hallmarks	 of	 evading	 immune	destruction	and	deregulating	cellular	energetics	have	been	proposed(44).			At	the	molecular	level,	SCCHN	carcinogenesis	is	a	complex	process	involving	a	plethora	of	potential	genetic	and	epigenetic	abnormalities	 in	DNA	repair,	cell	signalling,	cellular	differentiation,	 angiogenesis,	 apoptosis,	 and	 cell	 cycle	 regulation,	 which	 has	 led	 to	publication	 of	 countless	 studies	 on	 the	 identification	 of	 candidate	 cancer	 genes	 in	SCCHN(42).	 To	 complicate	matters	 further,	 despite	 a	 common	origin	 in	 the	 squamous	mucosa	 of	 the	 upper	 aerodigestive	 tract,	 as	 alluded	 to	 in	 previous	 sections,	 there	 are	
D 
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Hypopharynx cancer (ICD-10 C12 and C13)
Trends in the 
incidence of 
hypopharynx 
cancer in England, 
1990–2006
Year
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Incidence of hypopharynx cancer by SHA, 2002–2006
 Total 
cases 
Cases per 
Year ASIR*
95% CI
Lower Upper
England 1808 361.6 0.63 0.60 0.66
Q30 North East 144 28.8 0.94 0.78 1.10
Q31 North West 338 67.6 0.87 0.78 0.97
Q32 Yorkshire and The Humber 228 45.6 0.79 0.68 0.89
Q33 East Midlands 143 28.6 0.54 0.45 0.64
Q34 West Midlands 221 44.2 0.70 0.60 0.79
Q35 East of England 152 30.4 0.43 0.36 0.50
Q36 London 196 39.2 0.61 0.53 0.70
Q37 South East Coast 130 26.0 0.50 0.41 0.59
Q38 South Central 114 22.8 0.51 0.42 0.61
Q39 South West 142 28.4 0.41 0.34 0.48
*ASIR is (directly) age-standardised rate per 100,000 population
Source: National Cancer Information Service
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several	sources	of	heterogeneity	that	hinder	consideration	of	SCCHN	as	a	single	disease	entity.	 In	addition	 to	anatomical	 subsite	differences,	molecular	analyses	have	revealed	biological	 heterogeneity	 independent	 of	 subsite,	 identifying	 distinct	 subclasses	 of	SCCHNs	 with	 particular	 mRNA	 expression	 profiles	 or	 patterns	 of	 DNA	 copy	 number	alterations	 predictive	 of	 clinical	 behaviour(45-47).	 The	 most	 clear-cut	 differences,	however,	relate	to	HPV	status(48,	49)	and	there	 is	now	a	general	consensus	that	HPV-related	 disease	 should	 be	 considered	 as	 distinct	 molecular	 entity	 within	 SCCHN(42),	something	 which	 has	 now	 been	 recognised	 in	 the	 most	 recent	 edition	 of	 the	 TNM	classification	system(50).		Despite	such	heterogeneity,	genetic	alterations	in	particular	cancer-associated	signalling	pathways	are	frequently	observed	in	SCCHN,	and	these	will	form	the	focus	of	discussion	in	 the	 remainder	 of	 this	 section.	 Findings	 from	 three	 recent	 independent	 and	comprehensive	 sequencing	 studies,	 conducted	 on	 over	 350	 SCCHN	 specimens	collectively,	 provided	 significant	 advances	 in	 our	 understanding	 of	 the	 molecular	pathogenesis	of	SCCHN(51-53).	Interestingly,	this	work	highlighted	the	relative	paucity	of	classical	proto-oncogenes,	such	as	RAS	and	MYC,	targeted	by	activating	mutations,	and	the	 importance	 of	 mutational	 “knock-out”	 of	 tumour	 suppressor	 pathways	 including	p53,	retinoblastoma	(Rb),	and	Notch	in	SCCHN	pathogenesis(51-53).		Of	 the	 various	 molecular	 alterations	 found	 in	 SCCHN,	 and	 indeed	 in	 most	 human	cancers,	 the	 inactivation	 of	 the	 p53	 tumour	 suppressor	 pathway,	 best	 known	 for	 its	complex	 and	 critical	 roles	 in	 the	 regulation	 of	 processes	 including	 cell	 proliferation,	death,	 and	 responses	 to	 exogenous	 stress	 (discussed	 in	 section	 1.2.),	 seems	 to	 be	paramount	in	tumour	development(42).	Mutation	of	the	TP53	gene	is	the	most	common	genetic	alteration	in	SCCHN	by	some	margin,	harboured	in	60-85%	of	all	cases(51-53).	As	 in	 other	 human	 cancers,	 the	 majority	 of	 mutations	 (≈75%)	 are	 missense	 point	mutations	 occurring	 primarily	 within	 the	 central	 DNA	 binding	 domain	 of	 the	 p53	protein(54),	 which	 typically	 exert	 dominant-negative	 regulation	 over	 any	 remaining	wild-type	p53,	and	may	exhibit	oncogenic	gain-of-function	(GOF)	properties	(discussed	in	more	depth	in	section	1.2.7.)(55).	Furthermore,	TP53	mutation	also	contributes	to	the	clinical	 behaviour	 of	 SCCHNs,	 correlating	 with	 reduced	 survival	 following	 treatment	with	primary	surgery	with	or	without	adjuvant	radiotherapy	(RT),	as	well	as	treatment	resistance(56-58).	 Interestingly,	 the	 majority	 of	 this	 association	 was	 specific	 to	truncating	and	function-disrupting	TP53	mutations	(discussed	in	more	depth	in	section	1.2.7.)(56,	58).	
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	Although	 contentious,	 TP53	 mutation	 is	 thought	 to	 be	 one	 of	 the	 earliest	 genetic	alterations	in	SCCHN	carcinogenesis,	based	on	the	fact	that	mutations	frequently	occur	in	precursor	 lesions	prior	 to	 conversion	 to	 the	 invasive	 state,	 and	also	 in	 surrounding	mucosa(59,	 60).	 Furthermore,	 sequencing	 of	 primary	 SCCHNs	 and	 matched	 nodal	metastatic	 lesions	 revealed	 no	 differences	 in	TP53	 mutations(61).	 Such	 findings	 have	also	 led	 to	 proposals	 of	 a	 “patch-field”	 progression	model	 of	 SCCHN	 development,	 in	which	 the	 invasive	 carcinoma,	 as	 well	 as	 any	 local	 recurrences	 or	 metachronous	tumours,	 develop	 from	 a	 field	 of	 genetically	 abnormal	 mucosa,	 in	 turn	 the	 result	 of	expansion	 of	 a	 clonal	 patch	 originating	 from	 a	 putative	 stem	 cell	 containing	 a	 TP53	mutation(62).		Yet	 further	 evidence	 that	 attests	 to	 the	 importance	 of	 p53	 inactivation	 in	 SCCHN	carcinogenesis	 comes	 from	 the	mechanisms	 of	 HPV-mediated	 oncogenesis,	 which	 are	predominantly	 a	 function	of	 the	 two	viral	 oncoproteins	E6	and	E7(63).	 In	HPV-driven	SCCHNs,	 in	which	 p53	 is	 typically	wild-type(64),	 the	 HPV	 E6	 oncoprotein	 specifically	inactivates	wild-type	p53,	providing	an	alternative	pathway	to	the	classical	mutational	“knock-out”	of	p53-regulated	pathways.	E6	 forms	a	 trimeric	 complex	with	 the	 cellular	E3	 ubiquitin	 ligase,	 termed	 E6-associated	 protein,	 and	 host	 cell	 wild-type	 p53,	 which	results	 in	 ubiquitylation	 of	 p53	 and	 its	 rapid	 proteasomal	 degradation(65).	Furthermore,	 E6	 can	 inhibit	 p53-mediated	 gene	 transcription	 through	 direct	binding(66).			The	other	major	HPV	viral	oncoprotein,	E7,	acts	to	inactivate	another	important	tumour	suppressor	pathway,	the	Rb	pathway,	which	plays	a	key	role	in	the	regulation	of	the	cell	cycle(63).	 Rb	 activity	 is	 regulated	 through	 its	 phosphorylation	 status,	 which	 is	dependent	 on	 cell	 cycle	 regulators	 such	 as	 p16	 and	 cyclin	 D1(67,	 68).	Underphosphorylated	 Rb	 forms	 a	 complex	 with	 the	 transcription	 factor,	 E2F,	 which	prevents	the	transcription	of	genes	essential	for	transition	from	G1	to	S	phase,	resulting	in	 inhibition	 of	 the	 cell	 cycle	 at	 the	 G1-S	 checkpoint(67).	 In	 contrast,	 Rb	phosphorylation,	which	is	initiated	by	the	binding	of	cyclin-dependent	kinase	(CDK)4/6	and	cyclin	D1	to	form	an	active	protein	complex,	leads	to	E2F	dissociation,	activation	of	S	phase	genes,	 and	cell	 cycle	entry(67).	The	 tumour	 suppressor	p16	 is	 also	 intricately	linked	here	and	binds	to	the	CDKs,	thus	interfering	with	the	interaction	between	cyclin	D1	 and	 CDK4/6	 and	 preventing	 Rb	 phosphorylation(69).	 The	 viral	 oncoprotein,	 E7,	causes	 destabilisation	 of	 Rb	 through	 a	 ubiquitin/proteasome-dependent	 mechanism,	
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allowing	E2F	to	induce	transcription	of	S	phase	promoting	genes(63).	This	results	in	an	overexpression	of	p16	 in	an	attempt	 to	block	cell	 cycle	progression,	and	consequently	assaying	of	 p16	 expression	 in	 tumour	 cells	 by	 immunohistochemistry	 is	 often	utilised	clinically	to	determine	HPV	status,	either	alone	or	in	combination	with	other	detection	techniques(70)	 (discussed	 in	 section	 1.1.4.).	 Inactivation	 of	 the	 Rb	 pathway	 is	 also	 a	crucial	molecular	event	in	SCCHN	carcinogenesis	more	widely.	In	HPV-negative	disease	the	 CCND1	 gene,	 which	 encodes	 cyclin	 D1,	 has	 been	 shown	 to	 display	 copy	 number	gains/amplification	 in	 more	 than	 80%	 of	 cases(47),	 and	 has	 been	 consistently	associated	 with	 poor	 prognosis(71).	 Furthermore,	 although	 mutations	 in	 CDKN2A,	which	 encodes	 p16,	 were	 observed	 in	 only	 approximately	 7%	 of	 tumours	 in	 the	aforementioned	 sequencing	 studies,	 copy	 number	 losses	 were	 noted	 in	 another	 20–30%(51-53)	 and	 previous	 data	 suggest	 that	 overall	 inactivation	 of	 CDKN2A,	 (through	mutation,	deletion,	or	epigenetic	 inactivation)	occurs	 in	up	 to	75%	of	SCCHNs(46,	72).	The	resulting	 loss	of	p16	expression	has	also	been	associated	with	decreased	disease-specific	survival	and	early	recurrence(73).		Perhaps	 the	most	 novel	 finding	 to	 emerge	 from	 the	whole-exome	 sequencing	 studies	was	 the	 relatively	 high	 frequency	 of	mutations	within	 the	NOTCH	 genes,	 in	 particular	
NOTCH1,	 present	 in	 20–25%	 of	 cases(51-53).	 Although	 previous	 work	 in	 certain	haematological	 malignancies	 demonstrated	 predominantly	 activating	 mutations	 and	translocations	in	the	genes	involved	in	Notch	signalling,	suggestive	of	a	pro-tumorigenic	role(74,	 75),	 mutations	 observed	 in	 SCCHN	 were	 generally	 inactivating	 mutations,	implying	 tumour	 suppressor	 function.	 Interestingly,	 Notch	 activity	 has	 been	 linked	 to	suppression	 of	 HPV	 E6	 and	 E7	 oncoprotein	 expression(76),	 which	 intuitively	 would	provide	 selective	pressure	 for	 inactivation	of	Notch	 in	HPV-driven	disease.	Otherwise,	Notch	 signalling	 has	 been	 linked	 to	 regulation	 of	 self-renewal	 capacity,	 cell	 cycle	 exit,	and	 cell	 survival(77,	 78).	 Additionally,	 in	 stratified	 epithelia	 Notch	 activity	 plays	 a	central	role	in	promoting	squamous	differentiation,	suggesting	that	dysregulation	of	this	may	be	 involved	 in	SCCHN	carcinogenesis(79).	Consistent	with	 this	notion,	 the	whole-exome	sequencing	studies	demonstrated	that	at	least	30%	of	cases	harboured	mutations	in	either	NOTCH	genes	or	other	genes	that	regulate	squamous	differentiation(51-53).			Another	dysregulated	pathway	involved	in	SCCHN	pathogenesis,	and	the	target	of	one	of	the	 first	 molecularly	 targeted	 therapies	 that	 has	 been	 approved	 for	 clinical	 use	 for	SCCHN,	 is	 the	epidermal	growth	 factor	 (EGF)	signalling	pathway(1,	80,	81).	Epidermal	growth	 factor	 receptor	 (EGFR)	 is	 overexpressed	 in	many	 SCCHNs(82),	which	 has	 also	
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been	linked	with	shorter	overall	and	relapse-free	survival,	more	advanced	stage	disease,	and	increased	lymph	node	metastasis(83).	EGFR	is	a	transmembrane	glycoprotein	that	belongs	 to	 the	ErbB	 family	of	 receptor	 tyrosine	kinases	and	can	bind	multiple	 ligands,	most	 importantly	 EGF	 and	 transforming	 growth	 factor	 α	 (TGF-α)(84).	 Ligand	 binding	results	 in	 a	 conformational	 change	 in	 EGFR,	 promoting	 homo-	 or	 hetero-dimerisation	with	 other	 ErbB/HER	 family	 members(84).	 This	 triggers	 internalisation	 and	 tyrosine	kinase	induced	autophosphorylation	of	its	cytoplasmic	domain,	which	in	turn	initiates	a	mitogenic	signalling	cascade	through	Ras-Raf	and	phosphatidylinositol	3-kinase/protein	kinase-B	(PI3K-AKT)(84).	Furthermore,	when	bound	to	EGF,	it	has	been	proposed	that	EGFR	can	 translocate	 to	 the	nucleus,	where	 it	 can	 function	as	a	 transcription	 factor	 to	promote	 cyclin	 D1	 expression,	 and	 thus	 stimulate	 cell	 cycle	 progression	 as	 described	above(85).	Interestingly,	dysregulation	of	EGFR	expression	is	considered	to	be	an	early	event	 in	 SCCHN	 carcinogenesis.	 As	 with	 TP53	 mutations,	 seemingly	 normal	 mucosa	surrounding	SCCHNs	tend	to	display	moderately	 increased	EGFR	expression	and	when	cells	 become	 dysplastic	 there	 is	 a	 further	 marked	 increase	 in	 expression(82,	 86),	findings	 which	 also	 support	 the	 “patch-field”	 progression	 model	 of	 SCCHN	 discussed	above.		Because	 of	 its	 prevalence	 and	 important	 role	 in	 SCCHN	 pathogenesis,	 therapeutic	targeting	 of	 EGFR	 has	 been	 the	 subject	 of	 intensive	 study.	 In	 2006,	 cetuximab,	 a	monoclonal	 antibody	 against	 EGFR,	 became	 the	 first	molecularly	 targeted	 agent	 to	 be	approved	 and	 introduced	 into	 clinical	 practice	 for	 the	 treatment	 of	 SCCHN(87).	Cetuximab	 was	 approved	 for	 use	 primarily	 in	 combination	 with	 RT	 in	 the	 context	 of	loco-regionally	 advanced	 SCCHN	 following	 on	 from	 a	 landmark	multi-national	 clinical	trial	 that	demonstrated	that	the	addition	of	cetuximab	significantly	 increased	five-year	overall	survival	from	36.4%	to	45.6%	compared	with	RT	alone	in	this	patient	group(88).	Additionally,	cetuximab	was	approved	for	single	agent	use	for	the	treatment	of	patients	with	 recurrent	 or	 metastatic	 SCCHN	 refractory	 to	 platinum-based	 therapy(87),	 and	more	 recently	 cetuximab	 has	 been	 shown	 to	 improve	 the	 outcome	 of	 palliative	chemotherapy	in	a	large	randomised	phase	III	study(89).			
1.1.4.	Diagnosis	and	staging	Diagnosis	 of	 early-stage	 SCCHN	 or	 pre-malignant	 lesions,	 such	 as	 oral	 or	 laryngeal	dysplasia,	is	typically	hindered	by	an	absence	of	symptoms,	compounded	by	the	fact	that	such	lesions	are	frequently	overlooked	by	both	patient	and	examiner,	if	indeed	medical	or	 dental	 consult	 is	 sought(1,	 2).	 As	 such,	 there	 is	 often	 a	 delay	 of	 up	 to	 a	 year	 in	
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diagnosis(5).	When	patients	do	become	symptomatic,	SCCHNs	can	manifest	in	a	variety	of	ways,	often	depending	on	the	function	of	the	site	where	they	originate,	as	alluded	to	in	 section	 1.1.1.	 Laryngeal	 cancers	 commonly	 present	 with	 dysphonia	 (particularly	hoarseness),	while	pharyngeal	 cancers	 frequently	present	 late	with	dysphagia(1,	2,	5).	However,	seemingly	non-specific	and	benign	symptoms,	such	as	sore	throat	or	ear	pain	(referred	pain	owing	to	the	complex	innervation	of	regional	anatomy),	are	also	common	presentations,	 and	 others	 may	 first	 present	 simply	 with	 a	 painless	 neck	 lump	 as	 a	manifestation	of	regional	lymph	node	metastases(1,	2,	5).	Such	symptoms	and	signs	are	reflected	 in	 current	 practice	 guidelines	 for	 specialist	 referral	 (figure	 1.1.4.1.),	 which	have	 been	 developed	 to	 expedite	 specialist	 assessment,	with	UK	 guidelines	 specifying	that	 patients	 meeting	 these	 criteria	 warrant	 a	 specialist	 consultation	 within	 two	weeks(90).		
Figure	1.1.4.1:	Urgent	specialist	referral	guidelines	for	SCCHN	in	England.	Reproduced	from	reference	(90).		Initial	assessment	of	any	lesion	of	the	head	or	neck	is	centred	on	physical	examination	and	should	include	palpation	of	the	entire	neck	for	lymph	nodes,	visual	inspection	of	the	oral	 cavity	 and	 oropharynx,	 and	 flexible	 nasolaryngoscopy,	 which	 allows	 proper	examination	 of	 the	 nasal	 cavities,	 postnasal	 space,	 base	 of	 the	 tongue,	 larynx,	 and	hypopharynx(1,	2,	5).	If	such	examination	confirms	the	presence	of	a	suspicious	looking	lesion	 a	 diagnosis	 of	 cancer	 is	 confirmed	 or	 refuted	 with	 biopsy	 and	 subsequent	histopathological	examination.	 In	the	case	of	epithelial	primary	site	biopsies,	 these	are	usually	performed	during	an	examination	under	general	anaesthetic,	while	in	the	case	of	enlarged	 cervical	 lymph	 nodes	 with	 no	 identifiable	 primary	 lesion	 fine	 needle	
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aspiration,	 typically	under	ultrasound	guidance,	and	subsequent	cytological	evaluation	is	usually	performed(5,	90).			Following	 confirmation	 of	 a	 SCCHN	 diagnosis,	 accurate	 staging	 is	 one	 of	 the	 most	important	 factors	 that	 guides	 therapeutic	 decision-making.	 Pre-treatment	 disease	staging	 is	 formulated	on	 the	aforementioned	clinical	 examination	 in	 combination	with	radiological	 assessment	 that	 usually	 entails	 imaging	 of	 the	 neck	 with	 computed	tomography	(CT),	magnetic	resonance	imaging	(MRI),	or	both	to	evaluate	the	extent	of	invasion	of	surrounding	anatomy	and	detection	of	regional	lymph	node	involvement.	In	cases	where	there	 is	a	high	 index	of	suspicion	of	SCCHN	based	on	clinical	examination	such	 radiological	 evaluation	 is	 often	undertaken	prior	 to	 biopsy	 to	 avoid	 upstaging	 of	the	 disease.	 In	 addition,	 thoracic	 and	 abdominal	 imaging	 (typically	 CT)	 should	 be	performed	to	exclude	the	presence	of	a	synchronous	primary	bronchogenic	carcinoma	or	 distant	 metastases(2,	 5,	 90).	 Indeed,	 up	 to	 36%	 of	 SCCHNs	 metastasise	 to	 distant	sites,	 with	 the	 risk	 being	 higher	 for	 locally	 advanced	 disease	 with	 nodal	involvement(91),	and	in	approximately	4-5%	of	cases	a	synchronous	pulmonary	tumour	will	 be	 detected(92).	 The	 relatively	 new	 technique	 of	 positron	 emission	 tomography	(PET),	 which	 detects	 uptake	 of	 the	 glucose	 analogue	 2-deoxy-2-(18F)fluoro-D-glucose	(18F-FDG)	and	is	described	in	detail	 in	section	1.3.3.,	 fused	with	normal	CT	imaging	for	anatomical	detail,	has	also	become	an	important	diagnostic	and	staging	adjunct	to	help	identify	 occult	 primary	 tumours	 not	 detectable	 by	 examination	 and	 conventional	imaging(93).	 This	 information	 is	 then	 assimilated	 using	 TNM	 classification	 and	 the	Union	 for	 International	 Cancer	 Control	 (UICC)/American	 Joint	 Committee	 on	 Cancer	(AJCC)	staging	systems(50).	Staging	criteria	vary	according	to	the	primary	site	of	origin,	and	 account	 for	 the	 anatomical	 extent	 of	 disease,	 and	 following	 recent	 revisions	 now	incorporate	 certain	 pathological	 and	 biological	 aspects	 of	 tumour	 behaviour,	 such	 as	extra-capsular	spread	(ECS),	HPV-status,	and	depth	of	invasion(50).		The	 now	 widespread	 consensus	 that	 HPV-related	 oropharyngeal	 SCC	 represents	 a	separate	 disease	 entity	 from	HPV-negative	 disease,	 conferring	 favourable	 survival(94-96)	 (discussed	 in	 section	 1.1.5.),	 has	 led	 to	 the	 introduction	 of	 HPV-16	 testing	 in	 the	diagnostic	 work-up	 and	 staging	 process	 for	 SCCHN.	 Specifically,	 several	 recently	published	evidence-based	clinical	management	guidelines	recommend	such	 testing	 for	SCCHNs	 arising	 in	 the	 oropharynx	 and	 also	 in	 the	 case	 of	metastatic	 SCC	 of	 unknown	origin(97).	However,	a	variety	of	laboratory	detection	methods	are	available,	each	with	particular	 benefits	 and	 detractions,	 and	 currently	 there	 is	 insufficient	 evidence	 to	
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recommend	one	particular	testing	regime	over	another	to	establish	HPV	status(97,	98).	Nonetheless,	 the	 combination	 of	 immunohistochemical	 testing	 for	 p16	 expression,	 a	downstream	product	of	HPV	DNA	transcription	(discussed	previously	in	section	1.1.3.),	with	 either	 an	 HPV	 DNA	 directed	 polymerase	 chain	 reaction	 (PCR)	 amplification	technique	or	detection	of	HPV	DNA	using	signal	amplification	in-situ	hybridisation	(ISH)	have	 been	 proposed(98).	 One	 such	 tiered	 diagnostic	 algorithm	 published	 by	 the	 John	Hopkins	Institution	and	commonly	utilised	in	clinical	practice,	including	in	our	regional	head	and	neck	network,	is	illustrated	in	figure	1.1.4.2.		
	
Figure	 1.1.4.2:	 Diagnostic	 algorithm	 for	 the	 detection	 of	 biologically	 relevant	 HPV	
infection. This	 tiered	 diagnostic	 algorithm	 proposed	 by	 Westra(99)	 uses	 p16	immunohistochemistry	 (IHC)	 for	 initial	 screening	 of	 cases,	 because	 it	 has	 high	 sensitivity,	followed	by	HPV-16	type	specific	ISH,	which	is	highly	specific.	In	equivocal	cases	(p16	positive/	HPV-16	negative)	a	consensus	HPV	in-situ	probe	is	used	to	detect	a	broader	range	of	oncogenic	HPVs.	(CISH	=	chromogenic	in-situ	hybridisation).	Reproduced	from	reference(98).		
1.1.5.	Treatment	and	prognosis	As	 the	 recognition	 of	 HPV-related	 oropharyngeal	 SCC	 as	 a	 distinct	 disease	 entity	 has	evolved,	 its	prognostic	 importance	has	also	been	revealed.	 Initial	 indications	 that	HPV	status	influenced	survival	came	from	a	single-institution	case	series	of	tonsillar	SCCs,	in	which	risk	of	disease	relapse	at	three	years	was	less	in	HPV-positive	cases	(OR	=	4.18)	and	respective	three-year	overall	survival	rates	of	65.3%	and	31.5%	were	observed	 in	the	 HPV	 positive	 and	 negative	 groups(100).	 This	 initial	 association	was	 subsequently	corroborated	 by	 a	 meta-analysis	 of	 individual	 retrospective	 case	 series(101),	 and	further	 by	 the	 landmark	 HPV	 status	 specific	 analysis	 of	 outcomes	 in	 the	 Eastern	Cooperative	Oncology	Group	2399	phase	II	trial,	which	demonstrated	a	73%	(HR	=	0.27,	
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95%	CI:	0.1–0.75)	reduction	in	risk	of	disease	progression	and	a	64%	(HR	=	0.36;	95%	CI:	0.15–0.85)	reduction	in	risk	of	mortality	for	patients	with	HPV-positive	disease(94).	Moreover,	the	differential	survival	benefit	appears	to	hold	true	irrespective	of	treatment	modality	 employed,	 with	 similar	 results	 demonstrated	 in	 surgically	 treated	 patients	with	or	without	postoperative	RT(96),	following	treatment	RT	alone(102),	and	in	those	treated	 with	 primary	 chemoradiotherapy	 (CRT)(95).	 Interestingly,	 further	 prognostic	stratification	combining	HPV	status	and	 tobacco	exposure	has	been	suggested.	Results	from	 the	 Radiation	 Therapy	 Oncology	 Group	 0129	 trial	 demonstrated	 that	 tobacco	smoking	 was	 independently	 associated	 with	 overall	 survival	 and	 progression-free	survival	in	both	HPV	positive	and	negative	subgroups,	with	a	similar	magnitude	of	effect	in	 both	 groups,	 which	 led	 the	 authors	 to	 propose	 a	 survival	 classification	 (high,	intermediate	and	 low	risk	categories)	based	on	HPV	status,	 tobacco	consumption,	and	tumour	stage(95).			HPV	 status	 notwithstanding,	 the	 strongest,	 and	 indeed	 traditional,	 prognostic	 factors	include	tumour	site	of	origin,	disease	stage,	and	the	presence	of	ECS	 in	cervical	 lymph	node	 metastases(80,	 103).	 As	 would	 be	 expected,	 tumours	 that	 are	 larger	 and	 have	spread	 to	 cervical	 lymph	 nodes	 and	 other	 tissues	 are	 associated	 poorer	 survival(80,	103).	ECS	has	shown	to	confer	poorer	oncological	outcomes	in	numerous	retrospective	case	series	of	SCCHNs	from	different	subsites,	and	in	a	large-scale	study	of	400	patients	with	oral	SCC	ECS	was	observed	to	be	the	most	significant	adverse	prognostic	indicator,	doubling	the	incidence	of	local	recurrence	and	distant	metastases,	and	tripling	the	risk	of	 regional	 failure(104).	 Furthermore,	 a	 meta-analysis	 including	 all	 SCCHN	 subsites	showed	 that	 ECS	more	 than	 halved	 the	 chances	 of	 surviving	 for	 five	 years	 (OR	 =	 2.7,	95%	CI:	2.1-3.7)(105).	Other	prominent	prognostic	factors	have	been	reported,	such	as	histological	grade,	pattern	of	invasion,	and	proximity	of	carcinoma	to	surgical	resection	margins,	all	of	which	are	included	as	accepted	features	related	to	clinical	outcome	in	the	UK	Royal	College	of	Pathologists	guidelines(106).		The	treatment	of	SCCHN	is	typically	complex	and	often	multi-modal,	comprising	various	combinations	of	surgery,	RT,	and	chemotherapy,	and	as	such	is	increasingly	delivered	by	multi-disciplinary	 teams	 of	 health	 professionals(1,	 80).	 The	 specifics	 of	 treatment	depend	 largely	 on	 the	 primary	 site	 of	 the	 tumour	 and	 the	 stage	 of	 disease,	 as	well	 as	patient	 performance	 status	 and	 preference.	 In	 the	 broad	 context	 of	 SCCHN,	 RT	 and	surgery	are	the	most	common	treatment	modalities,	with	the	former	indicated	in	74%	of	all	 cases	 at	 some	 point	 during	 the	 treatment	 pathway,	 either	 as	 primary	 or	 adjuvant	
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therapy,	 if	 current	 treatment	 guidelines	 are	 followed(107).	 Patients	 with	 early	 stage	SCCHN	 are	 generally	 treated	with	 single	modality	 therapy,	 either	 surgery	 or	 RT,	with	curative	intent(1,	80,	81).	In	early	stage	oral	cavity	SCC,	although	efficacy	of	surgery	and	RT	appear	equitable,	surgery	is	usually	preferred	to	avoid	late	toxic	effects	of	radiation	and	 to	 enable	 more	 accurate	 pathological	 staging	 from	 surgical	 resection	specimens(108).	 Similarly,	 in	 terms	 of	 oncological	 control	 RT	 and	 surgery	 stand	 in	clinical	equipoise	 for	early	 stage	oropharyngeal	and	 laryngeal	SCC,	with	 the	 treatment	choice	largely	dependent	on	the	treating	centre’s	expertise	and	patient	preference(109-111).	 There	 is	 an	 increasing	 body	 of	 evidence,	 however,	 that	 use	 of	 contemporary,	endoscopic	 surgical	 techniques	 may	 be	 associated	 with	 favourable	 functional	outcomes(112-114).	For	advanced	SCCHN,	which	represents	approximately	 two-thirds	of	all	SCCHN	cases(1,	81),	single	modality	treatment	is	generally	associated	with	poorer	outcomes,	and	several	seminal	studies	have	demonstrated	that	combined	use	of	surgery	and	 adjuvant	 RT,	 or	 combined	 post-operative	 platinum-based	 CRT,	 or	 perhaps	 most	commonly	 primary	 CRT,	 offer	 the	 most	 favourable	 disease	 control	 rates	 and	survival(115-119).	Unfortunately,	 however,	 such	multi-modality	 treatment	 also	 comes	with	considerable	 toxicity	and	carries	significant	 functional	morbidity	 for	 the	majority	of	patients(120,	121).		In	 addition	 to	 treating	 the	 primary	 tumour,	 it	 is	 typically	 considered	 mandatory	 to	electively	treat	the	neck,	either	surgically	or	with	RT,	even	in	the	absence	of	clinical	and	radiological	 evidence	 of	 lymph	 node	 involvement	 when	 the	 estimated	 likelihood	 of	occult	metastasis	 is	more	 than	15-20%(122).	This	assessment	 is	based	predominantly	on	disease	stage	and	the	lymphatic	drainage	of	the	primary	tumour	site(122).		As	 alluded	 to	 above,	 a	 major	 advancement	 in	 the	 treatment	 of	 SCCHN	 has	 been	 the	advent,	 and	 more	 widespread	 adoption,	 of	 organ	 preserving	 surgical	 techniques,	specifically	transoral	laser	microsurgery	and	transoral	robotic	surgery.	These	minimally	invasive	approaches	obviate	the	need	for	an	external	skin	incision	and	limit	the	extent	of	tissue	 dissection,	 disruption	 to	 speech	 and	 swallowing	 muscles,	 damage	 to	 major	neurovascular	 structures,	 and	 injury	 to	 normal	 tissue(123).	 Furthermore,	 these	techniques	 allow	 for	 intraoperative	 microscopic	 evaluation	 of	 the	 tumour	 resection,	which	can	be	undertaken	in	a	transtumoural	manner,	maximising	appreciation	of	three-dimensional	 orientation(123).	 Another	 major	 recent	 advancement	 has	 been	 the	introduction	of	 intensity-modulated	RT	(IMRT),	which	represents	an	advanced	form	of	radiation	 in	 three	 dimensions(124).	 Computer-driven	 linear	 accelerators	 are	 used	 to	
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produce	multiple	RT	beams,	in	which	the	intensity	is	optimised	to	deliver	a	high	dose	of	radiation	 to	 specified	 tissues,	 while	 reducing	 the	 dose	 to	 adjacent	 non-target	tissues(124).	 IMRT,	 therefore,	 allows	 for	 better	 control	 of	 radiation	dose	delivery	 and	has	 been	 shown	 in	 a	 recent	 phase	 III	 multi-centre	 randomised	 controlled	 trial	 to	significantly	 reduce	 radiation-induced	 xerostomia	 (the	 main	 long	 term	 side	 effect	 of	standard	RT)	 from	74%	 (95%	CI:	 56-87%)	 to	 39%	 (95%	CI:	 23-55%)	 and	 from	83%	(95%	 CI:	 63-95%)	 to	 29%	 (95%	 CI:	 14-48%)	 at	 one	 and	 two	 years	 after	 treatment	respectively(125).	 Other	 advancements	 in	 RT	 relate	 to	 delivery	 schedules,	 such	 as accelerated	RT	(radiation	delivered	over	a	shorter	time	period)	or	hyperfractionated	RT	(delivery	of	a	higher	dose	of	 radiation	 in	 two	 to	 three	 low	dose	 fractions	a	day)(126).	Use	 of	 concomitant	 chemotherapy,	 as	 discussed	 above,	 is	 a	 relatively	 recent	development	 in	SCCHN	treatment,	having	evolved	 from	the	palliative	care	setting,	 and	more	 recently	 the	 concurrent	 administration	 of	 cetuximab	 has	 been	 shown	 to	 be	beneficial	in	specific	therapeutic	contexts	(see	section	1.1.3.)(81).	 	Despite	 such	 advances	 in	 therapeutic	 strategies,	 as	 well	 as	 recent	 developments	 in	diagnostics,	 overall	 survival	 outcomes	 for	 HPV-negative	 SCCHN	 have	 not	 improved	significantly	over	the	last	20-30	years	(figure	1.1.5.1.	shows	UK	data),	still	accounting	for	nearly	 350,000	 deaths	 annually	 worldwide(10-12,	 38,	 127).	 To	 a	 large	 extent,	 this	reflects	the	failure	of	currently	available	treatment	regimes	to	achieve	loco-regional	and	long-term	 distant	 control	 in	 advanced	 disease,	 and	 overall	 survival	 rates	 for	 such	patients	 remain	 as	 low	 as	 35%(38,	 127).	 Furthermore,	 it	 is	 generally	 not	 a	 feasible	option	to	escalate	RT	and/or	chemotherapy	dosage	in	these	patients	owing	to	concerns	over	 normal	 tissue	 toxicity(128,	 129).	 In	 contrast,	 HPV-driven	 oropharyngeal	 SCC	 is	associated	with	favourable	survival	outcomes,	as	discussed	above,	which	together	with	the	fact	that	HPV-related	disease	tends	to	affect	younger	and	generally	medically	fitter	patients(30),	who	are	therefore	likely	to	experience	the	functional	ramifications	of	their	treatment	 long-term,	 has	 led	 many	 to	 propose	 treatment	 de-intensification	 for	 these	patients	 in	 order	 to	 avoid	 potential	 overtreatment	 with	 associated	 toxic	 effects(130,	131).	Despite	this	apparent	clinical	paradox	of	the	need	for	treatment	escalation	versus	de-escalation	 in	 HPV-negative	 and	 HPV-positive	 disease	 respectively,	 there	 remains	 a	common	 goal	 from	 a	 translational	 research	 perspective:	 to	 identify	 more	 effective	treatment	 strategies,	 and	 a	 major	 focus	 for	 this	 includes	 to	 identifying	 ways	 of	sensitising	 these	 tumours	 to	 the	 effects	 of	 existing	 treatments,	 not	 only	 to	 improve	efficacy,	 but	 also	 to	 minimise	 the	 substantial	 toxic	 effects.	 Fundamental	 to	 this	 is	 to	elucidate	 the	 cellular	 processes	 that	 may	 determine	 radio-	 and	 chemo-sensitivity	 to	
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facilitate	 therapeutic	 targeting	 of	 the	 key	 pathways	 that	 may	 impinge	 on	 these	processes.		
	
Figure	1.1.5.1:	SCCHN	survival/mortality	trends	in	the	UK	over	time.	Graphs	illustrating	the	mortality	rates	in	the	UK	from	1971-2012	for	oral	cavity	and	pharyngeal	cancers	combined	(A),	and	the	 five-year	overall	 survival	rates	 from	1971-2011	 for	 laryngeal	cancer	alone	(B).	Figures	reproduced	from	Cancer	Research	UK	website(11).			
1.2.	The	p53	tumour	suppressor	protein		The	TP53	tumour	suppressor	gene,	which	encodes	the	p53	protein,	plays	a	critical	role	in	 orchestrating	 cellular	 damage	 control	 pathways	 that	 suppress	 the	 development	 of	
A 
B 
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cancer(132).	The	fact	that	TP53	has	the	greatest	number	of	cancer-associated	mutations	of	any	known	gene,	mutated	directly	 in	approximately	half	of	all	human	cancers(133),	attests	to	the	importance	of	this	role,	which,	as	touched	on	previously	in	section	1.1.3.,	is	also	evident	specifically	in	SCCHN.	
	
1.2.1.	Structural	organisation	of	p53		The	TP53	tumour	suppressor	gene	is	20	kilobase	pair	gene	comprising	11	exons	and	is	located	on	the	short	arm	of	chromosome	17(134).	The	resulting	p53	protein	consists	of	393	 amino	 acid	 residues	 and	 functions	 as	 a	 tetramer(135).	 From	 a	 structural	perspective,	 the	p53	protein	 is	divided	 into	 three	 regions:	 the	N-terminal	domain,	 the	central	core	domain,	and	the	C-terminal	domain	(figure	1.2.1.1.)(135).		
	
Figure	1.2.1.1:	Domain	structure	of	full-length	p53	protein.	The	p53	protein	consists	of	393	amino	 acid	 residues	 and	 contains	 an	 N-terminal	 transactivation	 domain	 (TAD),	 followed	 by	 a	proline-rich	region	(PRR),	 the	central	DNA-binding	domain	(p53C),	 the	tetramerisation	domain	(TET),	 and	 the	 extreme	 C	 terminus	 (CT)	 containing	 the	 regulatory	 region.	 Figure	 reproduced	from	reference	(135).		The	N-terminal	domain	 is	natively	unfolded,	encompasses	 residues	1-93,	and	contains	an	 acidic	 transactivation	 domain	 (this	 can	 be	 further	 subdivided	 into	 two	 ill-defined	subdomains)	 and	 a	 proline-rich	 region(136,	 137).	 The	 transactivation	 domain	 is	 a	binding	 site	 for	 numerous	 interacting	 proteins,	 including	 general	 transcription	factors(138,	 139),	 transcriptional	 co-activators(140),	 and	 the	 negative	 regulators	murine	 double	 minute	 (MDM)2/MDMX	 (see	 section	 1.2.2.)(141,	 142).	 Notably,	 the	residues	F19,	L22,	and	W23	are	thought	to	be	essential	for	transcriptional	activation	by	p53	 as	 they	 interact	 directly	 with	 the	 components	 of	 the	 transcriptional	machinery(143).	The	precise	 role	 of	 the	 following	proline-rich	 region,	which	 links	 the	transactivation	domain	to	the	central	core	domain,	 is	poorly	understood.	However,	the	region	 contains	 five	 PXXP	motifs	 (where	 P	 represents	 proline	 and	 X	 any	 amino	 acid),	which	 are	 generally	 known	 to	 mediate	 protein-protein	 interactions	 in	 signal	transduction	 through	 binding	 to	 Src	 homology	 3	 domains	 (SH3),	 and	 it	 has	 been	suggested	 that	 this	 may	 play	 a	 role	 in	 the	 transmission	 of	 anti-proliferative	 signals	down-stream	of	the	p53	protein(137).	
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	The	central	 core	 region	consists	of	 residues	102-292,	and	 is	made	up	of	a	β-sandwich	that	serves	as	a	scaffold	for	two	large	loops	and	a	loop-sheet-helix	motif,	which	form	the	α-helical	sequence-specific	DNA-binding	element	of	the	p53	protein(135,	144).	The	two	loops,	which	are	held	together	by	a	tetrahedrally	coordinated	zinc	atom,	and	the	 loop-sheet-helix	 motif	 contain	 the	 evolutionarily	 conserved	 regions	 of	 the	 core	 domain:	region	 II	117-142;	 III	 171-181;	 IV	234-	258;	 and	V	270-286(144,	145).	Residues	 from	the	loop-sheet-helix	motif	interact	in	the	major	groove	of	the	DNA,	while	arginine	from	one	 of	 the	 two	 large	 loops	 interacts	 in	 the	 minor	 groove(135,	 144).	 Residues	 K120,	S241,	R273,	A276,	and	R283	are	also	involved	in	the	sequence-specificity	of	p53	as	they	make	 direct	 contact	 with	 the	 phosphate	 backbone	 in	 the	 major	 grove	 of	 DNA,	 while	residues	K120,	R248,	C277	and	R280	form	hydrogen	bonds	with	DNA	bases	in	the	minor	grove	 of	 DNA(144).	 Importantly,	 the	majority	 of	TP53	 mutations	 identified	 in	 human	cancers	 affect	 the	 central	 core	 domain,	 particularly	 the	 highly	 conserved	 regions,	resulting	in	the	loss	or	alteration	of	sequence-specific	DNA	binding(54,	145).			The	C-terminal	domain,	consisting	of	residues	300-393,	is	multi-functional	and	is	further	subdivided	 into	 three	 regions:	 a	 flexible	 linker	 (residues	 300-320),	 a	 tetramerisation	domain	 (residues	 325-356),	 and	 a	 regulatory	 domain	 (residues	 363-393)(135).	 The	monomeric	tetramerisation	domain	consists	of	a	short	β-strand	and	an	α-helix	linked	by	a	 sharp	 turn,	 which	 can	 homodimerise	 to	 form	 a	 primary	 dimer,	 which	 can	 in	 turn	associate	with	another	such	primary	dimer	through	their	helices	to	form	the	functional	p53	tetramer	(figure	1.2.1.2.)(146,	147).	The	tetramer	 interface	 is	stabilised	 largely	by	strong	hydrophobic	 interactions	between	 the	 surfaces	of	 each	helix	pair(146,	147).	At	the	extreme	C	terminus	of	p53	lies	the	regulatory	domain,	which	is	a	natively	unfolded	region,	is	rich	in	basic	amino	acids	(mainly	lysines),	and	is	capable	of	binding	DNA	non-specifically(135,	145).	Additionally,	this	region	has	been	reported	to	bind	damaged	DNA	and	to	promote	re-annealing	of	complementary	DNA	or	RNA	strands(135).		
Introduction	
	 23	
	
Figure	1.2.1.2:	Structure	of	the	tetrameric	DNA-binding	domain	of	p53	binding	to	DNA.	p53	core	domains	bound	to	two	consecutive	DNA	half-site	motifs	(purple	and	turquoise	chains).	The	grey	and	green	subunits	form	one	dimer,	and	the	blue	and	yellow	subunits	form	the	other.	Zinc	atoms	are	depicted	as	beige	spheres.	Figure	reproduced	from	reference	(135).		
1.2.2.	Regulation	of	p53	Given	 that	 p53	 regulates	 such	 a	 large	 number	 of	 cellular	 processes	 and	 is	 a	 potent	inhibitor	of	cell	growth,	its	activity	has	to	be	tightly	regulated	during	development	and	normal	 growth(148,	 149).	 Under	 normal	 conditions,	 p53	 is	 maintained	 at	 low,	 often	undetectable	levels,	predominantly	due	to	the	function	of	its	negative	regulators	MDM2	and	MDMX	(also	known	as	MDM4)(148,	149).	MDM2	is	the	main	negative	regulator	of	p53,	acting	both	to	promote	its	degradation	and	inhibit	its	transcriptional	activity(148).	Perhaps	 most	 importantly,	 as	 a	 RING-finger	 E3	 ubiquitin	 ligase,	 MDM2	 binds	 to	 and	ubiquitylates	 p53,	 ultimately	 targeting	 it	 for	 proteasomal	 degradation(150).	 Such	ubiquitylation	 can	 also	 hamper	 the	 transcriptional	 activity	 of	 p53	 through	 control	 of	sub-cellular	 localisation.	 The	 transcriptional	 activity	 of	 p53	 relies	 on	 its	 nuclear	localisation,	and ubiquitylation	of	p53	by	MDM2	can	cause	exposure	of	the	C-terminus	nuclear	 export	 sequence	 within	 the	 tetramerisation	 domain	 of	 p53,	 resulting	 in	 p53	export	from	the	nucleus	to	the	cytoplasm(151).	MDM2	can	also	negatively	regulate	the	transcriptional	 activity	 of	 p53	 more	 directly	 by	 binding	 to	 the	 p53	 N-terminal	transactivation	domain,	which	prevents	binding	of	the	components	of	the	transcription	machinery(152).	A	 further	mechanism	by	which	MDM2	can	 inhibit	p53	transcriptional	activity	 is	 through	 inhibition	 of	 histone	 acetyltransferase-mediated	 p53	 acetylation,	which	normally	enhances	the	DNA-binding	capacity(153).	Importantly,	p53	and	MDM2	are	engaged	 in	an	auto-regulatory	 feedback	 loop,	which	 titrates	 the	 levels	of	both	p53	
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and	MDM2(150).	p53	stimulates	 the	expression	of	MDM2	by	binding	 to	 the	MDM2	P2	promoter,	with	MDM2	 then	 inhibiting	p53	 function,	while	on	 the	other	hand,	 low	p53	activity	leads	to	decreased	steady	state	levels	of	MDM2(150).	Moreover,	MDM2	can	also	target	itself	for	degradation,	ensuring	it	is	not	present	at	excessive	levels(150).			The	 function	 of	MDMX,	 a	 homologue	 of	MDM2,	 in	 regulating	 p53	 stability	 is	 less	well	understood.	MDMX	lacks	the	robust	E3	ubiquitin	ligase	function	of	MDM2	but	is	thought	to	 regulate	p53	 stability	 indirectly	 (328),	 primarily	by	 interacting	with	 and	 stabilising	MDM2,	hence	stimulating	 the	ability	of	MDM2	to	 inhibit	p53	 function(154).	 It	has	also	been	suggested	that	 in	a	similar	manner	 to	MDM2,	MDMX	can	negatively	regulate	p53	through	inhibition	of	its	acetylation	by	the	histone	acetyltransferase	p300/CBP(155).			p53	can	become	activated	 in	response	 to	a	wide	variety	of	stimuli	 including	genotoxic	stress,	 hypoxia,	 and	 aberrant	 growth	 signalling(149).	 Such	 activation	 in	 response	 to	these	 stress	 signals	 is	 almost	 always	 accompanied	 by	 stabilisation,	 leading	 to	 a	 rapid	increase	in	p53	levels(148,	149).	This	largely	results	from	a	disruption	of	the	interaction	between	 p53	 and	 its	 negative	 regulators,	 MDM2	 and	 MDMX,	 thereby	 liberating	 p53,	rather	 than	 through	de	novo	 synthesis(148,	 149).	 Indeed,	 transcriptional	 activation	 of	p53	would	create	a	delay	in	the	DNA-damage	response,	which	would	also	carry	a	risk	of	producing	a	mutated	and	non-functional	p53	protein	as	the	DNA	may	be	damaged(148).	One	of	 the	main	mechanisms	of	abrogating	 the	 interaction	between	p53	and	MDM2	 is	post-translational	modification	of	both	proteins(149).	In	response	to	ionising	radiation	(IR),	p53	is	phosphorylated	at	serine	15	by	ataxia	telangiectasia	mutated	(ATM)	kinase	and	 at	 serine	 20	 by	 checkpoint	 kinase	 2	 (Chk2),	 and	 in	 response	 to	 ultra-violet	 (UV)	radiation	ATR	(ATM-related)	kinase	causes	phosphorylation	at	serines	15	and	37,	all	of	which	prevent	MDM2	from	binding	to	the	transactivation	domain	of	p53(156-158).	ATM	kinase	 and	 ATR	 kinase	 can	 also	 phosphorylate	 MDM2,	 resulting	 in	 its	 functional	inactivation	and/or	destabilisation(159,	160).	Additionally,	acetylation	of	p53	at	 lysine	residues	clustered	around	the	C-terminus	can	also	compete	with	MDM2	ubiquitylation	of	the	same	lysine	residues,	enhancing	the	stability	of	p53(161)			Another	mechanism	by	which	 the	p53-MDM2	 interaction	 can	be	 abrogated	 is	 through	the	binding	of	p14ARF	to	MDM2,	which	results	in	the	inhibition	of	MDM2-mediated	p53	nuclear	 export,	 thus	 preventing	 ubiquitylation	 of	 p53(162).	 p14ARF	 is	 an	 alternative	reading	 frame	 product	 of	 the	 CDKN2A	 gene	 and	 is	 activated	 in	 response	 to	 aberrant	growth	 signals	 secondary	 to	 oncogene	 activation(163).	 The	 mechanistic	 basis	 of	 the	
Introduction	
	 25	
interaction	 between	 p14ARF	 and	 MDM2,	 however,	 is	 not	 fully	 understood	 and	 may	involve	sequestration	of	MDM2	into	the	nucleolus,	formation	of	ARF-MDM2-p53	ternary	complexes	 in	 the	nucleoplasm,	 or	 inhibition	of	MDM2	nuclear	ubiquitin	 ligase	 activity	(162).			In	 addition	 to	 mechanisms	 liberating	 p53	 from	 the	 negative	 regulation	 of	 MDM2,	 a	number	 of	 post-translational	 modifications	 of	 p53,	 including	 acetylation,	 adenosine	diphosphate	 (ADP)-ribosylation,	 ubiquitination,	 NEDDylation,	 or	 SUMOylation,	 have	been	 suggested	 to	 enhance	 the	 sequence-specific	 DNA-binding	 and	 transcriptional	activities	 of	 p53	 in	 response	 to	 stress(164).	 These	 modifications	 may	 result	 in	 a	conformational	change	of	the	protein,	and	whilst	the	precise	details	of	how	all	of	these	promote	p53	function	remain	to	be	clarified,	 it	appears	that	modification,	 in	particular	acetylation,	of	p53	near	 the	C-terminus	can	 interfere	with	 the	 folding	of	 this	 region	of	the	protein(164).	In	the	unmodified	protein	the	C-terminus	usually	folds	back	inhibiting	the	 DNA-binding	 domain	 in	 the	 central	 core	 region,	 with	 the	 modifications	 therefore	enhancing	the	DNA-binding	capacity	of	p53(164).	
		
1.2.3.	Functions	of	p53	Following	 activation	 and	 stabilisation	 in	 response	 to	 stress	 signals,	 the	 p53	 protein	integrates	 numerous	 signals	 that	 function	 ultimately	 to	 control	 decisions	 between	cellular	life	and	death,	which	together	act	to	prevent	errors	in	the	duplication	process	of	a	cell	that	is	under	stress	and	thus	prevent	cancers	from	arising(165).	For	instance,	p53-mediated	induction	of	cell	cycle	arrest	in	response	to	acute	DNA	damage	signals	allows	time	 for	 DNA	 repair	 before	 further	 cellular	 proliferation,	 which	 prevents	 the	propagation	 of	 potentially	 deleterious	mutations,	while	 induction	 of	 apoptosis	 by	 p53	directly	 eliminates	 abnormal	 cells	 harbouring	 mutations	 that	 would	 otherwise	contribute	 to	 genomic	 instability(166).	 The	 outcome	 of	 p53	 activation	 depends	 on	 a	wide	 range	 of	 factors,	 including	 the	 tissue	 type,	 the	 state	 of	 the	 cell,	 the	 presence	 of	other	oncogenic	changes	in	the	cell,	whether	p53-independent	death	or	survival	signals	that	 cooperate	 with	 p53	 are	 present,	 and	 the	 type	 and	 severity	 of	 the	 stress	stimuli(166).		p53	 functions	 predominantly	 as	 a	 sequence-specific	 transcription	 factor	 that	 can	regulate	 the	 expression	 of	 a	 large	 and	disparate	 group	of	 responsive	 genes.	 Indeed,	 it	has	 been	 suggested	 that	 there	may	 be	 as	many	 as	 4000	 such	 human	 genes,	 covering	various	 functions	 involved	 in	 cell	 cycle	 regulation,	 apoptosis,	 senescence,	 DNA	 repair	
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after	genotoxic	 stress,	oxidative	 stress,	 angiogenesis,	differentiation,	 cell	 adhesion,	 cell	migration,	 extracellular	 matrix	 and	 cytoskeleton	 organisation,	 and	 metabolic	homeostasis(167-169).	 These	 p53	 responsive	 genes	 either	 contain	 a	 p53	 response	element	(RE)	or	are	situated	close	to	DNA	harbouring	such	a	RE(167,	169).	These	p53	REs	are	composed	of	a	consensus	DNA	sequence	to	which	p53	binds	with	high	affinity	and	specificity,	which	has	striking	internal	symmetry	and	consists	of	two	copies	of	a	10	base	pair	motif	5′-RRRCWWGYYY-3′,	where	R	is	a	purine,	Y	is	a	pyrimidine,	W	is	either	adenine	or	thymine,	G	is	a	guanine,	and	C	is	cytosine,	separated	by	0-13	base	pairs(167,	170).	 Whilst	 the	 binding	 of	 p53	 to	 the	 majority	 of	 p53	 REs	 is	 associated	 with	transcriptional	 activation	 of	 gene	 expression,	 a	 considerable	 number	 of	 REs	(approximately	 15%)	 are	 linked	 to	 transcriptional	 repression(167).	 At	 present	 it	remains	 unclear	 what	 differentiates	 a	 RE	 from	 being	 a	 transcriptional-activator	 site	versus	 a	 transcriptional-repressor	 site.	 p53-mediated	 transcriptional	 activation	 is	typically	 achieved	 through	 direct,	 sequence-specific	 DNA	 binding,	 whereas	 there	 are	several	 generally	 accepted	 direct	 methods	 of	 repression:	 binding-site	 overlap	 that	interferes	 with	 another	 transcriptional	 activator;	 inactivation	 of	 other	 transcriptional	activators	 through	 protein-protein	 interactions;	 and	 recruitment	 of	 histone	deacetylases(167).	Indirect	p53-mediated	repression	may	also	occur	through	binding	to	another	transcription	factor	and,	together,	repressing	a	gene	without	a	p53-specific	RE,	or	 in	 the	 instance	of	 activation	of	 CDKN1A	 (otherwise	 known	as	p21Cip1/Waf1,	and	 from	hereon	 referred	 to	 simply	 as	 p21),	which	 inhibits	 formation	 of	 the	 CDK4/6-cyclin	 D1	complex	and	ultimately	repression	of	S	phase	genes	(see	section	1.1.3.)(167).			In	addition	to	the	 importance	of	 transcriptional	regulation,	p53	also	exerts	some	of	 its	downstream	 effects	 by	 transcriptionally	 independent	 means,	 chiefly	 related	 to	 its	apoptotic	 activity(165).	 The	 details	 of	 these	 effects	 remain	 to	 be	 clarified	 but	 may	include	 the	 relocalisation	 of	 death	 receptors	 to	 the	 cell	 surface(171),	 a	 direct	cytoplasmic	 function	 of	 p53	 in	 the	 regulation	 of	 mitochondrial	 membrane	permeabilisation(172),	 and	 direct	 regulation	 of	 translation	 by	 p53	 binding	 to	 the	 5′	untranslated	region	of	certain	mRNAs(173).			Perhaps	 the	 best	 characterised	 functions	 of	 p53	 are	 induction	 of	 cell-cycle	 arrest,	apoptosis,	 and	 more	 recently	 senescence	 in	 response	 to	 acute	 DNA-damage	signals(165),	and	as	such	will	be	discussed	in	more	detail	in	the	subsequent	sections	of	this	 chapter	 (sections	 1.2.4-5.).	 In	 addition,	 and	of	 particular	 relevance	 to	 the	 topic	 of	this	thesis,	recent	studies	have	revealed	that	p53	also	plays	a	central	role	 in	metabolic	
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homeostasis,	balancing	glycolytic	activity	and	mitochondrial	 respiration(174),	and	 this	will	be	discussed	further	in	section	1.3.2.		
1.2.4.	Cell	cycle	regulation	The	cell	cycle	comprises	a	coordinated	series	of	events,	which	results	in	the	duplication	of	all	cell	components	and	division	to	produce	two	cells,	a	mother	and	a	daughter	cell.	Although	 cell	 proliferation	 is	 a	 continuous	 process,	DNA	 synthesis	 and	mitosis	 can	 be	divided	into	distinct	phases	as	follows:	G1	(pre-synthetic	gap);	S	phase	(DNA	synthesis);	G2	 (post-synthetic	 gap);	 and	 M	 phase	 (mitosis)	 (figure	 1.2.4.1.)(175).	 Progression	through	 the	 cell	 cycle	 depends	 on	 a	 series	 of	 regulatory	 events,	 principally	 the	sequential	 activation	 and	 inactivation	 of	 the	 CDKs,	 which	 are	 active	 in	 facilitating	successful	 progression	 through	 the	 cell	 cycle	 only	when	bound	 in	 complexes	with	 the	cyclins(175,	 176).	 Progression	 through	G1	 is	 dependent	 on	 CDKs	binding	 to	 cyclins	D	and	 E,	 while	 S	 and	 M	 phase	 progression	 relies	 upon	 CDKs	 binding	 to	 cyclins	 A	 and	B(176).	G1/S	and	G2/M	cell	cycle	checkpoints	maintain	an	accurate	sequence	of	events	by	 ensuring	 the	 next	 phase	 of	 the	 cell	 cycle	 is	 not	 initiated	 until	 completion	 of	 the	current	 phase(175),	 and	 enable	 induction	 of	 temporary	 cell	 cycle	 arrest,	 allowing	damaged	DNA	to	be	repaired	before	allowing	the	cell	to	continue	replication	of	the	DNA	or	subsequent	division(175,	176).		
	
Figure	1.2.4.1:	Diagrammatic	representation	of	the	cell	cycle.	The	distinct	phases	of	the	cell	cycle	 include	G1	 (pre-synthetic	 gap),	 S	 phase	 (DNA	 synthesis),	 G2	 (post-synthetic	 gap),	 and	M	phase	(mitosis).	Progression	through	G1	is	dependent	on	CDKs	binding	to	cyclins	D	and	E,	while	S	
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and	M	phase	progression	relies	upon	CDKs	binding	to	cyclins	A	and	B.	Figure	reproduced	from	reference	(177).		One	of	the	principal	functions	of	p53	in	the	majority	of	mammalian	cells	is	induction	of	cell	cycle	arrest,	a	function	which	p53	executes	via	a	number	of	pathways.	p21	was	the	first	 p53	 target	 discovered	 with	 a	 role	 in	 cell	 cycle	 arrest(178),	 and	 is	 the	 main	downstream	target	of	p53	 for	G1/S	cell	cycle	arrest	 in	response	 to	DNA	damage(179).	p53	transcriptionally	activates	the	expression	of	p21,	which	results	in	potent	inhibition	of	 the	 CDKs(179).	 At	 high	 concentrations	 of	 p21	 (as	 would	 be	 induced	 upon	 p53	activation),	p21	binds	 to	and	 inhibits	a	wide	range	of	cyclin-CDK	complexes,	 including	cyclin	D1–CDK4	or	6,	cyclin	E–CDK2,	cyclin	A–CDK1	or	2,	and	cyclin	B1–CDK1,	thereby	blocking	cell	cycle	progression	at	both	G1/S	and	G2/M	checkpoints(179).	Furthermore,	p21	 is	 also	 able	 to	 bind	 and	 inhibit	 the	 activity	 of	 proliferating	 cell	 nuclear	 antigen	(PCNA),	 a	 DNA	 polymerase	 activator	 in	 DNA	 replication,	 contributing	 to	 G1/S	arrest(180).	 In	 addition	 to	p53,	 several	 other	 factors	 can	 regulate	 the	 transcription	of	p21	in	a	p53-independent	fashion	and	thus	influence	cell	cycle	progression	(reviewed	in	(179)).			The	 ability	 of	 p53	 to	 induce	 cell	 cycle	 arrest	 also	 involves	 the	 gene	GADD45	 (growth	arrest	 and	 DNA-damage-inducible	 protein	 45)(181).	 Following	 certain	 genotoxic	stresses,	p53	transcriptionally	activates	GADD45,	which	is	implicated	in	the	induction	of	G2/M	arrest	 through	 inhibition	of	 the	 activity	of	 the	 cyclin	B1–CDK1	 complexes(181).	Inhibition	 of	 cyclin	 B1–CDK1	 complexes	 also	 underlies	 another	 of	 the	 pathways	 by	which	 p53	 can	 achieve	 cell	 cycle	 arrest	 –	 up-regulation	 of	 14-3-3σ(182).	 14-3-3σ	promotes	cell	cycle	arrest	in	the	G2	phase	by	sequestering	cyclin	B1-CDK1	complexes	in	the	cytoplasm	preventing	their	nuclear	import	and	entry	into	mitosis(182).	Akin	to	14-3-3σ	and	GADD45,	Reprimo,	a	candidate	tumour-suppressor	gene,	is	a	further	potential	mediator	of	p53-dependent	cell	 cycle	arrest	 in	 the	G2	phase	by	 interfering	with	cyclin	B1–CDK1	 complex	 activity(183).	 Although	 there	 is	 currently	 no	 evidence	 for	 the	presence	 of	 a	 p53	 consensus	 binding	 site	 within	 the	 promoter	 region	 of	 Reprimo,	 its	induction	upon	p53	expression	suggests	that	Reprimo	expression	is	positively	regulated	by	p53(183).			
1.2.5.	Apoptosis	Apoptosis,	 or	 programmed	 cell	 death,	 is	 crucial	 to	 the	 maintenance	 of	 healthy	multi-cellular	 organisms,	 occurs	 in	 response	 to	 a	 wide	 variety	 of	 stimuli,	 and	 is	 tightly	
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controlled	by	a	numerous	pro-	and	anti-apoptotic	proteins(184,	185).	As	mentioned	in	section	1.1.3.,	the	inactivation	of	apoptosis	is	central	to	the	development	of	cancer	such	that	 it	 is	 considered	 to	 be	 one	 of	 the	 fundamental	 hallmarks	 of	 cancer(43,	 44).	 It	 is	perhaps	unsurprising	then,	 that	 traditional	 thinking	dictates	 that	anti-cancer	therapies	work	 by	 triggering	 cancer	 cells	 to	 undergo	 apoptosis,	 and	 that	 cells	 resistant	 to	apoptosis	will	be	resistant	to	therapy(186).		Cells	 undergoing	 apoptosis	 are	 conspicuous	 by	 the	 following	 morphological	 features:	the	 cell	 shrinks,	 its	 chromosomes	 condense,	 the	 nucleus	 fragments,	 the	 cellular	membranes	 bleb	 and	 form	 small	 apoptotic	 bodies,	 which	 are	 then	 removed	 by	phagocytes(185).	 It	 is	 the	 organised	 removal	 of	 cell	 debris	 and	 the	 prevention	 of	 an	unwanted	immune	response	that	distinguishes	apoptosis	from	necrotic	cell	death(187).	There	are	currently	three	recognised	pathways	that	result	in	the	initiation	of	apoptosis:	the	 extrinsic	 apoptotic	 pathway,	 the	 intrinsic	 apoptotic	 pathway,	 and	 the	 granzyme	B	pathway	 (detailed	 in	 figure	 1.2.5.1.).	 The	 extrinsic	 and	 granzyme	 B	 pathways	 are	initiated	by	extracellular	signals,	while	the	intrinsic	pathway	is	initiated	by	intracellular	signals.	Regardless,	all	 three	pathways	converge	at	the	mitochondrial	outer	membrane	(MOM),	 where	members	 of	 the	 Bcl-2	 protein	 family	 interact	 to	 control	 the	 release	 of	cytochrome	 C,	 which	 triggers	 the	 caspase	 cleavage	 cascade,	 in	 turn	 leading	 to	 the	destruction	of	structures	within	the	cell(185).			The	Bcl-2	family	of	proteins	is	divided	into	three	broad	subclasses	based	on	their	areas	of	 Bcl-2	 like	 homology	 (BH	 domains)	 and	 function(184,	 185).	 The	 anti-apoptotic	members	include	Bcl-2,	Bcl-w,	Bcl-xL	Mcl-1,	Bfl-1/A1,	and	Bcl-B,	and	contain	all	four	BH	domains(184,	 185).	 The	 pro-apoptotic	members	 comprise	multi-BH	 domain	members	(Bax,	Bak,	and	Bok),	which	contain	BH	domains	1-3,	and	a	separate	group	of	BH3-only	members,	including	Bid,	Bim,	Puma,	Hrk,	Noxa,	Bad,	Bmf,	and	Bik(184,	185).		Under	normal	conditions	at	 the	MOM,	 the	anti-apoptotic	Bcl-2	 family	members	 inhibit	apoptosis	 by	 preventing	 the	 oligomerisation	 of	 Bax	 and	 Bak(188).	 In	 response	 to	 a	death-inducing	signal,	however,	the	pro-apoptotic	proteins	Bax	and	Bak	can	be	activated	to	 oligomerise.	 As	 homodimers	 they	 can	 become	 inserted	 into	 the	 MOM	 and	 create	channels	that	allow	the	release	of	cytochrome	c,	and	other	pro-apoptotic	proteins,	from	the	 intermembrane	 space	 (IMS),	 so-called	 MOM	 permeabilisation	 (MOMP)(188).	 It	 is	thought	to	be	the	balance	of	Bcl-2	pro-	and	anti-apoptotic	family	members	on	the	MOM	that	 determines	 whether	 to	 prevent	 or	 to	 allow	 MOMP(188).	 Subsequently,	 released	
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cytochrome	c	interacts	with	apoptosis	protease	activating	factor-1	(Apaf-1),	which	then	recruits	 pro-caspase-9	 to	 form	 the	 apoptosome(184,	 185).	 Pro-caspase-9,	 an	 initiator	caspase,	 is	 then	 cleaved	 and	 auto-activated	 within	 the	 apoptosome,	 and	 can	 then	proceed	 to	 cleave	 and	 activate	 the	 executioner	 caspases-3	 and	 -7,	 which	 triggers	 the	caspase	 cascade,	 ultimately	 resulting	 in	 the	 demolition	 of	 the	 cell(184,	 185)	 (figure	1.2.5.1.).		The	 intrinsic	apoptotic	pathway	 is	 initiated	exclusively	by	signals	 from	within	 the	cell,	independent	of	any	extracellular	signalling,	and	such	signals	include	but	are	not	limited	to	 growth	 factor	 deprivation,	 DNA	 damage,	 cytokine	 deprivation,	 and	 hypoxia(184,	185).	Intrinsic	apoptosis	is	mediated	by	the	BH3-only	family	of	pro-apoptotic	proteins,	which	are	signalled	 to	undergo	post-translational	modifications	or	are	up-regulated	 in	response	 to	 pro-apoptotic	 stimuli(184,	 185).	 For	 instance,	 Noxa	 and	 Puma	 are	 up-regulated	by	 increased	 transcription,	Bid	 is	 cleaved	 into	 its	 active	 form,	 tBid,	 and	Bad	requires	 activation	 by	 de-phosphorylation(189).	 Following	 this,	 these	 BH3-only	proteins	can	promote	Bax	and	Bak	activation	and	apoptosis	then	proceeds	as	described	above	(figure	1.2.5.1.).		The	 extrinsic	 apoptotic	 pathway	 is	 initiated	 by	 transmembrane	 receptor	 and	 ligand	interactions	 involving	death	 receptors	of	 the	 tumour	necrosis	 factor	 receptor	 (TNF-R)	family	and	Fas	receptor	(FasR)(184,	185).	Both	TNF-R	and	FasR	are	characterised	by	the	presence	of	a	common	cytoplasmic	region	termed	the	death	domain,	an	80–100	amino	acid	motif	 involved	 in	 the	 transduction	 of	 the	 apoptotic	 signal(190).	 Upon	TNF-R	 and	FasR	binding	with	 their	 ligands,	TNF-α	and	FasL	 respectively,	 the	death	domain	binds	and	activates	an	associated	protein,	FADD	(Fas-associated	death	domain	protein)(190).	The	 resulting	 complex,	 the	 death-inducing-signalling-complex	 (DISC),	 then	 activates	pro-caspases-8	 and	 -10,	 which	 then	 go	 on	 to	 activate	 the	 executioner	 caspases	independently	 of	 the	 intrinsic	 mitochondrial	 pathway,	 and	 the	 caspase	 cascade	 that	leads	 to	 apoptosis	 ensues	 (figure	 1.2.5.1.)(184).	 Caspase-8	 also	 cleaves	 the	 BH3-only	domain	protein	Bid	into	its	active	form,	tBid,	which	then	translocates	to	and	inserts	into	the	MOM,	resulting	 in	activation	of	Bax	and	Bak	and	 leading	 to	apoptosis	as	described	previously	(figure	1.2.5.1.)(184).		
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Figure	 1.2.5.1:	 Apoptotic	 pathways.	 The	 caspase	 cascade	 and	 apoptosis	 can	 be	 triggered	 in	three,	not	necessarily	exclusive,	ways:	1)	The	intrinsic	pathway;	2)	the	extrinsic	pathway;	and	3)	the	 granzyme	 B	 pathway.	 Importantly,	 the	 intrinsic	 pathway	 is	 dependent	 on	 Bax/Bak	oligomerisation	 and	 the	 resultant	 mitochondrial	 outer	 membrane	 permeabilisation,	 release	 of	cytochrome	 c,	 and	 formation	 of	 the	 apoptosome	 to	 trigger	 the	 caspase	 cascade,	 whereas	 the	extrinsic	and	granzyme	B	pathways	can	also	activate	the	executioner	caspases	independently	of	the	mitochondria.		Figure	reproduced	from	reference	(184).		The	 third	 apoptotic	 pathway	 is	 the	 granzyme	 B	 pathway,	 through	which	 cytotoxic	 T-lymphocytes	are	able	to	eliminate	transformed	tumour	cells	or	virally	 infected	cells	by	delivering	 granules	 containing	 a	 pore	 forming	 protein	 called	 perforin	 and	 serine	proteases	called	granzymes(184).	Perforin	can	 form	pores	 in	 the	plasma	membrane	of	the	target	cells,	permitting	entry	of	granzyme	B,	which	can	cleave	and	activate	caspase-3	and	the	BH3-only	protein	Bid,	both	leading	to	apoptosis	as	detailed	above(184).			
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appear in numbers that overwhelm the ability of phago-
cytes to dispose of them quickly14,19. Thus, what happens 
to a cell as it undergoes apoptosis may be as much geared 
towards preventing inappropriate immune activation as 
it is towards terminating the life of the cell.
Caspases: agents of demolition
Caspases are normally present in healthy cells as inactive 
precursor enzymes (zymogens) with little or no protease 
activity3,4,20,21 (BOX 2). However, all stimuli that trigger 
apoptosis seem to do so by initiating events that culmi-
nate in caspase activation, albeit in somewhat different 
ways. To date, three main routes to apoptosis-associated 
caspase activation have been firmly established in mam-
mals4,22 (FIG. 2), and one or two other possible routes have 
been proposed but remain controversial. Irrespective 
of the actual route to caspase activation, all pathways 
lead to the activation of the major effector caspases, 
caspase-3, caspase-6 and caspase-7, and these enzymes 
carry out much of the proteolysis that is seen during the 
demolition phase of apoptosis.
Weakening key structures
Just as it is important to weaken the major structural 
components of a building, such as load-bearing walls, 
when carrying out its controlled demolition — a task 
often achieved through the strategic positioning of small 
explosive charges at key points along these structures 
— a similar strategy seems to be in operation during 
apoptosis. Here, the caspases take the place of explosives 
and their actions undermine the fabric of several key 
cellular structures (FIG. 3).
Components of the cytoskeleton. On activation, caspases 
cleave many of the major constituents of the cell cyto-
skeleton. These substrates include components of actin 
microfilaments, such as actin itself, and actin-associated 
proteins, including myosin, spectrins, ?-actinin, gelsolin 
and filamin23–28. Several microtubular proteins are also 
substrates for caspases, including tubulins and micro-
tubule-associated proteins such as tau, cytoplasmic 
dynein intermediate chain and p150Glued (REFS 29–31). In 
addition, intermediate filament proteins such as vimentin, 
keratins and nuclear lamins are also targeted32–34. Proteolysis 
of these cytoskeleton constituents probably contributes to 
the rounding and retraction of the cell that is seen in the 
early stages of apoptosis (FIG. 1a).
Another consequence of weakening of the cyto-
skeleton is likely to be dynamic membrane blebbing (a 
distinctive feature of apoptosis) as the cell cytoplasm 
flows against unsupported areas of the plasma membrane. 
Ind ed, dissolution of the actin network typically abro-
gates this feature of apoptosis, so it seems that membrane 
blebbing requires at least some intact actin filaments35. 
Pharmacological inhibitors of caspases efficiently block 
apoptosis-associated plasma-membrane blebbing.
A caspase substrate that is strongly implicated in 
this phase of apoptosis is the Rho effector ROCK1, a 
regulator of actin cytoskeleton dynamics. Removal of 
the C-terminus of ROCK1 through caspase-mediated 
proteolysis results in constitutive activation of this kinase, 
Figure 2 | Caspase activation pathways. Caspase activation by the extrinsic pathway 
(route 1) involves the binding of extracellular death ligands (such as FasL or tumour 
necrosis factor-? (TNF?)) to transmembr ne death re eptors. Engagement of death 
receptors with their cognate ligands provokes the recruitment of adaptor proteins, such 
as the Fas-associated death domain protein (FADD),  which in turn recruit and aggregate 
several molecules of caspase-8, thereby promoting its autoprocessing and activation. 
Active caspase-8 then proteolytically processes and activates caspase-3 and -7, 
provoking further caspase activation events that culminate in substrate proteolysis and 
cell death. In some situations, extrinsic death signals can crosstalk with the intrinsic 
pathway through caspase-8-mediated proteolysis of the BH3-only protein BID (BH3-
inte acting domain death agonist). Truncated BID (tBID) can promote mitochondrial 
cytochrome c release and assembly of the apoptosome (comprising ~7 molecules of 
apoptotic protease-activating factor-1 (APAF1) and the same number of caspase-9 
homodimers). In the intrinsic pathway (route 2), diverse stimuli that provoke cell stress or 
damage typically activate one or more members of the BH3-only protein family. BH3-only 
proteins act as pat ay-specific sensors for various stimuli and are eg lated in distin t 
ways (BOX 1). BH3-only protein activation above a crucial threshold overcomes the 
inhibitory effect of the anti-apoptotic B-cell lymphoma-2 (BCL-2) family members and 
promotes the assembly of BAK–BAX oligomers within mitochondrial outer membranes. 
These oligomers permit the efflux of intermembrane space proteins, such as 
cytochrome c, into the cytosol. On release from mitochondria, cytochrome c can seed 
apoptosome assembly. Active caspase-9 then propagates a proteolytic cascade of 
further caspase activation events. The granzyme B-dependent route to caspase 
activation (route 3) involves the delivery of this protease into the target cell through 
specialized granules that are release  from cytot xic T lymphocytes (CTL) or natural 
killer (NK) cells. CTL and NK granules contain numerous granzymes as well as a pore-
forming protein, perforin, which oligomerizes in the membranes of target cells to permit 
entry of the granzymes. Granzyme B, similar to the caspases, also cleaves its substrates 
after Asp residues and can process BID as well as caspase-3 and -7 to initiate apoptosis. 
BAD, BCL-2 antagonist of cell death; BAK, BCL-2-antagonist/killer-1; BAX, BCL-2-
associated X protein; BID, BH3-interacting domain death agonist; BIK, BCL-2-interacting 
killer; BIM, BCL-2-like-11; BMF, BCL-2 modifying factor; HRK, harakiri (also known as 
death protein-5); PUMA, BCL-2 binding component-3.
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In	 addition	 to	 the	 three	 described	 apoptotic	 pathways,	 reactive	 oxygen	 species	 (ROS)	can	also	be	involved	in	the	initiation	of	apoptosis(191).	Mitochondrial	integrity	may	be	influenced	by	the	redox	status	of	the	cell,	with	excessively	high	levels	of	ROS	resulting	in	significant	 damage	 to	 mitochondria(191).	 This	 can	 cause	 leakage	 of	 calcium	 and	mitochondrial	proteins,	including	cytochrome	c,	into	the	cytoplasm,	in	turn	resulting	in	activation	 of	 the	 caspase	 cascade(191).	 Furthermore,	 the	 pro-apoptotic	 activity	 of	cytochrome	 c	 itself	 can	 be	 influenced	 by	 its	 redox	 state.	 Under	 normal	 conditions	cytochrome	 c	 has	 been	 shown	 to	 be	 reduced	 and	 held	 inactive	 by	 intracellular	antioxidant	 systems,	 whereas	 under	 conditions	 of	 oxidative	 stress	 it	 is	 oxidised	 and	becomes	active	in	driving	cytochrome	c-mediated	apoptosis(192).		p53	plays	a	central	role	in	mediating	the	induction	of	apoptosis,	which	it	can	influence	through	numerous	mechanisms.	 Importantly,	 however,	 these	 are	highly	dependent	 on	the	nature	of	pro-apoptotic	stimulus	and	the	tissue	type	involved	(reviewed	in(193)).	As	described	 previously,	 p53	 functions	 predominantly	 as	 a	 transcription	 factor	 and	 can	promote	 the	 transcription	 of	 the	 pro-apoptotic	 protein	 Bax(194),	 as	well	 as	 the	 BH3-only	 pro-apoptotic	 family	 members	 Noxa(195)	 and	 Puma(196),	 all	 of	 which	 are	 key	players	in	promoting	initiation	of	apoptosis	at	the	mitochondria.	Furthermore,	another	transcriptional	 target	 of	 p53,	 p53-regulated	 apoptosis-inducing	 protein-1,	 which	 is	 a	non-Bcl-2	family	member,	can	localise	to	the	mitochondria	and	through	binding	to	Bcl-2	stimulate	MOMP(197).	p53	can	also	promote	the	up-regulation	of	proteins	 involved	 in	the	 extrinsic	 apoptotic	 pathway	 as	 follows:	 the	 cell	 surface	 death	 receptor	 FasR(198)	and	its	ligand	FasL(199);	DR5/KILLER	(a	TNF-R	family	death	receptor)(200);	and	p53-induced	protein	with	a	death	domain	(PIDD),	which	is	a	cytoplasmic	protein	that	upon	binding	 an	 adaptor	 protein	 RAIDD	 activates	 caspase-2,	 triggering	 the	 caspase	cascade(201).	p53	has	also	been	reported	to	transcriptionally	activate	the	expression	of	Apaf-1(202)	and	caspase-6(203),	further	contributing	to	the	stimulation	of	the	caspase	cascade.		A	collection	of	genes	termed	p53-induced	genes	(PIGs)	have	also	been	identified,	which	encode	proteins	with	activities	related	to	the	increase	of	cellular	ROS	levels,	and	as	such	are	 implicated	 in	 ROS-mediated	 apoptosis(191).	 p53	 promotes	 the	 induction	 of	 such	pro-oxidant	genes	when	at	hyper-physiological	levels,	which	is	in	contrast	to	its	role	in	under	 basal	 conditions(204).	 At	 basal	 levels,	 p53	 induces	 the	 expression	 of	 several	genes	 encoding	 proteins	 with	 anti-oxidant	 activities,	 including	 mammalian	 sestrin	homologues	1	and	2	 (SESN1	and	SESN2),	 glutathione	peroxidase	1	 (GPX1),	 and	TP53-
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inducible	 glycolysis	 and	 apoptosis	 regulator	 (TIGAR),	 which	 act	 to	maintain	 ROS	 at	 a	non-toxic	 levels(204,	 205).	 This	 dual	 action	 of	 p53	 in	 relation	 to	 ROS	 ensures	 that	 in	unstressed	 cells	 the	 levels	of	ROS	are	 controlled,	preventing	DNA	damage	and	genetic	instability,	while	in	the	context	of	cellular	stress	ROS	up-regulation	results	in	induction	of	apoptosis(204).		In	 addition	 to	 transcriptional	 activation,	 p53	 can	 also	 repress	 the	 transcription	 of	 the	anti-apoptotic	protein	Bcl-2	through	a	transcription	repressing	p53	RE	in	the	promoter	of	the	BCL-2	gene(206).	A	role	for	the	direct,	transcription-independent	involvement	of	p53	 in	 eliciting	 an	 apoptotic	 response	 has	 also	 been	 described.	 It	 is	 thought	 that	cytosolic	 p53	 can	 translocate	 to	 the	 mitochondria	 where	 it	 can	 directly	 activate	Bax(207),	 or	 form	 an	 inhibitory	 complex	 with	 the	 anti-apoptotic	 proteins	 Bcl-XL	 and	Bcl-2(208).		The	 undoubted	 role	 of	 p53	 as	 a	 critical	 mediator	 of	 apoptosis,	 together	 with	 the	importance	 of	 apoptosis	 in	 determining	 responses	 to	 anti-cancer	 therapies,	 has	 led	 to	the	 assumption	 that	 cells	 deficient	 in	 wild-type	 p53	 (through	 mutation	 for	 example)	would	 be	 resistant	 to	 apoptosis,	 and	 by	 extension	 such	 anti-cancer	 therapies(186).	However,	 a	 number	 of	 studies	 have	 revealed	 that	 apoptosis	 can	 also	 be	 induced	independently	 of	 p53,	 and	 the	 study	 of	 many	 cancer	 cell	 lines	 has	 shown	 that	 p53-mutated	cells	do	not	 lose	their	ability	to	undergo	apoptosis(209).	For	instance,	several	relatively	 recent	 studies	 have	 shown	 that	 the	 induction	 of	 the	 pro-apoptotic	 proteins	Puma,	Noxa,	 Fas,	 and	DR5	 can	be	orchestrated	 in	p53-independent	manner(210-213).	The	 check-point	 kinases	 Chk1	 and	 Chk2,	 along	 with	 E2F	 and	 p73,	 have	 also	 been	reported	 to	 function	 in	 a	 pathway	 controlling	 p53-independent	 apoptosis	 induced	 by	cytotoxic	 drugs(214),	 and	 p53-independent	 apoptosis,	 involving	 p73	 and	 caspase-2	signalling,	 has	 been	 observed	 in	 melanoma	 cells	 following	 treatment	 with	 a	 DNA	topoisomerase	 I	 inhibitor(215).	 A	 further	 mechanism	 implicated	 in	 p53-independent	apoptosis	 involves	 nuclear	 factor-κB	 (NF-κB),	which	 although	 typically	 anti-apoptotic,	can	display	pro-apoptotic	activity	in	certain	contexts(209).	To	this	end,	ROS	have	been	shown	to	induce	apoptosis	through	NF-κB-mediated	transcription	of	FasL(216).	Finally,	another	 factor	 implicated	 in	 p53-independent	 apoptosis	 involves	 degradation	 of	 the	anti-apoptotic	 protein	Bcl-2,	 although	 the	mechanistic	 basis	 of	 this	 still	 remains	 to	 be	clarified(209).		
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1.2.6.	Senescence	Cellular	 senescence	 is	 another	 fail-safe	 mechanism	 involved	 in	 preventing	 the	development	 of	 cancer,	 and	 is	 becoming	 increasingly	 recognised	 as	 an	 important	alternative	 means	 by	 which	 anti-cancer	 treatments	 act	 in	 some	 cell	 types(217,	 218),	SCCHN	cells	 included(57).	Cellular	senescence	is	a	type	of	 irreversible	cell	cycle	arrest,	where	the	cell	remains	metabolically	active	but	can	no	longer	divide	and	proliferate,	and	which	 is	characterised	by	a	number	of	specific	phenotypic	changes	that	differentiate	 it	from	quiescence	 (reversible	 cell	 cycle	 arrest)(218).	 Such	 features	 include	 an	 enlarged	and	 flattened	 morphology,	 condensed	 chromatin,	 and	 senescence-associated	β-galactosidase	(SA-βgal)	activity	(described	in	more	detail	in	section	2.7.1.)(218,	219). Senescence	 was	 first	 formally	 identified	 in	 normal	 cells	 as	 a	 physiological	 process	related	 to	 ageing	 and	 replicative	 stress(220).	 Most	 somatic	 cells	 have	 a	 limited	replicative	 lifespan	 related	 to	 telomere	 (the	 repetitive	 DNA	 sequence	 at	 the	 ends	 of	chromosomes)	shortening.	Every	cell	cycle	is	accompanied	by	a	shortening	of	telomeres,	and	 in	 cells	 that	 lack	 endogenous	 telomerase	 (an	 enzyme	 which	 can	 extend	 the	telomeres)	 it	 is	 this	 telomere	 erosion	 that	 results	 in	 so-called	 replicative	senescence(218).	 Cell	 ageing	 is	 associated	 with	 the	 accumulation	 of	 mutations	 that	could	result	 in	genetic	instability	and	eventually	lead	to	malignant	transformation,	and	consequently	 senescence	 is	 now	 recognised	 to	 be	 an	 important	 tumour	 suppressive	response(218).	 In	 keeping	 with	 this,	 a	 senescent	 state	 can	 also	 be	 induced	 by	 other	distinct	stress	signals	such	as	oncogene	activation,	excessive	DNA	damage,	and	oxidative	stress(218).		It	comes	as	no	surprise,	therefore,	that	p53	plays	an	important	role	as	an	effector	in	the	induction	of	 cellular	 senescence(221).	 p53	 is	 activated	 in	 response	 to	 the	 senescence-inducing	signals	of	telomere	erosion,	DNA	damage,	and	oncogenic	signalling	(discussed	previously	in	section	1.2.3.),	and	subsequently	promotes	the	transcription	of	p21,	which	can	 inhibit	 cell	 cycle	 regulators	 to	 induce	 senescence(221).	 Although	 stimuli	 that	generate	 a	 DNA	 damage	 response	 induce	 senescence	 primarily	 through	 this	 p53-dependent	pathway,	senescence	can	also	be	induced	through	the	p16–Rb	pathway(218).	Senescence	signals	 can	 induce	 the	expression	of	p16,	which,	by	binding	and	 inhibiting	the	CDKs,	prevents	Rb	phosphorylation	and	cell	cycle	progression	(discussed	previously	in	 section	 1.1.3.)(218).	 Whilst	 there	 is	 cross-talk	 between	 the	 p53	 and	 p16–Rb	pathways,	 these	pathways	can	both	 independently	halt	 cell	 cycle	progression	and	give	
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rise	 to	 a	 senescent	 phenotype(218).	 Moreover,	 other	 examples	 of	 senescence	 that	appear	to	be	independent	of	these	pathways	have	also	been	reported(222,	223).		As	 with	 apoptosis,	 cellular	 redox	 status	 appears	 to	 play	 an	 important	 role	 in	 cellular	senescence(224).	High	levels	of	ROS	appear	to	be	involved,	not	only	as	inducers	of	DNA	damage	and	thus	senescence,	but	also	in	maintaining	a	senescent	phenotype.	Persistent	activation	of	p21	has	been	shown	to	 induce	mitochondrial	dysfunction	and	production	of	 ROS,	 which	 in	 turn	 propagates	 the	 DNA	 damage	 response,	 thereby	 setting	 up	 a	positive	 feed-back	 loop	 that	 is	 necessary	 for	 establishing	 a	 stable	 senescent	phenotype(225,	 226).	 Similarly,	 activation	 of	 the	 other	 major	 senescence-inducing	pathway,	 the	 p16-Rb	 pathway,	 has	 been	 shown	 to	 induce	 elevated	 intracellular	 ROS	levels,	which	 activate	 protein	 kinase	 Cδ,	 in	 turn	 promoting	 further	 generation	 of	 ROS	and	thus	establishing	a	positive	feed-back	loop(227).	The	resulting	sustained	activation	of	ROS-protein	kinase	Cδ	signalling	was	reported	 to	 irreversibly	block	cytokinesis	and	lock	the	cell	into	an	actively	maintained	state	of	“deep”	cellular	senescence(227).		
1.2.7.	TP53	mutation	in	cancer	As	discussed	 in	 section	1.1.3.,	 the	most	 common	molecular	 alteration	 found	 in	human	cancers,	 SCCHN	 included,	 is	 inactivation	 of	 the	 p53	 tumour	 suppressor	 pathway.	Typically,	 this	 is	 achieved	 through	mutation	of	 the	TP53	 gene	 itself,	which	 is	 found	 in	~50%	of	all	human	cancers(133)	and	in	60-85%	of	SCCHNs(51-53),	but	may	also	result	from	 defects	 preventing	 p53	 activation,	 altered	 subcellular	 localisation	 of	 the	 p53	protein,	defects	in	the	signalling	pathways	downstream	of	p53(174),	and,	in	the	case	of	HPV-related	SCCHN,	viral	oncoprotein-induced	inactivation	of	p53	(see	section	1.1.3.).			It	is	interesting	to	note	the	mutational	spectra	of	TP53,	which	differs	markedly	from	that	of	other	tumour	suppressor	genes.	For	most	 tumour	suppressor	genes,	such	as	APC	or	
RB,	nonsense	point	mutations	and	frameshift	mutations,	which	result	in	the	production	of	a	truncated	protein	or	no	protein	expression	at	all,	predominate(228).	In	contrast,	the	vast	 majority	 of	 TP53	 mutations	 (≈75%)	 are	 missense	 mutations,	 resulting	 in	 the	production	 of	 a	 full-length	 protein	 with	 single	 amino	 acid	 substitutions(54).	 This	suggests	 that	 there	 is	 a	 selective	 advantage	 of	 the	 mutant	 p53	 protein	 over	 the	truncation,	 which	 can	 be	 explained	 by	 considering	 Knudson’s	 two-hit	 hypothesis	together	with	 the	 fact	 that	p53	 functions	 as	 a	 tetramer	 (see	 section	1.2.1.).	Knudson’s	two-hit	 hypothesis	 dictates	 that	 most	 tumour	 suppressor	 genes	 are	 recessive,	 with	inactivation	of	both	alleles,	so-called	loss	of	heterozygosity	(LOH),	therefore	required	for	
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loss	 of	 tumour	 suppressor	 function	 and	 initiation	 of	 cancer	 development(229).	Accordingly,	 whilst	 the	 presence	 of	 a	 nonsense	 mutation	 in	 one	 TP53	 allele	 would	potentially	 result	 in	 no	 protein	 expression	 or	 expression	 of	 a	 truncated	 protein,	 the	remaining	 wild-type	 protein	 expressed	 from	 the	 second	 allele	 would	 retain	 p53	transcriptional	 activity	 and	 suppress	 tumour	 formation.	 In	 the	 context	 of	 missense	mutation,	 however,	 hetero-oligomerisation	 can	 occur	 between	 such	 mutants	 and	 the	remaining	wild-type	p53,	which	prevents	p53	from	functioning	as	a	tetramer	and	thus	neutralises	the	wild-type	protein(230,	231).	This	phenomenon	is	known	as	a	dominant-negative	effect	and	 less	competent	sequence-specific	DNA	binding	of	 the	mutant/wild-type	 p53	 hetero-oligomer	 has	 been	 implicated	 as	 the	 underlying	 mechanism(231).	Furthermore,	It	has	also	been	suggested	that	in	these	complexes	mutant	p53	is	capable	of	 shifting	 the	 wild-type	 p53	 into	 a	 mutant	 conformation(232).	 In	 support	 of	 this	concept	of	negative	dominance,	mice	that	are	heterozygous	for	a	dominant-negative	p53	mutant	 still	 have	 a	 tendency	 to	 develop	 tumours(230).	 Interestingly,	 however,	 LOH	 is	still	 frequently	 observed	 in	 cancers	 harbouring	 TP53	 mutations,	 suggesting	 that	 the	dominant-negative	 effects	 of	 the	 mutants	 may	 not	 lead	 to	 complete	 loss	 of	 p53	function(233).			The	 overwhelming	 majority	 of	 tumour-derived	 TP53	 mutations	 affect	 the	 conserved	regions	within	 the	 central	 DNA-binding	 domain	 of	 the	 protein,	most	 of	which	 exert	 a	dominant-negative	effect	resulting	in	loss	of	wild-type	p53	transcriptional	activity(135,	144,	 234).	 Furthermore,	 although	 the	 spectrum	 of	 missense	 mutations	 within	 DNA-binding	domain	is	wide,	certain	codons	have	a	particularly	high	frequency	of	mutation,	with	more	 than	40%	of	 all	mutations	 found	 at	 only	 six	 p53	 residues	 –	 175,	 245,	 248,	249,	273	and	282	–	the	so-called	mutational	hotspots(54,	135)	(figure	1.2.7.1.).										
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Figure	 1.2.7.1:	Mutational	 hotspots	 in	 the	 p53	 protein.	The	majority	of	 p53	mutations	 are	found	in	the	DNA-binding	domain	of	the	protein	(p53C)	with	six	mutational	hot-spots	at	residues	175,	245,	248,	249,	273	and	282.	These	are	depicted	on	a	schematic	of	the	domain	structure	of	the	full-length	p53	protein	in	A,	and	on	a	ribbon	diagram	of	DNA	bound	core	p53	domain.	In	B,	the	two	strands	of	bound	consensus	DNA	are	shown	in	blue	and	magenta,	and	the	bound	zinc	ion	is	shown	as	a	golden	sphere.	Figures	adapted	from	reference	(135).		It	 is	 now	widely	 recognised	 that	 different	 p53	mutants,	 even	within	 the	DNA-binding	domain,	 confer	 varying	 oncogenic	 potency(235),	which	 has	 led	 to	 the	 classification	 of	p53	mutants.	On	the	basis	of	the	crystal	structure	of	the	core	domain	of	p53,	mutations	can	 be	 divided	 into	 two	 main	 classes	 –	 contact	 and	 structural	 mutations(144).	 The	contact	 mutations	 affect	 residues	 that	 make	 direct	 contact	 with	 DNA,	 the	 two	 most	common	 of	which	 are	 found	 at	 residues	 R248	 and	R273,	with	 frequencies	 of	 8%	 and	7.5%	 respectively(54).	 In	 contrast,	 the	 structural	mutations	 disrupt	 the	 folding	 of	 the	p53	 protein	 and	most	 commonly	 occur	 at	 residues	 R175	 (5.5%),	 G245	 (3.5%),	 R249	(3%)	and	R282	(3%)(54).	It	has	been	suggested	that	structural	mutations	confer	greater	
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Domain structure of full-length p53 consisting of an N-terminal transactivation domain (TAD), followed
by a proline-rich region (PRR), the central DNA-binding domain (p53C), the tetramerization domain
(TET), and the extreme C terminus (CT). p53C, the domain where most cancer-associated p53
mutations are located, is highlighted with a rainbow color gradient from blue at its N terminus to red at
its C terminus. The bars above the diagram indicate the relative frequency of oncogenic missense
mutations at each residue according to version R11 (October 2006, N = 17,015) of the International
Agency for Research on Cancer TP53 mutation database (http://www-p53.iarc.fr).
proteins, regions of nascent helical structure
that are present in the native state rigidify
and become fully folded. A fragment com-
prising residues 15–29, for example, adopts
an α-helical conformation upon binding to a
hydrophobic cleft in the N-terminal domain
of MDM2 and MDM4 (20, 27). A similar in-
duction of helical structure in the MDM2-
binding region is observed when embedded in
a membrane-like environment (28). Regions
within TAD2 fold into amphipathic α-helices
upon binding to replication protein A (29) and
to the Tfb1 subunit of yeast TFIIH (17). The
MDM2-binding region of the p53TADover-
laps with parts of the binding site for the tran-
scriptional coactivator p300,which is essential
for the transcriptional function of p53. p300
is thought to relax the chromatin structure
t rough its histone acetyltra sferase activity
but can also acetylate nonhistone targets, such
as specific lysine residues in theC-terminal re-
gion of p53 (reviewed in Reference 30). A p53
TAD construct spanning both transactiva-
tion subdomains (residues 1–57) binds tightly
to four different folded domains of p300
in vitro [Taz1/cysteine-histidine-rich region
1 (CH1), Kix, Taz2/CH3, IBiD] (19). The
greatest affinity is observed for the Taz2/CH3
domain (KD = 27 nM), which is about six
times higher than that of the N-terminal
domai of MDM2 for the same p53 do-
main construct. TAD mutations that are as-
sociatedwith transactivation-deficient pheno-
types (L22Q/W23S, W53Q/F54S) strongly
weaken binding of p53 to each of the four
p300 domains, thus linking the phenotypic
response to impaired protein-protein interac-
tions (19, 31). Since p300 and MDM2 com-
pete for the same binding site, binding to p300
would protect p53 from MDM2-mediated
proteasomal degradation. Conversely, bind-
ing of the negative regulators MDM2 and
MDM4 occludes TAD and prevents the coac-
tivator p300 or components of the transcrip-
tion machinery from binding. The signal re-
ceived will thus depend on the concentrations
and dissociation constants of the proteins
competing for the p53 N terminus. It is fur-
thermodulated by posttranslationalmodifica-
tions. The p53 activation process in respo se
to stress signals is very complex and involves
multiple phosphorylation of N-terminal ser-
ine and threonine residues by several differ-
ent protein kinases (reviewed in References 6
and 32). These modifications shift the relative
affinity for the different proteins that compete
for p53 binding. As an example, p53-MDM2
binding is impaired upon phosphorylation of
Thr-18 (21, 33, 34), nd there is evidence sug-
gesting that N-terminal phosphorylation at
this and other sites strengthens binding of the
coactivators p300/CBP (35, 36).
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oncogenic	potency	than	contact	mutants(235),	which	is	thought	to	relate	to	the	degree	of	 the	 dominant-negative	 effect.	 Structural	mutants	 can	 shift	 the	 remaining	wild-type	p53	into	a	mutant	conformation	upon	hetero-oligomerisation,	resulting	in	complete	loss	of	 p53	 function,	 whereas	 contact	 mutants	 are	 more	 likely	 to	 retain	 a	 native	conformation	 and	 when	 incorporated	 into	 tetramers	 with	 wild-type	 p53	 would	therefore	retain	some	residual	wild-type	activity(236).	Consistent	with	this,	100%	LOH	has	been	observed	with	expression	of	contact	p53	mutants	in	SCCHN,	while	expression	of	 structural	mutants	 has	 been	 associated	with	 LOH	 in	 only	 50%	of	 cases,	 implying	 a	stronger	 dominant-negative	 effect	 on	 wild-type	 p53,	 and	 by	 association	 a	 lesser	selective	 pressure	 for	 losing	 the	wild-type	 allele(237).	 Interestingly,	 however,	 contact	mutations	 were	 associated	 with	 higher	 tumour	 stages,	 higher	 propensity	 for	 lymph	node	 metastasis,	 and	 shorter	 recurrence-free	 and	 overall	 survival	 than	 structural	mutations	 in	 this	 study,	 suggesting	 that	 dominant-negative	 inhibition	 of	 the	wild-type	allele	is	not	complete	and	LOH	remains	an	important	event	during	tumorigenesis(237).		An	 alternative	 classification	 of	 p53	 mutants	 that	 has	 been	 applied	 to	 SCCHN	 is	 the	designation	 of	 mutants	 as	 either	 disruptive	 or	 non-disruptive.	 This	 classification	specifically	 defines	 disruptive	 mutations	 as	 either	 nonsense	 mutations	 or	 missense	mutations	 in	 the	 L2–L3	DNA-binding	 domain	 of	 p53	 leading	 to	 an	 amino	 acid	 change	that	 results	 in	 a	 residue	with	 a	 different	 polarity	 or	 charge,	 with	 all	 other	mutations	classified	 as	 non-disruptive(56).	 On	 the	 basis	 of	 this	 classification,	mice	 injected	with	SCCHN	cells	harbouring	disruptive	TP53	mutations	have	been	reported	to	exhibit	faster	tumour	 growth,	 greater	 incidence	 of	 cervical	 lymph	 node	 metastasis,	 and	 shorter	survival	 than	 mice	 injected	 with	 cells	 harbouring	 either	 wild-type	 TP53	 or	 non-disruptive	TP53	mutations(238).	Consistent	with	this,	a	study	of	TP53	mutation	status	in	420	 patients	 with	 surgically	 treated	 SCCHN	 demonstrated	 that	 TP53	 mutations	 were	associated	 with	 decreased	 survival	 relative	 to	 patients	 with	 wild-type	TP53	 tumours,	and	 that	 disruptive	 TP53	 mutations	 were	 associated	 with	 the	 shortest	 survival(56).	Furthermore,	 in	 a	 subsequent	 study	 of	 74	 SCCHN	 patients	 treated	 with	 surgery	 and	post-operative	 RT	 although	 TP53	 mutation	 alone	 was	 not	 a	 clinical	 prognosticator,	disruptive	TP53	mutation	was	 a	 strong	 negative	 predictor	 of	 locoregional	 recurrence,	which	was	shown	to	relate	 to	 increased	radioresistance	mediated	via	 the	 inhibition	of	senescence(57).				More	 recently,	 a	 computational	 strategy	 for	 mutant	 p53	 classification	 based	 on	phylogenetic	 divergence	 and	 predicted	 functional	 impact	 has	 been	 proposed.	 This	 so-
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called	 evolutionary	 action	 score	 or	 EAp53	 classifies	mutations	 as	 either	 high-	 or	 low-risk,	 with	 sequence	 variations	 giving	 rise	 to	 larger	 phylogenetic	 divergences	 ascribed	higher	 scores	 than	 those	 resulting	 in	 conservative	 amino	 acid	 changes(58).	Interestingly,	high-risk	TP53	mutations,	as	determined	using	this	classification	system,	have	been	associated	with	more	invasive	and	tumorigenic	characteristics	than	low-risk	mutations	in	both	in	vitro	and	in	vivo	SCCHN	models(58),	with	poorer	survival	outcomes	and	a	higher	rates	of	distant	metastases	 in	SCCHN	patients(58),	and	with	resistance	to	cisplatin-based	chemotherapy(239).		A	further	important	concept	to	consider	when	it	comes	to	varying	oncogenic	potency	of	
TP53	 mutants	 is	 that	 of	 oncogenic	 GOF.	 Dominant-negative	 effects	 on	 the	 wild-type	protein	notwithstanding,	some	p53	mutants	have	been	suggested	to	acquire	additional	oncogenic	properties	contributing	to	accelerated	cell	growth	and	tumorigenic	potential	–	so	called	oncogenic	GOF(55).	This	concept	that	mutant	p53	may	be	more	than	simply	an	 inactivated	 tumour	suppressor	came	 from	a	study	showing	 that	point	mutations	 in	wild-type	 TP53	 activate	 it	 for	 cellular	 transformation	 in	 cooperation	 with	 the	 RAS	oncogene(240),	 and	 the	 term	GOF	was	 first	 proposed	 in	 1990	when	 different	mutant	forms	of	p53	were	reported	to	gain	transforming	potential(241).	More	recently,	further	studies	 have	 provided	 more	 convincing	 evidence	 of	 mutant	 p53	 GOF	 properties.	 In	particular,	 studies	 of	 two	mouse	models	 of	 Li-Fraumeni	 syndrome,	 which	 focused	 on	R175H	and	R273H	p53	mutants,	 demonstrated	 that	 although	 the	 two	TP53	mutations	did	not	distinguish	on	overall	survival,	mice	heterozygous	for	the	mutant	p53	(p53M/+)	developed	 different	 tumour	 spectra	 than	mice	 hemizygous	 for	wild-type	 p53	 (p53+/-)(242,	 243).	 Furthermore,	 mice	 hemizygous	 for	 the	 mutant	 TP53	 allele	 (p53M/-)	developed	novel	tumours	compared	to	p53-null	(p53-/-)	mice	suggesting	that	these	two	p53	mutants	 play	 a	 role	 in	 stimulating	 tumorigenesis(242,	 243).	 Additionally,	 each	 of	the	 p53	 mutants	 demonstrated	 distinct	 tumour	 spectra,	 importantly	 indicating	 that	different	mutants	exhibit	distinct	profiles	with	respect	to	GOF	activity(243).	In	support	of	 this,	 the	p53	mutant	R248Q	has	a	consistently	strong	GOF	phenotype	 in	contrast	 to	the	G245S	mutant	in	mutant	TP53–knock-in	mice(244).		Despite	the	evidence	suggestive	of	GOF	properties,	the	mechanistic	basis	remains	poorly	understood.	 To	 date,	 three	 main	 mechanisms	 of	 action	 have	 been	 proposed	 to	understand	 the	 possible	 role	 of	 mutant	 p53	 GOF	 in	 regulation	 of	 novel	 gene	transcription:	firstly,	direct	DNA	binding	of	mutant	p53	to	novel	target	gene	promoters	in	 a	 DNA	 structure-specific	 manner	 to	 activate	 them(55);	 secondly,	 binding	 and	 co-
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operation	of	mutant	p53	with	other	transcription	factors	such	as	p63,	p73,	NF-κB,	NF-Y,	E2F1,	VDR,	SP1,	SREBP,	and	ETS	to	enhance	or	repress	target	gene	expression(55);	and	lastly,	through	epigenetic	regulation	of	chromatin	remodelling(245).				
1.3.	Metabolism	in	cancer		The	concept	that	metabolism	in	tumour	cells	is	altered	from	that	in	normal	tissues	was	first	introduced	over	80	years	ago	by	Otto	Warburg	(reviewed	in	(246)).	Only	relatively	recently,	however,	has	it	become	clear	that	many	key	oncogenic	signalling	pathways	are	fundamentally	involved	in	adapting	tumour	cell	metabolism	in	order	to	support	growth	and	survival,	 thus	providing	links	between	tumour	metabolism	and	the	causal	changes	determining	 the	 cancer	 phenotype(247).	 In	 light	 of	 this,	 Hanahan	 and	Weinberg	 have	recently	added	a	 state	of	 “deregulated	 cellular	 energetics”	 to	 the	original	hallmarks	of	cancer	described	 in	 their	 seminal	paper	 from	2000(43,	44),	 reflecting	 the	now	widely	held	consensus	that	cellular	metabolism	is	substantially	altered	during	oncogenesis	and	tumour	 progression.	 Indeed,	 the	 fact	 that	 interfering	 with	 these	 altered	 metabolic	programs	in	cancer	mouse	models	profoundly	limits	tumour	cell	growth	highlights	the	dependence	 of	 cancers	 on	 metabolic	 re-programming(248,	 249).	 It	 is	 important	 to	recognise,	however,	 that	 the	precise	ways	 in	which	metabolism	 is	 re-programmed	can	vary	widely	 between	 cancers,	 depending	 both	 on	 genotype	 and	 tissue	 of	 origin(250),	highlighting	the	need	for	cancer-specific	study	of	metabolic	perturbations.	
	
1.3.1.	Principles	of	altered	tumour	metabolism	Since	Warburg’s	seminal	observation	 that	cancer	cells	metabolise	glucose	 in	a	manner	distinct	 from	 that	 used	 by	 normal	 eukaryotic	 cells(246),	 it	 has	 become	 evident	 that	rewiring	of	tumour	cellular	metabolism	is	highly	complex	and	may	differ	in	many	ways	from	that	in	normal	eukaryotic	cells,	including	use	of	secondary	metabolic	pathways	and	increased	 anaplerotic	 and	 cataplerotic	 flux(251-254).	 Nonetheless,	 Warburg’s	observation	 that	 cancer	 cells	 have	 a	 propensity	 to	 “ferment”	 glucose	 using	 glycolysis	under	both	anaerobic	and	aerobic	conditions	–	often	referred	to	as	the	Warburg	effect	–	remains	chief	among	the	recognised	metabolic	perturbations	of	the	cancer	phenotype,	is	certainly	 the	 best	 characterised,	 and	 consequently	 will	 be	 the	 focus	 throughout	 this	thesis.	Indeed,	microarray	studies	have	shown	that	glycolytic	genes	comprise	one	of	the	most	 up-regulated	 gene	 sets	 in	 cancer(255,	 256),	 and	 it	 is	 on	 the	 principle	 of	 the	Warburg	 effect	 that	 18F-FDG	 PET	 imaging	 is	 based,	 which	 has	 come	 into	 widespread	
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clinical	 use	 in	 the	 diagnosis,	 staging,	 and	 assessment	 of	 treatment	 response	 of	 many	cancers,	SCCHN	included(93).		Most	cells	in	normal	tissues	first	catabolise	glucose	to	pyruvate	through	glycolysis	and,	provided	 there	 is	 sufficient	 oxygen	 tension,	 convert	 pyruvate	 into	 acetyl-CoA	 in	 the	mitochondria	 by	 pyruvate	 decarboxylation	 before	 completely	 oxidising	 most	 of	 that	acetyl-CoA	 to	 carbon	 dioxide	 and	water	 in	 the	mitochondrial	 tricarboxylic	 acid	 (TCA)	cycle.	 This	 produces	 reduced	 nicotinamide	 adenine	 dinucleotide	 (NADH)	 and	 flavin	adenine	dinucleotide	 (FADH2),	which	 then	 fuel	oxidative	phosphorylation	 to	maximise	adenosine	triphosphate	(ATP) production(257).	Only	under	anaerobic	conditions	is	the	pyruvate	 generated	 by	 glycolysis	 redirected	 away	 from	 mitochondrial	 oxidative	phosphorylation	to	produce	large	amounts	of	lactate(257).	In	contrast,	cancer	cells	often	appear	 to	 have	 a	 predilection	 for	 the	 latter	 regardless	 of	 whether	 or	 not	 oxygen	 is	present,	which	is	also	accompanied	by	an	increase	in	glucose	uptake	and	glycolytic	flux,	necessitated	 by	 the	 fact	 that	 aerobic	 glycolysis	 is	 far	 less	 efficient	 in	 terms	 of	 ATP	generation	than	oxidative	phosphorylation(257).		The	 fact	 that	 this	 switch	 in	 glucose	metabolism	 is	 an	 energetically	 inefficient	 process,	yielding	only	two	molecules	of	ATP	per	molecule	of	glucose	consumed	as	opposed	to	up	to	 36	 with	 oxidative	 phosphorylation,	 invites	 scrutiny	 of	 the	 impetus	 driving	proliferating	 cancer	 cells	 to	 engage	 in	 such	 a	 process.	 Whilst	 Warburg	 originally	proposed	 that	 such	 reliance	 on	 glycolytic	 metabolism	 was	 compensatory	 for	 energy	deficiency	resulting	from	defective	mitochondrial	oxidative	phosphorylation(246),	more	recent	studies	have	demonstrated	that	mitochondrial	function	is	frequently	unimpaired	in	cancer	cells	and	many	tumours	retain	the	capacity	for	oxidative	phosphorylation	and	consume	 oxygen	 at	 rates	 similar	 to	 those	 observed	 in	 normal	 tissues(249,	 258-261).	Alternatively,	it	has	been	suggested	that	such	a	metabolic	switch	is	an	adaptive	response	to	 hypoxic	 conditions	 during	 the	 early	 avascular	 phase	 of	 tumour	 development,	 as	 it	allows	 for	 ATP	 production	 in	 the	 absence	 of	 oxygen(257).	 However,	 considering	 that	certain	leukemic	cells	have	been	observed	as	highly	glycolytic(262,	263)	despite	existing	in	 the	 bloodstream	at	 higher	 oxygen	 tensions	 than	 found	 in	most	 normal	 tissues,	 and	that	bronchogenic	tumours,	which	are	exposed	to	a	continuous	supply	of	oxygen	during	tumorigenesis,	also	exhibit	aerobic	glycolysis(264,	265),	it	seems	that	hypoxia	may	not	be	a	major	 factor	 in	 the	 switch	 to	aerobic	glycolysis	by	 cancer	 cells.	Accordingly,	 such	traditional	 views	 of	 tumour	metabolism	 as	 a	 self-correcting,	 homeostatic	 system	have	largely	given	way	to	more	contemporary	thinking	that	metabolic	switching	is	a	dynamic	
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process	 adopted	 by	 cancer	 cells	 to	 fit	 the	 requirements	 of	 rapid	 cell	 proliferation.	Indeed,	 the	 ever-evolving	 intricate	 links	 between	 metabolism	 and	 critical	 oncogenic	events,	 such	 as	 TP53	 mutation,	 Myc	 and	 Ras	 overexpression,	 persistent	 activation	 of	PI3K–AKT	 growth	 signalling,	 and	 enhanced	 mammalian	 target	 of	 rapamycin	 (mTOR)	activity,	 lend	 credence	 to	 this	 notion,	 suggesting	 metabolic	 switching	 is	 central	 to	malignant	transformation	rather	than	a	secondary	consequence(247).		Evidently,	cancer	cells	have	important	metabolic	requirements	that	extend	beyond	ATP	generation	 to	 support	 cell	 growth	 and	 proliferation,	 but	 the	 principal	 selective	advantage	 that	 glycolytic	 metabolism	may	 provide	 is	 not	 entirely	 clear.	 One	 possible	rationale	is	that	glycolysis,	although	inefficient	in	yield	of	ATP	produced	per	molecule	of	glucose	 consumed,	 has	 the	 capacity	 to	 generate	 ATP	 at	 a	 higher	 rate	 compared	 with oxidative	 phosphorylation,	 which	 would	 be	 advantageous	 provided	 glucose	 supplies	were	 not	 limited(266).	 Perhaps	 more	 tenable	 explanations,	 however,	 relate	 to	 the	concepts	of	1)	anabolic	biosynthesis	to	enhance	production	of	proper	 intermediates	to	allow	for	cell	growth	and	proliferation,	and	2)	regulation	of	cellular	redox	potential	 to	minimise	 the	damaging	effects	of	ROS(247,	257,	267).	 In	order	 to	support	growth	and	proliferation	a	cell	must	replicate	all	of	its	cellular	contents	to	yield	two	daughter	cells,	which	 in	 the	 context	 of	 an	 incessantly	 proliferating	 cancer	 cell	 requires	 liberal	generation	of	nucleotides,	amino	acids,	and	lipids,	without	which	rapid	cell	proliferation	will	 halt	 irrespective	 of	 how	 vast	 a	 supply	 of	 ATP	 is	 provided.	 This	 in	 turn	 demands	production	 of	 intermediates	 such	 as	 carbon,	 nitrogen,	 nicotinamide	 adenine	dinucleotide	phosphate	(NADPH),	ribose,	and	acetyl-CoA,	which	are,	 for	 the	most	part,	generated	 from	 high	 flux	 of	 substrate	 through	 glycolysis	 and	 utilisation	 of	 subsidiary	metabolic	 pathways(247,	 257).	 Such	 increased	 generation	 of	 intermediates,	 chiefly	NADPH,	may	also	be	important	for	cancer	cells	to	up-regulate	their	antioxidant	systems	to	quench	 the	 increased	ROS	 levels	 resulting	 from	heightened	oxidative	 substrate	 flux	and	deregulated	cellular	proliferation,	giving	rise	to	the	enigmatic	situation	of	high	ROS	production	 in	 the	 presence	 of	 high	 antioxidant	 levels	 (192,	 247,	 267,	 268).	 Although	conceivably	 advantageous	 to	 tumour	 cells	 at	 moderate	 levels	 –	 stimulating	 cell	proliferation,	 anchorage-independent	 growth,	 survival	 pathways,	 and	 induction	 of	genetic	 instability(269-271)	–	excessively	high	ROS	 levels	 result	 in	DNA	damage(271),	activation	of	protein	kinase	Cδ	prompting	senescence	(detailed	 in	section	1.2.6.)(227),	and	 permeabilisation	 of	 mitochondria	 leading	 to	 cytochrome	 c	 release	 and	 apoptosis	(detailed	in	section	1.2.5.)(192).	In	line	with	the	potential	importance	of	ROS	limitation	in	 tumour	 growth,	 several	 oncogenes	 actively	 suppress	 ROS	 through	 increased	
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transcription	of	Nrf2	–	a	 transcription	 factor	 that	promotes	ROS	detoxification	–	while	deletion	of	Nrf2	in	vivo	reduces	the	ability	of	the	oncogenic	K-Ras	to	induce	proliferation	and	 tumorigenesis(272).	 Importantly,	 pyruvate,	 oxaloacetate,	 and	 α-ketoglutarate	 can	all	act	as	ROS	scavengers(273-275),	while	NADPH	is	centrally	involved	in	redox	control,	providing	the	reducing	power	for	the	major	cellular	antioxidant	systems,	specifically	the	glutathione	and	thioredoxin	systems,	which	scavenge	ROS	and	protect	against	oxidative	damage-induced	cell	death(276).		In	 support	 of	 these	 concepts,	 several	 independent	 lines	 of	 investigation	 have	demonstrated,	in	addition	to	the	Warburg	effect,	activation	of	alternative	carbohydrate	metabolic	pathways	in	cancer	cells	that	use	glycolytic	intermediates	as	precursors.	Such	pathways	include	the	hexosamine	pathway,	uridine	diphosphate–glucose	synthesis,	and	the	 pentose	 phosphate	 pathway	 (PPP)(277-279),	 all	 of	 which	 generate	 the	macromolecular	 precursors	 and/or	 reducing	 equivalents	 necessary	 to	 support	 cell	proliferation	 and	 combat	 oxidative	 stress.	 Increased	 PPP	 shunting,	 which	 produces	phosphopentoses	 and	 ribonucleotides	 and	 is	 also	 a	 major	 source	 of	 NADPH,	 may	 be	particularly	 significant	 given	 the	 bipartite	 importance	 of	 NADPH	 in	 promoting	 both	macromolecular	biosynthesis	and	redox	control(280).	In	further	support	of	the	selective	advantage	conferred	by	utilisation	of	such	subsidiary	carbohydrate	metabolic	pathways,	cancer	 cells	 have	 a	 propensity	 to	 express	 the	 M2	 isoform	 of	 pyruvate	 kinase	(PKM2)(248,	281,	282)	–	a	relatively	inefficient	isoform	of	the	enzyme	that	catalyses	the	rate-limiting,	 ATP-generating	 step	 of	 glycolysis(281,	 283,	 284).	 Although	 on	 initial	consideration	this	may	seem	counter-intuitive	as	glycolytic	flux	is	slowed,	this	facilitates	effective	shunting	of	carbon	into	the	aforementioned	key	subsidiary	pathways.	Similarly,	TIGAR,	 an	 enzyme	 discovered	 relatively	 recently	 through	microarray	 analysis	 of	 gene	expression	 following	 p53	 activation(205,	 285),	 also	 promotes	 such	 advantageous	shuttling	and	has	been	shown	to	be	overexpressed	in	cancer	cells(286-288).	TIGAR	acts	principally	 as	 a	 fructose-2,6-bisphosphatase,	 thereby	 reducing	 the	 concentration	 of	intracellular	 fructose-2,6-bisphosphate,	 a	 powerful	 allosteric	 activator	 of	phosphofructokinase-1	 (PFK-1)(205)	 –	 an	 essential	 glycolytic	 enzyme	 that	 catalyses	conversion	 of	 fructose-6-phosphate	 to	 fructose-1,6-bisphosphate.	 Thus,	 by	 decreasing	PFK-1	 activity	 TIGAR	 limits	 glycolytic	 flux	 downstream	 of	 this	 point,	 redirecting	 the	metabolites	 to	 subsidiary	 pathways(205)	 (figure	 1.3.1.1.).	 Furthermore,	 the	 resulting	accumulation	 of	 fructose-6-phosphate	 can	 also	 increase	 flux	 into	 the	 non-oxidative	branch	of	 the	PPP	(figure	1.3.1.1.),	 and	under	hypoxic	conditions	TIGAR	has	also	been	shown	to	translocate	to	the	mitochondria	and	bind	to	hexokinase-II	(an	 isoform	of	the	
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first	enzyme	of	the	glycolytic	pathway),	stimulating	hexokinase-II	activity	independently	of	 its	 bisphosphatase	 activity.	 This	 results	 in	 an	 increase	 in	 glycolytic	 flux	 and	availability	 of	 glycolytic	 intermediates	 for	 use	 in	 subsidiary	 pathways,	 implying	 that	TIGAR	 is	 a	 positive	 regulator	 of	 the	 PPP	 in	 both	 a	 phosphatase-dependent	 and	independent	manner(280,	289).		
	
Figure	1.3.1.1:	Relationship	of	TIGAR,	glycolysis	and	subsidiary	pathways	of	carbohydrate	
metabolism.	TIGAR	functions	primarily	as	a	fructose-2,6-bisphosphatase	and	therefore	reduces	the	concentration	of	fructose-2,6-bisphosphate,	which	is	an	allosteric	activator	of	PFK-1.	TIGAR	is	predicted	to	promote	both	the	PPP	and	hexosamine	pathways	by	lowering	the	levels	of	fructose-2,6-bisphosphate	and	redirecting	glycolytic	intermediates.	Figure	reproduced	from	(290).		Accumulating	 evidence	 that	 some	 tumour	 cells	 metabolise	 substantial	 amounts	 of	alternative	oxidisable	substrates	such	as	glutamine(252,	253,	291)	also	lends	support	to	the	notions	 that	biosynthetic	and	redox	balance	advantages	underpin	 the	rationale	 for	metabolic	re-programming	in	cancer	cells.	During	glutaminolysis	mitochondrial	activity	is	diverted	 towards	biomass	production	whereby	TCA	cycle	 intermediates	are	used	 to	generate	essential	macromolecular	building	blocks.	Following	cellular	uptake,	glutamine	is	 converted	 to	 glutamate	 by	 mitochondrial	 glutaminase	 enzymes,	 which	 is	 then	converted	 to	 ử–ketoglutarate,	 which	 supplies	 the	 carbon	 input	 required	 for	 the	 TCA	cycle	 to	 engage	 in	 the	 production	 of	 other	 amino	 acids	 and	 fatty	 acids(252,	 292).	Moreover,	initial	conversion	of	glutamine	to	glutamate	releases	and	facilitates	potential	capture	of	nitrogen	from	the	amino	group	for	nucleoside	and	amino	acid	synthesis(252,	
and TIGAR was found to contribute to cell death in
cardiac myocytes, an utc e that is also linked to a
decrease in glycolysis [63]. However, in most cells where
TIGAR functions to limit ROS, the effect of TIGAR
expression was closely associated with protection against
ROS-induced cell death [55,69-71,80]. More confusing is
the association of TIGAR with senescence, where loss of
TIGAR can induce senescence in glio lastoma cells [64]
but can also inhibit this process in adult T-cell leukaemia
cells [81].
A clearer understanding of the physiological role of
TIGAR can be provided by the analysis of the role of
TIGAR in vivo (Figure 2). Unlike many metabolic enzymes,
which are essential for normal development [82,83],
TIGAR deficient mice showed no profound develop-
mental defect [79]. However, these mice have revealed
a role for TIGAR in the response to various forms of
stress, such as canc r and heart failure.
Cardiac myocytes are known to undergo cell death fol-
lowing ischaemia-reperfusion injury, where greater tissue
damage occurs due to the return of oxygenated blood
following an ischaemic period, resulting in inflammation
and oxidative stress. Both p53 and TIGAR protein ex-
pression are induced after myocardial infarction surgery,
and both have been linked to an increase in apoptosis
due to a decrease in glycolysis, resulting in decreased levels
of phosphocreatine (a high energy phosphate important
in tissues, such as muscles, with high fluctuating energy
demands) [63]. In addition, the role of p53 and TIGAR
following cardiac damage was also s ggested to be due
to their ability to inhibit autophagy, particularly in the
form of mitophagy. p53- or TIGAR-deficient animals
Figure 1 TIGAR functions as a fructose-2,6-bisphosphatase. Schematic of glycolysis, the pentose phosphate pathway (PPP) and the hexosamine
pathway. TIGAR is predicted to promote both the PPP and hexosamine pathways by lowering the levels of fructose-2,6-bisphosphate and redirecting
glycolytic intermediat s.
Figure 2 Understanding the role of TIGAR in vivo. Loss of TIGAR results in reactive oxygen species (ROS) accumulation and tissue-dependent
changes in response to stress [51,79].
Lee et al. Cancer & Metabolism 2014, 2:1 Page 4 of 9
http://www.cancerandmetabolism.com/content/2/1/1
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292).	 In	 addition	 to	 fuelling	 biosynthesis,	 glutamate	 can	 be	 converted	 directly	 into	reduced	 glutathione	 (GSH)	 by	 the	 enzyme	 glutathione	 cysteine	 ligase,	 and	 recent	evidence	also	suggests	that	glutamine-derived	carbon	may	exit	the	TCA	cycle	as	malate,	serving	as	a	substrate	for	malic	enzyme	1,	which	produces	NADPH(252).		
1.3.2.	The	role	of	p53	in	altered	tumour	metabolism	Although	 the	 precise	 sequence	 of	 events	 and	 driving	 forces	 that	 converge	 to	 perturb	core	 cellular	 metabolism	 in	 cancer	 cells	 remain	 unclear,	 it	 has	 become	 evident	 that	multiple	 events	 critical	 in	 initiating	 oncogenesis	 are	 intricately	 linked	with	metabolic	regulation,	and	as	such	are	likely	implicated	this	metabolic	switch(247,	267).	One	such	fundamental	oncogenic	event	that	may	contribute	to	metabolic	re-programming	is	 loss	of	 wild-type	 p53	 function,	 which	 is	 particularly	 pertinent	 to	 SCCHN	 given	 its	 crucial	importance	 in	SCCHN	 tumorigenesis	 (discussed	 in	 sections	1.1.3.	 and	1.2.7.).	Although	p53,	 an	 extensively	 studied	 tumour	 suppressor,	 is	 best	 known	 for	 its	 complex	 and	critical	 roles	 in	 the	 regulation	 of	 processes	 including	 cell	 proliferation,	 death,	 and	responses	 to	 exogenous	 stress	 (detailed	 in	 sections	 1.2.3	 –1.2.6.),	 recent	 studies	 have	revealed	that	p53	also	plays	a	central	role	in	metabolic	homeostasis,	balancing	glycolytic	activity	 and	 mitochondrial	 respiration(174).	 Indeed,	 recent	 studies	 have	 raised	questions	 regarding	 the	 relative	 importance	 of	 the	 “classical”	 p53	 functions	 in	 p53-mediated	 tumour	 suppression,	 suggesting	 the	 possibility	 that	 emerging	 p53-regulated	processes,	 such	 as	 metabolic	 homeostasis,	 may	 be	 central	 in	 limiting	tumorigenesis(293).		In	keeping	with	its	tumour	suppressor	properties,	p53	appears	to	counteract	metabolic	alterations	 typically	 associated	 with	 cancer	 development,	 with	 loss	 of	 wild-type	 p53	function	 potentially	 leading	 to	 acquisition	 of	 a	 glycolytic	 phenotype	 at	 the	 expense	 of	mitochondrial	respiration(247,	267,	294).	p53	can	exert	 influence	over	both	glycolysis	and	oxidative	phosphorylation	through	multiple	mechanisms,	which	may	also	modulate	the	 activity	 of	 related	 subsidiary	 pathways	 (figure	 1.3.2.1.).	 PFK-1	 represents	 a	 key	regulatory	point	in	the	glycolytic	pathway	and,	as	alluded	to	above,	p53	plays	a	role	in	regulating	glycolysis	at	this	critical	point.	By	inducing	the	transcription	of	TIGAR,	which	acts	primarily	as	a	bisphosphatase	that	reduces	intracellular	fructose-2,6-bisphosphate	concentration,	 allosteric	 activation	 of	 PFK-1	 is	 lost,	 resulting	 in	 a	 dampening	 of	glycolytic	 flux.	 Additionally,	 activation	 of	 p53	 typically	 decreases	 the	 activity	 of	phosphoglycerate	mutase	(PGAM)	–	the	catalyst	for	conversion	of	3-phosphoglycerate	to	2-phosphoglycerate	 –	 through	 increased	 ubiquitylation	 and	 subsequent	 proteosomal	
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degradation(295),	mediated	via	direct	binding	to	MDM2(296).	p53	has	also	been	shown	to	 repress	 the	 expression	 of	 pyruvate	 dehydrogenase	 kinase	 (PDK),	 an	 enzyme	which	inactivates	 the	 pyruvate	 dehydrogenase	 complex	 (PDC),	 activity	 of	which	 is	 crucial	 in	determining	the	fate	of	pyruvate,	with	PDC	acting	to	convert	pyruvate	to	acetyl-CoA	at	the	 expense	 of	 lactate	 production(297).	 Thus,	 p53	 activates	 PDC,	 promoting	 pyruvate	decarboxylation	 and	 TCA	 cycle	 flux(297).	 In	 concert	 with	 negatively	 regulating	glycolytic	enzymatic	activity,	p53	may	also	curb	glycolysis	by	down-regulating	relevant	transporter	molecules:	 the	 expression	 of	 the	 glucose	 transporters	 GLUT1	 and	 GLUT4,	which	 are	 involved	 in	 cellular	 glucose	 uptake,	 is	 transcriptionally	 repressed	 by	p53(298),	 while	 further	 downstream	 in	 glycolysis	 p53	 suppresses	 monocarboxylate	transporter-1	 (MCT-1)	 expression,	 which	 prevents	 lactate	 efflux	 under	 hypoxic	conditions,	a	necessity	in	sustaining	elevated	rates	of	glycolysis(299).		Complementary	to	its	proposed	actions	to	restrict	glycolytic	flux,	p53	is	also	thought	to	be	 coupled	 to	 the	maintenance	 of	mitochondrial	 integrity	 and	 promotion	 of	 oxidative	phosphorylation.	p53	has	been	reported	to	regulate	stability	of	mitochondrial	DNA	and	mitochondrial	biomass	through	induction	of	genes	such	as	the	ribonucleotide	reductase	subunit	 p53R2(300-302),	 and	may	play	 a	 role	 in	 repairing	 or	 removing	 compromised	mitochondria	via	induction	of	mitochondria-eating	protein	(Mieap),	thereby	modulating	mitochondrial	 quality	 control(303).	 Specific	 to	 oxidative	 phosphorylation,	 p53	 can	enhance	 transcription	 of	 Parkin,	 which	 promotes	 mitochondrial	 respiration	 by	increasing	 the	 cellular	 level	 of	 acetyl-CoA	 through	 upregulation	 of	 pyruvate	dehydrogenase(304).	p53	can	also	transcriptionally	activate	the	gene	for	subunit	I	of	the	cytochrome	 c	 oxidase	 (COX)	 complex	 (complex	 IV	 in	 the	 mitochondrial	 electron	transport	chain	[ETC]	and	major	site	of	cellular	oxygen	utilisation)(305),	as	well	as	the	gene	for	synthesis	of	COX	2,	which,	 in	conjunction	with	synthesis	of	COX	1,	 is	required	for	 the	 assembly	 of	 the	 COX	 complex(286,	 306,	 307).	 Moreover,	 apoptosis	 inducing	factor,	 which	 is	 crucial	 to	 the	 maintenance	 of	 ETC	 complex	 I,	 has	 been	 shown	 to	 be	subject	 to	 positive	 transcriptional	 regulation	 by	 p53(308),	 while	 p53	 localised	 to	 the	mitochondria	may	promote	assembly	of	the	ATP	synthase	complex	(the	final	complex	in	the	 ETC	 involved	 in	 generation	 of	 ATP)	 in	 a	 p53-transcription-independent	manner(309).		
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Figure	1.3.2.1:	Proposed	actions	of	p53	on	glycolysis	and	mitochondrial	 respiration.	p53	has	been	reported	to	exert	influence	over	both	glycolysis	and	oxidative	phosphorylation	through	numerous	 mechanisms,	 all	 of	 which	 are	 depicted	 in	 this	 schematic.	 In	 general	 p53	 acts	 to	restrict	glycolysis	and	promote	mitochondrial	respiration.	Figure	reproduced	from	(294).			Further	 to	 direct	 regulatory	 effects	 promoting	 a	 glycolytic	 phenotype,	 there	 is	 also	 a	substantial	 degree	 of	 cross-talk	 between	 the	 p53	 system	 and	 several	 other	 key	metabolic	mediating	pathways,	resulting	in	indirect	p53	regulation.	Perhaps	of	foremost	importance,	activation	of	p53	inhibits	the	activities	of	two	master	regulators	of	cellular	metabolism,	the	PI3K/Akt	and	mTOR	pathways,	which	ultimately	results	in	suppression	of	glycolysis	together	with	inhibition	of	cell	growth,	and	possibly	p53-directed	apoptosis	and	 autophagy.	 In	 general,	 p53	 exercises	 such	 inhibition	 through	 upstream	transcriptional	 regulation(310,	 311):	 for	 instance,	 p53	 promotes	 transcription	 of	phosphatase	 and	 tensin	 homolog	 (PTEN),	 IGF-binding	 protein-3	 (IGFBP3),	 tuberous	sclerosis	protein	2	(TSC2),	and	the	Ữ	subunit	of	AMP-activated	protein	kinase	(AMPK),	all	of	which	negatively	regulate	PI3K/Akt	and	mTOR	pathways(310).	Furthermore,	p53	promotes	 the	 expression	 of	 SESN1	 and	 SESN2,	 which	 also	 serves	 to	 stimulate	 AMPK	
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activity(311,	 312).	 AMPK	 was	 also	 recently	 identified	 to	 inhibit	 the	 hypoxia-induced	factor-1ử	(HIF-1ử)	pathway(313),	which	in	turn	negatively	regulates	aerobic	glycolysis	given	that	HIF-1ử	acts	to	enhance	the	transcription	of	numerous	glycolytic	transporters	and	enzymes(314),	adding	 further	 to	 the	web	of	 indirect	p53	effects	 impeding	aerobic	glycolysis.	 To	 this	 end,	 p53	 has	 also	 been	 implicated	 in	 direct	 upregulation	 of	HIF-1ử	ubiquitylation	 and	degradation(315).	Additionally,	 p53	 can	 inhibit	 the	NF-kỮ	 pathway	through	 inhibition	 of	 IKKỮ,	 which	 also	 results	 in	 decreased	 glucose	 transporter	expression,	and	by	association	a	dampening	of	glycolytic	flux(316).		Although	 for	 the	 most	 part	 p53	 acts	 to	 repress	 the	 malignant	 metabolic	 phenotype,	dampening	 glycolysis	 and	 promoting	 mitochondrial	 respiration,	 seemingly	contradictory	 roles	 have	 also	 been	 described.	 For	 instance,	 the	 promoters	 for	 the	glycolytic	 enzymes	 PGAM	 and	 hexokinase-II	 contain	 p53-REs(317,	 318),	 and	 p53	 has	been	shown	to	both	promote	and	 inhibit	PPP	flux(294).	Whilst	 the	precise	reasons	for	these	 opposing	 p53	 responses	 remain	 to	 be	 elucidated,	 it	 is	well	 recognised	 that	 p53	does	not	act,	nor	is	it	regulated,	in	the	same	manner	in	the	wide	variety	of	tissues	from	which	cancers	develop(193).	 It	 is	highly	 likely,	 therefore,	 that	p53-mediated	metabolic	regulation	is	tissue-dependent(174,	294),	emphasising	the	importance	of	cancer-specific	study	of	metabolic	perturbations.	Consistent	with	this,	in	contrast	to	the	p53-dependent	destabilisation	of	PGAM	in	fibroblasts	detailed	above(295),	a	muscle-specific	isoform	of	PGAM	is	transcriptionally	activated	by	p53	in	cardiocytes(317).	It	is	also	likely,	as	with	many	p53-induced	responses,	that	there	is	environmental	context	dependency(166).		Notwithstanding	a	minority	of	ostensibly	 conflicting	effects,	 in	general	p53	appears	 to	play	a	role	in	metabolic	homeostasis	by	balancing	glycolytic	activity	and	mitochondrial	respiration,	with	 loss	 of	wild-type	 p53	 function,	 therefore,	 potentially	 involved	 in	 the	acquisition	 of	 the	 unbalanced	 malignant	 metabolic	 phenotype.	 Furthermore,	 as	discussed	 in	 section	 1.2.7,	 some	 mutated	 forms	 of	 p53	 may	 acquire	 oncogenic	 GOF	properties,	 further	 contributing	 to	 tumorigenesis(55).	 Although	 the	 underlying	mechanisms	 involved	 remain	 relatively	 poorly	 characterised,	 interestingly	 a	 recent	study	 revealed	 the	 first	 link	 between	 such	 GOF	 properties	 and	 metabolic	regulation(319).	In	contrast	to	wild-type	p53,	which	increases	AMPK	activity(310),	GOF	mutant	 p53	 proteins	 were	 shown	 to	 inhibit	 specifically	 AMPK	 activation	 and	 AMPK	signalling	in	SCCHN	cells	through	a	direct	and	distinct	protein-protein	interaction	with	the	 AMPKử	 subunit,	 leading	 to	 increased	 aerobic	 glycolytic	 capacity,	 lipid	 anabolism,	and	invasive	cell	growth(319).	
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1.3.3.	Evidence	for	metabolic	re-programming	in	SCCHN	Although	 metabolic	 reprogramming	 is	 now	 recognised	 as	 an	 emerging	 hallmark	 of	cancer(44),	 the	 specific	 nature	 and	 extent	 of	 the	 metabolic	 perturbations	 can	 differ	significantly	 between	 cancers,	 depending	 both	 on	 genotype	 and	 tissue	 of	 origin(250).	For	 instance,	 aerobic	 glycolysis	 is	 the	 best-documented	metabolic	 phenotype,	 yet	 it	 is	not	a	universal	feature	of	all	cancers:	glutaminolysis	has	been	shown	to	predominate	in	cervical	 cancer	 and	 glioblastoma(252,	 320),	 while	 enhanced	 rather	 than	 reduced	oxidative	 phosphorylation	 is	 a	 feature	 of	 both	 breast	 cancer(321)	 and	 chronic	lymphocytic	leukaemia(322).		In	keeping	with	this,	there	is	wide	variability	clinically	in	FDG-PET	uptake	between	tumours,	and	up	to	30%	of	tumours	are	considered	FDG–PET-negative(323).	 Clearly,	 this	 further	 highlights	 the	 importance	 of	 detailed	 study	 of	metabolism	in	cancer	site-specific	experimental	systems.		Specific	to	SCCHN,	metabolic	studies	had	been	somewhat	lacking	and	for	the	most	part	have	 focused	 on	 isolated	 or	 limited	 transporter	 or	 enzyme	 expression	 and	 their	prognostic	 significance,	 rather	 than	 characterising	 dynamic	 metabolic	 flux	 and	presenting	 a	 clear	 picture	 of	 the	 metabolic	 phenotype.	 Several	 retrospective	pathological	studies	have	investigated	GLUT-1	expression	and	have	consistently	shown	overexpression	 relative	 to	normal	mucosa	and/or	benign	 squamous	 lesions(324-328),	with	one	study	also	demonstrating	overexpression	in	early	pre-neoplastic	lesions(324).	Moreover,	expression	was	associated	with	the	extent	of	dysplasia,	implying	that	GLUT-1	upregulation	 is	 a	 relatively	 early	 event	 during	 development	 of	 SCCHN.	 GLUT-1	expression	may	also	have	clinical	utility	in	SCCHN:	GLUT-1	staining	is	discernibly	higher	in	 recurrent	 disease	 compared	 to	 primary	 disease(329);	 correlates	 inversely	 with	degree	 of	 tumour	 differentiation(329);	 and	 has	 been	 shown	 to	 be	 an	 independent	marker	of	prognosis	 in	both	oral	 cavity	and	hypopharyngeal	 SCC,	with	a	high	 staining	index	 associated	with	 a	 significant	 reduction	 in	 survival(330,	 331).	 Furthermore,	 pre-treatment	 GLUT-1	 overexpression	 has	 also	 been	 identified	 as	 a	 marker	 of	radioresistance	 in	 oral	 cavity	 SCC(332).	 Whilst	 GLUT-1	 is	 the	 glucose	 transporter	typically	 associated	 with	 SCCHN,	 other	 members	 of	 the	 GLUT	 family	 have	 also	 been	examined,	albeit	less	extensively.	In	a	study	of	48	cases	of	laryngeal	SCC,	although	GLUT-1	was	universally	expressed,	GLUT-3–positive	cases	were	associated	with	more	poorly	differentiated	 tumours	 and	 reduced	 overall	 survival,	 and	 in	 a	more	 recent	 and	 large-scale	study	utilising	a	 tissue	microarray	comprising	142	oral	 cavity	SCCs	both	GLUT-1	and	GLUT-3	expression	was	shown	to	negatively	prognosticate(333).	Similarly,	in	a	gene	
Introduction	
	 50	
expression	profile	study	GLUT-3	overexpression	was	 identified	as	a	prognosticator	 for	increased	 depth	 of	 tumour	 invasion,	 larger	 tumour	 size,	 advanced	 pathologic	 stage,	recurrence,	and	unfavourable	survival(334).		Importantly,	 GLUT	 overexpression,	 unlike	 most	 other	 tumour	 markers,	 has	 a	biochemical	 and	clinically	utilised	 correlate	 in	 18F-FDG-PET.	The	glucose	analogue	 18F-FDG	 is	 taken	 up	 rapidly	 into	 tumour	 cells	 by	 the	 glucose	 transporters	 GLUT	 1	 and	 3	whereupon	 phosphorylation	 by	 hexokinase	 prevents	 release	 from	 the	 cell,	 while	 the	absence	 of	 the	 2'	 hydroxyl	 group	 present	 in	 normal	 glucose	 prevents	 further	glycolysis(93).	 Thus,	 18F-FDG	 is	 trapped	 in	 the	 cell	 allowing	 PET	 detection	 prior	 to	radioactive	decay,	and	the	resulting	18F-FDG	signal	primarily	reflects	the	cells’	capacity	for	 glucose	 uptake(93).	 Despite	 some	 limitations,	 18F-FDG-PET	 with	 computed	tomography	 is	 currently	 used	 successfully	 in	 the	 initial	 diagnosis,	 staging	 work-up,	monitoring	 of	 response	 to	 therapy,	 and	 post-treatment	 surveillance	 for	 recurrence	 in	SCCHN(93).	 Furthermore,	 a	 recent	 meta-analysis	 demonstrated	 both	 pre-	 and	 post-treatment	18F-FDG	signal,	as	measured	by	standard	uptake	value,	as	a	reliable	predictor	of	 long-term	 survival	 in	 SCCHN(335).	 This,	 together	with	 the	 above	 GLUT	 expression	data,	 does	 suggest	 that	 protein	 levels	 are	 indeed	 linked	 to	 a	 functional	 tumour	phenotype.		Aside	 from	 the	 GLUTs,	 only	 a	 handful	 of	 studies	 have	 characterised	 other	 metabolic	markers	 in	 SCCHN.	 Using	 immunohistochemistry,	 Deron	 et	 al	 observed	 hexokinase	overexpression,	 particularly	 hexokinase-I,	 in	 a	 panel	 of	 oropharyngeal	 and	 oral	 cavity	SCCs(336),	 and	 similarly	 Chen	 et	 al	 reported	 significantly	 higher	 hexokinase-II	expression	 in	 laryngeal	 SCC	 than	 in	 benign	 squamous	 laryngeal	 lesions(337).	Furthermore,	 in	 the	 latter	 study	 stable	 knock-down	 of	 hexokinase-II	 expression	 in	laryngeal	 SCC	 cells	 resulted	 in	 cell	 cycle	 arrest,	 increased	 apoptosis,	 and	 reduced	viability,	findings	which	were	paralleled	in	vivo	where	xenograft	tumours	derived	from	such	 cells	 were	 smaller	 and	 exhibited	 reduced	 proliferation	 relative	 to	 those	 from	untransfected	or	control-plasmid-transfected	cells,	suggesting	that	hexokinase-II,	and	by	extension	 glycolytic	 flux,	 plays	 an	 important	 role	 in	 the	 development	 of	 laryngeal	SCC(337).	One	study	has	also	examined	PDC	activity	and	found	that	negative	regulation	of	the	PDC	occurs	as	a	consequence	of	enhanced	expression	of	PDK-1,	which	in	turn	is	partially	 attributable	 to	 the	 glycolytic	 phenotype	 observed	 in	 SCCHN	 cell	 lines(338).	Furthermore,	 normoxic	 stabilisation	 of	 HIF-1ử	 by	 glycolytic	metabolites	 secondary	 to	PDC	 inhibition	 was	 observed,	 which	 given	 that	 PDK-1	 is	 a	 HIF-1ử-regulated	 gene,	
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suggests	a	feed-forward	effect	is	at	play	in	contributing	to	malignant	progression(338).	Similarly,	 study	of	 SCCHN	cell	 lines	harbouring	mitochondrial	mutations	also	 suggests	interplay	 between	 PDK-2	 upregulation,	 and	 the	 resulting	 attenuation	 in	 PDC	 activity,	pyruvate	accumulation,	and	HIF-1ử	stabilisation(339).	Consistent	with	these	findings,	a	parallel	 study	 also	 demonstrated	 the	 importance	 of	 PDK-1	 expression	 in	maintaining	glycolysis	 in	 SCCHN	 cells	 and	 additionally	 showed	 PDK-1	 overexpression	 in	 SCCHN	tissue,	which	was	strongly	related	to	poor	survival	outcome(340).	Data	regarding	PKM2	
–	 a	 relatively	 inefficient	 isoform	 of	 the	 enzyme	 that	 catalyses	 the	 rate-limiting,	 ATP-generating	step	of	glycolysis(281,	283,	284)	–	are	equivocal.	Although	one	study	found	PKM2	expression	to	be	an	unsuitable	tool	for	differentiating	oral	cavity	SCC	from	normal	tissues(341),	Wong	et	al	observed	PKM2	overexpression	in	a	small	cohort	of	oral	tongue	specimens(342),	and	a	more	recent	analysis	of	the	cancer	genome	atlas	RNA	sequencing	and	exon	array	datasets	demonstrated	PKM2	overexpression,	which	correlated	strongly	with	 poor	 prognosis,	 despite	 an	 absence	 of	 PKM1	 to	 PKM2	 isoform	 switching	 in	SCCHN(343).		Whilst	 these	 findings	 collectively	 provide	 evidence	 of	 increased	 glucose	 uptake	 and	possibly	increased	expression	of	a	number	of	glycolytic	markers	in	SCCHN,	particularly	in	poorly	differentiated	and	more	aggressive	tumours,	such	findings	in	isolation	do	not	necessarily	demonstrate	 increased	glycolytic	 flux,	 and	are	 limited	 in	 their	mechanistic	insights	 into	 SCCHN	 metabolism	 and	 its	 role	 in	 tumorigenesis.	 For	 instance,	 an	important	 caveat	 of	 many	 of	 these	 studies	 relates	 to	 the	 role	 of	 glucose	 uptake	 and	catabolism	 in	 supporting	 rapid	 cell	 proliferation:	 overexpression	 of	 these	 glycolytic	markers	 may	 simply	 be	 a	 surrogate	 for	 cell	 proliferation	 akin	 to	 other	 markers	 of	proliferation	such	as	Ki-67.		As	 the	 final	 by-product	 of	 glycolysis,	 lactate	 has	 also	 been	 examined	 as	 a	 proxy	 of	glycolytic	 activity	 in	 several	 SCCHN	 studies.	 Brizel	 et	 al	 demonstrated	 high	 pre-treatment	tumour	lactate	 levels,	which	despite	bearing	no	relationship	to	presenting	T	or	 N	 classification,	 did	 correlate	 with	 decreased	 overall	 and	 metastasis-free	survival(344).	A	recent	prospective	study	 following	SCCHN	patients	 for	up	to	15	years	also	 correlated	 high	 lactate	 levels	 with	 both	 reduced	 overall	 survival	 and	 tumour	recurrence	post-irradiation(345).	Congruous	with	this,	findings	from	the	same	research	group	 from	 two	 in	vivo	 studies,	 in	which	SCCHN	cell	 lines	were	xenografted	 into	nude	mice,	suggest	that	increased	tumour	lactate	levels	confer	relative	radioresistance,	which	was	attributed	to	the	antioxidative	capacity	of	lactate(346,	347).	Interestingly,	although	
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similar	 results	 were	 observed	 in	 a	 comparative	 study	 of	 cryobiopsies	 of	 SCCHN	 and	normal	mucosa,	expression	of	lactate	dehydrogenase	(LDH)	(the	catalyst	for	conversion	of	pyruvate	to	lactate)	did	not	correlate	with	tumour	lactate	content(348).	This	arguably	lends	credence	to	the	notion	that	the	raised	lactate	content	was	indeed	a	by-product	of	increased	glycolytic	flux	rather	than	a	result	of	any	dysregulation	of	LDH	expression.	At	odds	with	this,	however,	are	findings	from	two	recent	studies	examining	LDH	isoenzyme	expression	 in	oral	 cavity	SCC,	which	demonstrated	LDH	expression	as	an	 independent	predictor	 of	 disease	 recurrence	 and	 poor	 survival	 outcomes,	 as	 well	 as	 specifically	conferring	resistance	to	the	chemotherapeutic	agent	paclitaxel(349,	350).		Recent	 studies	 employing	 magic	 angle	 spinning	 nuclear	 magnetic	 resonance	 (MAS	NMR)-spectroscopy	to	enable	broad-spectrum	metabolomic	analyses,	have	also	utilised	lactate	 levels	 to	 infer	 glycolytic	 activity.	 Two	 MAS	 NMR-spectroscopy	 studies,	 which	scrutinised	 SCCHN	 cell	 lines(351)	 and	 snap-frozen	 tumour	 specimens(352),	demonstrated	 a	 diversity	 of	 metabolic	 derangements	 reliably	 distinct	 from	 normal	tissue,	with	heightened	lactate	levels	a	consistent	feature.	In	contrast,	however,	a	further	NMR-spectroscopy	 study	 reported	 no	 evidence	 of	 elevated	 lactate	 in	 the	 observed	metabolomic	profile	in	a	cohort	of	oral	cavity	SCC	specimens(353).		Findings	 from	 several	 therapeutic	 studies,	 which	 have	 explored	 the	 use	 of	 the	hexokinase	inhibitor	2-deoxy-D-glucose	(2-DG),	also	lend	some	support	to	the	notion	of	a	 glycolytic	 phenotype	 in	 SCCHN.	 These	 studies	 have	 demonstrated	 2-DG	 to	 exhibit	selective	 cytotoxicity	 in	both	 in	vitro	 and	 in	vivo	 SCCHN	models,	 and	 to	potentiate	 the	effects	 of	 conventional	 treatments	when	used	 in	 combination,	 suggestive	of	 a	 survival	dependence	 of	 these	 tumours	 on	 glycolysis(354-356).	 Nonetheless,	 findings	 have	 not	been	universal(357),	and	the	observed	effects	of	2-DG	may	not	be	simply	the	result	of	a	catabolic	block(358).		A	 recent	 study,	 also	 utilising	 2-DG,	 sought	 to	 compare	 dependence	 on	 different	metabolic	 pathways	 in	 SCCHN	 cell	 lines(359).	 In	 this	 study,	 glycolytic	 inhibition	 was	reported	 to	 suppress	 proliferation	 and	 anchorage-independent	 growth	 to	 a	 greater	extent	 than	 inhibition	 of	 glutaminolysis,	 suggesting	 a	 predominant	 dependence	 on	glucose	catabolism(359).	As	with	previous	studies,	however,	significant	heterogeneity	in	response	 among	 the	 SCCHN	 cell	 lines	 was	 observed.	 Interestingly	 though,	 further	analysis	 revealed	 that	 a	 pair	 of	 isogenic	 cell	 lines	 derived	 from	 the	 same	 patient	 but	divergent	on	TP53	mutational	status	displayed	differing	degrees	of	sensitivity	to	glucose	
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deprivation,	with	 the	wild-type	TP53	 cell	 line	exhibiting	relative	resistance,	suggesting	for	 the	 first	 time	 in	SCCHN	a	possible	role	 for	p53	 in	determining	response	 to	glucose	starvation,	and	by	extension	the	metabolic	underpinnings(359).	A	follow-on	study	from	the	same	research	group	examined	this	 further,	again	using	the	same	isogenic	cell	 line	pair	divergent	on	TP53	status(360).	Using	fluorescence-based,	extracellular	flux	analysis	the	mutant	TP53	cell	 line	was	observed	to	exhibit	a	metabolic	phenotype	distinct	from	the	 wild-type	 TP53	 cell	 line,	 with	 a	 seemingly	 greater	 utilisation	 of	 glycolysis	 and	reduced	utilisation	of	oxidative	phosphorylation	in	the	mutant	TP53	cells(360).	This	was	also	 associated	 with	 ionising	 radiation	 (IR)	 response	 following	 glycolytic	 inhibition,	which	 potentiated	 IR	 effects	 in	 mutant	 TP53	 but	 not	 wild-type	 TP53	 cells,	 again	suggestive	of	a	role	of	TP53	status	in	determining	metabolic	phenotype	in	SCCHN(360).			Considering	 this	 possible	 association	 between	 loss	 of	 wild-type	 p53	 function	 and	glycolytic	 dependence,	 together	 with	 the	 importance	 of	 the	 HPV	 E6	 oncoprotein	 in	targeting	p53	 for	proteasomal	degradation	 in	HPV-positive	SCCHN	(see	section	1.1.3.),	invites	scrutiny	of	metabolism	in	HPV-driven	disease.	Only	one	study	has	addressed	this	issue	to	date,	examining	both	resected	HPV-positive	oropharyngeal	SCC	specimens	and	an	 in	 vitro	 HPV-positive	 cell	 line,	 albeit	 one	 derived	 from	 a	 hypopharyngeal	tumour(361).	Perhaps	surprisingly,	HPV-positive	tumours	exhibited	increased	levels	of	proteins	 indicative	 of	 oxidative	 phosphorylation	 and	 a	 relatively	 lower	 level	 of	extracellular	 lactate	 accumulation(361).	 Again,	 however,	 this	 study	 represents	 an	isolated	and	relatively	limited	analysis	of	biomarker	expression,	which	has	also	utilised	a	cell	line	model	from	an	unusual	sub-site.			Interestingly,	 evidence	 from	 several	 of	 the	 aforementioned	 therapeutic	 studies	implicates	 oxidative	 stress	 as	 the	 mechanism	 underlying	 the	 cytotoxic	 effects	 of	glycolytic	 inhibition,	which	 accords	with	 the	proposed	 impetus	driving	 cancer	 cells	 to	acquire	a	glycolytic	phenotype,	and	is	suggestive	of	involvement	of	subsidiary	metabolic	pathways	critical	to	cellular	reducing	potential,	such	as	the	PPP.	For	instance,	glycolytic	inhibition	 has	 been	 shown	 to	 cause	 perturbations	 in	 surrogates	 of	 oxidative	 stress,	including	 decreased	 intracellular	 total	 glutathione	 with	 a	 reduced	 proportion	 of	GSH(354),	 lessened	 cellular	 reducing	 potential(359),	 and	 significantly	 elevated	 ROS	levels(360).	Consistent	with	this,	simultaneous	treatment	with	the	thiol	antioxidant	N-acetyl	 cysteine	 (NAC)	 has	 been	 shown	 to	 reverse	 these	 surrogates	 as	 well	 as	 the	cytotoxic	effects	of	glycolytic	 inhibition(354,	359,	360).	Moreover,	under	conditions	of	glucose	 deprivation,	 addition	 of	 excess	 pyruvate	 only	 partially	 rescued	 the	 cytotoxic	
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effects	of	inhibiting	glycolysis,	further	suggesting	the	importance	of	upstream	subsidiary	pathways	 in	 limiting	 oxidative	 stress(359).	 In	 keeping	with	 this,	 recent	 research	 that	sought	to	examine	the	reprogramming	of	metabolism	associated	with	the	development	of	radioresistance,	using	a	matched	model	of	radio-resistant	and	-sensitive	SCCHN	cells,	demonstrated	 that	 in	 addition	 to	 an	 increased	 dependence	 on	 overall	 glucose	catabolism,	 radioresistant	 cells	 specifically	 exhibited	 increased	 PPP	 flux(277,	 362).	Specifically,	 radioresistant	 SCCHN	 cells	 displayed	 elevated	 expression	 of	 key	 PPP	enzymes,	 increased	production	of	NADPH,	and	higher	 levels	of	TIGAR	expression(277,	362).	Unfortunately,	however,	this	study	only	included	two	cell	lines	and	information	on	
TP53	 status	 was	 conspicuously	 absent,	 thereby	 preventing	 any	 inferences	 on	 the	relationship	between	TP53	status,	PPP	flux,	and	TIGAR	expression.	Further	evidence	in	support	 of	 heightened	 PPP	 flux	 in	 SCCHN	 generally,	 comes	 from	 three	 studies	scrutinising	 transketolase-like	 protein	 (TKTL1,	 another	 PPP	 enzyme),	 which	 have	shown	the	gene	encoding	TKTL1	to	be	hypomethylated	and	TKTL1	to	be	overexpressed	in	SCCHN	cell	lines	and	tissues.	These	studies	also	suggested	that	TKTL1	overexpression	promotes	 SCCHN	 tumorigenicity	 in	 vitro	 and	 in	 vivo	 through	 a	 feed-forward	 effect	 on	glycolysis(363-365).		Notwithstanding	 the	 evidence	 supporting	 a	 glycolytic	 phenotype	 in	 SCCHN,	 perhaps	mediated	 by	 loss	 of	 wild-type	 p53	 function,	 one	 research	 group	 has	 offered	 an	alternative	 model	 of	 SCCHN	 metabolism.	 In	 a	 recent	 biomarker	 analysis	 of	 SCCHN	resection	 specimens,	 three	metabolically	 and	morphologically	distinct	 cell	populations	were	 identified:	 highly	 proliferative	 epithelial	 cancer	 cells	 utilising	 oxidative	phosphorylation	 with	 high	 lactate	 and	 ketone	 body	 uptake;	 and	 non-proliferative	epithelial	 tumour	 cells	 and	 stromal	 cancer-associated	 fibroblasts	 both	 deficient	 in	mitochondria	with	elevated	lactate	and	ketone	body	generation(366).	Furthermore,	in	a	subset	 of	 specimens	 both	 non-proliferative	 compartments	 were	 noted	 to	 be	 highly	glycolytic	and	observed	to	represent	a	significant	proportion	of	the	tumour(366).	Based	on	this	analysis,	the	authors	propose	a	model	of	metabolic	symbiosis	whereby	the	non-proliferative	glycolytic	stromal	and	cancer	epithelial	cells	generate	catabolites	which	are	released	into	the	tumour	microenvironment	and	subsequently	taken	up	and	utilised	by	the	mitochondrial	rich	cancer	cells	to	drive	energy	production	and	proliferation	through	oxidative	 phosphorylation(366).	 Indeed,	 similar	 findings	 of	 metabolic	 coupling	 have	been	 reported	 for	other	 tumour	 types(367,	368),	 and	 clearly	 further	 and	more	 robust	exploration	 in	 SCCHN	 is	 required	 to	 reconcile	 these	 discrepancies	 and/or	 reveal	underlying	mechanistic	explanations.	
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1.4.	Aims		As	outlined	in	section	1.1.5.,	there	remains	a	common	goal	in	the	treatment	of	both	HPV-	negative	and	HPV-driven	SCCHN:	to	 identify	means	of	sensitising	these	tumours	to	the	effects	of	current	treatment	regimes.	In	the	context	of	traditional	HPV-negative	SCCHN	there	 is	 a	need	 to	 improve	 treatment	efficacy	 to	enhance	 survival	outcomes,	while	 for	HPV-related	oropharyngeal	SCC	there	is	a	drive	to	minimise	the	substantial	treatment-associated	 toxicity.	 RT	 remains	 a	 mainstay	 of	 treatment	 for	 all	 SCCHN,	 with	 74%	 of	SCCHN	 patients	 recommended	 to	 receive	 RT	 at	 some	 point	 during	 their	 treatment	pathway,	 either	 as	 stand-alone	 or	 as	 adjuvant	 therapy(27).	 Consequently,	 it	 is	imperative	to	identify	novel	radiosensitising	therapeutic	approaches.			Alteration	 to	cellular	metabolism	 is	now	widely	considered	 to	be	a	crucial	hallmark	of	the	cancer	phenotype	and	intrinsic	to	malignant	transformation(44)	(section	1.3.1.),	and	as	such	presents	a	potentially	attractive	therapeutic	target.	This	is	particularly	the	case	in	 the	 context	of	 identifying	novel	 radiosensitising	 strategies	given	 the	proposed	 links	between	altered	 tumour	metabolism	and	cellular	 redox	status	 (section	1.3.1.),	 and	 the	fact	 that	 the	mechanism	 underlying	 the	 therapeutic	 effect	 of	 RT	 relies	 on	 free	 radical	formation(369).	Whilst	a	generalised	disruption	of	normal	metabolic	homeostasis	may	occur	 to	 some	 degree	 in	 all	 tumours,	 there	 is	 undoubtedly	 heterogeneity	 between	cancers,	 which	may	 reflect	 both	 tissue-specific	 effects	 and	 differing	 oncogenic	 events	driving	tumorigenesis	in	different	tumour	types(250,	258,	267).	As	such,	detailed	study	and	 consideration	 of	 the	 metabolic	 phenotype	 of	 individual	 cancers	 is	 paramount	 if	effective	therapeutic	strategies	targeting	metabolism	are	to	be	developed	and	effectively	deployed.		Primary	studies	of	metabolism	specific	 to	SCCHN,	however,	have	been	 limited,	have	at	times	produced	conflicting	results,	and	have	failed	present	a	clear	picture	of	the	SCCHN	metabolic	 phenotype	 (section	 1.3.3.).	 Interestingly	 though,	 recent	 findings	 from	 one	research	 group	 have	 suggested	 that	 TP53	 status	 may	 play	 a	 key	 role	 in	 determining	metabolic	 re-programming	 in	 SCCHN,	 with	 associated	 therapeutic	 implications(359,	360).	Consequently,	the	aims	of	this	project	were	primarily	to	explore	in	greater	depth	the	metabolic	phenotype	in	SCCHN,	with	a	specific	focus	on	elucidating	any	correlation	with	TP53	status,	and	to	determine	whether	anti-metabolic	therapy	might	be	employed	to	 potentiate	 the	 effects	 of	 IR.	 Secondary	 aims	 of	 the	 project	 were	 to	 examine	 the	
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mechanistic	 basis	 of	 any	 observed	 metabolic	 re-programming	 and	 any	 observed	therapeutic	effects	of	anti-metabolic	treatment.		
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2.	Materials	and	Methods	
	
2.1.	List	of	reagents	
	
2.1.1.	General	reagents	
Reagent	or	product		 	 	 	 	 Manufacturer	Acetic	acid	(glacial)	100%	anhydrous			 	 Merck,	Feltham,	UK	Acrylogel	40%	solution	 	 	 	 VWR,	Lutterworth,	UK	ADP	disodium	 salt	hydrate		 	 	 	 Sigma-Aldrich,	Gillingham,	UK	Ammonium	persulfate	(APS)	 	 	 	 Sigma-Aldrich	Albumin	from	bovine	serum	(BSA),	96%		 	 Sigma-Aldrich	BSA	solution,	fatty	acid	free	(10%)	 	 	 Sigma-Aldrich	Aprotinin	 	 	 	 	 	 Roche,	Welwyn,	UK	L-ascorbic	acid		 	 	 	 	 Sigma-Aldrich	Blotting	grade	blocker,	non-fat	dry	milk	 	 Bio-Rad,	Hemel	Hempstead,	UK	5-Bromo-4-chloro-3-indolyl	β-D-galactopyranoside		 	(X-gal)			 	 	 	 	 	 VMR	Bromophenol	blue	 	 	 	 	 Sigma-Aldrich	Calcium	chloride	 	 	 	 	 Sigma-Aldrich	Citric	acid	monohydrate		 	 	 	 Merck	Chloroform	 	 	 	 	 	 Sigma-Aldrich	Crystal	Violet		 	 	 	 	 	 Sigma-Aldrich	CyQUANT®	cell	proliferation	assay	kit	 	 Invitrogen,	Paisley,	UK	Dichloroacetic	acid	(DCA),	potassium	salt	 	 Sigma-Aldrich	2’-7’-Dichlorodihydrofluorescein	diacetate	(DCF-DA)	 Life	Technologies,	Paisley,	UK	Dimethyl	Sulphoxide	(DMSO)		 	 	 	 Sigma-Aldrich	N,N-dimethylformamide	 	 	 	 Sigma-Aldrich		3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl	 	 	tetrasodium	bromide	(MTT)	 	 	 	 Molekula,	Newcastle,	UK	DNA	ladder	(100bp)	 	 	 	 	 New	England	Biolabs,	Ipswich,	UK	ECL	Prime	 	 	 	 	 	 GE	Healthcare,	Little	Chalfont,	UK	Ethanol,	absolute	 	 	 	 	 Sigma-Aldrich	Ethidium	bromide	 	 	 	 	 Roche	Ethylenediaminetetraacetic	acid	(EDTA)	 	 Sigma-Aldrich	Ethylene	glycol-bis(β-aminoethyl	ether)-	 	 	
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N,N,N’,N’-	tetracetic	acid	(EGTA)		 	 	 Sigma-Aldrich	Fluorescein	isothiocyanate	(FITC)-conjugated	 Cambridge	Bioscience,	Cambridge,	annexin	V	solution		 UK			Formaldehyde	solution	37%	 	 	 	 Merck		GenSieve	LE	agarose		 	 	 	 	 Flowgen,	Nottingham,	UK			D-glucose	 	 	 	 	 	 Sigma-Aldrich	Glutamic	acid	 	 	 	 	 	 Sigma-Aldrich	Gluteraldehyde	solution	(25%)	 	 	 VWR	Glycerol	 	 	 	 	 	 Sigma-Aldrich	Glycerol-3-phosphate		 	 	 	 	 Sigma-Aldrich	 	Glycine		 	 	 	 	 	 Thermo	 Fisher	 Scientific,	 Paisley,	UK	HEPES	free	acid,	molecular	biology	grade	 	 Calbiochem,	Beeston,	UK		Hi-DiTM	formamide	 	 	 	 	 Thermo	Fisher	Scientific	Hydrogen	peroxide	solution	(30%)	 	 	 Sigma-Aldrich	Isoamyl	alcohol	 Sigma-Aldrich	ISOTON®	solution	 Beckmann	 Coulter, High	Wycombe,	UK	Leupeptin	 	 	 	 	 	 Roche	Magnesium	chloride	 	 	 	 	 Sigma-Aldrich	L-malic	acid	 	 	 	 	 	 Sigma-Aldrich	Malonic	acid	 	 	 	 	 	 Sigma-Aldrich	Mannitol		 	 	 	 	 	 Sigma-Aldrich	β-mercaptoethanol		 	 	 	 	 Sigma-Aldrich	Methanol,	analytical	grade	 	 	 	 Thermo	Fisher	Scientific	NADP/NADPH	quantification	kit	 	 	 Sigma-Aldrich	Pepstatin	 	 	 	 	 	 Roche	Phenol	 	 	 	 	 	 	 Thermo	Fisher	Scientific	Phenylmethylsulphonyl	fluoride	(PMSF)	 	 Sigma-Aldrich	Ponceau	S		 	 	 	 	 	 Sigma-Aldrich		Potassium	dihydrogen	phosphate			 	 	 Merck	Potassium	hexacyano-ferrate	(II)	trihydrate		 	 Merck	Potassium	hexacyano-ferrate	(III)	 	 	 Merck	Pre-stained	protein	marker,	broad	range	 	 New	England	Biolabs	Propidium	iodide	(PI)	 	 	 	 	 Sigma-Aldrich	Protein	assay	dye	reagent	 	 	 	 Bio-Rad	
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Proteinase	K	 	 	 	 	 	 Sigma-Aldrich	RNase		A	 	 	 	 	 	 Qiagen,	Manchester,	UK	Sodium	acetate	 	 	 	 	 Sigma-Aldrich	Sodium	chloride	 	 	 	 	 VWR	Sodium	dodecyl	suphate	(SDS)	 	 	 Thermo	Fisher	Scientific	Sodium	dihydrogen	phosphate	dihydrate	 	 Sigma-Aldrich	 	 	 	Sodium	phosphate	dibasic	dihydrate	 	 	 Sigma-Aldrich	Sodium	pyruvate	solution	(100mM)	 	 	 Sigma-Aldrich	Succinic	acid	 	 	 	 	 	 Sigma-Aldrich	Sucrose	 	 	 	 	 	 Sigma-Aldrich	N,	N,	N’,	N’-tetramethylenediamine	(TEMED)		 	 VWR	
N,N,N′,N′-tetramethyl-p-phenylenediamine	 	 	Dihydrochloride	(TMPD)	 	 	 	 Sigma-Aldrich	Tris	base	 	 	 	 	 	 Calbiochem	Tris	EDTA	buffer	(20x)	 	 	 	 Invitrogen	Triton	X-100	 	 	 	 	 	 GE	Healthcare	Trypan	blue	solution	(0.4%)	 	 	 	 Invitrogen	Trypsin	inhibitor	from	soybean	(STI)	 	 	 Roche	Tween-20		 	 	 	 	 	 Sigma-Aldrich	XF	plasma	membrane	permeabiliser	(PMP)	 Seahorse	Bioscience,	 Copenhagen,	Denmark	XF	calibrant	solution	 Seahorse	Bioscience	
	
2.1.2	Tissue	culture	reagents	Dulbecco’s	modified	Eagle’s	medium	(DMEM),	 Sigma-Aldrich	HEPES	modification	Dulbecco’s	phosphate	buffered	Saline	(PBS)	 	 Sigma-Aldrich	Eagle’s	Minimum	essential	medium	 	 	 Sigma-Aldrich	Fetal	bovine	serum	(FBS)	 	 	 	 Sigma-Aldrich	L-glutamine	solution	200mM	 	 	 	 Sigma-Aldrich	MEM	non-essential	amino	acid	solution	(100x)	 Sigma-Aldrich	Penicillin-streptomycin	 	 	 	 Sigma-Aldrich	Trypsin-EDTA	solution	(1×)		 	 	 	 Sigma-Aldrich	XF	base	medium	 	 	 	 	 Seahorse	Bioscience	
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2.1.3	Drugs	2-deoxy-D-glucose	(2-DG):	stock	solution	prepared	by	dissolving	to	1M	in	PBS.	Supplied	by	Sigma-Aldrich.	Stored	at	-20°C	for	six	weeks.		3-bromopyruvate	 (3-BP):	 stock	 solution	 prepared	 by	 dissolving	 to	 20mM	 in	 PBS.	Supplied	by	Sigma-Aldrich.	Stored	at	-20°C	for	six	weeks.		6-aminonicotinamide	 (6-AN):	 stock	 solution	 prepared	 by	 dissolving	 to	 2mM	 in	 PBS.	Supplied	by	Sigma-Aldrich.	Stored	at	-20°C	for	six	weeks.		Antimycin	 A:	 stock	 solution	 prepared	 by	 dissolving	 to	 2mM	 in	 95%	 (w/v)	 ethanol.	Supplied	by	Sigma-Aldrich.	Long-term	storage	was	at	-20°C.		Carbonyl	 cyanide	 4-(trifluoromethoxy)phenyl-hydrazone	(FCCP):	 stock	 solution	prepared	 by	 dissolving	 to	 10mM	 in	 95%	 (w/v)	 ethanol.	 Supplied	 by	 Sigma-Aldrich.	Long-term	storage	was	at	-20°C.		Geneticin:	 various	 concentrations	 prepared	 in	 DMEM	 as	 described	 in	 section	 2.5.2.	Supplied	by	Calbiochem.		Metformin:	 stock	 solution	 prepared	 by	 dissolving	 to	 1M	 in	 PBS.	 Supplied	 by	 Sigma-Aldrich.	Stored	at	-20°C	for	six	weeks.		N-acetylcysteine	(NAC):	a	final	working	concentration	of	25mM	was	used	and	prepared	freshly	on	each	occasion.	Supplied	by	Sigma-Aldrich.		Oligomycin:	 stock	 solution	 prepared	 by	 dissolving	 to	 5mM	 in	 95%	 (w/v)	 ethanol.	Supplied	by	Sigma-Aldrich.	Long-term	storage	was	at	-20°C.		Plasmocin:	a	final	working	concentration	of	25μg/ml	was	used	and	prepared	freshly	on	each	occasion.	Supplied	by	Invivogen,	Toulouse,	France.		Rotenone:	 stock	 solution	 prepared	 by	 dissolving	 to	 2mM	 in	 95%	 (w/v)	 ethanol.	Supplied	by	Sigma-Aldrich.	Long-term	storage	was	at	-20°C		
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Staurosporine:	stock	solution	prepared	by	dissolving	to	1mM	in	DMSO.	Supplied	by	LC	Laboratories,	Woburn,	MA,	USA.	Long-term	storage	was	at	4°C.		UK-5099:	 stock	 solution	prepared	by	dissolving	 to	1mM	 in	DMSO.	 Supplied	by	 Sigma-Aldrich.	Long-term	storage	was	at	4°C.		
2.1.4	Antibodies	for	Western	blotting	The	 following	 primary	 antibodies	were	 diluted	 from	 stock in	 5%	blotting	 grade	milk-PBS-Tween	solution	at	the	indicated	concentrations:	α-6PGD	(G-2),	mouse	monoclonal	antibody,	 final	 concentration	of	2μg/ml,	 supplied	by	Santa	Cruz	Biotechnology,	Heidelberg,	Germany.		α-G6PD	 (D5D2),	 rabbit	monoclonal	 antibody,	 final	dilution	of	1:1000,	 supplied	by	Cell	Signaling	Technology,	Leiden,	Netherlands.		α-actin	 (C-2),	mouse	monoclonal	 antibody,	 final	 concentration	 of	 3μg/ml,	 supplied	 by	Santa	Cruz	Biotechnology.		α-GLUT-1	 (ab652),	 rabbit	 polyclonal	 antibody,	 final	 dilution	 of	 1:500,	 supplied	 by	Abcam,	Cambridge,	UK.			α-hexokinase-II	(4C5),	mouse	monoclonal	antibody,	final	dilution	of	1:1000,	supplied	by	Novus	Biologicals,	Abingdon,	UK.		α-MCT-1	(AB3538P),	rabbit	polyclonal	antibody,	final	concentration	of	5μg/ml,	supplied	by	Merck		α-MDM2	(IF-2),	mouse	monoclonal	antibody,	final	concentration	of	3μg/ml,	supplied	by	Calbiochem.		α-p21	 (F-5),	 mouse	 monoclonal	 antibody,	 final	 concentration	 of	 3μg	 ml,	 supplied	 by	Santa	Cruz	Biotechnology.		α-p53	 (DO-1),	mouse	monoclonal	antibody,	 final	 concentration	of	3μg/ml,	 supplied	by	Calbiochem.		
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α-PDK-2	 (NBP1-87307),	 rabbit	 polyclonal	 antibody,	 final	 concentration	 of	 1μg/ml,	supplied	by	Novus	Biologicals.		α-PGAM	(D3J9T),	rabbit	monoclonal	antibody,	final	dilution	of	1:1000,	supplied	by	Cell	Signaling	Technology.		α-TIGAR	(AB10545),	rabbit	polyclonal	antibody,	final	concentration	of	1μg/ml,	supplied	by	Merck.		α-vinculin	(V9131),	mouse	monoclonal	antibody,	final	dilution	of	1:100	000,	supplied	by	Sigma-Aldrich.		The	 following	secondary	antibodies	were	also	diluted	 from	stock in	5%	blotting	grade	milk-PBS-Tween	solution	at	the	indicated	concentrations:	Sheep	 α-mouse	 antibody	 (RPN4201),	 used	 at	 a	 1:2500	 dilution,	 supplied	 by	 GE	Healthcare.				Donkey	 α-rabbit	 antibody	 (NA934),	 used	 at	 a	 1:5000	 dilution,	 supplied	 by	 GE	Healthcare.	
	
	
2.2	Cell	culture	
	
2.2.1.	Cell	lines	The	 parental	 cell	 lines	 included	 in	 this	 work	 are	 summarised	 in	 table	 2.2.1.1.	accompanied	by	details	of	SCCHN	subsite	of	origin,	 reported	HPV	status,	and	reported	
TP53	status.		The	 majority	 of	 cell	 lines	 used	 were	 parental	 University	 of	 Michigan	 squamous	 cell	carcinoma	 (UM-SCC)	 cell	 lines,	 which	 were	 kindly	 provided	 by	 Professor	 T.	 Carey	(University	 of	 Michigan	 Medical	 School).	 UM-SCC-17A	 cells	 stably	 expressing	 short-hairpin	RNA	 (shRNA)	 specific	 for	p53	 (shp53)	or	 an	 empty	 vector	 control	 (lenti),	 and	several	 derivative	 cell	 lines	 of	 UM-SCC-1,	 transduced	 with	 various	 TP53	 mutations	(R282W,	C176F,	R175H),	wild-type	TP53,	or	an	empty	vector	(pBABE)	were	also	utilised	and	were	obtained	 through	collaboration	with	Professor	 J.	Myers (University	of	Texas	MD	Anderson	Cancer	Center,	TX,	USA).	These	derivative	cells	 lines	had	been	produced	
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using	 standard	 cloning	 and	 transfection	 techniques.	 Briefly,	 after	 infection	with	 green	fluorescent	protein	(GFP)-tagged	empty	lentiviral	vector	or	encoding	an	shRNA	against	p53,	 cells	 were	 cultured	 for	 several	 passages,	 and	 sorted	 using	 flow	 cytometry.	TP53	constructs	(C176F,	R282W,	R175H,	wild-type)	were	generated	by	extracting	RNA	from	cell	 lines	known	to	express	these	mutants.	Reverse	transcriptase	PCR	was	then	carried	out	using	TP53-specific	primers,	and	the	resulting	products	purified	and	inserted	into	a	pBABE	 retroviral	 vector	 containing	 a	 puromycin-resistance	 insert.	 After	 transfection	and	packaging	 in	293T	 cells,	 the	 viral	 supernatant	was	 centrifuged	 to	 remove	 cellular	debris	and	added	to	UM-SCC-1	cells	 in	combination	with	polybrene.	After	one	passage,	the	cells	underwent	selection	with	puromycin.				UPCI:SCC	 154	 was kindly	 provided	 by	 Professor	 S.	 Gollin	 (University	 of	 Pittsburgh	School	 of	 Public	 Health,	 PA,	 USA),	 while	 93-VU-147T	 was	 obtained	 from	 Dr.	 J.	 Risk,	(University	of	Liverpool,	Liverpool,	UK).		
Table	2.2.1.1:	Parental	cell	lines	used	in	this	study.	
Cell	Line	 Subsite	of	
Origin	
Type	of	Lesion	 Reported	
TP53	Status	
Reported	
HPV	Status	
Primary	
References	UM-SCC-1	 Floor	of	mouth	 Primary	 Splice	site	mutation	 Negative	 (238,	370,	371)	UM-SCC-5	 Supraglottis	 Primary	 Mutant:	V157F	 Negative	 (370-372)	UM-SCC-10A	 True	vocal	cord	 Primary	 Mutant:	G245C	 Negative	 (238,	370,	372,	373)	UM-SCC-11A	 Supraglottis	 Primary:	pre-treatment	biopsy	
Wild-type	 	 (374-376)	
UM-SCC-11B	 Supraglottis	 Primary:	post-chemotherapy	surgery	
Mutant:	C242S	 Negative	 (238,	370-374)	
UM-SCC-17A	 Supraglottis	 Primary	 Wild-type	 Negative	 (370-373)	UM-SCC-17AS	 Supraglottis	 Primary	 Wild-type	 Negative	 (370-373)	UM-SCC-81B	 Tonsil	 Metachronous	primary	 Mutant:	H193R	 Negative	 (370-372,	374,	377)	UM-SCC-104	 Floor	of	mouth	 Primary	 Wild-type	 Positive	 (378,	379)	UPCI:SCC154	 Lateral	tongue	 Primary	 Wild-type	 Positive	 (378,	380)	93VU147T	 Floor	of	mouth	 Primary	 Wild-type	 Positive	 (378,	381)		
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2.2.2.	Cell	medium	and	growth	environment	Cells	were	grown	 in	NuncTM	cell	 culture	 treated	 flasks	with	 filter	 caps	 (Thermo	Fisher	Scientific)	of	various	sizes	(T25,	T75,	T175)	in	a	humidified	cell	incubator	at	37°C	with	5%	 CO2.	With	 the	 exception	 of	 UPCI:SCC154,	 all	 cell	 lines	 were	maintained	 in	 DMEM	supplemented	 with	 10%	 FBS,	 1%	 penicillin/streptomycin,	 1%	 L-glutamine,	 and	 1%	Non-Essential	Amino	Acids.	UPCI:SCC154	was	maintained	in	Eagle’s	minimum	essential	medium	supplemented	with	15%	FBS,	with	additional	supplements	as	before.		
2.2.3.	Cell	sub-culture	technique	Aseptic	technique	was	observed	at	all	times	in	order	to	avoid	contamination	and	tissue	culture	work	was	carried	out	in	a	class	II	laminar	flow	tissue	culture	cabinet.			All	 cell	 lines	 used	 in	 this	 study	 grew	 as	 adherent	 monolayers	 on	 cell	 culture	 treated	surfaces.	Regular	 sub-culture,	 or	 passage,	 of	 cells	was	performed	 to	 ensure	 cells	were	maintained	 at	 optimum	 health,	 as	 once	 cells	 reach	 maximum	 confluence	 in	 culture,	death	can	result	from	overcrowding	and	the	associated	stress.	Passaging	was	carried	out	when	 cell	 reached	 approximately	 70-90%	 confluence	 and	 was	 performed	 as	 follows:	media	was	 aspirated	 and	 the	 cell	monolayer	was	washed	 once	 in	 PBS,	 typically	 10ml	when	using	a	T75	tissue	culture	flask.	PBS	was	then	aspirated	before	3-5ml	of	trypsin-EDTA	was	added	to	the	monolayer	and	the	culture	flask	returned	to	the	cell	incubator	at	37	°C.	The	flask	was	agitated	as	required	to	facilitate	the	detachment	of	cells,	which	was	regularly	 assessed	by	 examination	under	 light	microscopy.	Once	 adequately	detached,	the	 trypsin-EDTA	 was	 neutralised	 by	 the	 addition	 of	 an	 excess	 of	 media,	 the	 precise	volume	 of	 which	 was	 dependent	 on	 the	 ratio	 of	 the	 cell	 split,	 which,	 in	 turn,	 was	dependent	 on	 the	 growth	 characteristics	 of	 the	 individual	 cell	 line.	 For	 instance,	relatively	 slowly	 growing	 cell	 lines	were	 typically	 split	 1:10,	 and	 rapidly	 proliferating	cell	 lines	1:20.	The	relevant	volume	of	 the	re-suspended	cells	was	then	aspirated	from	the	flask	before	fresh	media	was	added	–	typically	25ml	for	a	T75	flask.		
2.2.4	Cryopreservation	and	recovery	of	cryopreserved	cell	stocks		For	 the	 cryopreservation	 of	 cells,	 cells	were	 harvested	 by	 trypsinisation	 as	 described	above	(section	2.2.3.)	and	pelleted	by	centrifugation	at	300	x	g	 for	five	minutes	at	4°C.	The	 supernatant	was	 aspirated	 and	 the	 resulting	 cell	 pellet	 re-suspended	 in	 1-2ml	 of	freezing	media	(10%	DMSO	in	FBS),	before	transfer	to	NuncTM	cryovials	(Thermo	Fisher	Scientific).	The	cryovials	were	then	placed	in	a	pre-cooled	Styrofoam	rack	and	stored	at	-
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80°C,	allowing	gradual	freezing	of	the	cells.	Subsequently,	cryovials	were	transferred	to	liquid	nitrogen	for	long-term	storage	after	approximately	24–48	hours.		When	 recovering	 cells	 from	 stocks	 stored	 in	 liquid	 nitrogen,	 cryovials	 were	 thawed	expediently	in	a	37°C	water	bath.	Recognising	that	DMSO	toxic	to	cells	at	concentrations	above	0.5%,	 the	 cells	were	 re-suspended	 in	 a	 tissue	 flask	 containing	 at	 least	 25	ml	 of	media	 that	was	 pre-warmed	 to	 37°C.	 Once	 the	 cells	 had	 adhered	 to	 the	 flask	 surface,	typically	the	following	day,	the	media	was	changed.				
2.3.	Verification	and	optimisation	of	cell	lines		
	
2.3.1.	STR	profiling	Prior	to	use	 in	experiments,	all	cell	 lines	were	subjected	to	short	tandem	repeat	(STR)	profiling	 to	verify	 their	 identity,	 as	determined	by	comparison	with	published	profiles	for	 each	 individual	 cell	 line.	 Firstly,	 genomic	 DNA	was	 isolated	 from	 cells.	 Cells	 were	harvested	by	trypsinisation	and	pelleted	by	centrifugation	as	described	in	sections	2.2.3.	and	2.2.4.	The	cell	pellet	was	then	re-suspended	in	500μl	of	genomic	DNA	preparation	lysis	buffer	(50mM	Tris	[pH	8.0],	100mM	EDTA	and	0.5%	SDS)	with	250μg	proteinase	K	at	a	 final	concentration	of	5μg/μl	and	incubated	overnight	 in	a	heat	block	at	55°C.	The	following	 day,	 DNA	was	 extracted	 using	 an	 organic	 solvent-based	 extraction	method.	The	cell	lysate	was	mixed	with	500μl	phenol	and	left	for	one	hour	with	gentle	shaking.	Samples	 were	 then	 mixed	 thoroughly	 by	 hand	 for	 five	 minutes	 before	 undergoing	centrifugation	at	13,000	x	g	for	five	minutes.	Next,	the	aqueous	phase	was	transferred	to	a	fresh	Eppendorf®	1.5ml	microcentrifuge	tube	(Sigma-Aldrich)	and	mixed	with	500μl	PCI	(phenol,	chloroform,	 isoamyl	alcohol	at	 the	ratio	24:25:1)	 for	 five	minutes	each	by	hand	and	centrifugation	as	before.	The	aqueous	phase	was	again	transferred	into	a	fresh	Eppendorf®	1.5ml	microcentrifuge	tube,	and	the	DNA	then	precipitated	by	adding	50μl	of	3M	sodium	acetate	solution	(pH	6.0)	and	500μl	of	100%	ethanol	to	each	tube.	Tubes	were	 then	mixed	by	hand	 for	one	minute	and	centrifuged	 for	10	minutes	 (13,000	x	g)	before	the	supernatant	was	removed	and	the	pellet	washed	with	70%	ethanol.	The	DNA	pellet	 was	 re-suspended	 in	 50μl	 of	 TE	 buffer	 (10mM	 Tris	 and	 1mM	 EDTA	 [pH	 8.0])	containing	 ribonuclease	 (RNase)	 A	 at	 a	 final	 concentration	 of	 10μg/ml,	 and	 the	concentration	 of	 DNA	 and	 its	 purity	 determined	 using	 a	 NanoDrop®	 UV	spectrophotometer	(Thermo	Fisher	Scientific).	Samples	were	then	serially	diluted	with	ddH2O	to	achieve	a	DNA	concentration	of	2ng/µl	in	preparation	for	subsequent	PCR	and	
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STR	 profiling,	 which	 were	 performed	 using	 the GenePrint®	 10	 System	 (Promega,	Southampton,	 UK)	 as	 per	 the	manufacturer’s	 instructions.	 The	 appropriate	 volume	 of	PCR	amplification	mix	was	first	made	up	(7.5µl/reaction),	which	comprised	3.5µl	ddH2O,	and	2µl	each	of	master	mix	and	primer	pair	mix	from	the	pre-amplification	box	from	the	GenePrint®	10	System.	Next,	7.5µl	of	PCR	amplification	mix	was	added	to	each	well	in	a	96-well	MicroAmp®	plate	(Thermo	Fisher	Scientific),	along	with	2.5µl	sample	template	DNA,	 or	 in	 the	 case	 of	 positive	 and	 negative	 controls	 GenePrint®	 10	 control	 DNA	 or	ddH2O	respectively.	After	 thorough	mixing	by	pipetting	and	sealing	of	 the	plate,	 a	Px2	thermal	 cycler	 (Thermo	 Fisher	 Scientific)	 was	 used	 to	 perform	 the	 following	 thermal	cycle:	
o 96°C	–	1	minute	
o 94°C	–	10	seconds		
o 59°C	–	1	minute	 	 30	cycles		
o 72°C	–	30	seconds	
o 60°C	–	20	minutes	
o 4°C	–	soak		Following	amplification,	a	 loading	cocktail	was	prepared	by	combining	and	mixing	 the	GenePrint®	 10	 Internal	 Lane	 Standard	 600	 and	 Hi-DiTM	 formamide,	 with	 respective	volumes	of	0.5µl	and	9.5µl	required	for	each	sample.	10µl	of	this	was	then	added	to	each	well	in	a	fresh	96-well	MicroAmp®	plate	before	adding	1µl	of	amplified	sample	(or	1μl	of	 GenePrint®	 10	 Allelic	 Ladder	 Mix	 for	 the	 positive	 control).	 	Samples	 were	 then	denatured	at	95°C	for	three	minutes	using	a	heat	block,	and	then	immediately	chilled	on	crushed	ice	for	a	further	three	minutes.	 	Samples	were	subsequently	transferred	to	the	Applied	 Biosystems	 3130	 Genetic	 Analyser	 (Thermo	 Fisher	 Scientific)	 for	 processing,	and	data	was	analysed	using	GeneMapper®	software	(Thermo	Fisher	Scientific).		
2.3.2.	Mycoplasma	testing	Following	verification	of	 cell	 line	 identity,	 all	 cell	 lines	were	 screened	 for	mycoplasma	infection	 as	 mycoplasma	 contamination	 is	 characteristically	 unapparent	macroscopically	 or	 microscopically	 and	 may	 alter	 any	 parameter	 measured	 in	 cell	culture	 or	 in	 experimental	 investigations(371,	 382).	 Screening	 for	 mycoplasma	contamination	 was	 performed	 using	 the	 e-MycoTM	 mycoplasma	 PCR	 detection	 kit	(ChemBio,	Luton,	UK)	 to	detect	mycoplasma-specific	 sequences.	Cells	were	brought	 to	confluence	 in	 T75	 cell	 culture	 flasks	 and	 then	 harvested	 using	 trypsin-EDTA,	 as	described	 in	 section	 2.2.3,	 before	 1ml	 of	 cell	 suspension	 was	 transferred	 to	 an	
	
Materials	&	Methods	
	 67	
Eppendorf®	1.5ml	microcentrifuge	 tube.	Following	centrifugation	at	13,000	x	g	for	30	seconds,	the	supernatant	was	carefully	removed	and	the	cells	resuspended	in	1ml	PBS.	This	 process	 was	 then	 repeated	 for	 a	 second	 PBS	 wash	 before	 the	 cells	 were	 again	resuspended	in	100µl	PBS,	heated	for	10	minutes	at	100°C	in	a	heat	block,	vortexed	for	15	 seconds,	 and	 centrifuged	at	13,000	x	g	for	 two	minutes.	The	 supernatant	was	 then	removed	and	aliquoted	into	a	fresh	Eppendorf®	1.5ml	microcentrifuge	tube.	Next,	10µl	of	this	supernatant,	which	was	used	as	the	DNA	template	in	the	PCR,	was	added	to	a	pre-prepared	e-MycoTM	reaction	tube	along	with	10µl	of	ddH2O.	This	was	repeated	for	each	sample.	 Negative	 and	 positive	 controls	 comprising	 20µl	 ddH2O	 and	 1µl	 of	 e-MycoTM	control	DNA	with	19µl	ddH2O	 respectively	were	 also	 included	 in	 each	 reaction.	A	Px2	thermal	cycler	(Thermo	Fisher	Scientific)	was	used	to	perform	the	following	PCR:	
o 94°C	–	1	minute	
o 94°C	–	30	seconds		
o 60°C	–	20	seconds	 	 35	cycles		
o 72°C	–	1	minute	
o 72°C	–	5	minutes		A	2%	agarose	gel,	comprising	2g	GenSieve	LE	agarose	in	100ml	TAE	buffer	(40mM	Tris-Base,	1mM	EDTA	[pH	8.0],	and	1.142%	glacial	acetic	acid)	supplemented	with	0.5μg/ml	ethidium	bromide,	was	then	used	to	separate	the	DNA	fragments	by	gel	electrophoresis.	Once	 fully	dissolved,	 the	agarose	 solution	was	allowed	 to	 cool	 and	 then	poured	 into	a	sealed	 gel	 cast,	with	 comb,	 to	 set.	 Once	 set,	 the	 comb	 and	 sealing	 tape	were	 carefully	removed	and	the	assembled	gel	submerged	in	TAE	buffer	inside	an	electrophoresis	tank.	Amplified	 samples	were	 then	prepared	 for	 loading	by	mixing	2µl	 of	 each	 sample	with	16µl	ddH2O	and	2µl	with	10%	(v/v)	orange	G	loading	buffer	in	a	fresh	PCR	reaction	tube.	Samples	(10µl)	were	then	loaded	carefully	into	the	wells	along	with	a	100bp	DNA	ladder	in	 the	 first	 well.	 Subsequently,	 electrophoresis	 was	 performed	 in	 horizontal	 gel	 units	(Scie-Plas,	 Cambridge,	 UK)	 using	 a	 two-gel	 Mini-PROTEAN®	 Tetra	 cell	 (Bio-Rad)	 at	100V	until	the	desired	band	separation	had	taken	place	(typically	35	minutes).	Finally,	DNA	bands	were	visualised,	enabled	by	the	presence	of	ethidium	bromide	in	the	agarose	gel,	 by	 placing	 the	 gel	 onto	 a	 High	 Performance	 UV-transilluminator,	 and	 a	 picture	recorded	 digitally	 using	 a	 Kodak	 EDAS	 290	 (Kodak,	 Watford,	 UK).	 Further	 image	processing	was	performed	using	CorelDRAW	graphics	suite	X7	(Corel,	Luton,	UK).	If	cell	lines	were	 found	 to	be	positive	 for	mycoplasma	 contamination	 (see	 appendix	 [section	5.1]	 for	 details)	 alternative	 stocks	 were	 sought	 and	 also	 tested	 for	 the	 presence	 of	mycoplasma	contamination.	 If	no	negative	stocks	were	available	eradication	treatment	
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was	instigated	accordingly	until	subsequent	testing	was	negative	(see	appendix	[section	5.2]	for	details).			
2.4.	Metabolic	profiling	using	microplate-based	extracellular	flux	analysis	
	
2.4.1.	Principles	of	microplate-based	extracellular	flux	analysis	Metabolic	 profiling	 was	 performed	 using	 microplate-based	 extracellular	 flux	 (XF)	analysis,	which	is	a	high-throughput	means	of	measuring	the	rate	of	change	of	dissolved	oxygen	 and	 pH,	 resulting	 from	 the	 extrusion	 of	 protons,	 in	 the	 media	 immediately	surrounding	 living	 cells	 cultured	 in	 a	 microplate(383).	 These	 measurements	 were	performed	 using	 the	 XF24	 instrument	 (Seahorse	 Bioscience),	 which	 utilises	 optical	fluorescent	 biosensors	 embedded	 in	 disposable	 XF24	 sensor	 cartridges	 (Seahorse	Bioscience,)	 that	 are	 placed	 into	 a	 24-well	 tissue	 culture	 microplate	 (Seahorse	Bioscience)	 (figure	 2.4.1.1.).	 This	 experimental	 system	 is	 able	 to	 make	 accurate	 and	repeatable	 measurements	 over	 short	 periods	 of	 time	 during	 measurement	 cycles	 by	isolating	small	volumes	of	media	above	the	cell	monolayer,	which	allows	for	detection	of	precise	changes	to	analyte	levels	resulting	from	cellular	metabolism(383).	Experimental	readouts	 are	 oxygen	 consumption	 rate	 (OCR)	 in	 pmol/min	 and	 extracellular	acidification	rate	(ECAR)	in	mpH/min,	surrogate	measures	of	oxidative	phosphorylation	and	 glycolysis	 respectively.	 These	 measurements	 can	 be	 taken	 at	 baseline	 as	 well	 as	following	the	administration	of	a	variety	metabolic	substrates	and/or	inhibitors	during	specifically	 designed	 stress	 test,	 which	 will	 be	 detailed	 further	 in	 sections	 2.4.6.	 and	2.4.7.,	giving	this	system	quantitative	and	real-time	capacity.		
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Figure	2.4.1.1:	An	illustration	of	how	the	XF24	experimental	system	works	(adapted	from	reference(384).	Optical	fluorescent	biosensors	embedded	in	a	disposable	XF24	sensor	cartridge	that	is	placed	over	a	24-well	tissue	culture	microplate,	in	which	cells	are	seeded,	enable	the	XF24	instrument	 to	measure	 the	oxygen	 consumption	 rate	 (OCR)	 and	 extracellular	 acidification	 rate	(ECAR).	There	are	also	four	drug	delivery	ports	per	well	in	the	sensor	cartridge,	which	allows	for	the	administration	of	compounds	during	specifically	designed	stress	tests.	
	
2.4.2.	Media	preparation	When	undertaking	 both	mitochondrial	 and	 glycolytic	 stress	 tests	 (detailed	 in	 sections	2.4.6.	 and	 2.4.7.	 respectively)	 unbuffered	 XF	 base	 medium	 was	 used.	 For	 glycolytic	stress	tests	this	was	supplemented	with	2mM	L-glutamine	only,	while	for	mitochondrial	stress	tests	2mM	of	sodium	pyruvate	and	10mM	D-glucose	were	also	added.	Media	was	then	adjusted	 to	pH	7.4	 and	 sterile	 filtered.	These	media	will	 be	herein	 referred	 to	 as	“Seahorse	glycolytic	assay	medium”	and	“Seahorse	mitochondrial	assay	medium”.		For	 XF	 PMP	 assays	 (detailed	 in	 section	 2.4.9.)	 a	 non-ionic	 medium	was	 used	 as	 salt-based	buffers	can	increase	cell	detachment	from	the	monolayer.	3X	mitochondrial	assay	solution	(MAS)	was	made	up	as	the	base	assay	medium	according	to	the	follow	recipe:	660mM	mannitol	210mM	sucrose	30mM	KH2PO4	15mM	MgCl2	6mM	HEPES	
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3mM	EGTA	0.6%	(w/v)	fatty	acid	free	BSA		On	the	day	of	the	assay	the	required	volume	of	3x	MAS	was	aliquoted	and	diluted	to	1x	using	ddH2O.		
2.4.3	Preparation	of	the	XF24	instrument	All	 assay	designs	 and	 calibration	 steps	described	 in	 the	 following	 sections	were	 setup	and	executed	using	either	XF	or	Wave	software	(Seahorse	Bioscience).	Subsequent	data	analysis	was	carried	out	using	Wave	software.	
	
2.4.4.	Preparation	of	the	XF24	sensor	cartridge	In	 order	 to	 hydrate	 the	 XF24	 sensor	 cartridge	 in	 preparation	 for	 any	 Seahorse	 assay,	1mL	of	XF	calibrant	solution	was	added	to	each	well	in	the	XF24	calibration	microplate	before	 placing	 the	 sensor	 cartridge	 into	 the	 microplate.	 This	 was	 then	 incubated	overnight	 in	 the	 XF24	 Prep	 station	 (Seahorse	 Bioscience)	 at	 37°C	 under	 ambient	atmospheric	conditions	and	used	within	24	hours.			
2.4.5	Cell	seeding	and	preparation	of	the	XF24	microplate	The	 day	 prior	 to	 any	 Seahorse	 assay,	 cells	 were	 harvested	 using	 trypsin-EDTA	 as	described	previously	 (section	2.2.3.)	 and	 cellular	 concentrations	determined	using	 the	mean	 from	three	 independent	cell	 counts	 from	a	Coulter	counter	 (Beckmann	Coulter).	Prior	to	counting	the	cells	the	Coulter	counter	was	calibrated	by	flushing	with	ISOTON®	solution.	 Flushing	 was	 repeated	 until	 a	 cell	 count	 of	 less	 than	 3000	 cells/ml	 for	ISOTON®	 solution	 alone	 was	 achieved.	 For	 ease	 of	 subsequent	 seeding,	 cells	 were	pelleted	 by	 centrifugation	 at	 300	 x	 g	 for	 five	minutes	 at	 ambient	 temperature	 before	being	 re-suspended	 in	 the	 appropriate	 volume	 of	 DMEM	 to	 obtain	 a	 concentration	 of	1x106	 cells/ml.	 Cells	 were	 then	 seeded	 in	 each	 well	 of	 the	 XF24	 microplate	 at	 pre-determined	densities	(with	the	exception	of	the	designated	blank	wells	–	A1,	B4,	C3,	and	D6	–	that	served	as	background	temperature	control	wells),	with	each	well	then	topped	up	with	an	excess	of	DMEM	to	give	a	total	volume	of	500μl	per	well.	Following	this,	the	microplate	was	 incubated	overnight	at	37°C	with	5%	CO2	 to	allow	 for	cell	attachment.	Optimal	cell	seeding	densities	were	determined	for	each	individual	cell	 line	in	the	first	instance	by	visual	assessment	using	light	microscopy,	with	the	aim	of	achieving	evenly	distributed	 cells	 at	 50-90%	 confluence	within	 each	well.	 Basal	 OCR	 and	 ECAR	 values	obtained	during	subsequent	cell	titration	assays,	in	which	several	cell	seeding	densities	
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were	evaluated,	were	 then	used	 to	 confirm	or	 refute	whether	optimal	 seeding	density	had	 been	 achieved,	 with	 respective	 target	 values	 of	 50-400pmol/min	 and	 20-120mpH/min	as	per	manufacturer’s	guidelines.	Seeding	densities	used	for	each	cell	line	are	shown	in	table	2.4.5.1.			
Table	2.4.5.1:	Seeding	densities	used	for	each	cell	line	in	XF	assays.	
Cell	Line	 Number	of	Cells/Well	UM-SCC-1	(and	derivative	lines)	 25	000	UM-SCC-5	 50	000	UM-SCC-10A	 100	000	UM-SCC-11A	 75	000	UM-SCC-11B	 75	000	UM-SCC-17A	(and	derivative	lines)	 375	000	UM-SCC-17AS	 500	000	UM-SCC-81B	 50	000	UM-SCC-104	 100	000	UPCI:SCC154	 150	000	93VU147T	 75	000		On	the	day	of	the	assay,	relevant	compounds	were	prepared	and	added	in	appropriate	volumes	 to	 the	 designated	 stress	 test	 injection	 ports	 in	 the	 previously	 hydrated	 XF	sensor	cartridge,	dependent	on	the	assay	type	being	performed	(see	sections	2.4.6.	and	2.4.7.).	This	sensor	cartridge,	with	the	XF24	calibration	plate	prepared	previously,	was	then	used	to	calibrate	the	XF24	instrument.			Simultaneously,	 cell	 attachment	 to	 the	 XF24	 microplate	 was	 confirmed	 using	 light	microscopy.	 The	 DMEM	 was	 then	 aspirated	 from	 each	 well	 and	 cells	 were	 carefully	washed	 with	 1ml	 of	 pre-warmed	 relevant	 assay	 media	 to	 ensure	 all	 FBS	 containing	media	 was	 completely	 removed.	 Subsequently,	 in	 the	 case	 of	 mitochondrial	 and	glycolytic	stress	tests,	500μl	of	relevant	assay	media	was	slowly	added	per	well	without	disrupting	the	monolayer,	 the	 integrity	of	 the	monolayer	re-checked,	and	the	plate	 left	to	equilibrate	for	one	hour	in	the	XF24	Prep	station	at	37°C	under	ambient	atmospheric	conditions	 before	 being	 loaded	 into	 the	 pre-calibrated	 XF24	 instrument.	 For	 XF	 PMP	assays,	1x	MAS	media	was	supplemented	with	the	desired	substrates,	ADP,	and	XF	PMP	reagent	(see	section	2.4.9.	for	details),	500μl	of	which	was	then	carefully	added	per	well.	The	microplate	was	then	transferred	immediately	to	the	calibrated	XF24	instrument	to	minimise	cell	exposure	time	to	the	MAS	and	to	avoid	cell	lifting	from	the	microplate.	
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2.4.6.	Mitochondrial	stress	test	During	mitochondrial	stress	tests	cells	were	metabolically	perturbed	by	the	sequential	addition	 of	 three	 different	 mitochondrial	 stressor	 compounds	 as	 follows:	 oligomycin,	FCCP,	and	a	combination	of	antimycin-A	and	rotenone.	10x	stock	concentrations	of	each	of	 these	 compounds	 were	 first	 prepared	 in	 Seahorse	 mitochondrial	 assay	 media	 and	added	to	injection	ports	A	(oligomycin),	B	(FCCP),	and	C	(antimycin-A/rotenone)	in	the	designated	stress	 test	wells	so	 that	upon	 injection	of	respective	volumes	of	55μl,	61μl,	and	 68μl	 the	 desired	 working	 concentrations	 in	 the	 microplate	 wells	 were	 achieved.	Equal	volumes	of	Seahorse	mitochondrial	assay	media	were	added	to	the	injection	ports	in	the	allocated	control	wells.	Desired	working	concentrations	of	both	antimycin-A	and	rotenone	 were	 1μM,	 while	 concentrations	 of	 oligomycin	 and	 FCCP	 required	 careful	titration	because	the	effects	of	these	compounds	can	vary	between	different	cell	types,	and	 relatively	 small	 changes	 in	 concentration	 can	affect	 final	measurement(383,	384).	Data	generated	during	 the	course	of	such	optimisation	 is	presented	 later	 in	 this	 thesis	(section	3.1.2.).		Following	instrument	calibration	and	loading	of	the	cell	microplate	as	described	above,	a	 baseline	was	 established	 to	 start	 the	 assay.	 This	was	 achieved	 by	 programming	 the	instrument	as	follows:	initial	measurement,	mixing	the	plate	for	two	minutes,	allowing	a	delay	of	 two	minutes,	 and	 then	 taking	a	 further	measurement	 (mix	 two	minutes,	wait	two	minutes,	measure	 two	minutes).	This	 cycle	was	 repeated	 five	 times	 to	 establish	a	robust	 baseline	OCR.	 Following	 this,	 the	 oligomycin	was	 delivered	 into	 the	 stress	 test	wells	 through	port	A.	Oligomycin	 inhibits	ATP	synthase	(ETC	complex	V)	and	causes	a	drop	 in	 OCR,	 which	 can	 be	 used	 to	 distinguish	 the	 amount	 of	 oxygen	 consumption	devoted	to	ATP	synthesis	from	that	required	to	overcome	the	natural	proton	leak	across	the	 inner	 mitochondrial	 membrane(383,	 384)	 (figure	 2.4.6.1).	 At	 this	 point	 the	instrument	was	 programmed	 to	 undertake	 three	measurement	 cycles	 as	 before.	Next,	FCCP	 was	 delivered	 into	 the	 stress	 test	 wells	 via	 port	 B,	 after	 which	 three	 further	instrument	measurement	cycles	were	performed.	FCCP	is	an	ionophore,	which	disrupts	ATP	synthesis	by	transporting	hydrogen	ions	across	the	inner	mitochondrial	membrane	instead	 of	 through	 the	 proton	 channel	 of	 ATP	 synthase,	 and	 as	 such	 uncouples	 the	mitochondria	from	the	ETC(383).	This	leads	to	collapse	of	the	mitochondrial	membrane	potential	 that	 results	 in	 a	 rapid	 and	 uncontrolled	 consumption	 of	 energy	 and	 oxygen	without	the	generation	of	ATP,	which	manifests	 in	a	maximal	 increase	 in	OCR	that	can	be	 used	 to	 calculate	 the	 spare	 respiratory	 capacity	 of	 cells(383,	 384)	 (figure	 2.4.6.1).	
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Finally,	 antimycin-A	 and	 rotenone	 were	 added	 through	 port	 C,	 after	 which	 two	measurement	cycles	were	taken.	These	compounds	are	ETC	complex	III	and	I	inhibitors	respectively,	 the	 combination	 of	 which	 shuts	 down	 mitochondrial	 respiration	completely,	 enabling	 identification	 of	 residual	 respiration	 that	 is	 non-mitochondrial,	which	then	needs	to	be	subtracted	from	the	previous	measurements(383,	384)	(figure	2.4.6.1).	
	
Figure	2.4.6.1:	Experimental	read-out	from	the	mitochondrial	stress	test.	This	depicts	how	the	 sequential	 delivery	 of	 the	 three	 compounds	 (oligomycin,	 FCCP,	 and	 a	 combination	 of	antimycin	A	and	rotenone)	allows	derivation	of	several	metabolic	parameters	(basal	respiration,	ATP-linked	 respiration,	 proton	 leak-linked	 respiration,	 maximal	 respiration,	 spare	 respiratory	capacity,	an	non-mitochondrial	respiration).	The	underlying	mechanisms	are	as	described	in	the	text.		
2.4.7.	Glycolytic	stress	test	Akin	to	the	mitochondrial	stress	test	described	above,	the	glycolytic	stress	test	involves	the	 sequential	 injection	 of	 three	 compounds	 that	 manipulate	 cellular	 metabolism	 to	facilitate	 derivation	 of	 several	 key	 glycolytic	 parameters.	 In	 this	 instance	 the	 injected	compounds	 comprise	 D-glucose,	 oligomycin,	 and	 2-DG(383,	 384).	 Again,	 10x	 stock	concentrations	of	 each	of	 these	 compounds	were	 first	prepared	 in	 Seahorse	 glycolytic	assay	media,	such	that	upon	injection	of	respective	volumes	of	55μl,	61μl,	and	68μ,	final	working	 concentrations	 of	 10mM	 D-glucose	 and	 50mM	 2-DG	 were	 achieved	 in	 the	designated	 stress	 test	 microplate	 wells.	 As	 described	 previously	 the	 desired	
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concentration	of	oligomycin	was	titrated	and	the	relevant	data	is	presented	later	in	this	thesis	(section	3.1.2.).	Equal	volumes	of	Seahorse	glycolytic	assay	media	were	added	to	the	injection	ports	in	the	allocated	control	wells.		Again	similar	 to	 the	mitochondrial	 stress	 test,	 the	assay	commenced	with	 initial	ECAR	measurement,	mixing	 the	plate	 for	 two	minutes,	 allowing	a	delay	of	 two	minutes,	 and	then	taking	a	further	ECAR	measurement	(mix	two	minutes,	wait	two	minutes,	measure	two	 minutes),	 and	 this	 cycle	 was	 repeated	 five	 times.	 Next,	 the	 first	 injection	 of	 a	saturating	concentration	of	glucose	was	delivered	through	port	A	to	the	stress	test	wells.	The	 cells	 catabolise	 this	 through	 the	glycolytic	pathway	and	 the	 resulting	extrusion	of	protons	into	the	surrounding	medium	causes	an	increase	in	ECAR,	which	gives	the	rate	of	 glycolysis	 under	 basal	 conditions	 (383,	 384)(figure	 2.4.7.1.).	 Following	 three	measurement	 cycles	 as	 before,	 oligomycin	was	 then	 injected	 through	 port	 B,	 before	 a	further	 three	 measurement	 cycles.	 As	 detailed	 previously,	 oligomycin	 inhibits	mitochondrial	ATP	production,	which	also	 results	 in	 cells	 shifting	 to	a	more	glycolytic	state	 to	maintain	 energy	 requirements,	with	 a	 consequent	 increase	 in	ECAR	 reflecting	the	 cellular	 maximal	 glycolytic	 capacity(383,	 384)	 (figure	 2.4.7.1.).	 Finally,	 2-DG	 was	delivered	through	port	C	and	two	final	measurement	cycles	performed.	2-DG	is	a	stable	glucose	analogue,	which	inhibits	glycolysis	through	competitive	binding	to	hexokinase	–	the	 first	 enzyme	 in	 the	 glycolytic	 pathway	 –	 and	 results	 in	 a	 significant	 decrease	 in	ECAR(383,	 384).	 The	 residual	 ECAR	 is	 attributable	 to	 cellular	 processes	 other	 than	glycolysis	and	is	subtracted	from	previous	measurements.		
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Figure	2.4.7.1:	Experimental	 read-out	 from	 the	glycolytic	 stress	 test.	This	depicts	how	the	sequential	delivery	of	the	three	compounds	(glucose,	oligomycin,	and	2-DG)	allows	derivation	of	several	metabolic	parameters	(basal	glycolysis,	maximal	glycolysis,	spare	glycolytic	capacity,	an	non-glycolytic	acidification).	The	underlying	mechanisms	are	as	described	in	the	text.		
2.4.8.	Normalisation	to	cellular	DNA	content	To	enable	comparison	of	metabolic	measurements	between	cell	 lines,	normalisation	of	the	 OCR	 and	 ECAR	 data	 was	 necessary.	 Consequently,	 following	 completion	 of	 all	mitochondrial	 and	 glycolytic	 stress	 tests,	 the	 XF	 microplate	 was	 removed	 from	 the	instrument	and	 the	media	 removed	 from	each	of	 the	wells,	before	 the	microplate	was	stored	at	-80°C	for	future	normalisation.				At	a	later	date,	typically	within	one	month,	DNA	content	in	each	of	the	microplate	wells	was	determined	to	facilitate	normalisation	of	data	to	DNA	content.	Measurement	of	total	DNA	content	was	performed	using	the	CyQUANT®	cell	proliferation	assay	kit	as	per	the	manufacturer’s	 instructions.	Experiments	were	carried	out	 in	Corning®	96-well	black-bottom	plates	(Sigma-Aldrich),	which	allowed	for	normalisation	of	three	XF	microplates	simultaneously	 during	 each	 experiment.	 Lysis	 buffer	 was	 prepared	 using	 38ml	 of	solution	containing	180mM	NaCl	in	1mM	of	EDTA	and	2ml	of	stock	cell	lysis	buffer	from	the	CyQUANT®	kit.	Next,	150μl	of	RNase	A	was	added	to	7.5ml	of	this	lysis	buffer,	and	100μl	of	 this	 final	 solution	was	 then	added	 to	each	well	of	 the	XF24	microplates,	with	the	exception	of	the	designated	blank	wells	(A1,	B4,	C3,	and	D6).	The	microplates	were	then	placed	on	an	orbital	 shaker	 for	one	hour	at	 room	 temperature	 to	extract	 cellular	
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DNA.	 In	 the	 interim,	 in	 order	 to	 generate	 a	 standard	 curve	 for	 DNA	 content,	 DNA	standards	were	prepared	using	the	stock	DNA	standard	from	the	CyQUANT®	kit	diluted	in	lysis	buffer	without	RNase	A	to	the	following	concentrations:	0,	10,	50,	100,	200,	400,	800,	and	1000ng/ml.	50μl	of	each	of	 the	standards	was	then	added	in	duplicate	to	the	designated	wells	in	the	96-well	plate.	Following	the	aforementioned	lysis	step,	the	lysed	cells	were	diluted	1:5	with	lysis	buffer	without	RNase	A,	and	50μl	also	transferred	to	the	pre-designated	 wells	 of	 the	 96-well	 plate.	 Subsequently,	 dye	 solution	 was	 prepared	(20μl	 of	 dye	 from	 the	 CyQUANT®	 kit	 and	 200μl	 of	 2x	 TE	 buffer	 made	 up	 to	 a	 final	volume	of	4ml	using	dH2O)	and	added	to	each	well	 in	a	1:1	dilution.	This	was	then	left	for	 two	minutes	 prior	 to	measurement	 using	 a	 POLARstar	 Omega	 plate	 reader	 (BMG	LABTECH,	 Ortenberg,	 Germany),	 on	 which	 fluorescence	 measurements	 were	 taken	using	 excitation	 and	 emission	wavelengths	 of	 508nm	 520nm	 respectively.	 The	 values	obtained	were	then	multiplied	by	the	sample	dilution	factor	of	five	and	converted	from	ng/ml	to	ng	of	DNA	by	accounting	for	the	original	sample	volume	of	50μl.		
2.4.9.	Measurement	 of	 electron	 transport	 chain	 complex	 activity	 in	 permeabilised	
cells	To	 further	 investigate	 the	 possible	 contribution	 of	 altered	 mitochondrial	 substrate	oxidation	in	any	observed	differences	in	the	metabolic	phenotypes	of	the	cell	lines,	cells	were	permeabilised	using	XF	PMP,	supplied	with	varying	substrates	and	inhibitors,	and	subjected	to	mitochondrial	stress	tests	(section	2.4.6.)	to	assess	the	activity	of	individual	ETC	complexes.	Many	oxidisable	substrates	are	unable	 to	cross	 the	plasma	membrane	freely,	 which	 prevents	 control	 over	 which	 substrates	 the	 mitochondria	 are	oxidising(385,	 386).	 Permeabilising	 cells	 using	 XF	 PMP,	 which	 contains	 a	 mutant	cholesterol-dependent	 recombinant	 perfringolysin	 that	 selectively	 permeabilises	 the	plasma	membranes	of	adherent	cell	monolayers,	affords	this	experimental	control,	and	by	 exploiting	 the	 fact	 that	 specific	 substrates	 feed	 differentially	 into	 mitochondrial	pathways	(figure	2.4.9.1.)	any	defects	in	function	of	ETC	complexes	responsible	for	the	altered	OCR	 originally	 observed	 in	 intact	 cells	 can	 be	 isolated(385,	 386).	 Accordingly,	substrates	 bypassing	 potentially	 defective	 ETC	 complexes	 were	 sequentially	 added,	along	 with	 relevant	 ETC	 complex	 inhibitors,	 in	 each	 new	 experiment	 to	 determine	whether	any	OCR	defects	could	be	rescued.	Given	that	this	experimental	design	did	not	allow	for	the	bypassing	of	complex	IV	(see	figure	2.4.9.1.),	and	thus	the	detection	of	any	contributing	 defective	 complex	 IV	 function,	 direct	measurement	 of	 complex	 IV-linked	respiration	was	determined	by	supplying	permeabilised	cells	with	TMPD	and	ascorbate	
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along	with	the	complex	III	inhibitor	antimycin	A,	and	comparing	normalised	OCR	values	between	cell	lines.	
	
Figure	 2.4.9.1:	 Oxidisable	 substrates	 feed	 into	 different	 parts	 of	 the	 respiratory	 chain	(adapted	 from	 reference	 (387)). Plasma	 membrane	 permeabilisation	 allows	 for	 controlled	delivery	of	endogenous	substrates	into	mitochondria.	Complex	I-linked	substrates	are	labeled	in	red.	Oxidation	of	pyruvate	in	the	TCA	cycle	in	the	mitochondrial	matrix	promotes	the	reduction	of	 NAD+	 to	 NADH.	 Electrons	 from	 NADH	 enter	 complex	 I,	 and	 are	 transferred	 through	 to	complexes	 III	 and	 IV.	 The	 oxidation	 of	 succinate	 to	 fumarate	 causes	 the	 reduction	 of	 FAD+	 to	FADH,	 the	 electrons	 of	 which	enter	 complex	 II,	 thereby	 bypassing	 complex	 I.	 Glycerol-3-phosphate,	an	FADH-linked	substrate,	donates	electrons	to	complex	III	via	the	Q-cycle.	TMPD,	in	the	 presence	 of	 ascorbate,	 can	 donate	 electrons	 to	 cytochrome	 c	 to	 reduce	 complex	 IV,	which	then	 reduces	 oxygen	 to	 water.	 The	 overall	 proton	 gradient	 across	 the	 inner	 mitochondrial	membrane	 created	 by	 these	 redox	 reactions	 drives	 the	 phosphorylation	 of	 ADP	 to	ATP	by	 the	ATP	synthase	(complex	V).			Prior	to	XF	PMP	assays,	stock	solutions	of	 the	substrates	were	prepared	using	1x	MAS	and	are	detailed	in	table	2.4.9.1.	On	the	day	of	the	assay,	the	required	volume	of	1x	MAS	was	aliquoted	(typically	6ml	of	one	condition	per	microplate)	and	the	desired	substrates	and	inhibitors	added,	the	final	concentrations	of	which	are	also	listed	in	table	2.4.9.1.	In	initial	experiments,	the	NADH-linked	complex	I	substrates	pyruvate	and	glutamate	were	added.	Subsequently,	 in	order	to	bypass	ETC	complexes	and	analyse	OCRs	attributable	to	the	remaining	ETC	complexes,	the	following	substrates	and	inhibitors	were	supplied:	succinate	 with	 rotenone	 to	 bypass	 and	 inhibit	 complex	 I;	 glycerol-3-phosphate	 with	malonate	to	bypass	and	inhibit	complex	II;	and	ascorbate	and	TMPD	with	antimycin	A	to	bypass	and	inhibit	complex	III.	Additionally,	a	volume	of	3x	MAS	equivalent	to	half	the	volume	 of	 substrate	 supplemented	 was	 also	 added	 to	 maintain	 solution	 osmotic	strength	 (e.g.	 500μl	 of	 3x	MAS	 for	 every	 1ml	 of	 substrate).	 ADP	 and	 XF	 PMP	 reagent	
USING XF PLASMA MEMBRANE PERMEABILIZER (PMP) TO MEASURE SUBSTRATE OXIDATION BY MITOCHONDRIAL RESPIRATORY COMPLEXES WITHOUT ISOLATING MITOCHONDRIA 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods  
The assay workflow (Figure 1) describes the procedure used 
to prepare the cells and the XF PMP reagent. For detailed 
materials and methods, refer to the Seahorse Protocol: 
Conducting an assay using cells treated with XF-PMP 
(www.seahorsebi .com).  
The experiments described in this Technical Brief used a 
Seahorse XF96 Extracellular Flux Analyzer. These methods 
can be adapted for all XFe 96/24 and XF 96/24 Analyzers. 
 
 
 
Table 1:  Substrates and Inhibitors 
Substrate 
Final 
Conc. 
Add with… Relevant Inhibitors 
Pyruvate 10 mM 
1 mM malate 
2 mM DCA* 
2 μM rotenone  
2 μM UK5099 
Glutamate 10 mM 10 mM malate 
2 μM rotenone 
titrated aminooxyacetate 
β-hydroxybutyrate 10 mM 1 mM malate 2 μM rotenone 
Palmitoylcarnitine/ 
Octanoylcarnitine 
40 μM 1 mM malate 2 μM antimycin A 
α-ketoglutarate 10 mM 
No additions 
necessary 
2 μM rotenone 
Succinate 10 mM 2 μM rotenone 
2 μM antimycin A   
2 μM myxothiazol 
20 mM malonate 
Glycerol-3-
phosphate 
5–10mM 2 μM rotenone 
2 μM antimycin A  
2 μM myxothiazol 
Ascorbate 10 mM 
100 μM TMPD 
2 μM 
antimycin A 
20 mM azide 
    
NADH-linked (Complex I) substrates    
Q-linked (Complex II or III) substrates      
Cytochrome oxidase-linked (Complex IV) substrates 
*Optional: DCA will relieve potential kinase inhibition of pyruvate 
dehydrogenase 
Adapted from Divakaruni, et al, 2014 [4]. 
 
Figure 2:  Oxidizable substrates fee  nto diff rent parts of th  respiratory chain  
Oxygen consumption rate (OCR) is a measure of respiratory chain activity involving subsets of the electron transport chain complexes. Complex I-linked substrates are labeled 
in red, and those linked directly to th  ubiquinone pool are labeled in blue (note th t fatty acid oxidation involves both). Electrons are delivered to cytochrome oxidase 
(Complex IV) with ascorbate and TMPD, as labeled in green. PDH, pyruvate dehydrogenase; GDH, glutamate dehydrogenase; AsAT, aspartate aminotransferase; ETF, electron 
transfer flavoprotein-related enzymes; G-3-PDH, glycerol-3-phosphate dehydrogenase; TMPD, N,N,N′,N′ Tetramethyl-p-phenylenediamine; cy. c, cytochrome c; Pi, inorganic 
phosphate.  Adapted from Divakaruni, et al 2013 [1]. 
NOTE: When planning an XF PMP assay, Seahorse recommends 
characterizing the cell seeding density and optima  reage t 
concentrations prior to starting the assay. Visit our web site 
www.seahorsebio.com or contact Seahorse Technical Support  
with any questions.  
 
Assay Optimization Hints:  
1. Table 1 lists the starting concentration for oxidizable substrates 
and inhibitors used in the assay. Cells may have specific substrate 
preferences based on the tissue origin and culture conditions.  
2. Assay duration should be as short as possible to avoid cell lifting 
from the microplate.  
3. Perform the wash steps as quickly (but gently) a  possible to 
minimize the cell-exposure time to the MAS buffer.  
4. When pipetting BSA-supplemented assay medium, bubbles can 
form in the assay plate. Therefore, do not push past the stopper 
when either was ing or loading the plate. 
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were	also	added	at	final	concentrations	of	4mM	and	1nM	respectively.	Subsequently,	it	was	ensured	that	the	pH	of	any	assay	medium	was	7.2		Subsequent	 to	 addition	of	 the	 relevant	 supplemented	MAS	media	 and	 insertion	of	 the	microplate	into	the	XF24	instrument	as	described	previously,	a	mitochondrial	stress	test	(section	 2.4.6.)	 was	 performed	 with	 the	 following	 modifications:	 compounds	 for	injection	were	prepared	 in	 the	 relevant	 supplemented	MAS	 rather	 than	mitochondrial	assay	 media,	 with	 injections	 into	 designated	 control	 wells	 comprising	 supplemented	MAS	alone;	measurement	 cycles	were	 reduced	 in	duration	 to	mix	30	seconds,	wait	30	seconds,	 measure	 two	 minutes;	 measurement	 cycles	 were	 only	 repeated	 twice	 at	baseline	 and	 following	 each	 compound	 injection.	 These	 time	 deviations	 from	 the	standard	 XF	 assay	 with	 intact	 cells	 were	 designed	 to	 minimise	 time-dependent	 cell	detachment	and	safeguard	against	 time-dependent	 loss	of	mitochondrial	 function(385,	386).				
Table	2.4.9.1:	Oxidisable	substrates	added	during	XF	PMP	assays.	
Substrate	 Stock	Concentration	 Final	Concentration	 Additives	Pyruvate	 1M	 10mM	 10mM	malate,	2mM	DCAa	Glutamate	 1M	 10mM	 10mM	malateb	Succinate	 1M	 10mM	 2μM	rotenone	Glycerol-3-phosphate	 250mM	 10mM	 20mM	malonate	Ascorbate	 2M	 10mM	 2μM	antimycin	A,	100μM	TMPDc	a	 –	 DCA	 is	 used	 to	 relieve	 potential	 kinase	 inhibition	 of	 the	 pyruvate	 dehydrogenase	 (PDH)	complex.		b	–	An	equimolar	concentration	of	malate	is	added	to	ensure	maximal	aminotransferase	activity.		c	–	TMPD	is	stored	with	10mM	ascorbate	to	ensure	its	reduction.				
2.5.	Cell	proliferation	and	viability	assays			
2.5.1.	Trypan	blue	exclusion	assay	This	assay	is	based	on	the	principle	that	in	viable	cells	cell	membranes	remain	intact	and	exclude	the	dye,	while	in	non-viable	cells	membranes	are	compromised	and	absorb	the	dye(388).	Thus,	under	microscopic	examination	viable	cells	remain	colourless	and	non-viable	cells	appear	blue(388).	
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	Cells	 were	 harvested	 using	 trypsin-EDTA	 and	 cellular	 concentrations	 determined	 as	described	 previously.	 Cells	were	 then	 seeded	 at	 a	 density	 of	 7.5	 x	 105	in	 NuncTM	 6cm	culture	dishes	(Thermo	Fisher	Scientific),	4ml	of	DMEM	added,	and	incubated	overnight	at	37°C	with	5%	CO2	 to	allow	 for	cell	attachment.	The	 following	day,	 cells	were	either	left	 untreated	 or	 treated	 with	 25mM	 2-DG	 and/or	 2μM	 UK5099	 (an	 inhibitor	 of	 the	mitochondrial	pyruvate	carrier)	as	indicated.	Cells	were	then	re-incubated	at	37°C	with	5%	CO2	for	8,	16	or	24	hours	before	being	harvested	with	trypsin-EDTA	and	suspended	in	 10ml	 of	 DMEM.	 10μl	 of	 cell	 suspension	 was	 then	 transferred	 in	 duplicate	 to	 each	enclosed	 chamber	 within	 a	 disposable	 CountessTM	 cell	 counting	 chamber	 slide	(Invitrogen),	 to	which	10μl	of	0.4%	Trypan	blue	 stain	was	also	 loaded.	Next,	 the	 slide	was	inserted	into	the	CountessTM	automated	cell	counter	(Invitrogen)	to	determine	total	cell	 count/ml,	 live	 cell	 count/ml,	 and	 cell	 viability.	 The	 CountessTM	 automated	 cell	counter	 was	 calibrated	 and	 cell	 mode	 parameters	 setup	 as	 per	 the	 manufacturer’s	instructions	to	avoid	falsely	low	or	falsely	high	counts.			
2.5.2.	MTT	assay	The	MTT	assay	 is	a	rapid	colorimetric	assay	 that	relies	on	mitochondrial	 function	as	a	surrogate	indicator	of	cell	viability.	Mitochondrial	dehyrodgenase	enzymes	in	living	cells	are	capable	of	cleaving	the	tetrazolium	ring	in	MTT,	reducing	yellow	MTT	into	a	purple	formazan	precipitate,	which	 can	be	dissolved	with	DMSO(389).	Therefore,	 absorbance	at	570nm	can	be	used	as	a	surrogate	indicator	of	the	viability	of	cells	treated	with	MTT.			Cells	were	brought	to	80-90%	confluence	in	T75	cell	culture	flasks	and	then	harvested	using	 trypsin-EDTA	 as	 described	 in	 section	 2.2.3.	 Cellular	 concentrations	 were	 then	determined	using	the	mean	from	three	independent	cell	counts	from	a	Coulter	counter	(Beckmann	 Coulter)	 as	 described	 previously	 (section	 2.4.5.).	 Serial	 dilutions	 were	performed	on	the	cells	in	culture	medium,	ensuring	cells	were	thoroughly	mixed	before	each	 dilution,	 to	 give	 desired	 concentrations	 of	 cells/ml.	 Cells	 were	 then	 seeded	 in	NuncTM	96-well	plates	(Thermo	Fisher	Scientific)	using	a	Costar®	multi-channel	pipette	(Corning	Life	 Sciences,	Kings	Norton,	UK)	with	 a	 total	 volume	of	 200μl	 added	 to	 each	well	 and	 incubated	 overnight	 at	 37°C	 with	 5%	 CO2	 to	 allow	 for	 cell	 attachment.	 The	following	day	desired	concentrations	of	geneticin	were	prepared	in	200μl	of	DMEM.	The	media	 from	each	well	was	 then	carefully	 suctioned	and	replaced	with	 the	appropriate	geneticin	 solution	 (except	 in	 control	 wells	 where	 DMEM	 alone	 was	 added).	Subsequently,	 20μl	 of	 5	mg/mL	MTT	was	 added	 to	 each	well	 using	 a	 Costar®	multi-
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channel	pipette	 (Corning	Life	Sciences)	on	day	0,	2,	4,	6,	or	10	as	 indicated.	Following	addition	on	MTT	on	the	relevant	day	the	96-well	plate	was	incubated	at	37	°C	with	5%	CO2	 for	 three	hours.	Following	 incubation,	all	of	 the	 liquid	 in	was	aspirated	 from	each	well	 and	 100μl	 of	 DMSO	 added	 to	 lyse	 the	 cells	 and	 dissolve	 the	 purple	 formazan	precipitate.	After	further	incubation	at	37	°C	with	5%	CO2	for	15	minutes	and	agitation	on	 a	 shaker	 at	 room	 temperature	 for	 one	 minute,	 plates	 were	 sealed	 and	 optical	absorbance	at	570nm	was	measured	using	a	GENios	plate	reader	(TECAN,	Reading,	UK).			
2.6.	Clonogenic	survival	assay			The	 clonogenic	 or	 colony-formation	 assay	 aims	 to	 determine	 the	 ability	 of	 cells	 to	continue	to	proliferate	and	form	colonies	following	exposure	to	a	certain	insult	such	as	IR.	A	colony	is	defined	as	a	collection	of	≥50	cells,	which	represents	more	than	five	cell	divisions(390).		
	Cells	were	harvested,	 counted,	 seeded	 at	 a	 density	 of	 7.5	 x	 105	in	NuncTM	6cm	 culture	dishes,	 and	 incubated	 overnight	 at	 37°C	with	 5%	 CO2	 to	 allow	 for	 cell	 attachment	 as	described	 above.	 The	 following	 day,	 cells	 were	 irradiated	 in	 the	 NuncTM	 6cm	 culture	dishes	 at	 doses	 of	 0Gy	 (untreated),	 2Gy,	 4Gy,	 or	 6Gy	 at	 room	 temperature	 using	 a	CellRad cabinet	X-ray	cell	irradiator	(Faxitron	Bioptics	LLC,	Tucson,	AZ,	USA)	calibrated	to	 deliver	 2Gy/min	 of	 X-ray	 radiation.	 Prior	 to	 irradiation	 cells	 were	 either	 left	untreated	 or	 treated	 for	 one	 hour	 with	 varying	 combinations	 of	 the	 following	 drugs:	25mM	 2-DG;	 25mM	 NAC;	 20mM	 metformin;	 5μM	 3-BP;	 5μM	 6-AN.	 Subsequent	 to	irradiation	the	cell	culture	media	was	aspirated	and	replaced	with	4ml	of	 fresh	DMEM	before	 cells	 were	 returned	 to	 a	 humidified	 cell	 incubator	 (37°C	 with	 5%	 CO2)	 for	between	 two	 and	 three	 hours.	 Next,	 cells	 were	 harvested	 by	 trypsinisation	 and	 cell	suspension	concentrations	determined	as	described	previously.	Cells	were	then	seeded	in	 triplicates	 into	NuncTM	 six-well	 plates	 (Thermo	Fisher	 Scientific)	 at	 pre-determined	seeding	 densities	 optimised	 to	 generate	 a	 feasibly	 countable	 number	 of	 colonies	 out	with	 the	 margin	 of	 error	 (30-100	 colonies)	 at	 the	 end	 of	 the	 experiment.	 Optimal	seeding	densities	were	dependent	 on	 cell	 line,	 dose	of	 IR,	 and	presence	or	 absence	of	drug,	and	were	determined	through	trial	and	error	by	seeding	initially	at	a	wide	range	of	densities	before	 tailoring	 this	 for	each	cell	 line.	Typically	cell	 seeding	densities	ranged	from	100/well	to	102	400/well.	Each	well	was	then	topped	up	with	DMEM	to	give	a	final	volume	of	5ml/well	and	plates	were	gently	agitated	to	distribute	the	cells	evenly,	before	
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plates	 were	 placed	 in	 the	 incubator	 (37°C,	 5%	 CO2)	 and	 incubated	 for	 14	 days	 until	sufficiently	large	colonies	had	formed.				Following	14	days	of	incubation,	a	fixing	and	staining	solution	of	crystal	(methyl)	violet	0.5%	w/v	in	6%	glutaraldehyde	v/v	was	prepared.	Media	was	then	aspirated	from	the	wells	of	all	6-well	plates	and	each	well	washed	with	an	excess	of	PBS	(≈2ml).	Next,	2ml	of	the	crystal	violet	solution	was	added	to	each	well	and	left	to	fix	and	stain	for	at	least	30	minutes	at	room	temperature.	Subsequently,	the	crystal	violet	solution	was	removed	and	plates	were	washed	by	immersion	in	cold	H2O.	After	air	drying	overnight,		a	marker	was	used	to	divide	the	wells	into	quadrants	and	colonies	were	counted	manually	under	the	light	microscope.			The	 plating	 efficiency	 (PE)	 was	 calculated	 from	 the	 0Gy	 conditions	 by	 dividing	 the	number	 of	 colonies	 formed	 by	 the	 number	 of	 cells	 seeded.	 The	 number	 of	 colonies	formed	after	 treatment	was	 then	used	 to	calculate	 the	surviving	 fraction	 (SF)	 for	each	treatment	 condition,	 accounting	 for	 the	 plating	 efficiency:	 SF	 =	 (number	 of	 colonies	formed/number	of	cells	seeded)	×	PE.	Survival	parameters	to	generate	treatment-dose	survival	 curves	 for	 treatment	 conditions	 were	 then	 derived	 from	 fitting	 the	 data	 by	weighted,	 stratified,	 linear	 regression	 according	 to	 the	 linear–quadratic	 formula	S(D)=exp(αD+βD2),	where	S	is	survival	following	a	given	dose	(D)	of	IR,	using	IBM	SPSS	version	21	 (Armonk,	NY,	USA)(390).	 Such	modelling	 also	 enabled	 statistical	 testing	 of	the	 difference	 between	 two	 survival	 curves,	where	 the	 null	 hypothesis	 states	 that	 the	data	 scatter	was	described	best	with	one	 curve.	Thus,	p	 values	of	<0.05	 state	 that	 the	data	 scatter	 is	 best	 described	 with	 two	 curves,	 i.e.	 a	 statistical	 difference	 in	 survival	parameters	between	the	two	curves(390).				
2.7.	Cytochemical	detection	of	cellular	senescence	
	
2.7.1.	General	principles	of	Senescence-associated	β-galactosidase	staining	SA-βgal	staining	was	used	to	investigate	whether	different	treatment	conditions	induced	cellular	 senescence	 in	 SCCHN	 cell	 lines.	 This	 cytochemical	 assay	 is	 based	 upon	 the	chromogenic	 substrate	 5-bromo-4-chloro-3-indoyl	 β-D-galactopyranoside	 (X-gal),	which	 yields	 an	 insoluble	 blue	 compound	 that	 can	 be	 visualized	when	 cleaved	 by	 the	enzyme	 β-galactosidase(219).	 Whilst	 acidic	 β-galactosidase	 activity,	 detectable	 at	 pH	4.0,	 is	present	 in	all	 cells,	SA-βgal	activity	 is	detectable	at	pH	6.0	and	can	 therefore	be	
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distinguished	 by	 using	 a	 citric	 acid/sodium	 phosphate	 buffer	 at	 pH	 6.0(219).	 This	enzymatic	 activity	 at	 suboptimal	 pH	 is	 due	 to	 an	 increase	 in	 the	 abundance	 of	 the	lysosomal	 enzyme,	 secondary	 to	 the	 increased	 lysosomal	 biogenesis	 observed	 in	senescent	cells(219).	
	
2.7.2.	Reagents	prepared	for	cytochemical	detection	of	cellular	senescence	
Fixation	solution:	2%	(v/v)	formaldehyde	0.2%	(v/v)	glutaraldehyde	Solution	made	up	in	PBS.	
	
Staining	solution:		40	mM	citric	acid/sodium	phosphate	buffer	(pH	6.0)	5	mM	potassium	hexacyano-ferrate	(II)	trihydrate		5	mM	potassium	hexacyano-ferrate	(III)	150	mM	sodium	chloride	2	mM	magnesium	chloride	1	mg/ml	X-gal			
2.7.3.	Using	senescence-associated	β-galactosidase	for	detection	of	cellular	
senescence	Cells	were	harvested,	 counted,	 seeded	 at	 a	 density	 of	 2.5	 x	 105	in	NuncTM	6cm	 culture	dishes,	 and	 incubated	 overnight	 at	 37°C	with	 5%	 CO2	 to	 allow	 for	 cell	 attachment	 as	described	previously.	Cells	were	seeded	at	a	 lower	density	in	this	assay	because	of	the	requirement	for	subconfluent	cell	populations,	as	higher	confluence	may	induce	SA-βgal	activity(219).	The	following	day,	cells	were	irradiated	as	described	above,	either	in	the	absence	 of	 drug	 or	 following	 a	 one	 hour	 pre-treatment	 with	 25mM	 2-DG.	 Following	twenty-four	hours	of	 incubation	(37°C	with	5%	CO2),	cells	were	washed	twice	with	an	excess	 of	 PBS	 (≈2ml),	 before	 2ml	 of	 fixation	 solution	 was	 added	 to	 each	 dish	 and	incubated	 for	 five	 minutes	 at	 room	 temperature.	 The	 fixation	 solution	 was	 then	removed	and	the	 fixed	cells	were	washed	twice	with	≈2ml	PBS,	before	2ml	of	staining	solution	was	added	per	dish.	Cells	were	then	incubated	overnight	for	16	hours	at	37	°C	without	 CO2.	 After	 the	 incubation,	 cells	were	 again	washed	 twice	with	 ≈2ml	 PBS,	 and	once	with	1ml	methanol.	Dishes	were	 then	allowed	 to	 air	dry	before	being	viewed	by	
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bright	field	microscopy	to	count	the	proportion	of	blue	cells	in	the	total	cell	population,	thus	determining	the	proportion	of	senescent	cells.				
2.8.	Detection	of	apoptosis	by	flow	cytometry		
2.8.1.	General	principles	of	flow	cytometry	Flow	 cytometry	 is	 a	 high-throughput	 means	 of	 obtaining	 detailed	 quantitative	information	on	every	single	cell	in	a	larger	population	of	cells.	 	A	flow	cytometer	aligns	cells	 in	 single	 file	 in	 an	 annular	 fluid	 stream	 before	 propelling	 these	 cells	 from	 the	sample	tube	through	a	cuvette	by	air	pressure.	The	machine	then	focuses	a	laser	beam	on	the	cuvette,	where	the	cell	perturbs	 the	beam	direction,	which	 is	dependent	on	the	difference	 in	 refractive	 index	between	 the	 cell	 contents	and	 the	 surrounding	 fluid,	 the	size	of	the	cell,	and	particulate	elements	within	the	cell.	The	resulting	deflected	light	is	measured	by	 suitably	positioned	detectors,	which	 collect	 information	on	 light	 emitted	out	of	 the	cell	 in	 the	 forward	direction	(forward	scatter	channel))	and	 light	emitted	at	90°	(side	scatter	channel).	The	extent	of	forward	scatter	(FS)	is	generally	related	to	cell	size	and	can	be	used	to	distinguish	between	cell	debris	and	live	cells,	while	side	scatter	(SS)	 is	 characteristically	 associated	with	 cellular	 granularity.	 Individual	 cells	 from	 the	same	cell	 line	display	similar	degrees	of	FS	and	SS	to	each	other,	and	as	such	this	data	can	be	used	to	 isolate	 this	group	of	cells	 from	analysis,	excluding	data	 from	either	cell	debris	 or	 clumps	 of	 cells.	 Generating	 FS	 versus	 SS	 dot	 plots	 and	 “gating”	 the	 central	population	of	cells	achieves	this.		Using	 specific	 markers	 (usually	 antibodies)	 conjugated	 with	 fluorochromes,	 a	 flow	cytometer	 can	 be	 used	 to	 detect	 cell	 surface	 or	 intracellular	 components.	 A	fluorochrome	 is	 a	 compound	 that	 absorbs	 light	 energy	 from	 the	 laser	 beam	 and	 then	emits	 this	 energy	 in	 the	 form	 of	 light	 energy	 (fluorescence),	 which	 is	 of	 a	 relatively	longer	 wavelength,	 and	 thus	 a	 different	 colour.	 The	 difference	 between	 the	 energy	absorbed	from	the	laser	and	that	emitted,	in	the	form	of	fluorescence,	is	known	as	shift.	Numerous	 fluorochromes	are	available,	which	all	 share	 this	property,	but	differ	 in	 the	wavelength,	 and	 therefore	 colour,	 of	 light	 they	 emit.	 The	 different	 colours	 of	 emitted	light	are	separated	from	each	other	by	a	system	of	optical	filters	and	mirrors,	at	which	point	appropriately	placed	photomultiplier	tubes	can	register	the	shift	and	quantify	this	in	terms	of	intensity.		
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During	 this	project,	 initial	 flow	cytometry	 studies	were	 conducted	on	a	FACSCaliburTM	instrument	(BD	Biosciences,	Oxford,	UK)	and	data	analysed	with	CellQuest	Pro	Software	(BD	Biosciences),	 but	 following	mechanical	 failure	of	 this	machine	 subsequent	 studies	were	conducted	using	an	Attune®	acoustic	focusing	cytometer	(Life	Technologies)	and	data	analysed	with Attune®	Cytometric	Software	(Life	Technologies).	
	
2.8.2.	Reagents	prepared	for	detection	of	apoptosis	
10x	annexin	binding	buffer:	0.1M	HEPES/NaOH	(pH	7.4)	1.4M	NaCl	25mM	CaCl2	
	
PI	solution:	100μg/ml	PI	10mM	potassium	phosphate	(pH	7.4)	150mM	NaCl	
	
2.8.3.	Using	annexin	V	and	propidium	iodide	to	detect	apoptosis	Phosphatidylserine	 (PS)	 is	 a	 phospholipid	membrane	 component	 that	 is	 actively	 held	facing	 the	 cytosolic	 side	of	 the	 cell	membrane,	 completely	 sequestered	away	 from	 the	outer	membrane	in	healthy	mammalian	cells(391).	During	the	early	stages	of	apoptosis,	however,	 there	 is	a	 loss	of	 this	phospholipid	membrane	asymmetry,	with	PS	no	 longer	restricted	 to	 the	 cytosolic	 side	 of	 the	 membrane(391).	 This	 exposure	 of	 PS	 on	 the	extracellular	 surface	 acts	 as	 a	 signal	 for	macrophages	 to	 engulf	 the	 cells	 in	 vivo(391).	Annexin	V	is	a	protein	that	can	bind	to	PS	in	a	calcium-dependent	manner(392).	Thus,	annexin	V	conjugated	 to	 the	 fluorochrome	FITC	allows	 for	 identification	of	cells	 in	 the	early	 stages	 of	 apoptosis(392).	 During	 late	 apoptosis,	 there	 is	 loss	 of	 normal	 cell	membrane	integrity,	which	permits	the	influx	of	the	fluorescent	DNA	intercalating	agent	PI(393).	 Exploiting	 these	 facts,	 a	 population	 of	 unfixed	 cells	 can	 be	 stained	simultaneously	 with	 FITC-conjugated	 annexin	 V	 (green	 fluorescence)	 and	 PI	 (red	fluorescence)	and	the	emitted	fluorescence	measured	by	flow	cytometry	to	identify	four	distinct	populations	of	cells,	distinguished,	or	gated,	based	on	the	fluorescence	emitted.	Cells	 that	 remain	 unstained	 are	 healthy	 cells,	 cells	 that	 stain	 with	 just	 annexin	 V	 are	undergoing	early	apoptosis,	cells	that	stain	with	just	PI	are	necrotic	cells,	and	cells	that	stain	with	both	annexin	V	and	PI	are	cells	which	have	entered	late	apoptosis.	These	four	
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populations	 can	 be	 clearly	 depicted	 on	 a	 dot	 plot	 graph	 of	 annexin	 V	 versus	 PI	 using	quadrants	(figure	2.7.3.1).		
	
Figure	2.8.3.1:	Populations	of	cells	after	annexin	V/PI	staining.	Dot-plot	output	summarising	positions	 of	 distinct	 cell	 populations	 determined	 by	 differential	 staining	with	 FITC-conjugated	Annexin	V	(A/V-FITC)	and	propidium	iodide	(PI),	and	analysis	by	flow	cytometry.			Cells	were	harvested,	 counted,	 seeded	 at	 a	 density	 of	 7.5	 x	 105	in	NuncTM	6cm	 culture	dishes,	 and	 incubated	 overnight	 at	 37°C	with	 5%	 CO2	 to	 allow	 for	 cell	 attachment	 as	described	 above.	 The	 following	 day,	 the	 designated	 negative	 control	 cells	 were	 left	untreated	and	the	positive	control	cells	treated	with	1μM	staurosporine.	Staurosporine	is	tyrosine	kinase	inhibitor,	which	is	a	known	potent	inducer	of	apoptosis.	The	negative	and	positive	control	cells,	known	healthy	and	apoptotic	populations	of	cells	respectively,	were	required	for	calibration	of	the	positioning	of	the	four	quadrants	for	each	of	the	cell	lines	 during	 subsequent	 analysis.	 Otherwise,	 cells	 were	 treated	 as	 indicated	 with	combinations	of	6Gy	IR,	25mM	2-DG,	25mM	NAC,	all	delivered	as	described	previously.	Cells	were	then	transferred	back	to	a	humidified	cell	incubator	at	37°C	with	5%	CO2	for	either	24	or	48	hours.	 Cells	were	 then	 trypsinised	as	described	previously	 –	modified	such	 that	 the	 media	 in	 which	 the	 cells	 were	 cultured	 was	 also	 collected	 in	 order	 to	obtain	 dead	 cells	 that	 may	 have	 detached	 from	 the	 surface	 –	 and	 pelleted	 by	
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Figure 2.3.2.1 Schematic summarizing populations of cells after Annexin V/PI 
staining.  Diagram summarizing positions of cell populations on a dot plot after 
treatment with FITC-conjugated Annexin V (A/V-FITC) and propidium iodide (PI) 
and analysis by flow cytometry. 
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centrifugation	at	300	x	g	 for	5	minutes	 in	a	pre-cooled	centrifuge	at	4°C. Supernatant	was	 removed	 and	 cells	 were	 re-suspended	 and	washed	 twice	 in	 5ml	 of	 ice	 cold	 PBS.	Samples	 were	 kept	 on	 ice	 hereafter.	 Following	 this,	 cells	 were	 counted	 as	 described	previously	 and	 density	 was	 adjusted	 to	 1x106	 cells	 per	 sample.	 Following	 a	 final	centrifugation	 at	 300	 x	g	 for	 5	minutes,	 cell	 pellets	were	 re-suspended	 in	385μl	 of	 1x	annexin	 binding.	 FITC-conjugated	 annexin	 V	 (5μl)	 was	 then	 added	 to	 385μl	 of	 cell	suspension	and	incubated	in	the	dark	on	ice	for	10	minutes.	PI	solution	(10μl)	was	then	added	to	each	sample	before	being	passed	into	the	flow	cytometer	for	analysis.				
2.9.	Detection	of	reactive	oxygen	species	by	flow	cytometry	
	DCFH-DA,	a	chemically	reduced	and	acetylated	form	of	reduced	fluorescein	and	calcein,	was	utilised	for	the	detection	of	ROS	by	flow	cytometry.	Although	non-fluorescent,	DCF-DA	is	cell	permeable,	and	on	entering	the	cell	is	cleaved	at	the	two	ester	bonds	by	intra-cellular	esterases,	which	yields	a	charged	form	of	the	dye	that	is	much	better	retained	by	cells	 than	 is	 the	 parent	 compound(394).	 As	 such,	 this	 compound	 accumulates	intracellularly	 and	 subsequent	 oxidation	 by	 ROS	 generates	 the	 highly	 fluorescent	product	2′,7′-di-chlorofluorescein	(DCF),	which	can	be	detected	and	quantified	by	flow	cytometry(394)	by	the	principles	described	in	section	2.8.1.		Cells	were	harvested,	 counted,	 seeded	 at	 a	 density	 of	 7.5	 x	 105	in	NuncTM	6cm	 culture	dishes,	 and	 incubated	 overnight	 at	 37°C	with	 5%	 CO2	 to	 allow	 for	 cell	 attachment	 as	described	above.	The	 following	day,	 the	designated	negative	and	positive	 control	 cells	were	left	untreated.	Otherwise,	cells	were	treated	as	indicated	with	combinations	of	6Gy	IR,	 25mM	 2-DG,	 25mM	 NAC,	 all	 delivered	 as	 described	 previously.	 Cells	 were	 then	transferred	 back	 to	 a	 humidified	 cell	 incubator	 at	 37°C	with	 5%	CO2	 for	 a	 designated	amount	of	time	(1,	2,	4,	8,	16,	or	24	hours)	before	being	harvested	by	trypsinisation	as	described	previously,	modified	such	that	the	media	in	which	the	cells	were	cultured	was	also	collected	in	order	to	obtain	dead	cells	that	may	have	detached	from	the	surface.	On	the	 day	 of	 the	 assay,	 a	 fresh	 vial	 of	 DCFH-DA	 (50μg)	was	 reconstituted	 using	 85μl	 of	DMSO	and	was	then	diluted	in	an	appropriate	volume	of	PBS,	dependent	on	the	number	of	 samples,	 to	 give	 a	 final	working	 concentration	 of	 10μM.	 Following	 harvesting,	 cells	were	pelleted	by	 centrifugation	 at	300	x	g	 for	5	minutes	 in	 a	pre-cooled	 centrifuge	 at	4°C.	Supernatant	was	removed	and	cells	were	re-suspended	and	washed	twice	in	2ml	of	PBS.	Subsequently,	cells	were	counted	as	described	previously	and	density	was	adjusted	
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to	1x106	cells	per	sample.	After	a	final	centrifugation	at	300	x	g	for	5	minutes,	cell	pellets	were	 re-suspended	 in	 500μl	 of	 the	 10μM	 DCFH-DA	 solution.	 At	 this	 point,	 H2O2	 was	added	 to	 the	positive	control	 sample	 to	a	 final	 concentration	of	100μM.	Samples	were	then	 incubated	at	37°C	 for	15	minutes	before	being	 transferred	 to	 the	 flow	cytometer	for	 analysis.	 Positive	 and	 negative	 controls	 were	 first	 used	 to	 calibrate	 instrument	settings,	 after	 which	 treatment	 samples	 were	 analysed.	 The	 fluorescence	 output	histogram	 for	 the	 negative	 control	was	 used	 to	 tailor	 the	 position	 of	 a	marker,	which	included	approximately	90%	of	 cells	 in	 the	population.	This	marker	was	 then	used	 to	quantitatively	assess	the	shift	in	fluorescence	in	the	other	samples	tested.			
2.10.	Measurement	of	NADP/NADPH	
	
2.10.1.	Reagents	prepared	for	NADP/NADPH	measurement	
Master	reaction	mix	(100μl):		98μl	NADP	cycling	buffer	2μl	NADP	cycling	enzyme	mix	
	
2.10.2.	Protocol	for	Measurement	of	NADP/NADPH	Measurement	 of	 relative	 levels	 of	 intracellular	NADP	 and	NAPH	was	 performed	 using	the NADP/NADPH	quantification	kit	as	per	the	manufacturer’s	instructions.	Cells	were	harvested,	counted,	 seeded	at	a	density	of	7.5	x	105	in	NuncTM	6cm	culture	dishes,	and	incubated	 overnight	 at	 37°C	 with	 5%	 CO2	 to	 allow	 for	 cell	 attachment	 as	 described	above.	The	 following	day,	 cells	were	 either	 left	 untreated	or	 treated	 as	 indicated	with	5μM	6-AN,	all	administered	as	described	previously.	Cells	were	then	transferred	back	to	a	humidified	cell	incubator	at	37°C	with	5%	CO2	for	24	hours	before	being	harvested	by	trypsinisation	as	before.	Cells	were	then	pelleted	by	centrifugation	300	x	g	for	5	minutes	in	a	pre-cooled	centrifuge	at	4°C	and	washed	with	ice	cold	PBS.	Subsequently,	cells	were	counted	 as	 described	 previously	 and	 density	was	 adjusted	 to	 1x105	 cells	 per	 sample.	Each	 sample	was	 then	 transferred	 to	 an	 Eppendorf®	 1.5ml	microcentrifuge	 tube	 and	cells	pelleted	by	centrifugation	at	300	x	g	for	five	minutes.	Next,	cells	were	extracted	in	200μl	of	NADP/NADPH	extraction	buffer	by	 two	cycles	of	 freeze/thawing	using	 liquid	nitrogen.	Samples	were	then	vortexed	for	10	seconds	and	centrifuged	at	13,000	x	g	for	10	minutes,	before	being	deproteinised	by	filtering	through	a	10kDa	cutoff	spin	filter	to	prevent	 consumption	 of	 NADPH	 by	 lysate	 enzymes.	 To	 detect	 NADPH,	 NADP	 was	decomposed	by	aliquoting	100μl	of	 each	extracted	 sample	 into	a	new	microcentrifuge	
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tube	 and	heating	 to	 60°C	 for	 30	minutes	 in	 a	 dry	 block	heater	 (Anachem,	 Luton,	UK),	followed	by	cooling	on	 ice.	During	 this	 time,	 in	order	 to	generate	a	standard	curve	 for	NADPH	 content,	 NADPH	 standards	 were	 prepared	 using	 the	 stock	 NADPH	 standard	from	 the	 kit	 diluted	 in	 NADP/NADPH	 extraction	 buffer	 to	 a	 final	 volume	 of	 50μl	 in	designated	 wells	 of	 Corning®	 96-well	 clear-bottom	 plates	 (Sigma-Aldrich)	 at	 the	following	 concentrations:	 0,	 20,	 40,	 60,	 80,	 and	 100pmol/well.	 Each	 standard	 was	represented	 in	 duplicate.	 Subsequently,	 50μl	 each	 of	 both	 the	 NADPH	 (NADP	decomposed)	samples	and	the	original	extracted	total	NADP	samples	were	transferred	into	 the	 designated	wells	 of	 the	 96-well	 plate	 in	 duplicate.	 Next,	 100μl	 of	 the	master	reaction	 mix	 was	 added	 to	 each	 of	 the	 standard	 and	 sample	 wells,	 mixed	 well	 on	 a	horizontal	shaker,	and	incubated	for	five	minutes	at	room	temperature	to	convert	NADP	to	 NADPH.	 Subsequently,	 10μl	 of	 NADPH	 developer	was	 also	 added	 to	 each	well	 and	incubated	 at	 room	 temperature	 for	 two	 hours,	 before	 the	 absorbance	 measurements	were	 taken	 at	 450nm	 using	 SpectraMax®	 Plus	 384	 microplate	 reader	 (Molecular	Devices,	 Wokingham,	 UK).	 Results	 were	 obtained	 by	 comparison	 with	 the	 generated	standard	 curve.	The	values	obtained	 in	all	 samples	wells	were	 then	normalised	 to	 the	number	cells	added	to	each	well	to	give	values	expressed	in	pmol/1	x	106	cells.	Values	for	 the	 NADPH	 only	 samples	 were	 then	 subtracted	 from	 the	 values	 for	 the	corresponding	 total	 NADP	 samples	 (all	 NADP	 had	 been	 converted	 to	 NADPH	 by	 the	NADP	 Cycling	 Enzyme	 Mix	 in	 these	 samples)	 to	 determine	 the	 amount	 of	 NADP.	NADP/NADPH	ratios	were	also	then	calculated.			
2.11.	Western	blotting	
	
2.11.1.	General	principle	of	western	blotting	Western	 blotting	 is	 a	 technique,	 which	 is	 used	 for	 detection	 of	 specific	 proteins	 in	 a	studied	sample.	Proteins	are	 first	separated	by	size	using	gel	electrophoresis	and	then	transferred	 to	 a	membrane,	which	 is	 probed	with	 antibodies	 raised	 specifically	 to	 the	proteins	of	interest.		
	
2.11.2.	Reagents	prepared	for	western	blotting	
SLIP	(Stuart	Linn	Immunoprecipitation)	buffer:	50mM	HEPES	(pH	7.5)	10%	glycerol	0.1%	Triton	X-100	
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150mM	NaCl	0.5mg/ml	BSA		
PBS/tween:	65mM	Na2HPO4⋅2H2O		15mM	NaH2PO4⋅2H2O	75mM	NaCl	0.1%	(v/v)	Tween-20			
Tris-glycine	electrophoresis	running	buffer:	25mM	Tris	250mM	glycine	0.1%	(w/v)	SDS			
Tris-glycine	transfer	buffer:		25mM	Tris	192mM	glycine	20%	(v/v)	methanol			
4x	protein	sample	loading	buffer:		250mM	Tris	(pH	6.8)	8%	(w/v)	SDS	40%	(v/v)	glycerol	4mg/ml	bromophenol	blue	1%	(v/v)	β-mercaptoethanol		Diluted	with	dH2O	to	make	2x	and	1x	sample	buffer.		
Ponceau	S	solution:	0.2%	(w/v)	Ponceau	S		5%	(v/v)	acetic	acid		
		
2.11.3.	Bradford	assay	Proteins	for	analysis	were	extracted	from	either	untreated	cells	or	following	treatment	with	6Gy	IR	at	various	time	points.	Cells	were	harvested	by	trypsinisation	and	pelleted	by	centrifugation	at	300	x	g	for	five	minutes	at	4°C	as	described	previously.	The	pellets	were	washed	with	1ml	of	PBS,	transferred	to	Eppendorf®	1.5ml	microcentrifuge	tubes,	
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and	 the	 cells	 were	 again	 pelleted	 by	 centrifugation	 and	 the	 supernatant	 aspirated	 as	before.	The	pellets	were	then	frozen	at	-80°C	prior	to	further	processing.	On	the	day	of	sample	processing,	cell	pellets	were	lysed	by	re-suspension	in	SLIP	buffer	supplemented	with	 the	 following	protease	 inhibitors	 (hereafter	 referred	 to	as	 lysis	buffer):	aprotinin	(2μg/ml),	 leupeptin	 (0.5μg/ml),	 pepstatin	 A	 (1μg/ml),	 trypsin	 inhibitor	 from	 soybean	(100μg/ml)	and	PMSF	(1mM	in	100%	ethanol).	Samples	were	then	incubated	on	ice	for	10	minutes,	centrifuged	for	10	minutes	at	13,000	x	g	at	4°C,	before	the	supernatant	from	this	 centrifugation	 was	 transferred	 to	 a	 clean	 microcentrifuge	 tube.	 In	 the	 interim,	protein	standards	were	prepared	for	the	Bradford	assay.	Firstly,	a	solution	of	20mg/ml	BSA	in	lysis	buffer	was	prepared	and	a	serial	dilution	performed	to	produce	six	further	standards	 of	 the	 following	 BSA	 concentrations:	 10mg/ml,	 5mg/ml,	 2.5mg/ml,	1.25mg/ml,	 0.625mg/ml,	 and	 0.3125mg/ml.	 2μl	 of	 each	 of	 the	 standards	 was	 then	added	to	1ml	of	protein	assay	dye	reagent	(diluted	1:5	with	dH2O)	and	vortexed	for	10	seconds.	2μl	of	the	SLIP	buffer	was	also	added	to	1	ml	of	protein	assay	dye	reagent	and	assigned	as	the	blank.	A	standard	curve	was	prepared	on	a	BioPhotometer	(Eppendorf	AG,	 Hamburg,	 Germany)	 using	 the	 Bradford	 program,	 which	measures	 absorbance	 at	595nm.	 A	 coefficient	 of	 variable	 of	 less	 than	 5%	 was	 deemed	 an	 acceptable	 level	 of	calibration.	 Following	 generation	 of	 the	 standard	 curve,	 2μl	 of	 each	 of	 the	 protein	samples	was	added	 to	1ml	of	protein	assay	dye	reagent	 in	pre-chilled	microcentrifuge	tubes,	and	the	protein	concentrations	determined	based	on	the	prepared	standard	curve	using	 the	BioPhotometer.	 Samples	were	 then	 adjusted	 such	 that	 50μg	 of	 total	 protein	was	made	up	 in	sample	 loading	buffer	using	 indicated	volumes	of	1X,	2X	and	4X	(final	concentration	 of	 the	 buffer	 1X)	 to	 a	 total	 volume	 of	 20μl.	 These	 samples	 were	 then	frozen	at	-80°C	prior	to	gel	electrophoresis.		
2.11.4.	Polyacrylamide	gel	electrophoresis	A	 SDS	 polyacrylamide	 gel	 was	 used	 to	 separate	 proteins	 by	 gel	 electrophoresis.	 The	percentage	 of	 acrylamide	 used	 in	 the	 separating	 gel	 was	 dependent	 on	 the	 size	 of	proteins	to	be	resolved,	with	a	higher	percentage	acrylamide	gel	suited	to	the	resolution	of	low	molecular	weight	proteins	and	vice	versa.	The	separating	gels	were	prepared	as	detailed	 in	 table	2.11.4.1.	 	Glass	 slides	 for	making	0.75mm	thick	gels	were	assembled,	the	separating	gel	poured	into	the	gap,	overlaid	with	dH2O,	and	allowed	to	polymerise.	Once	the	gel	had	set	(typically	after	one	hour)	the	water	was	poured	off	and	the	stacking	gel	 table	 2.11.4.1	 poured,	 a	 10-well	 comb	 inserted,	 and	 the	 gel	 left	 to	 polymerise	(typically	20	minutes).			
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Table	2.11.4.1:	Composition	of	SDS-PAGE	gels	(volumes	required	to	make	10ml).	
Reagent	 Separating	Gel	 Stacking	Gel	
10%	 12%	40%	acrylamide	mix	 2.5ml	 3ml	 1.275ml	1.5M	Tris	(pH	8.8)	 2.5ml	 2.5ml	 	1M	Tris	(pH	6.8)	 	 	 1.25ml	10%	SDS	 100μl	 100μl	 100μl	10%	APS	 100μl	 100μl	 100μl	TEMED	 8μl	 8μl	 10μl	dH2O	 4.8ml	 4.3ml	 7.225ml			Following	polymerisation,	the	comb	was	removed	and	the	gels,	with	the	assembled	glass	slides,	 were	 placed	 in	 an	 electrophoresis	 tank	 filled	 with	 tris-glycine	 electrophoresis	running	buffer.	The	previously	prepared	protein	samples	were	retrieved	from	the	-80°C	freezer	 and	 were	 denatured	 by	 heating	 in	 a	 heat	 block	 at	 100°C	 for	 five	 minutes,	vortexed,	 and	 centrifuged	 at	 13,000	 x	 g	 at	 4°C	 for	 two	minutes.	 20μl	 of	 each	 sample	(containing	50	μg	of	total	protein)	was	then	loaded	into	the	designated	wells	of	the	gel,	alongside	 a	 blue	 broad-range	 pre-stained	 protein	 marker.	 SDS-polyacrylamide	 gel	electrophoresis	(PAGE)	was	performed	using	a	two-gel	Mini-PROTEAN®	Tetra	cell	(Bio-Rad)	at	200V	for	one	hour.		
	
2.11.5.	Protein	detection	Following	 SDS-PAGE,	 proteins	 were	 transferred	 onto	 a	 Hybond	 ECL	 nitrocellulose	membrane	(GE	Healthcare)	using	a	Mini	Trans-Blot®	Electrophoretic	Transfer	Cell	(Bio-Rad).	 Firstly,	 Hybond	 ECL	 nitrocellulose	 membrane,	 two	 pieces	 of	 Whatman®	chromatography	paper	(Sigma-Aldrich),	and	two	sponges	where	pre-soaked	in	transfer	buffer,	and	the	running	apparatus	dismantled.	Next,	the	gel	was	removed	from	between	the	glass	slides,	the	stacking	gel	discarded,	and	the	separating	gel	placed	in	between	the	nitrocellulose	membrane	and	chromatography	paper.	Another	piece	of	chromatography	paper	was	placed	on	the	opposing	side	of	the	nitrocellulose	membrane	and	two	sponges	were	added	on	the	outside	to	complete	the	assembly.	This	was	then	placed	in	a	transfer	cassette,	which	was	 then	placed	 in	a	 tank	 in	 such	a	way	 that	 the	membrane	 faced	 the	positive	 electrode	 whilst	 the	 gel	 faced	 the	 negative	 electrode,	 thereby	 enabling	 the	negatively	 charged	 proteins	 on	 the	 gel	 to	 run	 in	 the	 direction	 of	 the	 nitrocellulose	membrane	towards	the	cathode.	The	tank	was	filled	with	transfer	along	with	an	ice	pack	
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in	order	to	ensure	cooling	during	transfer.	The	transfer	was	performed	at	100	V	for	one	hour	using	a	two-gel	Mini-PROTEAN®	Tetra	cell.		Subsequently,	the	transfer	apparatus	was	dismantled	and	the	membrane	stained	briefly	with	 Ponceau	 S	 and	 rinsed	 with	 H2O	 to	 ensure	 the	 transfer	 of	 proteins	 had	 been	successful.	At	this	point,	the	membrane	was	cut	horizontally	into	strips	based	on	the	size	of	 proteins	 to	 be	 probed.	 The	 membrane	 was	 then	 washed	 briefly	 in	 PBS/Tween	 to	remove	 the	Ponceau	S	 stain	and	blocked	 in	5%	(w/v)	non-fat	dry	milk	 in	PBS/Tween	solution	 at	 4°C	 overnight	 (to	 prevent	 non-	 specific	 binding	 of	 antibodies	 to	 the	membrane).			The	following	day,	the	membranes	were	agitated	on	a	shaker	at	room	temperature	for	one	hour	before	blocking	milk	was	 removed	and	 the	membrane	 strips	 incubated	with	appropriate	primary	antibodies	(section	2.1.4.)	for	one	hour	at	room	temperature	on	a	shaker.	The	membranes	were	 then	washed	 for	15	minutes	 in	PBS/Tween	 three	 times,	after	 which	 horseradish	 peroxidase	 (HRP)-conjugated	 secondary	 antibodies	 (section	2.1.4.)	raised	to	 the	relevant	species	were	applied	and	the	membranes	 incubated	 for	a	further	 hour	 at	 room	 temperature.	Next,	 the	membranes	were	washed	 three	 times	 as	previously,	 before	 being	 transferred	 into	 dry	 trays.	 Amersham	 ECL	 Prime	 detection	reagent	(GE	Healthcare	Life	Sciences)	was	then	applied	(typically	1-2ml	per	membrane)	for	 five	 minutes,	 and	 the	 signal	 detected	 by	 chemiluminescence	 and	 recorded	 on	 a	Kodak	 IM4000	 image	 station	 using Carestream	 molecular	 imaging	 software	(Carestream	 Health	 UK,	 Hemel	 Hempstead,	 UK).	 Further	 image	 processing	 was	performed	using	CorelDRAW	graphics	suite	X7.	
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3.	Results		
3.1.	Investigating	the	metabolic	phenotype	in	SCCHN	
	
3.1.1.	Introduction	As	discussed	in	sections	1.3.1.	and	1.3.3.,	although	altered	metabolism	is	now	generally	considered	 to	 constitute	 an	 emerging	 hallmark	 of	 the	 cancer	 phenotype(44)	 and	 has	received	 renewed	 attention	 in	 the	 field	 of	 cancer	 research(257,	 267,	 395),	 primary	studies	 of	metabolism	 specific	 to	 SCCHN	have	been	 somewhat	 lacking.	 Several	 SCCHN	studies	have	examined	glucose	transporter	or	glycolytic	enzyme	expression	in	isolation,	often	focusing	on	their	prognostic	significance(324-334,	336-343,	348),	and	a	handful	of	studies	have	explored	the	effects	of	the	glycolytic	inhibitor	2-DG(354-357).	Nonetheless,	these	 studies	 have	 neglected	 to	 characterise	 dynamic	 metabolic	 flux,	 have	 at	 times	produced	 conflicting	 results,	 and	 have	 failed	 present	 a	 clear	 picture	 of	 the	 SCCHN	metabolic	 phenotype.	 Interestingly,	 two	 relatively	 recent	 studies	 from	 the	 same	research	group	have	implicated	TP53	status	as	a	determinant	of	metabolic	phenotype	in	SCCHN,	with	associated	therapeutic	implications(359,	360),	while	another	recent	study	has	proposed	an	alternative	 three-compartment	model	of	metabolism	 in	SCCHN	based	on	Paget’s	“seed	and	soil”	hypothesis(366).		Given	the	variation	in	metabolic	perturbations	between	cancers(250)	and	the	resulting	importance	 of	 cancer	 type	 specific	 study	 of	metabolism,	 the	 aim	 of	 this	 chapter	 is	 to	further	explore	the	metabolic	phenotype	in	SCCHN.	This	was	achieved	taking	advantage	of	 the	 relatively	 recent	 development	 of	 highly	 sensitive,	 fluorescence	 and	microplate-based	XF	analysis,	which	allows	quantitative	metabolic	analysis	that	provides	real-time	information	about	metabolic	phenotype	during	specifically	designed	mitochondrial	and	glycolytic	 stress	 tests(383,	384).	As	detailed	 in	sections	2.4.6.	and	2.4.7.,	by	examining	changes	in	OCR	and	ECAR	during	sequential	injections	of	substrates	and	inhibitors	that	form	 the	basis	of	 these	 stress	 tests, the	 following	parameters	 can	be	calculated:	basal	respiration	and	glycolysis;	ATP-linked	respiration,	proton	leak,	maximal	respiration	and	glycolysis,	and	spare	respiratory	and	glycolytic	capacity(383,	384).		
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3.1.2.	Optimising	the	concentration	of	compounds	for	injection	during	XF24	
metabolic	assays	Prior	to	conducting	XF	assays,	it	was	necessary	to	optimise	the	measurement	conditions	for	 the	 analysis	of	 SCCHN	cell	 lines.	 Firstly,	 cell	 seeding	 titrations	were	performed	 for	each	of	the	cell	lines	to	determine	optimal	seeding	densities,	as	previously	described	in	section	 2.4.5.	 The	 aim	 was	 to	 achieve	 evenly	 distributed	 cells	 at	 50-90%	 confluence	within	 each	well,	 and	 obtain	 basal	OCR	 and	ECAR	values	 of	 50-400pmol/min	 and	20-120mpH/min	respectively,	as	per	manufacturer’s	guidelines.	The	resulting	cell	seeding	densities	were	previously	summarised	in	table	2.4.5.1.		The	 next	 step	 in	 optimisation	 involved	 titrating	 the	 concentrations	 of	 oligomycin	 and	FCCP.	 This	 is	 because	 the	 effects	 of	 these	 compounds	 can	 vary	 between	 different	 cell	types,	 and	 relatively	 small	 changes	 in	 concentration	 can	 significantly	 affect	 final	measurements	–	particularly	the	case	for	FCCP(383,	384).	Optimisation	assays	were	first	performed	 for	 oligomycin,	 in	 which	 OCR	 measurements	 were	 taken	 at	 baseline	 and	following	the	addition	of	oligomycin	at	the	following	concentrations:	0.625,	1.25,	2.5,	5,	and	10μM.	These	concentrations	were	chosen	based	on	manufacturer’s	guidelines	and	were	 also	 consistent	 with	 concentrations	 used	 in	 other	 SCHNN	 cell	 lines	 published	elsewhere(360).	 Figure	 3.1.2.1.	 shows	 the	 resulting	 OCR	 responses	 in	 three	 selected	SCCHN	cell	lines.	Given	that	1.25μM	was	the	lowest	concentration	to	consistently	induce	a	maximal	decline	in	OCR,	and	therefore	in	mitochondrial	uncoupling,	together	with	the	fact	 that	 dose-dependent	 responses	 appeared	 highly	 conserved	 between	 SCCHN	 cell	lines,	this	concentration	of	oligomycin	was	selected	for	use	in	all	subsequent	XF	assays.		
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Figure	 3.1.2.1:	 Oligomycin	 titration.	 OCR	 responses	 following	 administration	 of	 0	 (control),	0.625,	1.25,	2.5,	5,	and	10μM	oligomycin	(point	A	on	each	graph).	Each	condition	was	performed	in	 triplicate	 for	 each	 cell	 line	 and	 error	 bars	 represent	 the	 standard	 error	 of	 the	mean	 (SEM).	Three	SCCHN	cell	lines	were	selected	for	optimisation	to	ensure	consistency	of	responses	across	cell	 lines.	 Panels	 A,	 B,	 and	 C	 depict	 results	 for	 UM-SCC-5,	 UM-SCC-11A,	 and	 UM-SCC-11B	respectively.			Following	titration	of	oligomycin,	optimisation	assays	were	then	performed	for	FCCP,	in	which	OCR	measurements	were	taken	at	baseline	and	following	the	addition	of	FCCP	at	the	 following	 concentrations:	 0.5,	 0.75,	 1.0,	 1.5	 and	 3μM.	 Again,	 these	 concentrations	were	selected	on	the	basis	of	manufacturer’s	guidelines	and	published	data(360).	Figure	3.1.2.2.	shows	the	resulting	OCR	responses	in	three	selected	SCCHN	cell	lines.	Given	that	1.5μM	was	the	lowest	concentration	to	consistently	 induce	a	maximal	 increase	in	OCR,	and	 thus	 in	 ETC	 acceleration,	 together	 with	 the	 fact	 that	 dose-dependent	 responses	appeared	similar	between	SCCHN	cell	lines,	this	concentration	of	FCCP	was	selected	for	use	in	all	subsequent	XF	assays.		
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Figure	3.1.2.2:	FCCP	titration.	OCR	responses	following	administration	of	0	(control),	0.5,	0.75,	1.0,	1.5	and	3μM	FCCP	(point	A	on	each	graph).	Each	condition	was	performed	 in	 triplicate	 for	each	 cell	 line	 and	 error	 bars	 represent	 SEM.	 Three	 SCCHN	 cell	 lines	 were	 selected	 for	optimisation	to	ensure	consistency	of	responses	across	cell	lines.	Panels	A,	B,	and	C	depict	results	for	UM-SCC-5,	UM-SCC-11A,	and	UM-SCC-11B	respectively.	
	
3.1.3.	The	metabolic	phenotype	of	SCCHN	cells	is	dependent	on	TP53	status	To	determine	the	metabolic	phenotype	of	our	panel	of	SCCHN	cell	lines	and	to	examine	any	 potential	 relationship	 between	 metabolic	 profile	 and	 TP53	 status	 we	 next	performed	 XF24	mitochondrial	 and	 glycolytic	 stress	 tests	 on	 our	 panel	 of	 SCCHN	 cell	lines,	 as	 described	 in	 sections	 2.4.6.	 and	 2.4.7.	 Outputs	 from	 the	 mitochondrial	 and	glycolytic	stress	tests	for	each	of	the	cell	 lines	are	shown	in	figures	3.1.3.1.	and	3.1.3.2.	respectively,	 with	 data	 scaled	 to	 the	 fractional	 change	 relative	 to	 baseline	 OCR	 and	ECAR,	 and	 thus	 presented	 as	 percentage	 increases	 or	 decreases	 from	 the	 assigned	baseline	 following	 injection	 of	 the	 relevant	 substrates	 and/or	 inhibitors.	 The	 mutant	
TP53	 SCCHN	 cell	 lines	 (UM-SCC-5,	 UM-SCC-10A,	 UM-SCC-11B,	 and	 UM-SCC-81B)	exhibited	a	distinct	metabolic	phenotype	 to	 that	of	wild-type	TP53	 cell	 lines	 (UM-SCC-11A,	 and	 UM-SCC-17AS):	 wild-type	 TP53	 cells	 maintained	 metabolic	 diversity,	displaying	 robust	 mitochondrial	 and	 glycolytic	 reserves,	 while	 mutant	 TP53	 cells	exhibited	markedly	reduced	mitochondrial	and	glycolytic	reserves,	 functioning	near	or	at	capacity	under	basal	conditions.			
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Figure	 3.1.3.1:	 Changes	 in	 oxidative	 phosphorylation	 indicated	 by	 OCR	 in	 response	 to	
mitochondrial	 stressors	 in	 a	 panel	 of	 SCCHN	 cell	 lines.	 SCCHN	 cells	 were	 subjected	 to	mitochondrial	 stress	 tests,	 in	 which	 oligomycin	 1.25μM	 (point	 A),	 FCCP	 1.5μM	 (point	 B),	 and	rotenone	 and	 antimycin-A	 1μM	 (point	 C)	 were	 sequentially	 injected,	 and	 OCR	 (pmol/min)	measured.	Data	 is	 presented	 as	 percentage	 increases	 or	 decreases	 in	 OCR	 relative	 to	 baseline	measurements.	The	baseline	is	shown	as	the	black	line	on	the	graphs.	(A)	TP53	wild-type	SCCHN	cell	 lines,	which	maintained	robust	spare	respiratory	capacities	(see	red	arrows	labelled	1)	and	(B)	mutant	TP53	cell	lines,	which	exhibited	reduced	spare	respiratory	capacities	(see	red	arrows	labelled	2).	Error	bars	represent	SEM.		
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Figure	3.1.3.2:	Glycolytic	 changes	 indicated	by	ECAR	monitored	 in	 response	 to	glycolytic	
substrates	 and	 stressors	 in	 a	 panel	 of	 SCCHN	 cell	 lines.	 SCCHN	 cells	 were	 subjected	 to	glycolytic	stress	tests,	in	which	glucose	10mM	(point	A),	oligomycin	1.25μM	(point	B),	and	2-DG	50mM	(point	C)	were	sequentially	 injected,	and	ECAR	(mpH/min)	measured.	Data	is	presented	as	percentage	increases	or	decreases	in	ECAR	relative	to	baseline	measurements.	The	baseline	is	shown	as	 the	black	 line	on	 the	graphs.	 (A)	TP53	wild-type	SCCHN	cell	 lines,	which	maintained	robust	 glycolytic	 reserves	 (see	 red	 arrows	 labelled	 1)	 and	 (B)	 mutant	 TP53	 cell	 lines,	 which	exhibited	reduced	glycolytic	reserves	(see	red	arrows	labelled	2).	Error	bars	represent	SEM.		In	 light	 of	 the	 consistent	 pattern	 of	 observed	 metabolic	 phenotypes	 in	 the	 panel	 of	SCCHN	cell	lines,	ostensibly	distinguished	by	TP53	status,	isogenic	cell	lines	divergent	on	
TP53	 status	were	next	 interrogated	 to	 further	 explore	 the	possibility	 of	 a	 cause-effect	relationship	 between	 metabolic	 phenotype	 and	 TP53	 status	 in	 SCCHN	 cells.	 These	groups	of	 isogenic	cell	 lines	comprised	 the	 following:	 the	wild-type	TP53	 cell	 line	UM-
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SCC-17A	 and	 its	 derivative	 lines,	 UM-SCC-17A	 shp53	 (cells	 stably	 expressing	 shRNA	specific	 for	 p53)	 and	 UM-SCC-17A	 lenti	 (cells	 stably	 expressing	 the	 empty	 vector	control);	 and	 the	 endogenously	 p53	 null	 cell	 line	 UM-SCC-1	 and	 its	 derivative	 lines	transduced	with	 wild-type	TP53	 (UM-SCC-1	wtp53),	 empty	 vector	 control	 (UM-SCC-1	pBABE),	 or	 several	 clinically	 relevant	 TP53	 mutations	 (UM-SCC-1	 R175H,	 UM-SCC-1	C176F,	UM-SCC-1	R282W).	Outputs	 from	 the	mitochondrial	 and	 glycolytic	 stress	 tests	for	UM-SCC-1	and	derivative	lines	are	shown	in	figure	3.1.3.3.,	and	in	figure	3.1.3.4.	for	UM-SCC-17A	 and	 derivative	 lines.	 Importantly,	 the	metabolic	 phenotypes	 observed	 in	these	 groups	 of	 isogenic	 cell	 lines	 followed	 a	 similar	 pattern	 to	 those	 observed	 in	 the	aforementioned	 panel	 of	 SCCHN	 cell	 lines.	 Specifically,	 forced	 expression	 of	wild-type	p53	in	UM-SCC-1	resulted	in	a	switch	in	metabolic	profile	from	limited	respiratory	and	glycolytic	 reserves,	 functioning	 near	 capacity	 at	 baseline,	 to	 a	 discernible	 increase	 in	these	 parameters,	 while	 metabolic	 profiles	 in	 the	 derivative	 lines	 expressing	 TP53	mutations	did	not	differ	from	that	of	the	parental	line.	In	keeping	with	this,	the	opposite	effect	was	observed	 in	 the	 context	 of	 stable	knock-down	of	wild-type	p53	 in	UM-SCC-17A.	 Such	 findings	 corroborate	 a	 functional	 dependence	 on	 p53,	 and	 further	demonstrate	that	 the	observed	switch	 in	metabolic	profile	 is	 the	result	of	 loss	of	wild-type	p53	function	rather	than	any	oncogenic	GOF	properties	harboured	by	a	particular	
TP53	mutation.			
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Figure	 3.1.3.3:	Metabolic	 profiles	 of	UM-SCC-1	 and	derivative	 cell	 lines	 in	mitochondrial	
and	 glycolytic	 stress	 tests.	UM-SCC-1,	UM-SCC-1	pBABE,	UM-SCC-1	wtp53,	UM-SCC-1	R175H,	UM-SCC-1	 C176F,	 and	 UM-SCC-1	 R282W	 cell	 lines	 were	 subjected	 to	 mitochondrial	 (A)	 and	glycolytic	 stress	 tests	 (B).	 As	 before,	 for	 mitochondrial	 stress	 tests	 points	 A,	 B,	 and	 C	 on	 the	graphs	refer	to	the	injections	of	oligomycin	1.25μM,	FCCP	1.5μM,	and	rotenone	and	antimycin-A	1μM	 respectively.	 For	 glycolytic	 stress	 tests,	 points	 A,	 B,	 and	 C	 on	 the	 graphs	 refer	 to	 the	injections	of	glucose	10mM,	oligomycin	1.25μM,	and	2-DG	50mM	respectively.	Data	is	presented	as	 percentage	 increases	 or	 decreases	 in	 OCR	 or	 ECAR	 relative	 to	 baseline	measurements.	 The	baseline	is	shown	as	the	black	line	on	the	graphs.	Forced	expression	of	wild-type	p53	in	UM-SCC-1,	an	endogenously	p53-null	cell	line,	resulted	in	a	marked	increase	in	respiratory	and	glycolytic	reserves	 (compare	 red	 arrows	 labelled	 1	 and	 2),	while	metabolic	 profiles	 in	 the	 empty	 vector	control	cell	line	(pBABE)	and	the	derivative	lines	expressing	TP53	mutations	did	not	differ	from	that	 of	 the	 parental	 line	 (compare	 red	 arrows	 labelled	 1	 with	 those	 labelled	 3-6).	 Error	 bars	represent	SEM.	
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Figure	3.1.3.4:	Metabolic	profiles	of	UM-SCC-17A	and	derivative	cell	lines	in	mitochondrial	
and	 glycolytic	 stress	 tests.	UM-SCC-17A,	UM-SCC-17A	 lenti,	and	UM-SCC-17A	shp53	cell	 lines	were	subjected	to	mitochondrial	(A)	and	glycolytic	stress	tests	(B).	As	before,	for	mitochondrial	stress	tests	points	A,	B,	and	C	on	the	graphs	refer	to	the	 injections	of	oligomycin	1.25μM,	FCCP	1.5μM,	and	rotenone	and	antimycin-A	1μM	respectively.	For	glycolytic	 stress	 tests,	points	A,	B,	and	C	on	the	graphs	refer	to	the	injections	of	glucose	10mM,	oligomycin	1.25μM,	and	2-DG	50mM	respectively.	Data	is	presented	as	percentage	increases	or	decreases	in	OCR	or	ECAR	relative	to	baseline	measurements.	The	baseline	is	shown	as	the	black	line	on	the	graphs.	Stable	knockdown	of	 wild-type	 p53	 in	 UM-SCC-17A	 resulted	 in	 a	 loss	 of	 mitochondrial	 and	 glycolytic	 reserves	(compare	red	arrows	 labelled	1	and	2),	while	there	was	no	change	 in	the	empty	vector	control	cell	line	(lenti)	(compare	red	arrows	labelled	1	and	3).	Error	bars	represent	SEM.		This	 observed	 relationship	 between	TP53	 mutation	 and	 loss	 of	metabolic	 diversity	 is	consistent	 with	 the	 limited	 metabolic	 data	 in	 SCCHN	 relatively	 recently	 published	elsewhere.	In	an	initial	study	examining	the	metabolic	pathways	on	which	SCCHN	cells	predominantly	 depend,	 although	 a	 general	 dependence	 on	 glucose	 catabolism	 over	glutaminolysis	was	 observed,	 significant	 heterogeneity	was	 noted	 among	 the	 panel	 of	cell	lines	evaluated(359).	Further	analysis	revealed	that	a	pair	of	cell	lines	derived	from	the	 same	 patient	 but	 divergent	 with	 respect	 to	 TP53	 mutational	 status	 displayed	differing	degrees	of	sensitivity	to	glucose	deprivation,	with	the	wild-type	TP53	cell	line	exhibiting	 relative	 resistance,	 suggesting	 a	 possible	 role	 for	 wild-type	 p53	 in	determining	 response	 to	 glucose	 starvation,	 and	 by	 extension	 the	 metabolic	underpinnings(359).	 A	 follow-on	 study	 from	 the	 same	 research	 group	 examined	 this	further,	 again	 using	 the	 same	 isogenic	 cell	 line	 pair	 divergent	 with	 respect	 to	 TP53	status,	utilising	a	similar	experimental	system	of	microplate-based	XF	analysis	as	used	in	 the	 present	 study(360).	Mutant	TP53	 cell	 lines	were	 observed	 to	 exhibit	markedly	reduced	spare	respiratory	capacity	relative	to	wild-type	TP53	cell	lines,	functioning	near	capacity	 under	 basal	 conditions,	 findings	which	were	 reproduced	 in	 a	wild-type	TP53	cell	 line	 and	 a	 derivative	 cell	 line	 with	 stable	 wild-type	 p53	 knockdown(360).	Interestingly,	 another	 recent	 metabolic	 study	 in	 SCCHN	 employing	 microplate-based	measurement	 of	 cellular	 oxygen	 consumption	 and	 proton	 efflux,	 which	 sought	 to	investigate	 the	 reprogramming	 of	 metabolism	 associated	 with	 the	 development	 of	radioresistance	 using	 a	 matched	model	 of	 radio-resistant	 and	 -sensitive	 SCCHN	 cells,	demonstrated	 that	 relatively	 radio-resistant	 cells	 displayed	 reduced	 respiratory	 spare	capacity(277).	 Whilst	 unfortunately	 information	 of	 TP53	 status	 of	 the	 cell	 lines	 was	lacking,	 sequential	 treatment	 of	 the	 parental	 radiation-sensitive	 cell	 line	with	 several	
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fractions	of	IR	to	generate	the	radio-resistant	cell	line	may	have	resulted	in	acquisition	of	a	TP53	mutation.	Clearly,	however,	this	is	highly	speculative.		It	 is	 perhaps	 unsurprising	 to	 consider	 that	 TP53	 status	 would	 strongly	 influence	metabolic	phenotype	in	SCCHN,	recognising	the	critical	importance	of	loss	of	wild-type	p53	 function	 in	 SCCHN	 oncogenesis	 and	 the	 intricate	 links	 between	 p53	 and	maintenance	of	metabolic	homeostasis.	TP53	mutation,	which	 in	 the	majority	of	 cases	results	in	loss	of	wild-type	function	(see	section	1.2.7.),	is	the	most	commonly	mutated	gene	 in	 SCCHN,	 harboured	 in	 upwards	 of	 60%	 of	 SCCHNs(52).	 Furthermore,	 TP53	mutation,	in	particular	disruptive	mutation,	is	characteristically	associated	with	a	more	aggressive	and	 treatment	 resistant	disease	phenotype(56,	57).	 In	keeping	with	 this,	 in	terms	of	our	metabolic	 findings,	p53	has	been	reported	to	exert	 influence	over	several	aspects	 of	 glucose	 catabolism	 both	 directly	 and	 indirectly,	 in	 general	 restricting	glycolytic	 flux,	 maintaining	 mitochondrial	 integrity	 and	 function,	 and	 promoting	oxidative	phosphorylation(247,	267,	294)	(discussed	in	section	1.3.2.).		Contrary	 to	 the	 reporting	 by	 Sandulache	 et	 al	 in	 the	 above	 study(360),	 XF	 data	demonstrating	that	TP53	mutation	confers	reduced	respiratory	and	glycolytic	reserves	in	 SCCHN	 cells,	 with	 cells	 functioning	 near	 capacity	 under	 basal	 conditions,	 can	 be	interpreted	 in	 one	 of	 two	 ways.	 Firstly,	 in	 mutant	 TP53	 cells	 functioning	 of	mitochondrial	 oxidative	 phosphorylation	 and/or	 glycolysis	 is	 compromised	 in	 some	way,	preventing	cells	 from	mounting	a	compensatory	response	 to	metabolic	stressors;	or	 secondly,	 that	 mutant	 TP53	 cells	 have	 significantly	 elevated	 rates	 of	 oxidative	phosphorylation	and/or	glycolysis	at	baseline	that	represent	maximal	cellular	rates.	 In	order	 to	 reconcile	 these	 differing	 accounts,	 we	 normalised	 our	 XF	 stress	 test	 data	 to	DNA	 content	 to	 capture	 absolute	 values	 of	 each	 of	 the	metabolic	 parameters	 derived	during	 the	 assays	 (detailed	 in	 section	 2.4.8.)	 and	 to	 facilitate	 comparison	 of	 these	measurements	 between	 cell	 lines,	 which	were	 seeded	 at	 varying	 densities.	 Results	 of	such	 analyses	 are	 summarised	 in	 figures	3.1.3.5	 and	3.1.3.6.	 In	 keeping	with	 the	 clear	patterns	 shown	 in	 the	 stress	 test	 graphs	 presented	 above,	 the	 absolute	 values	 for	maximal	 respiration,	 spare	 respiratory	 capacity,	 maximal	 glycolysis,	 and	 glycolytic	reserve	were	 significantly	 greater	 in	wild-type	TP53	 cell	 lines	 compared	with	mutant	
TP53	 cell	 lines.	 Interestingly,	 however,	 capturing	 absolute	 OCR	 and	 ECAR	 values	revealed	 that	wild-type	TP53	 cells	 exhibited	 discernibly	 higher	 rates	 of	mitochondrial	respiration	and	lower	rates	of	glycolysis	under	basal	conditions	compared	with	mutant	
TP53	cells,	findings	which	were	borne	out	more	definitively	when	analysing	the	relative	
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basal	 utilisation	 of	 mitochondrial	 respiration	 and	 glycolysis	 (figure	 3.1.3.7.).	Importantly,	 these	 findings	 again	 held	 true	 in	 the	 isogenic	 cell	 lines	 divergent	 with	respect	 to	 TP53	 mutational	 status.	 Taken	 together,	 these	 findings	 allow	 for	 a	 clearer	interpretation	 of	 the	 overall	 metabolic	 picture,	 which	 suggests	 that	 SCCHN	 cells	harbouring	 wild-type	 p53	 predominantly	 catabolise	 glucose	 through	 oxidative	phosphorylation	 under	 basal	 conditions	 and	 maintain	 robust	 mitochondrial	 function,	enabling	 these	 cells	 to	 mount	 a	 maximal	 increase	 in	 ETC	 activity	 when	 exposed	 to	mitochondrial	 stressors.	 In	 contrast,	 in	 the	 context	 of	 loss	 of	 wild-type	 p53	 function	mitochondrial	 function	 appears	 to	 be	 compromised	 as	 cells	 display	 reduced	 oxidative	phosphorylation	under	basal	conditions	and	are	unable	to	mount	an	increase	in	activity	in	 response	 to	 mitochondrial	 stressors.	 Glycolysis	 seemingly	 predominates	 with	significantly	 heightened	 basal	 levels,	 which	 are	 elevated	 to	 maximal	 cellular	 capacity	leaving	 little	or	no	glycolytic	reserve.	As	would	be	expected	the	observed	difference	 in	rates	 of	 basal	 glycolysis	 between	 the	 cell	 lines	 is	 more	 marked	 than	 that	 of	mitochondrial	 respiration.	 This	 reflects	 the	 fact	 that	 glycolysis	 is	 a	 relatively	energetically	 inefficient	 process,	 yielding	 only	 two	 molecules	 of	 ATP	 per	 molecule	 of	glucose	 consumed	 as	 opposed	 to	 up	 to	 36	 with	 oxidative	 phosphorylation,	 and	 thus	mutant	TP53	cells	would	have	 to	 increase	rates	of	glycolysis	at	an	order	of	magnitude	greater	 than	 the	 corresponding	 reduction	 in	 mitochondrial	 respiration	 to	 maintain	sufficient	ATP	production.	The	 fact	 that	ATP-linked	respiration	 is	consistently	reduced	in	mutant	TP53	cells	compared	with	wild-type	TP53	cells	lends	further	credence	to	the	notion	that	mutant	TP53	cells	have	compromised	ETC	function,	something	which	will	be	explored	 in	more	detail	 later	 in	 this	 thesis	 (section	3.4.2).	 It	 is	also	 interesting	 to	note	that	 in	 addition	 to	 displaying	 higher	 basal	 levels	 of	 glycolysis	 and	 thus	 having	 lower	glycolytic	reserves,	mutant	TP53	cells	also	exhibited	higher	overall	glycolytic	capacities.	This	 likely	 reflects	 the	 probable	 upregulation	 of	 glucose	 transporters	 and	 glycolytic	enzymes	needed	to	sustain	elevated	rates	of	basal	glycolysis.	Again,	this	will	be	explored	in	more	depth	later	in	this	thesis	(section	3.4.3).	
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Figure	 3.1.3.5:	 Absolute	 normalised	 data	 derived	 from	 mitochondrial	 stress	 tests.	 XF	mitochondrial	 stress	 test	 data	 was	 normalised	 to	 DNA	 content	 for	 all	 cell	 lines	 to	 capture	
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absolute	values	 for	basal	 respiration,	ATP-linked	 respiration,	proton	 leak,	maximal	 respiration,	and	 spare	 respiratory	 capacity	 that	 could	 be	 compared	 between	 cell	 lines.	 Values	 for	 basal	respiration,	ATP-linked	respiration,	maximal	respiration,	and	spare	respiratory	capacity	were	all	greater	 in	 the	 wild-type	 TP53	 cell	 lines,	 while	 values	 for	 proton	 leak-linked	 respiration	 were	broadly	similar.	Error	bars	represent	SEM	for	each	measurement.	Blue	bars	represent	wild-type	
TP53	 cell	 lines,	 red	 bars	 represent	 mutant	 TP53	 cell	 lines,	 orange	 bars	 represent	 UM-SCC-1	wtp53,	and	green	bars	represent	UM-SCC-17A	shp53.		
	
	
	
Figure	3.1.3.6:	Absolute	normalised	data	derived	from	glycolytic	stress	tests.	XF	glycolytic	stress	 test	data	was	normalised	 to	DNA	content	 for	all	 cell	 lines	 to	 capture	absolute	values	 for	basal	glycolysis,	glycolytic	capacity,	and	glycolytic	reserve	that	could	be	compared	between	cell	lines.	Values	 for	glycolytic	reserve	were	greater	 in	 in	the	wild-type	TP53	cell	 lines,	while	 in	the	
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mutant	TP53	cell	 lines	basal	glycolytic	values	were	considerably	greater	and	glycolytic	capacity	slightly	elevated.	Error	bars	represent	SEM	for	each	measurement.	Blue	bars	represent	wild-type	
TP53	 cell	 lines,	 red	 bars	 represent	 mutant	 TP53	 cell	 lines,	 orange	 bars	 represent	 UM-SCC-1	wtp53,	and	green	bars	represent	UM-SCC-17A	shp53.			
	
Figure	 3.1.3.7:	 Relative	 basal	 utilisation	 of	 mitochondrial	 respiration	 and	 glycolysis.	Normalised	basal	values	from	XF	glycolytic	and	mitochondrial	stress	tests	for	all	cell	lines	plotted	against	each	other.	There	is	clear	grouping	of	wild-type	TP53	and	mutant	TP53	cell	lines,	with	the	former	displaying	high	levels	of	mitochondrial	respiration	relative	to	glycolysis	and	the	latter	the	opposite.	Error	bars	represent	SEM	for	each	measurement.	Blue	diamonds	represent	wild-type	
TP53	cell	lines,	red	diamonds	represent	mutant	TP53	cell	lines,	the	orange	circle	represents	UM-SCC-1	wtp53,	and	the	green	circle	represents	UM-SCC-17A	shp53.		
3.1.4.	 Metabolic	 switching	 associated	 with	 loss	 of	 wild-type	 p53	 function	 confers	
increased	dependence	on	glycolysis	for	survival	Results	 presented	 in	 the	 previous	 section	 demonstrated	 that	mutational	 loss	 of	 wild-type	 p53	 function	 results	 in	 a	 metabolic	 switch,	 resulting	 in	 increased	 utilisation	 of	glycolysis	 accompanied	 by	 compromised	 oxidative	 phosphorylation.	 The	 proposed	impetus	 driving	 cancer	 cells	 to	 undergo	what	 is	 an	 energetically	 inefficient	metabolic	shift	most	 likely	 relates	 to	underlying	proliferation	 and	 survival	 requirements	 of	 such	cells:	 rapid	 ATP	 generation,	 combined	 with	 generation	 of	 intermediates	 for	 anabolic	biosynthesis	and	reducing	equivalents	 to	 regulate	cellular	 redox	potential	 to	minimise	the	damaging	effects	of	ROS(257,	267)	(see	section	1.3.1.).	Consequently,	our	next	aim	was	 to	 determine	 whether	 mutant	 TP53	 cells	 undergoing	 such	 metabolic	
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reprogramming	 were	 indeed	 dependent	 on	 this	 for	 survival,	 something	 which	 would	also	 have	 potential	 therapeutic	 implications.	 In	 order	 to	 do	 so,	 assessment	 of	 cell	proliferation	and	viability	was	performed	using	trypan	blue	exclusion	assays	following	inhibition	 of	 glycolysis	 and	 oxidative	 phosphorylation	 using	 2-DG	 and	 UK5099	respectively	 (section	 2.5),	 with	 analysis	 performed	 at	 16,	 24,	 and	 48	 hours	 following	treatment.	 Figures	 3.1.4.1	 and	 3.1.4.2.	 show	 viability	 data	 for	 the	 panel	 of	 SCCHN	 cell	lines	and	the	isogenic	cell	lines	respectively.	Mutant	TP53	cells	were	highly	sensitive	to	the	effects	of	2-DG	 in	 terms	of	viability	 from	24	hours	post-treatment,	while	wild-type	
TP53	cells	required	the	addition	of	UK5099	for	a	significant	reduction	in	viability.	These	findings	 also	 held	 true	 in	 the	 isogenic	 cell	 lines.	 UM-SCC-1	 and	 derivative	 lines	transduced	with	 TP53	mutations	 displayed	 sensitivity	 to	 2-DG	 treatment	 alone,	 while	with	 forced	 expression	 of	 wild-type	 p53	 the	 addition	 of	 UK5099	 was	 required	 for	 a	reduction	in	viability.	Similarly,	in	UM-SCC-17A	combination	treatment	was	required	to	reduce	 viability	 but	 stable	 p53	 knockdown	 (shp53)	 rendered	 cells	 sensitive	 to	 2-DG	alone.	Collectively,	these	findings	indicate	that	in	SCCHN	cells	with	loss	of	wild-type	p53	function	there	is	a	globalised	loss	of	metabolic	flexibility,	which	manifests	as	a	survival	dependence	on	glycolysis,	whereas	in	wild-type	TP53	SCCHN	cells	metabolic	plasticity	is	maintained	and	survival	does	not	depend	so	heavily	on	one	isolated	metabolic	pathway.		
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Figure	 3.1.4.1:	 Cell	 viability	 as	measured	 by	 trypan	 blue	 exclusions	 assays.	Viability	was	assessed	 in	 a	 panel	 of	 SCCHN	 cell	 lines	 following	 no	 treatment,	 treatment	 with	 25mM	 2-DG	(glycolytic	inhibitor)	alone,	treatment	with	2μM	UK5099	(inhibitor	of	the	mitochondrial	pyruvate	carrier),	or	combined	treatment	at	16	(A),	24	(B),	and	48	hours	(C).	In	mutant	TP53	cells	there	is	a	significant	reduction	in	viability	with	2-DG	treatment	alone	from	24	hours	but	not	in	wild-type	
TP53	 cells.	 The	 addition	 of	 UK5099	 was	 required	 in	 wild-type	 TP53	 cells	 for	 a	 discernible	reduction	in	viability,	which	again	was	observed	from	24	hours.	Values	represent	the	mean	from	three	separate	experiments	and	error	bars	represent	SEMs.	
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Figure	3.1.4.2:	Cell	viability	as	measured	by	trypan	blue	exclusion	assays	 in	 isogenic	cell	
lines.	Viability	was	assessed	the	isogenic	SCCHN	cell	lines	following	no	treatment,	treatment	with	25mM	 2-DG	 (glycolytic	 inhibitor)	 alone,	 treatment	 with	 2μM	 UK5099	 (inhibitor	 of	 the	mitochondrial	pyruvate	carrier),	or	combined	treatment	at	16	(A),	24	(B),	and	48	hours	(C).	 In	UM-SCC-1	and	derivatives	transduced	with	TP53	mutations	or	the	empty	vector	control	there	is	a	significant	 reduction	 in	 viability	 with	 2-DG	 treatment	 alone	 from	 24	 hours,	 while	 with	 forced	expression	of	wild-type	p53	the	addition	of	UK5099	was	required	for	a	discernible	reduction	in	viability,	 which	 again	 was	 observed	 from	 24	 hours.	 Similarly,	 in	 UM-SCC-17A	 and	 the	 empty	vector	 control	 (lenti)	 combination	 treatment	was	 required	 to	 reduced	 viability	 but	 stable	 p53	knockdown	 (shp53)	 rendered	 cells	 sensitive	 to	 2-DG	 alone.	 Values	 represent	 the	 mean	 from	three	separate	experiments	and	error	bars	represent	SEMs.		Similar	 results	were	 also	 reported	 in	 the	 aforementioned	 study	 examining	 the	 role	 of	
TP53	 mutational	 status	 in	 determining	 metabolic	 phenotype	 in	 SCCHN(360).	 In	 that	study,	using	microplate-based	XF	analysis,	ECARs	for	mutant	and	wild-type	SCCHN	cells	were	 compared	 when	 exposed	 to	 2-DG(360).	 Mutant	 TP53	 cells	 were	 observed	 to	display	a	greater	and	more	sustained	reduction	in	ECAR	compared	with	wild-type	cells,	and	on	the	basis	of	this	the	authors	insinuated	glycolytic	dependence(360).	However,	a	greater	absolute	reduction	in	ECAR	following	administration	of	2-DG	would	be	expected	in	mutant	TP53	cells	simply	as	a	result	of	 their	higher	basal	glycolytic	 levels,	and	does	not	 alone	 demonstrate	 glycolytic	 dependence	per	se.	Moreover,	 these	 findings	may	be	explained	by	the	fact	that	mutant	TP53	cells	would	likely	express	glucose	transporters	at	higher	 levels	 than	 wild-type	 cells	 and	 thus	 there	 would	 be	 a	 greater	 influx	 of	 2-DG.	
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Nonetheless,	 previous	 findings	 from	 proliferation	 assays	 conducted	 by	 the	 same	research	 group	 do	 lend	 support	 to	 the	 idea	 of	 glycolytic	 dependence	 in	mutant	TP53	cells(359)	(as	discussed	in	sections	1.3.3.	and	3.1.3.).			Such	dependence	on	glycolysis	potentially	presents	a	promising	therapeutic	window	to	preferentially	 target	 mutant	 TP53	 SCCHN,	 which	 is	 particularly	 attractive	 given	 the	frequency	 of	 TP53	 mutation	 in	 SCCHN	 (upwards	 of	 60%)(52)	 and	 the	 typically	aggressive	 and	 treatment-resistant	 phenotype	 it	 confers(56,	 57).	 This	 is	 explored	 in	greater	detail	later	in	this	thesis	(section	3.2.).		
3.1.5.	The	metabolic	phenotype	of	HPV-positive	SCCHN	suggests	functional	wild-type	
p53	Considering	 this	 association	 between	 mutational	 loss	 of	 wild-type	 p53	 function	 and	glycolytic	 dependence,	 together	 with	 the	 importance	 of	 the	 HPV	 E6	 oncoprotein	 in	targeting	 p53	 for	 proteasomal	 degradation	 in	 the	 molecular	 pathogenesis	 of	 HPV-related	SCCHN(63,	396),	invites	scrutiny	of	metabolism	in	HPV-driven	disease.	In	order	to	examine	this,	established	SCCHN	cell	lines	reported	to	be	HPV-positive	(UM-SCC-104,	UPCI:SCC154,	 and	93VU147T)	were	metabolically	profiled	as	before	using	microplate-based	 XF	 analysis.	 Figures	 3.1.5.1.	 and	 3.1.5.2.	 depict	 respective	 outputs	 from	 the	mitochondrial	and	glycolytic	stress	tests	for	each	of	the	cell	lines,	with	data	scaled	to	the	fractional	change	relative	to	baseline	OCR	and	ECAR,	and	thus	presented	as	percentage	increases	 or	 decreases	 from	 the	 assigned	 baseline	 following	 injection	 of	 the	 relevant	substrates	 and/or	 inhibitors.	 Akin	 to	 results	 observed	 in	 wild-type	 TP53	 cells	previously,	the	HPV-positive	SCCHN	cell	lines	maintained	metabolic	diversity,	displaying	robust	mitochondrial	and	glycolytic	reserves.			
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Figure	 3.1.5.1:	 Chronological	 changes	 in	 OCR	 in	 response	 to	 mitochondrial	 stressors	 in	
HPV-positive	 SCCHN	 cell	 lines.	 Cells	 were	 subjected	 to	 mitochondrial	 stress	 tests,	 in	 which	
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oligomycin	1.25μM	(point	A),	FCCP	1.5μM	(point	B),	and	rotenone	and	antimycin-A	1μM	(point	C)	were	 sequentially	 injected,	 and	 OCR	 (pmol/min)	 measured.	 Data	 is	 presented	 as	 percentage	increases	or	decreases	 in	OCR	relative	to	baseline	measurements.	The	baseline	 is	shown	as	the	black	 line	 on	 the	 graphs.	 HPV-positive	 SCCHN	 cell	 lines	maintained	marked	 spare	 respiratory	capacities.	Error	bars	represent	SEM.		
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Figure	 3.1.5.2:	 Chronological	 changes	 in	 ECAR	 in	 response	 to	 glycolytic	 substrates	 and	
stressors	 in	HPV-positive	 SCCHN	 cell	 lines.	Cells	were	subjected	 to	glycolytic	stress	 tests,	 in	which	 glucose	 10mM	 (point	 A),	 oligomycin	 1.25μM	 (point	 B),	 and	 2-DG	 50mM	 (point	 C)	were	sequentially	injected,	and	ECAR	(mpH/min)	measured.	Data	is	presented	as	percentage	increases	or	decreases	in	ECAR	relative	to	baseline	measurements.	The	baseline	is	shown	as	the	black	line	on	the	graphs.	HPV-positive	SCCHN	cell	lines	maintained	considerable	glycolytic	reserves.	Error	bars	represent	SEM.		These	cell	lines	may	be	criticised	as	model	systems	for	HPV-related	SCCHN,	in	that	they	were	 derived	 from	 patients	with	 traditional	 SCCHN	 risk	 factors,	 specifically	 excessive	tobacco	 and	 alcohol	 use,	 and	 from	 primary	 tumour	 sites	 outside	 of	 the	 oropharynx,	which	 arguably	 may	 not	 represent	 the	 same	 disease	 phenotype	 as	 HPV-related	oropharyngeal	 SCC.	 However,	 whilst	 there	 are	 now	 thousands	 of	 patients	 with	 HPV-positive	SCCHN	and	biopsy	specimens	available,	there	are	only	a	handful	of	documented	HPV-related	SCCHN	cell	 lines	available	worldwide	and	there	is	currently	an	absence	of	established	cell	lines	with	such	characteristics.	Indeed,	the	scarcity	of	established	HPV-positive	 SCCHN	 cell	 lines	 raises	 an	 important	 question	 as	 to	 why	 it	 has	 been	 so	challenging	 to	 isolate	 and	 propagate	 SCCHN	 cell	 lines	 from	 patients	with	HPV-related	tumours.		Moreover,	 the	 established	 cell	 lines	 utilised	 in	 this	 study	 have	 undergone	 recent	characterisation,	 which	 revealed	 integrated	 and/or	 episomal	 viral	 DNA	 that	 is	transcriptionally	 active	 in	 all	 cell	 lines,	 suggesting	 that	 these	 may	 indeed	 represent	suitable	model	systems(378).			
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It	 is	perhaps	surprising	that	these	HPV-positive	cell	 lines	displayed	a	metabolic	profile	similar	 to	 that	 observed	 in	 wild-type	 TP53	 cells	 rather	 than	 that	 seen	 in	 cells	 with	mutational	 loss	of	wild-type	p53	 function	given	 the	role	of	 the	HPV	E6	oncoprotein	 in	targeting	 p53	 for	 proteasomal	 degradation.	 It	 may	 be	 the	 case,	 however,	 that	 E6-mediated	inactivation	of	p53	is	incomplete,	leaving	sufficient	functional	wild-type	p53	to	maintain	 a	 balanced	 and	diversified	metabolic	 phenotype.	 In	 support	 of	 this,	 genome-wide	microarray	data	from	a	recent	study	examining	radiation	response	in	HPV-positive	and	HPV-negative	SCCHN	cell	lines	suggested	that	low	levels	of	wild-type	p53	remain	in	HPV-positive	 cell	 lines,	 that	 this	 p53	 can	 be	 activated	 by	 therapeutic	 stress	 such	 as	radiation,	 and	 that	 this	 effect	 can	 be	 overcome	 by	more	 complete	 knockdown	 of	 p53	using	shRNA(381).			Interestingly,	these	results	are	in	keeping	with	the	only	other	study	to	date	investigating	metabolism	 specifically	 in	 HPV-related	 SCCHN,	 which	 examined	 both	 resected	 HPV-positive	oropharyngeal	SCC	specimens	and	an	in-vitro	HPV-positive	cell	line(361).	HPV-positive	 tumours	 were	 observed	 to	 express	 increased	 levels	 of	 proteins	 indicative	 of	oxidative	 phosphorylation	 and	 a	 relatively	 lower	 level	 of	 extracellular	 lactate	accumulation(361).			
3.2.	Evaluating	anti-metabolic	therapeutic	strategies	in	SCCHN		
3.2.1.	Introduction	As	outlined	in	section	1.1.5.,	there	remains	a	common	goal	in	the	treatment	of	both	HPV-negative	and	HPV-driven	SCCHN	 from	a	 translational	 research	perspective:	 to	 identify	means	 of	 sensitising	 these	 tumours	 to	 the	 effects	 of	 current	 treatments,	 not	 only	 to	improve	 efficacy,	 but	 also	 to	 minimise	 the	 substantial	 toxic	 effects.	 In	 the	 context	 of	traditional	 HPV-negative	 SCCHN	 there	 is	 a	 need	 to	 improve	 treatment	 efficacy	 to	enhance	 survival	 outcomes,	 while	 for	 HPV-related	 oropharyngeal	 SCC	 the	 fact	 that	clinical	reports	provide	clear	evidence	of	 improved	outcomes(80,	94,	95,	397),	has	 led	many	 to	 propose	 treatment	 de-intensification	 for	 these	 patients	 in	 order	 to	minimise	associated	 treatment	 toxicity.	RT	 remains	a	 cornerstone	of	 treatment	 for	 SCCHN,	with	74%	 of	 all	 SCCHN	 patients	 recommended	 to	 receive	 RT	 at	 some	 point	 during	 their	treatment	pathway,	 either	 as	 stand-alone	or	 as	 adjuvant	 therapy,	 if	 current	 treatment	guidelines	are	followed(107).	As	such,	it	is	imperative	to	identify	novel	radiosensitising	therapeutic	approaches.		
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	Therapeutic	strategies	are	generally	predicated	on	a	discernible	therapeutic	index	of	the	chosen	agent.	Considering	this,	in	contrast	to	traditional	cytotoxic	agents,	which	largely	rely	on	the	inherently	more	incessant	proliferative	rate	of	cancer	cells	rather	than	true	tumour	 specificity,	 metabolic	 targeting	 could	 potentially	 exploit	 the	 fact	 that	 tumour	cells	may	become	predominantly	reliant	on	a	particular	metabolic	pathway	providing	a	selective	 therapeutic	 gain	 while	 sparing	 most	 normal	 cells.	 In	 keeping	 with	 this,	 the	limited	 numbers	 of	 anti-metabolic	 therapeutic	 studies	 in	 SCCHN	 have,	 in	 general,	demonstrated	 cytotoxicity	 and	 potentiation	 of	 the	 effects	 of	 conventional	 treatments	with	 glycolytic	 inhibition(354-357,	 359,	 360).	 Findings,	 however,	 have	 not	 been	universal(355,	 357),	 and	 recent	 therapeutic	 studies	 have	 suggested	 a	 role	 for	 TP53	status	 in	 determining	 such	 effects(355,	 359,	 360).	 The	 data	 presented	 in	 chapter	 3.1.	demonstrate	 that	 mutational	 loss	 of	 wild-type	 p53	 function	 confers	 a	 switch	 in	metabolic	 phenotype	 towards	 reduced	 oxidative	 phosphorylation	 and	 glycolytic	dependence.	 Consequently,	 we	 hypothesised	 that	 such	 SCCHN	 cells	 may	 display	increased	susceptibility	to	glycolytic	targeting	with	appropriate	agents	to	potentiate	the	effects	 of	 IR,	 while	 those	 harbouring	 wild-type	 p53,	 and	 thus	 maintaining	 metabolic	diversity,	may	be	relatively	resistant	to	such	an	approach.	This	aim	of	this	chapter	is	to	examine	this	hypothesis.		
3.2.2.	 Glycolytic	 inhibition	with	2-DG	potentiates	 IR	 effects	 in	mutant	TP53	 SCCHN	
cells	only	Following	optimisation	of	cell	 seeding	densities	 for	each	cell	 line	(described	 in	section	2.6.),	 clonogenic	 survival	 assays	were	 undertaken	 on	 our	 panel	 of	 SCCHN	 cell	 lines	 to	explore	whether	glycolytic	inhibition	could	potentiate	the	effects	of	IR,	and	to	define	the	role	of	TP53	mutational	 status	 in	determining	 this.	Clonogenic	assays	were	performed	and	 survival	 parameters	 calculated	 as	 described	 in	 section	 2.6.	 in	 the	 absence	 and	presence	 of	 the	 glycolytic	 inhibitor	 2-DG,	 which	 was	 administered	 one	 hour	 prior	 to	irradiation.	A	dose	of	25mM	was	selected	because	this	reflects	doses	used	in	previously	published	studies	utilising	2-DG	in	SCCHN	cell	 lines(354,	360),	and	also	because	this	is	equivalent	to	the	concentration	of	glucose	present	in	the	cell	culture	media,	with	which	2-DG	 competes	 for	 cellular	uptake.	Clonogenic	 survival	 curves	 for	 the	panel	 of	 SCCHN	cell	 lines	are	shown	in	figure	3.2.2.1.	Radiation	response	following	glycolytic	inhibition	was	observed	to	correlate	with	our	earlier	findings	from	the	metabolic	profiling	studies,	in	 that	 2-DG	 consistently	 potentiated	 radiation	 effects	 in	 cells	 harbouring	 TP53	mutations	but	not	in	those	harbouring	wild-type	TP53.	
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Figure	 3.2.2.1:	 Clonogenic	 survival	 curves	 for	 the	 panel	 of	 SCCHN	 cell	 lines	 with	 and	
without	 administration	 of	 2-DG.	 Clonogenic	 assays	 were	 performed	 on	 SCCHN	 cell	 lines	exposed	to	the	indicated	doses	of	IR.	Cells	were	either	left	untreated	or	pre-treated	with	25mM	2-DG	 for	one	hour	prior	 to	 irradiation.	Results	 for	mutant	TP53	 cells	 are	 shown	 first	 (A)	and	 for	wild-type	 TP53	 cell	 lines	 subsequently	 (B).	 2-DG	 consistently	 potentiated	 the	 effects	 of	 IR	 in	mutant	TP53	cells	but	not	in	wild-type	TP53	cells.	Survival	parameters	were	calculated	according	to	the	linear	quadratic	formula	S(D)=exp(αD+βD2),	as	described	in	section	2.6.	The	results	shown	represent	 the	 mean	 values	 obtained	 from	 at	 least	 three	 separate	 experiments	 and	 error	 bars	represent	 SEMs.	 p-values	 are	 shown	 where	 there	 was	 a	 statistically	 significant	 difference	between	 the	 clonogenic	 survival	 curves	 (<0.05),	 and	are	 labelled	as	NS	 (not	 significant)	where	there	was	no	statistically	significant	difference	(≥0.05).			Although	 the	 consistent	 relationship	 between	 radiation	 responses	 following	 glycolytic	inhibition	with	2-DG	and	TP53	status	appears	compelling,	in	line	with	findings	from	our	previous	metabolic	studies,	relative	resistance	or	sensitivity	can	be	driven	by	alterations	in	 the	 functionality	 of	 a	 single	 transporter	 or	 enzyme.	 Thus,	 we	 next	 set	 out	 to	investigate	whether	 this	 association	 is	 deterministically	 related	 to	TP53	 by	 examining	the	 groups	 of	 cell	 lines	 with	 an	 isogenic	 background	 using	 the	 same	 experimental	platform.	Clonogenic	survival	curves	for	these	cell	lines	are	shown	in	figure	3.2.2.2.				
				
Results	
	 130	
	
		
		
		
Results	
	 131	
	
		
	
	
	
Results	
	 132	
	
	
	
	
Figure	3.2.2.2:	Clonogenic	survival	curves	 for	 isogenic	SCCHN	cell	 lines	with	and	without	
administration	of	2-DG.	Clonogenic	assays	were	performed	on	SCCHN	cell	lines	with	an	isogenic	background	exposed	to	the	indicated	doses	of	IR.	Cells	were	either	left	untreated	or	pre-treated	with	25mM	2-DG	for	one	hour	prior	to	irradiation.	Results	for	UM-SCC-1	and	derivative	cells	are	shown	first	(A)	and	for	UM-SCC-17A	and	derivative	cell	lines	subsequently	(B).	UM-SCC-17A	and	the	empty	vector	control	(lenti)	displayed	no	sensitivity	to	2-DG,	stable	knockdown	of	wild-type	p53	resulted	in	sensitivity	to	the	potentiating	effects	of	2-DG.	2-DG	significantly	potentiated	the	effects	of	IR	in	UM-SCC-1,	the	empty	vector	control	(pBABE),	and	derivative	cell	lines	transduced	with	TP53	mutations.	 Forced	 expression	 of	wild-type	 p53	 in	 this	 cell	 line	 resulted	 in	 a	 loss	 of	sensitivity	to	the	potentiating	effects	of	2-DG.	Survival	parameters	were	calculated	according	to	the	 linear	quadratic	 formula	S(D)=exp(αD+βD2),	as	described	 in	section	2.6.	The	results	shown	represent	 the	 mean	 values	 obtained	 from	 at	 least	 three	 separate	 experiments	 and	 error	 bars	represent	 the	 SEMs.	 p-values	 are	 shown	 where	 there	 was	 a	 statistically	 significant	 difference	
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between	 the	 clonogenic	 survival	 curves	 (<0.05),	 and	are	 labelled	as	NS	 (not	 significant)	where	there	was	no	statistically	significant	difference	(≥0.05).		Importantly,	 the	 effects	 of	 2-DG	 on	 radiation	 response	 observed	 in	 these	 groups	 of	isogenic	 cell	 lines	 followed	 a	 pattern	 consistent	 with	 that	 observed	 in	 the	 panel	 of	SCCHN	cell	lines.	Specifically,	while	in	UM-SCC-1,	an	endogenously	p53-null	cell	line,	2-DG	significantly	potentiated	the	effects	of	IR,	forced	expression	of	wild-type	p53	in	this	cell	line	resulted	in	a	loss	of	sensitivity	to	the	potentiating	effects	of	2-DG.	Notably,	there	was	no	change	 in	2-DG	effects	 from	the	parental	 line	 in	the	empty	vector	control	or	 in	the	derivative	cell	lines	transduced	with	TP53	mutations.	Similarly,	in	UM-SCC-17A	and	the	 empty	 vector	 control	 2-DG	 had	 no	 effect	 on	 the	 efficacy	 of	 IR,	 while	 stable	knockdown	of	wild-type	p53	 resulted	 in	 susceptibility	 to	 the	potentiating	effects	of	2-DG.	 Again,	 such	 findings	 corroborate	 a	 functional	 dependence	 on	 p53.	 These	 findings	accord	with	those	from	the	aforementioned	studies	examining	effects	of	TP53	status	on	metabolism	and	response	to	2-DG	in	SCCHN(355,	360),	presaging	an	opportunity	 for	a	novel	 tailored	 anti-metabolic	 approach	 to	 the	 treatment	 of	 SCCHN	 that	 takes	 into	account	TP53	mutational	status,	which	would	be	preferentially	effective	in	overcoming	cellular	 resistance	 to	 radiation	 treatment	 in	 patients	with	 treatment-resistant	 disease	typically	 associated	 with	 TP53	 mutation.	 Clearly,	 however,	 such	 an	 approach	 will	require	extensive	testing	in	pre-clinical	 in	vivo	models	to	further	validate	these	 in	vitro	results.	 Interestingly,	 these	 findings	 may	 also	 offer	 an	 explanation	 for	 the	 variable	results	observed	in	therapeutic	studies	of	2-DG	and	other	glycolytic	inhibitors	in	SCCHN,	as	well	 as	other	 tumour	 types.	Akin	 to	our	 findings	 in	SCCHN,	 it	 is	 conceivable	 that	 in	tumours	 harbouring	 TP53	 mutations,	 concurrent	 glycolytic	 inhibition	 could	 result	 in	significant	chemo-	and/or	radiosensitisation,	while	those	expressing	wild-type	p53	may	be	resistant	to	such	an	approach.		Having	 shown	 in	 the	 previous	 section	 that	 HPV-positive	 SCCHN	 cell	 lines	 exhibited	 a	metabolic	 profile	 in	 keeping	 with	 functional	 wild-type	 p53,	 and	 given	 that	 in	 HPV-negative	SCCHN	cells	this	correlated	with	a	resistance	to	the	potentiating	effects	of	2-DG	on	 IR,	 the	 effects	 of	 2-DG	 were	 explored	 in	 HPV-positive	 SCCHN	 cell	 lines.	 The	clonogenic	survival	curves	are	shown	in	figure	3.2.2.3.		
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Figure	 3.2.2.3:	 Clonogenic	 survival	 curves	 for	 HPV-related	 SCCHN	 cell	 lines	 with	 and	
without	administration	of	2-DG.	Clonogenic	assays	were	performed	on	HPV-related	SCCHN	cell	lines	 exposed	 to	 the	 indicated	doses	of	 IR.	 Cells	were	 either	 left	 untreated	or	pre-treated	with	25mM	2-DG	for	one	hour	prior	to	irradiation.	2-DG	failed	to	have	any	effect	on	radiation	response	in	any	of	these	cell	 lines.	Survival	parameters	were	calculated	according	to	the	linear	quadratic	formula	S(D)=exp(αD+βD2),	as	described	 in	section	2.6.	The	results	 shown	represent	 the	mean	values	obtained	from	at	least	three	separate	experiments	and	error	bars	represent	the	SEMs.	p-values	are	 shown	where	 there	was	a	 statistically	 significant	difference	between	 the	 clonogenic	survival	curves	(<0.05),	and	are	labelled	as	NS	(not	significant)	where	there	was	no	statistically	significant	difference	(≥0.05).		Again	 in	 keeping	 with	 findings	 from	 our	 earlier	 metabolic	 profiling	 studies,	 in	 which	these	 HPV-positive	 SCCHN	 cell	 lines	 were	 seen	 to	 display	 metabolic	 diversity,	administration	of	 2-DG	had	no	 effect	 on	 IR	 effects	 in	 these	 cell	 lines.	As	mentioned	 in	section	 3.1.5.,	 only	 one	 previous	 study	 has	 examined	 metabolism	 in	 HPV-related	SCCHN(361),	 and	 although	 these	 findings	 accord	with	 our	metabolic	 profiling	 studies,	there	is	no	comparative	data	on	anti-metabolic	therapeutics	 in	these	tumour	types.	On	the	 basis	 of	 the	 present	 data,	 it	 appears	 that	 in	 order	 to	 potentiate	 the	 effects	 of	conventional	 treatments	 in	HPV-driven	SCCHN	a	broader	anti-metabolic	approach	will	be	required,	and	this	is	explored	further	later	in	this	chapter	(section	3.2.5.).		Whilst	it	was	not	the	aim	of	the	present	study	to	examine	radiation	sensitivity	between	HPV-negative	 and	 HPV-positive	 SCCHN	 cell	 lines,	 and	 as	 such	 no	 formal	 analysis	 has	been	 carried	 out	 in	 this	 regard,	 it	 is	 interesting	 to	 note	 the	 clear	 differences	 in	 the	clonogenic	 survival	 curves.	 Although	 there	 is	 considerable	 variation	 in	 radiation	sensitivity	 in	 both	 HPV-negative	 and	 HPV-positive	 cells,	 there	 is	 a	 clear	 pattern	 of	increased	 radiosensitivity	 in	 the	 HPV-positive	 cells,	 with	 reduced	 survival	 fractions	(compare	figures	3.2.2.1.	and	3.2.2.2.	with	figure	3.2.2.3.).	This	finding	certainly	accords	with	 clinical	 reports,	which	 have	 shown	 favourable	 survival	 outcomes	 for	HPV-driven	oropharyngeal	 SCC	 irrespective	of	 treatment	modality	 employed(80,	94,	 95,	 397),	 and	adds	 weight	 to	 the	 notion	 that	 these	 cell	 lines	 represent	 suitable,	 albeit	 potentially	limited	 model	 systems.	 Curiously,	 the	 paucity	 of	 previous	 experimental	 data	 in	 HPV-positive	 SCCHN	 cell	 lines	 is	 conflicting,	 with	 some	 reports	 suggesting	 enhanced	sensitivity	to	radiation	and	others	suggesting	reduced	sensitivity	or	no	effect(381,	398-400).	Consistent	with	our	findings,	however,	a	relatively	recent	study,	in	which	cell	line	HPV	 status	 was	 rigorously	 validated,	 demonstrated	 HPV-positive	 SCCHN	 cells	 to	 be	
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consistently	more	sensitive	to	radiation	than	HPV-negative	SCCHN	cells	both	in	vitro	and	
in	vivo(381).		
3.2.3.	 The	 potentiating	 effects	 of	 2-DG	 on	 IR	 in	mutant	 TP53	 SCCHN	 cells	 are	 on-
target	2-DG	 is	 a	 stable	 glucose	 analogue	 that	 is	 taken	 up	 by	 glucose	 transporters	 and	phosphorylated.	 2-DG,	 however,	 cannot	 be	 fully	 metabolised	 and	 2-DG-6-phosphate	accumulates	 in	 the	 cell	 and	 interferes	 with	 glycolysis	 by	 inhibiting	 the	 glycolytic	enzymes	 phosphoglucose	 isomerase	 and	 hexokinase.	 The	 general	 presumption,	therefore,	 is	 that	 the	 biological	 effects	 of	 2-DG	 are	 the	 consequence	 of	 this	 block	 in	carbohydrate	 catabolism.	 This	 presumption,	 however,	 has	 been	 challenged	 and	 any	observed	 effects	 of	 2-DG	may	 not	 be	 simply	 the	 result	 of	 a	 catabolic	 block(358).	 The	specificity	 of	 2-DG	 anti-glycolytic	 effects	 in	 suppressing	 cellular	 proliferation	 and	anchorage-independent	growth	 in	SCCHN	cell	 lines	has	been	demonstrated	previously,	with	 effects	 were	 reproduced	 under	 conditions	 of	 glucose	 deprivation(359).	Furthermore,	 differential	 sensitivity	 to	 halogenated	 2-DG	 analogues	 consistent	 with	their	 underlying	 chemical	 structure	 has	 been	 reported,	 and	 quantitative,	 broad-based	analysis	of	changes	in	intracellular	metabolite	levels	in	response	to	2-DG	revealed	time-dependent	 reductions	 in	 lactate	production	and	 levels	of	upstream	glycolytic	 and	TCA	cycle	 intermediates(359).	Nonetheless,	we	sought	 to	 investigate	whether	 the	observed	potentiating	effects	of	2-DG	on	IR	 in	mutant	TP53	SCCHN	cells	were	 indeed	a	result	of	glycolytic	inhibition	by	investigating	whether	these	effects	were	reproduced	using	3-BP,	a	 distinct	 glycolytic	 inhibitor	 also	 acting	 on	 hexokinase,	 in	 the	 SCCHN	 cells	 with	 an	isogenic	 background.	 Clonogenic	 assays	 were	 performed	 and	 survival	 parameters	calculated	 as	 before,	 but	 in	 the	 absence	 and	 presence	 of	 5μM	 3-BP,	 which	 was	administered	 one	 hour	 prior	 to	 irradiation.	 Clonogenic	 survival	 curves	 are	 shown	 in	figure	 3.2.3.1.	 Results	 were	 consistent	 with	 those	 obtained	 for	 2-DG,	 whereby	 3-BP	potentiated	radiation	effects	in	cells	with	abrogated	wild-type	p53	function	but	failed	to	do	so	in	cells	harbouring	wild-type	p53.	Although	3-BP	also	has	effects	beyond	those	of	glycolytic	 inhibition(401),	 the	 fact	 that	 two	 distinct	 glycolytic	 inhibiting	 agents	 both	acting	on	hexokinase	have	induced	the	same	pattern	of	potentiating	effects	on	IR	lends	support	 to	 the	 notion	 that	 antiglycolytic	 effects	 are	 the	 likely	 mechanism	 driving	toxicity.				
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Figure	3.2.3.1:	Clonogenic	survival	curves	 for	 isogenic	SCCHN	cell	 lines	with	and	without	
administration	of	3-BP.	Clonogenic	assays	were	performed	on	SCCHN	cell	lines	with	an	isogenic	background	exposed	to	the	indicated	doses	of	IR.	Cells	were	either	left	untreated	or	pre-treated	with	5μM	3-BP	 for	one	hour	prior	 to	 irradiation.	Results	 for	UM-SCC-1	and	derivative	cells	are	shown	first	(A)	and	for	UM-SCC-17A	and	derivative	cell	lines	subsequently	(B).	UM-SCC-17A	and	the	empty	vector	control	(lenti)	displayed	no	sensitivity	to	3-BP,	while	stable	knockdown	of	wild-type	p53	resulted	in	sensitivity	to	the	potentiating	effects	of	3-BP.	3-BP	significantly	potentiated	the	effects	of	IR	in	UM-SCC-1	and	the	empty	vector	control	(pBABE).	Forced	expression	of	wild-type	 p53	 in	 this	 cell	 line	 resulted	 in	 a	 loss	 of	 susceptibility	 to	 the	 potentiating	 effects	 of	 3-BP.	Survival	 parameters	 were	 calculated	 according	 to	 the	 linear	 quadratic	 formula	S(D)=exp(αD+βD2),	 as	 described	 in	 section	 2.6.	 The	 results	 shown	 represent	 the	mean	 values	obtained	from	at	 least	 three	separate	experiments	and	error	bars	represent	the	SEMs.	p-values	are	shown	where	there	was	a	statistically	significant	difference	between	the	clonogenic	survival	curves	 (<0.05),	 and	 are	 labelled	 as	 NS	 (not	 significant)	 where	 there	 was	 no	 statistically	significant	difference	(≥0.05).		
3.2.4.	Pentose	phosphate	pathway	inhibition	further	potentiates	IR	effects	in	SCCHN	
cells	with	loss	of	functional	wild-type	p53	As	discussed	previously	(section	1.3.1.),	a	major	impetus	for	metabolic	re-programming	in	 cancer	 cells	 is	 thought	 to	 relate	 to	 regulation	 of	 cellular	 redox	 potential,	 whereby	switching	the	balance	away	from	oxidative	phosphorylation	towards	glycolysis	enables	up-regulation	 of	 cellular	 antioxidant	 systems	 to	 quench	 the	 increased	 ROS	 levels	resulting	 from	 heightened	 oxidative	 substrate	 flux	 and	 de-regulated	 cellular	proliferation(257,	267).	This	up-regulation	of	anti-oxidant	systems	 largely	depends	on	the	generation	of	the	reducing	equivalent	NADPH,	the	principal	source	of	which	is	PPP	flux(280).	 Considering	 this,	 together	with	 the	 fact	 that	 disruption	 of	 thiol	metabolism	and	consequent	oxidative	stress	has	been	implicated	as	the	mechanism	underlying	the	cytotoxic	effects	of	glycolytic	inhibitors(354,	359,	360,	402),	prompted	us	to	investigate	whether	 inhibition	 of	 PPP	 flux,	 and	 by	 extension	 detoxifying	 antioxidant	 systems,	 has	potential	therapeutic	gain	over	and	above	the	potentiating	effects	of	glycolytic	inhibition	on	 IR	 in	 mutant	 TP53	 SCCHN	 cells.	 Clonogenic	 assays	 were	 performed	 on	 isogenic	SCCHN	cell	lines	treated	at	the	indicated	doses	of	IR	and	survival	parameters	calculated	as	before.	One	hour	prior	to	irradiation	cells	were	pre-treated	as	follows:	no	treatment,	25mM	 2-DG,	 5μM	 6-AN	 (an	 inhibitor	 of	 the	 key	 PPP	 enzyme	 6-phosphogluconate	dehydrogenase	 [6-PGD],	 which	 drives	 the	 second	 NADPH	 producing	 step	 in	 the	oxidative	 phase	 of	 PPP),	 or	 25mM	 2-DG	 in	 combination	 with	 5μM	 6-AN.	 Clonogenic	survival	curves	are	shown	in	figure	3.2.4.1.		
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Figure	3.2.4.1:	Clonogenic	survival	curves	 for	 isogenic	SCCHN	cell	 lines	with	and	without	
administration	of	2-DG	and	6-AN.	Clonogenic	assays	were	performed	on	SCCHN	cell	lines	with	an	isogenic	background	exposed	to	the	indicated	doses	of	IR.	Cells	were	either	left	untreated	or	pre-treated	with	25mM	2-DG	alone,	5μM	6-AN	alone,	or	the	combination	of	25mM	2-DG	and	5μM	6-AN	for	one	hour	prior	to	irradiation.	Results	for	UM-SCC-1	and	derivative	cells	are	shown	first	(A)	and	for	UM-SCC-17A	and	derivative	cell	 lines	subsequently	(B).	UM-SCC-17A	and	the	empty	vector	 control	 (lenti)	 displayed	 limited	 sensitivity	 to	 the	 addition	 of	 6-AN,	 while	 stable	knockdown	 of	wild-type	 p53	 resulted	 in	 sensitivity	 to	 the	 addition	 of	 6-AN.	 6-AN	 significantly	augmented	 the	 potentiating	 effects	 2-DG	 on	 IR	 in	 UM-SCC-1	 and	 the	 empty	 vector	 control	(pBABE).	Forced	expression	of	wild-type	p53	in	this	cell	line	resulted	in	a	loss	of	susceptibility	to	the	 addition	 of	 6-AN.	 Survival	 parameters	 were	 calculated	 according	 to	 the	 linear	 quadratic	formula	S(D)=exp(αD+βD2),	as	described	 in	section	2.6.	The	results	 shown	represent	 the	mean	values	obtained	 from	at	 least	 two	 separate	experiments	and	error	bars	 represent	 the	SEMs.	p-values	are	 shown	where	 there	was	a	 statistically	 significant	difference	between	 the	 clonogenic	survival	curves	(<0.05),	and	are	labelled	as	NS	(not	significant)	where	there	was	no	statistically	significant	difference	(≥0.05).	p-values	represent	comparison	between	the	survival	curves	for	IR	+	2-DG	and	IR	+	2-DG	+	6-AN.		Interestingly,	the	addition	of	6-AN	significantly	augmented	the	potentiating	effects	of	2-DG	 on	 IR	 in	 SCCHN	 cells	 with	 loss	 of	 functional	 wild-type	 p53,	 suggesting	 the	 PPP	 is	critical	to	maintaining	cellular	reducing	potential	and	an	important	subsidiary	pathway	in	SCCHN	oncogenesis	in	this	context,	something	which	is	explored	in	greater	detail	later	in	 this	 thesis	 (section	 3.4.).	 This	 accords	 with	 findings	 from	 two	 previous	 studies	examining	6-AN	use	in	SCCHN,	which	also	demonstrated	that	combining	2-DG	with	6-AN	results	in	an	enhanced	cytotoxic	effect	over	2-DG	alone(277,	403).	No	previous	studies	have	 stratified	 this	 effect	 on	 the	 basis	 of	 TP53	 status	 but	 in	 the	 study	 discussed	previously	aiming	to	investigate	the	reprogramming	of	metabolism	associated	with	the	development	of	radioresistance	using	a	matched	model	of	radio-resistant	and	-sensitive	SCCHN	cells,	treatment	with	6-AN	had	a	greater	inhibitory	effect	on	cell	proliferation	in	radioresistant	cells(277),	which	may	have	acquired	TP53	mutation	during	the	course	of	their	 generation.	 That	 6-AN	 further	 potentiated	 the	 effects	 of	 IR	 in	 SCCHN	 cells	dependent	on	glycolysis,	and	by	extension	related	subsidiary	pathways	such	as	the	PPP,	for	 survival	 was	 perhaps	 to	 be	 expected.	 Although	 2-DG,	 as	 an	 analogue	 of	 glucose	competes	for	uptake	and	entry	into	glycolysis,	thereby	creating	a	drug-induced	state	of	glucose	deprivation,	it	does	not	completely	inhibit	the	generation	of	NADPH	through	the	PPP	as	2-DG	is	 itself,	a	substrate	for	glucose-6-phosphate	dehydrogenase	(G6PD)	–	the	enzyme	catalysing	the	first	step	in	the	PPP(404).	
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3.2.5.	 SCCHN	 cells	 harbouring	 functional	 wild-type	 p53	 require	 a	 broader	 anti-
metabolic	therapeutic	approach	Having	 shown	 that	 SCCHN	 cells	 harbouring	 wild-type	 p53,	 including	 HPV-positive	SCCHN	 cells,	 display	 metabolic	 diversity	 with	 robust	 mitochondrial	 respiratory	 and	glycolytic	reserves,	and	consequently	are	resistant	to	therapeutic	targeting	of	glycolysis,	we	next	investigated	whether	a	broader	anti-metabolic	approach	could	be	employed	to	sensitise	 these	 cells	 to	 the	 effects	 of	 IR. Metformin	 is	 a	 biguanide	 commonly	 used	 in	clinical	practice	as	a	first	line	of	treatment	for	type	II	diabetes	with	minimal	toxicity,	and	has	 demonstrated	 activity	 against	 mitochondrial	 respiration,	 specifically	 against	 ETC	complex	 I(405).	 Thus,	metformin	was	 an	 appropriate	 choice	 to	 combine	with	 2-DG	 to	enable	 targeting	 of	 both	 glycolysis	 and	 mitochondrial	 respiration.	 Although	 more	specific	 mitochondrial	 inhibitors,	 such	 as	 rotenone	 and	 cyanide,	 are	 available,	 their	associated	toxicity	makes	them	unlikely	therapeutic	options.	Indeed,	there	has	been	an	ever-increasing	interest	in	re-purposing	metformin	as	a	therapeutic	agent	in	the	context	of	cancer	treatment(406),	an	interest	which	stems	from	several	epidemiological	studies	demonstrating	 a	 lower	 cancer	 incidence	 in	diabetic	 patients	 taking	metformin	 than	 in	the	general	diabetic	population(407),	and	retrospective	data	indicating	that	metformin	users	have	higher	rates	of	disease	control	when	treated	with	neoadjuvant	chemotherapy	for	breast	cancer(408).		HPV-negative	wild-type	TP53	SCCHN	cells	and	HPV-positive	SCCHN	cells	were	subjected	to	 clonogenic	 assays,	 in	 which	 cells	 were	 treated	 at	 the	 indicated	 doses	 of	 IR	 and	survival	parameters	calculated	as	before.	One	hour	prior	 to	 irradiation	cells	were	pre-treated	 as	 follows:	 no	 treatment,	 25mM	 2-DG,	 or	 25mM	 2-DG	 in	 combination	 with	20mM	metformin.	Clonogenic	survival	curves	are	shown	in	figures	3.2.5.1.	and	3.2.5.2.		
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Figure	 3.2.5.1:	 Clonogenic	 survival	 curves	 for	 wild-type	 TP53	 HPV-negative	 SCCHN	 cell	
lines	 with	 and	 without	 administration	 of	 2-DG	 and	 metformin.	 Clonogenic	 assays	 were	performed	on	HPV-negative	wild-type	TP53	 SCCHN	cell	 lines	exposed	 to	 the	 indicated	doses	of	
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IR.	 Cells	 were	 either	 left	 untreated	 or	 pre-treated	 with	 25mM	 2-DG,	 20mM	 metformin,	 or	combined	treatment	for	one	hour	prior	to	irradiation.	Whilst	2-DG	alone	failed	to	have	any	effect	on	radiation	response	in	any	of	these	cell	lines,	the	addition	of	metformin	resulted	in	a	significant	reduction	 in	 clonogenic	 survival	 (p	 values	 are	 shown	where	 statistically	 significant	differences	were	 observed	 and	 represent	 the	 difference	 between	 the	 survival	 curves	 for	 the	 untreated	condition	 and	 when	 combined	 pre-treatment	 with	 2-DG	 and	 metformin	 was	 administered.	Survival	 parameters	 were	 calculated	 according	 to	 the	 linear	 quadratic	 formula	S(D)=exp(αD+βD2),	 as	 described	 in	 section	 2.6.	 The	 results	 shown	 represent	 the	mean	 values	obtained	from	at	 least	 three	separate	experiments	and	error	bars	represent	 the	SEMs.	p-values	are	shown	where	there	was	a	statistically	significant	difference	between	the	clonogenic	survival	curves	 (<0.05),	 and	 are	 labelled	 as	 NS	 (not	 significant)	 where	 there	 was	 no	 statistically	significant	difference	(≥0.05).	p-values	represent	comparison	between	the	survival	curves	for	IR	+	2-DG	and	IR	+	2-DG	+	metformin.	
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Figure	 3.2.5.2:	 Clonogenic	 survival	 curves	 for	 HPV-positive	 SCCHN	 cell	 lines	 with	 and	
without	administration	of	2-DG	and	metformin.	Clonogenic	assays	were	performed	on	HPV-related	SCCHN	cell	lines	exposed	to	the	indicated	doses	of	IR.	Cells	were	either	left	untreated	or	pre-treated	with	 25mM	2-DG,	 20mM	metformin,	 or	 combined	 treatment	 for	 one	 hour	 prior	 to	irradiation.	Whilst	2-DG	alone	failed	to	have	any	effect	on	radiation	response	in	any	of	these	cell	lines,	 the	 addition	 of	 metformin	 resulted	 in	 a	 significant	 reduction	 in	 clonogenic	 survival	 (p	values	 are	 shown	 where	 statistically	 significant	 differences	 were	 observed	 and	 represent	 the	difference	 between	 the	 survival	 curves	 for	 the	 untreated	 condition	 and	 when	 combined	 pre-treatment	 with	 2-DG	 and	 metformin	 was	 administered.	 Survival	 parameters	 were	 calculated	according	 to	 the	 linear	 quadratic	 formula	 S(D)=exp(αD+βD2),	 as	 described	 in	 section	 2.6.	 The	results	shown	represent	the	mean	values	obtained	from	at	least	three	separate	experiments	and	error	 bars	 represent	 the	 SEMs.	 p-values	 are	 shown	where	 there	was	 a	 statistically	 significant	difference	 between	 the	 clonogenic	 survival	 curves	 (<0.05),	 and	 are	 labelled	 as	 NS	 (not	significant)	 where	 there	 was	 no	 statistically	 significant	 difference	 (≥0.05).	 p-values	 represent	comparison	between	the	survival	curves	for	IR	+	2-DG	and	IR	+	2-DG	+	metformin.		We	 hypothesised	 that	 the	 addition	 of	 metformin	 to	 2-DG	 would	 sensitise	 these	 cells,	which	maintain	a	diversified	metabolic	profile,	to	the	effects	of	IR,	given	that	this	dual-targeted	 anti-metabolic	 strategy	 would	 target	 both	 glycolysis	 and	 mitochondrial	respiration.	Accordingly,	this	is	what	was	observed.	This	fits	with	the	proposed	tailored	anti-metabolic	therapeutic	paradigm	discussed	previously,	with	this	approach	enabling	potentiation	 of	 radiation	 toxicity	 in	 those	 tumours	 resistant	 to	 the	 anti-glycolytic	approach	for	TP53	mutant	disease.		Our	findings	are	at	odds	with	one	previous	study	of	SCCHN	cell	 lines,	which	presented	evidence	 that	 metformin	 selectively	 radiosensitises	 cells	 with	 disruptive	 TP53	mutations,	 with	 little	 effect	 seen	 in	 cells	 expressing	 wild-type	 p53(57).	 Curiously,	
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however,	in	another	study	from	the	same	research	group	p53	proficient	SCCHN	cell	lines	were	reported	to	be	radiosensitised	by	metformin(360),	consistent	with	our	findings.	As	mentioned	 previously,	 no	 previous	 studies	 have	 examined	 anti-metabolic	 therapeutic	strategies	 in	 HPV-positive	 SCCHN.	 Our	 findings	 demonstrating	 that	 such	 cells	 can	 be	radiosensitised	with	 a	 combination	 of	 2-DG	 and	metformin,	 reflecting	 their	metabolic	profile,	may,	 therefore,	 be	 particularly	 promising	 insofar	 as	 they	potentially	 present	 a	novel	 platform	 to	 facilitate	 the	 proposed	 treatment	 de-intensification	 in	 carefully	selected	HPV-positive	 cases.	 Again,	 however,	 such	 an	 approach	will	 require	 extensive	testing	in	pre-clinical	in	vivo	models	to	further	validate	these	in	vitro	results.		The	mechanism	 underlying	 the	 effects	 of	metformin	 appears	 to	 relate	 to	 induction	 of	oxidative	stress,	as	demonstrated	by	several	studies(360,	409),	which	would	fit	with	the	reported	potentiation	of	radiation	toxicity	given	that	IR	induces	DNA	damage	through	a	mechanism	 that	 relies	 to	 a	 large	 extent	 on	 free	 radical	 formation(369).	 However,	 the	mechanistic	 basis	 for	 this	 oxidative	 stress	 remains	 unclear.	 From	 a	 metabolic	perspective	 metformin	 dampens	 ETC	 activity,	 which	 intuitively	 would	 not	 lead	 to	 an	increase	 in	 ROS.	 In	 addition	 to	 this	 effect	 on	 mitochondrial	 respiration,	 however,	metformin	 has	 also	 been	 reported	 to	 activate	 AMPK(410).	 Through	 this	 mechanism	metformin	may	act	to	dampen	glycolytic	flux,	and	by	extension	flux	through	subsidiary	pathways	 such	 as	 the	 PPP,	 which	 may	 result	 in	 reduced	 production	 of	 the	 reducing	equivalents	necessary	to	upregulate	cellular	anti-oxidant	systems	and	combat	oxidative	stress.			
3.3.	Examining	the	mechanistic	basis	underlying	the	potentiating	effects	of	
glycolytic	inhibition	on	IR	in	mutant	TP53	SCCHN		
3.3.1.	Introduction	Having	shown	 that	glycolytic	 inhibition	potentiates	 the	effects	of	 IR	 in	mutant	but	not	wild-type	 TP53	 SCCHN	 cells	 in	 accordance	 with	 the	 cellular	 metabolic	 profile,	 this	chapter	is	devoted	to	the	investigation	of	the	mechanisms	underlying	this	effect.			As	 discussed	 previously	 (see	 section	 1.3.1.),	 an	 important	 aspect	 of	 the	 selective	advantage	 that	 glycolytic	 metabolism	 may	 provide	 is	 regulation	 of	 cellular	 redox	potential	to	minimise	the	damaging	effects	of	excessive	ROS	resulting	from	heightened	oxidative	substrate	 flux	and	de-regulated	cellular	proliferation(257,	267).	Accordingly,	
Results	
	 148	
there	is	accumulating	evidence	implicating	inhibition	of	detoxifying	antioxidant	systems	and	associated	oxidative	stress	as	the	mechanism	underlying	the	therapeutic	effects	of	glycolytic	 inhibition,	 with	 profound	 disruptions	 in	 thiol	 metabolism	 demonstrated	 in	several	 solid	 tumour	 types,	 SCCHN	 included(354,	 360,	 402,	 411,	 412).	 This	 is	particularly	pertinent	 in	 the	 context	of	potentiation	of	 IR	effects	given	 that	 IR	 induces	DNA	 damage	 through	 a	 mechanism	 that	 relies	 predominantly	 on	 free	 radical	formation(369).		Despite	 evidence	 implicating	 the	 involvement	 of	 oxidative	 stress	 in	 the	 mechanism	underlying	 2-DG	 effects	 on	 cell	 viability	 in	 SCCHN,	 until	 now	 no	 studies	 have	characterised	this	further	in	terms	of	cell	fate.	Excessively	high	ROS	levels	can	result	in	DNA	 damage(271),	 activation	 of	 protein	 kinase	 Cδ	 prompting	 senescence(227),	 and	permeabilisation	of	mitochondria	 leading	 to	cytochrome	c	 release	and	apoptosis(192),	and	 both	 apoptosis	 and	 more	 recently	 cellular	 senescence	 have	 been	 shown	 to	 play	important	roles	in	radiation	response(186,	413,	414).	In	keeping	with	this,	studies	from	other	cancer	types	have	demonstrated	not	only	a	slowing	of	cell	cycle	progression	but	also	varying	degrees	of	apoptosis	following	glycolytic	inhibition,	mediated	through	both	intrinsic	 and	 extrinsic	 pathways(357,	 415,	 416).	 In	 addition,	 the	 combination	 of	metformin	 and	 2-DG	 has	 been	 shown	 to	 induce	 G2-M	 cell	 cycle	 arrest,	 typically	characteristic	 of	 the	 induction	 of	 senescence(218),	 as	 well	 as	 apoptosis	 in	 prostate	cancer	cell	lines(417).		
3.3.2.	 The	 potentiating	 effects	 of	 2-DG	on	 IR	 in	 SCCHN	 cells	with	 loss	 of	 functional	
wild-type	p53	are	driven	by	oxidative	stress	Given	the	general	consensus	that	regulation	of	cellular	redox	potential	provides	a	major	impetus	 for	cancer	cells	 to	undergo	metabolic	switching	 to	a	glycolytic	phenotype,	 the	body	 of	 evidence	 implicating	 a	 loss	 of	 this	 regulation	 as	 a	mechanism	 underlying	 the	effects	 of	 targeted	 glycolytic	 inhibition,	 and	 our	 previous	 findings	 that	 PPP	 inhibition	further	augments	 the	effects	of	2-DG	 in	potentiating	 IR	effects	 (section	3.2.4.),	we	 first	set	out	to	determine	whether	oxidative	stress	was	involved	in	the	potentiating	effects	of	2-DG	on	IR	 in	SCCHN	cells	with	 loss	of	 functional	wild-type	p53.	SCCHN	cell	 lines	with	loss	of	functional	wild-type	p53	that	were	sensitive	to	the	potentiating	effects	of	2-DG	on	IR	 (mutant	TP53	 cell	 lines	 and	UM-SCC-17A	shp53)	were	 first	 subjected	 to	 clonogenic	assays	 as	 described	 previously,	 and	 one	 hour	 prior	 to	 irradiation	 were	 either	 left	untreated	or	pre-treated	with	25mM	2-DG	alone,	25mM	of	 the	 free	 radical	 scavenging	
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agent	NAC,	or	25mM	2-DG	and	25mM	NAC	 in	combination.	Clonogenic	survival	curves	are	shown	in	figure	3.3.2.1.	
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Figure	3.3.2.1:	Clonogenic	survival	curves	for	SCCHN	cell	lines	with	loss	of	functional	wild-
type	 p53	 with	 and	 without	 administration	 of	 2-DG	 and	 NAC.	 Clonogenic	 assays	 were	performed	 on	 SCCHN	 cell	 lines	 exposed	 to	 the	 indicated	 doses	 of	 IR.	 Cells	 were	 either	 left	untreated	or	pre-treated	with	25mM	2-DG,	25mM	NAC,	or	a	combination	of	both	agents	for	one	hour	prior	 to	 irradiation.	NAC	consistently	 reversed	 the	potentiating	 the	effects	of	2-DG	on	 IR,	while	 treatment	 with	 NAC	 alone	 had	 no	 discernible	 effect	 on	 clonogenic	 survival.	 Survival	parameters	 were	 calculated	 according	 to	 the	 linear	 quadratic	 formula	 S(D)=exp(αD+βD2),	 as	described	 in	 section	 2.6.	 The	 results	 shown	 represent	 the	mean	 values	 obtained	 from	 at	 least	three	separate	experiments	and	error	bars	represent	the	SEMs.		The	addition	of	NAC	consistently	 reversed	 the	potentiating	effects	of	2-DG	on	 IR	 in	all	
TP53	mutant	 cell	 lines	and	also	 in	 the	 stable	p53	knock-down	UM-SCC-17A	derivative	cell	line,	suggestive	of	involvement	of	oxidative	stress	in	the	mechanism	attributable	to	the	effects	of	2-DG	in	SCCHN	with	loss	of	wild-type	p53	function.	To	examine	this	further	direct	 measurement	 of	 intracellular	 free	 radical	 production,	 and	 by	 association	 the	function	 of	 cellular	 antioxidant	 defences,	 was	 performed	 using	 the	 molecular	 probe	DCFH-DA	and	fluorescence	measured	by	flow	cytometry	(described	in	section	2.9.).	Cells	were	treated	with	6Gy	IR	alone,	or	6Gy	IR	following	pre-treatment	with	25mM	2-DG	or	a	combination	 of	 25mM	 2-DG	 and	 25mM	 NAC,	 with	 positive	 and	 negative	 controls	 for	each	 experiment	 comprising	 100μM	 H2O2	 and	 no	 treatment	 respectively.	 In	 the	 first	instance	 a	 time	 course	 experiment	 for	 UM-SCC-1	 was	 performed	 to	 determine	 the	optimal	 time	 point	 at	 which	 to	 assess	 ROS	 levels	 following	 treatment,	 so	 as	 to	 allow	sufficient	time	for	ROS	generation	following	treatment	but	prior	to	significant	cell	death.	Results	 are	 shown	 in	 figure	 3.3.2.2.	 with	 the	 following	 post-treatment	 time	 points	evaluated:	1,	2,	4,	8,	16,	and	24	hours.		
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Figure	3.3.2.2:	Time	course	analysis	of	intracellular	ROS	levels	in	UM-SCC-1	cells	following	
treatment	with	IR	with	and	without	2-DG.	UM-SCC-1	cells	were	either	left	untreated	or	treated	as	 follows:	100μM	H2O2	alone,	6Gy	 IR	alone,	6Gy	 IR	 following	pre-treatment	with	25mM	2-DG,	25mM	2-DG	 alone,	 or	 6Gy	 IR	 following	 pre-treatment	with	 25mM	2-DG	 and	 25mM	NAC.	 Cells	were	then	harvested	at	the	indicated	time	points	following	treatment	and	stained	with	DCFH-DA	and	 subjected	 to	 analysis	 by	 flow	 cytometry	 as	 described	 in	 Section	 2.9.	 Results	 shown	 are	representative	 of	 a	 typical	 experiment,	 all	 of	 which	were	 performed	 at	 least	 in	 duplicate.	 The	horizontal	bars	 labelled	M1	represent	 the	gating,	which	was	based	on	 including	approximately	90%	of	the	cell	population	in	the	no	treatment	experiment	to	facilitate	comparison	of	the	shift	in	fluorescence	under	treatment	conditions.	The	percentages	depicted	on	each	graph	represent	the	proportion	 of	 cells	 falling	 within	 the	 gated	 parameter.	 A	 shift	 in	 fluorescence	 indicative	 of	increased	ROS	was	evident	under	IR	and	IR	+	2-DG	conditions	from	8	hours	and	was	maximal	at	24	hours.	 It	 is	also	evident	 that	 in	UM-SCC-1	 there	 is	a	marked	 increase	 in	ROS	 levels	with	 the	addition	of	2-DG	over	IR	alone	and	that	this	is	then	reversed	by	the	addition	of	NAC.			Following	 treatment	 with	 IR	 alone	 and	 IR	 in	 combination	 with	 2-DG,	 ROS	 levels	increased	from	8	hours	post-treatment	and	were	maximal	at	24	hours.	Consequently,	24	hours	 was	 the	 chosen	 time	 point	 for	 subsequent	 experiments	 with	 other	 SCCHN	 cell	lines.		As	detailed	in	section	2.8.1.,	during	this	project	flow	cytometry	studies	were	conducted	using	two	separate	instruments	owing	to	mechanical	failure	of	the	initial	FACSCaliburTM	instrument.	Consequently,	there	are	differing	appearances	of	experimental	output	in	the	remainder	of	 this	section.	 In	order	 to	ensure	 that	results	were	consistent	between	 the	two	 instruments,	 and	 thus	 experiments	between	 cell	 lines	 comparable,	 an	 experiment	with	one	cell	line	was	repeated	on	both	instruments	to	determine	whether	results	were	reproducible.	Results	are	depicted	in	figure	3.3.2.3.	and	show	broadly	consistent	results	obtained	between	the	two	instruments.		
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Figure	3.3.2.3:	Analysis	of	intracellular	ROS	levels	in	a	selected	SCCHN	cell	line	using	two	
different	 flow	 cytometers.	Cells	were	either	 left	untreated	or	 treated	as	 follows:	100μM	H2O2	alone,	6Gy	IR	alone,	6Gy	IR	following	pre-treatment	with	25mM	2-DG,	25mM	2-DG	alone,	or	6Gy	IR	following	pre-treatment	with	25mM	2-DG	and	25mM	NAC.	Cells	were	then	harvested	24	hours	following	 treatment	 and	 stained	 with	 DCFH-DA	 and	 subjected	 to	 analysis	 by	 flow	 cytometry	using	the	FACSCaliburTM	instrument	(A)	or	the	Attune®	acoustic	focusing	cytometer	(B).	Results	shown	 are	 representative	 of	 a	 typical	 experiment,	 which	 was	 performed	 in	 duplicate.	 The	horizontal	bars	 labelled	M1	in	the	case	of	the	FACSCaliburTM	instrument	and	R1	in	the	case	the	Attune®	 acoustic	 focusing	 cytometer	 represent	 the	 gating,	 which	 was	 based	 on	 including	approximately	 90%	 of	 the	 cell	 population	 in	 the	 no	 treatment	 experiment	 to	 facilitate	
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comparison	of	the	shift	in	fluorescence	under	treatment	conditions.	The	percentages	depicted	on	each	 graph	 represent	 the	 proportion	 of	 cells	 falling	 within	 the	 gated	 parameter.	 Results	 are	broadly	consistent	between	the	two	instruments.		The	 results	 of	 subsequent	 experiments	 for	 other	 SCCHN	 cell	 lines	 with	 analysis	performed	24	hours	post-treatment	are	shown	in	figures	3.3.2.4	and	3.3.2.5.			
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Figure	 3.3.2.4:	 Analysis	 of	 intracellular	 ROS	 levels	 in	 the	 panel	 of	 SCCHN	 cells	 24	 hours	
following	treatment	with	IR	with	and	without	2-DG.	Cells	were	either	left	untreated	or	treated	as	 follows:	100μM	H2O2	alone,	6Gy	 IR	alone,	6Gy	 IR	 following	pre-treatment	with	25mM	2-DG,	25mM	2-DG	 alone,	 or	 6Gy	 IR	 following	 pre-treatment	with	 25mM	2-DG	 and	 25mM	NAC.	 Cells	were	then	harvested	24	hours	following	treatment	and	stained	with	DCFH-DA	and	subjected	to	analysis	 by	 flow	 cytometry	 as	 described	 in	 Section	2.9.	 Analysis	 following	 the	 addition	 of	NAC	was	only	undertaken	if	there	was	an	observed	effect	to	attempt	to	reverse	with	2-DG.	Results	are	shown	for	wild-type	TP53	SCCHN	cell	 first	(A)	and	mutant	TP53	cells	subsequently	(B).	Results	shown	 are	 representative	 of	 a	 typical	 experiment,	 all	 of	 which	 were	 performed	 at	 least	 in	duplicate.	The	horizontal	bars	 labelled	M1	 represent	 the	gating,	which	was	based	on	 including	approximately	 90%	 of	 the	 cell	 population	 in	 the	 no	 treatment	 experiment	 to	 facilitate	comparison	of	the	shift	in	fluorescence	under	treatment	conditions.	The	percentages	depicted	on	each	graph	represent	the	proportion	of	cells	falling	within	the	gated	parameter.	A	marked	shift	in	fluorescence	 indicative	 of	 increased	 ROS	 was	 evident	 following	 treatment	 with	 IR	 +	 2-DG	compared	with	IR	alone	in	mutant	TP53	cells	but	not	in	wild-type	TP53	cells,	an	effect	that	was	reversed	by	the	addition	of	NAC.				
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Figure	 3.3.2.5:	 Analysis	 of	 intracellular	 ROS	 levels	 in	 isogenic	 SCCHN	 cells	 24	 hours	
following	treatment	with	IR	with	and	without	2-DG.	Cells	were	either	left	untreated	or	treated	as	 follows:	100μM	H2O2	alone,	6Gy	 IR	alone,	6Gy	 IR	 following	pre-treatment	with	25mM	2-DG,	25mM	2-DG	 alone,	 or	 6Gy	 IR	 following	 pre-treatment	with	 25mM	2-DG	 and	 25mM	NAC.	 Cells	were	then	harvested	24	hours	following	treatment	and	stained	with	DCFH-DA	and	subjected	to	analysis	 by	 flow	 cytometry	 as	 described	 in	 Section	2.9.	 Analysis	 following	 the	 addition	 of	NAC	was	only	undertaken	if	there	was	an	observed	effect	to	attempt	to	reverse	with	2-DG.	Results	for	UM-SCC-1	and	derivative	cells	are	shown	first	(A)	and	for	UM-SCC-17A	and	derivative	cell	 lines	subsequently	 (B).	 Results	 shown	 are	 representative	 of	 a	 typical	 experiment,	 all	 of	which	were	performed	at	least	in	duplicate.	The	horizontal	bars	labelled	M1	represent	the	gating,	which	was	based	on	including	approximately	90%	of	the	cell	population	in	the	no	treatment	experiment	to	facilitate	 comparison	 of	 the	 shift	 in	 fluorescence	 under	 treatment	 conditions.	 The	 percentages	depicted	on	each	graph	 represent	 the	proportion	of	 cells	 falling	within	 the	gated	parameter.	A	marked	shift	in	fluorescence	indicative	of	increased	ROS	was	evident	following	treatment	with	IR	+	2-DG	compared	with	IR	alone	in	UM-SCC-1	and	the	empty	vector	control	(pBABE),	while	forced	expression	of	wild-type	p53	in	UM-SCC-1	resulted	in	a	loss	of	this	effect.	Similarly,	UM-SCC-17A	and	the	empty	vector	control	(lenti)	displayed	no	difference	in	ROS	levels	between	IR	and	IR	+	2-DG	conditions,	while	stable	knockdown	of	wild-type	p53	resulted	in	a	discernible	increase	in	ROS	following	treatment	with	IR	+	2-DG	compared	with	IR	alone.		In	 keeping	 with	 our	 previous	 clonogenic	 assay	 results,	 where	 the	 addition	 of	 NAC	reversed	the	potentiating	effects	of	2-DG	on	IR	in	SCCHN	cells	with	loss	of	wild-type	p53	function,	the	addition	of	2-DG	to	IR	resulted	in	a	marked	increase	in	ROS	compared	to	IR	alone	in	such	cells,	an	effect	which	was	reversed	by	the	further	addition	of	NAC.	These	findings	are	consistent	with	the	hypothesis	that	the	mechanism	underlying	the	potential	therapeutic	effects	of	glycolytic	inhibition	involves	inhibition	of	detoxifying	antioxidant	systems	(since	these	cells	have	no	capacity	for	increasing	ETC),	and	supports	the	notion	that	the	rationale	behind	metabolic	re-programming	towards	glycolysis	in	cancer	cells	is	at	least	partly	to	regulate	cellular	redox	status.	These	findings	are	also	in	keeping	with	those	 of	 numerous	 studies	 of	 drug-induced	 glycolytic	 inhibition	 in	 cancer	 cells	generally(402,	 411,	 412),	 and	 also	 with	 those	 of	 the	 limited	 number	 of	 studies	 in	SCCHN(354,	 359,	 360).	 For	 instance,	 in	 studies	 specific	 to	 SCCHN	glycolytic	 inhibition	has	 been	 shown	 to	 cause	 perturbations	 in	 parameters	 indicative	 of	 oxidative	 stress,	including	 decreased	 intracellular	 total	 glutathione	 with	 a	 reduced	 proportion	 of	GSH(354),	 lessened	 cellular	 reducing	 potential(359),	 and	 significantly	 elevated	 ROS	levels(360).	Furthermore,	simultaneous	treatment	with	NAC	has	been	shown	to	inhibit	such	parameters	and	reverse	the	cytotoxic	effects	of	glycolytic	inhibition(354,	359,	360).	
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	Given	that	generation	of	the	reducing	equivalent	NADPH	is	crucial	for	the	up-regulation	of	major	cellular	antioxidant	systems,	specifically	glutathione	and	thioredoxin	systems,	and	that	 the	PPP	 is	 the	principal	source	of	NADPH(280),	 it	seems	 likely	 that	glycolytic	inhibition	with	 2-DG	 is	 dampening	 PPP	 flux	 and	 thus	NADPH	 generation,	 leading	 to	 a	loss	of	ROS	quenching	capacity.	Indeed,	our	previous	observations	that	the	PPP	inhibitor	6-AN	 further	 potentiated	 the	 effects	 of	 2-DG	 on	 IR	 supports	 this	 suggestion	 and	 the	involvement	 of	 the	PPP	will	 be	 examined	 in	 greater	 detail	 later	 in	 this	 thesis	 (section	3.4.5.).		
3.3.3.	 The	 potentiating	 effects	 of	 2-DG	on	 IR	 in	 SCCHN	 cells	with	 loss	 of	 functional	
wild-type	p53	are	not	a	consequence	of	increased	cellular	senescence	Having	shown	that	inhibition	of	cellular	detoxifying	antioxidant	systems	and	associated	oxidative	 stress	 is	 involved	 in	 the	 mechanism	 underlying	 the	 potentiating	 effects	 of	glycolytic	 inhibition	on	 IR	 in	SCCHN	cells	with	 loss	of	wild-type	p53	 function,	we	next	examined	 this	 mechanism	 further	 in	 terms	 of	 cell	 fate.	 Cellular	 senescence	 was	 first	investigated	 as	 a	 possible	mechanism	 as	 high	 levels	 of	 ROS	 can	 result	 in	 activation	 of	protein	kinase	Cδ,	prompting	senescence(227),	and	ROS	are	thought	to	be	necessary	for	maintenance	 of	 the	 senescent	 phenotype(225,	 226).	 Furthermore,	 although	 the	 exact	role	of	senescence	in	the	response	to	radiation	remains	to	be	elucidated,	senescence	is	becoming	 increasingly	 recognised	 as	 an	 important	 contributor	 to	 radiation	response(413,	418),	and	has	been	shown	to	be	crucial	 in	determining	radio-sensitivity	or	radio-resistance	in	SCCHN	cell	lines(57).		As	described	in	section	2.7.	cellular	senescence	was	assessed	using	cytochemical	SA-βgal	staining.	 Cells	 were	 either	 left	 untreated	 or	 treated	 with	 6Gy	 IR	 alone,	 or	 6Gy	 IR	following	pre-treatment	with	25mM	2-DG,	and	after	24	hours	were	fixed	and	stained	at	pH	6.0.	Results	are	depicted	in	figure	3.3.3.1.	Interestingly,	in	all	SCCHN	cells	there	was	a	significant	increase	in	the	proportion	of	senescent	cells	following	treatment	with	IR	and	2-DG	 relative	 to	 IR	 alone,	 irrespective	 of	 TP53	 status.	 As	 such,	 although	 cellular	senescence	 is	 increased	under	 conditions	 of	 IR	 and	2-DG	 it	 is	 unlikely	 to	 underlie	 the	potentiating	 effects	 of	 2-DG	 on	 IR	 as	 these	 effects	were	 specific	 to	 those	 SCCHN	 cells	with	 abrogated	 wild-type	 p53	 function.	 Although	 higher	 levels	 of	 cellular	 senescence	were	 observed	 in	 SCCHN	 cells	 maintaining	 wild-type	 p53	 function,	 it	 is	 perhaps	surprising	 that	 there	 are	 such	 high	 levels	 of	 cellular	 senescence	 in	 the	 mutant	 TP53	SCCHN	 cell	 lines	 considering	 that	 cellular	 senescence	 is	 thought	 to	 be	 significantly	
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dependent	upon	wild-type	p53	function(418).	SA-βgal	activity	is	distinguished	from	the	acidic	 β-galactosidase	 activity,	 present	 in	 all	 cells,	 by	 using	 a	 citric	 acid/sodium	phosphate	 buffer	 at	 suboptimal	 pH,	 and	 it	 is	 possible	 that	 failure	 of	 this	 buffer	 to	maintain	the	pH	at	6.0	resulted	in	detection	of	acidic	β-galactosidase	activity.	However,	acidic	 β-galactosidase	 activity	 is	 a	 surrogate	 of	 lysosomal	 content,	 and	 the	 fact	 that	signal	did	vary	with	treatment	makes	this	an	improbable	explanation.	Induction	of	p21,	a	 transcriptional	 target	 of	 p53,	 is	 a	 critical	 mediator	 of	 cellular	 senescence	 and	 is	proposed	 to	 be	 involved	 in	 a	 feedback	 loop	 with	 ROS,	 which	 is	 required	 for	 DNA	damage-induced	senescence(57,	225).	The	senescence	observed	in	mutant	TP53	SCCHN	cells	here	may,	therefore,	be	the	result	of	p53-independent	induction	of	p21,	as	has	been	described	elsewhere(419,	420),	 or	may	be	attributable	 to	 residual	p53	 transcriptional	activity.	 Indeed,	 recent	 findings	 have	 suggested	 that	 only	 a	 minority	 of	 p53	transcriptional	targets	are	required	to	prompt	senescence(421),	with	a	small	remnant	of	transcriptional	function	conceivably	sufficient	to	induce	senescence.	
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Figure	 3.3.3.1:	 Levels	 of	 cellular	 senescence	 in	 SCCHN	 cells	 following	 treatment	with	 IR	
with	and	without	2-DG.	Following	either	no	treatment	or	treatment	with	6Gy	IR	alone	or	in	the	presence	of	25mM	2-DG,	cells	were	fixed	and	then	incubated	for	16	hours	in	staining	solution	as	described	in	section	2.7.	The	proportion	of	senescent	cells	in	the	population	was	then	determined	by	manual	counting	under	bright	field	microscopy.	Results	are	first	shown	for	the	panel	of	SCCHN	cell	 lines	 (A)	 and	 subsequently	 for	 the	 isogenic	 SCCHN	 cell	 lines	 (B).	 Experiments	 were	performed	 in	 triplicate	with	mean	values	depicted	 in	 the	histograms	and	SEMs	represented	by	error	bars.	Statistical	significance	was	tested	for	any	differences	using	the	Mann–Whitney	U	test	with	 a	 significance	 level	 of	 p	 ≤	 0.05.	 All	 results	 shown	 are	 normalised	 to	 the	 proportion	 of	senescent	cells	identified	following	no	treatment	for	that	particular	cell	line.	Significant	increases	in	the	proportion	of	senescent	cells	were	observed	following	treatment	with	IR	+	2-DG	compared	with	 IR	 alone	 in	 both	mutant	 and	wild-type	TP53	 SCCHN	 cells	 (A).	 This	was	 also	 the	 case	 for	isogenic	 cell	 lines,	 where	 all	 cell	 lines	 exhibited	 a	 significant	 increase	 in	 senescence	 following	treatment	with	IR	+	2-DG	over	and	above	IR	alone	(B).			
3.3.4.	Apoptosis	underlies	the	potentiating	effects	of	2-DG	on	IR	in	SCCHN	cells	with	
loss	of	functional	wild-type	p53	Following	 the	 demonstration	 that	 the	 effects	 of	 2-DG	 on	 IR	 in	 SCCHN	 cells	 with	abrogated	 wild-type	 p53	 function	 is	 not	 attributable	 to	 cellular	 senescence,	 we	 next	investigated	 apoptosis	 as	 a	 possible	 mechanism.	 High	 levels	 of	 ROS	 can	 result	 in	permeabilisation	of	mitochondria	 leading	 to	cytochrome	c	 release	and	apoptosis(192),	and	induction	of	apoptosis	is	an	important	factor	in	determining	therapeutic	response	to	anti-cancer	 treatments(186,	 414).	 In	 order	 to	measure	 levels	 of	 apoptosis,	 differential	staining	with	FITC-conjugated	annexin	V	and	PI,	analysed	by	 flow	cytometry	was	used	as	described	in	section	2.8.	Cells	were	treated	with	6Gy	IR	alone,	25mM	2-DG	alone,	or	
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6Gy	 IR	 following	 pre-treatment	with	 25mM	2-DG,	with	 positive	 and	negative	 controls	for	 each	 experiment	 comprising	 1μM	 staurosporine	 and	 no	 treatment	 respectively.	Again,	 as	 detailed	 in	 section	 2.8.1.,	 during	 this	 project	 flow	 cytometry	 studies	 were	conducted	 using	 two	 separate	 instruments	 owing	 to	 mechanical	 failure	 of	 the	 initial	FACSCaliburTM	 instrument,	 and	 is	 the	 reason	 for	 the	 differing	 appearance	 of	experimental	output	in	this	section.	In	section	3.3.2.	it	was	demonstrated	that	output	for	ROS	detection	and	quantification	was	broadly	consistent	between	the	two	instruments,	allowing	 comparison	 between	 experiments	 performed	 on	 the	 two	 instruments.	Similarly,	 in	order	 to	ensure	 that	results	pertaining	 to	 the	detection	of	apoptosis	were	also	 consistent	 between	 the	 instruments,	 detection	 of	 annexin	 V	 and	 PI	 staining	with	one	cell	line	was	repeated	on	both	instruments.	Results	are	depicted	in	figure	3.3.4.1	and	show	congruous	results	between	the	two	instruments.		
	
Figure	 3.3.4.1:	 Analysis	 of	 levels	 of	 apoptosis	 in	 a	 selected	 SCCHN	 cell	 line	 using	 two	
different	 flow	cytometers.	48	hours	following	treatment	with	6Gy	IR	alone,	25mM	2-DG	alone	or	 combined	 treatment,	 cells	were	 stained	with	 annexin	V	 and	PI	 and	 subjected	 to	 analysis	by	flow	 cytometry	 using	 the	 FACSCaliburTM	 instrument	 (A)	 or	 the	 Attune®	 acoustic	 focusing	cytometer	(B).	Results	shown	are	representative	of	a	typical	experiment,	which	was	performed	in	duplicate.	 Percentages	 shown	 represent	 the	 proportion	 of	 apoptotic	 cells	 (early	 and	 late	combined),	which	 is	 the	proportion	of	 cells	 in	 the	upper	 and	 lower	 right	 quadrants	 combined.	Results	are	broadly	consistent	between	the	two	instruments.			
Results	
	 166	
All	SCCHN	cell	lines	were	harvested	and	subjected	to	annexin	V	and	PI	staining	and	flow	cytometric	 analysis	 at	 both	 24	 and	 48	 hour	 time	 points.	 Results	 are	 shown	 in	 figures	3.3.4.2.	and	3.3.4.3.		
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Figure	 3.3.4.2:	 Levels	 of	 apoptosis	 in	 the	 panel	 SCCHN	 cells	 following	 treatment	with	 IR	
with	and	without	2-DG.	Following	treatment	with	6Gy	IR	alone,	25mM	2-DG	alone	or	combined	treatment,	cells	were	stained	with	annexin	V	and	PI	and	analysed	by	flow	cytometry	as	described	in	section	2.8.	at	24	and	48	hours.		Results	are	first	shown	for	wild-type	TP53	SCCHN	cell	lines	(A)	and	 subsequently	 for	 mutant	 TP53	 SCCHN	 cell	 lines	 (B).	 Results	 shown	 are	 representative	 of	typical	 experiments,	which	were	performed	at	 least	 in	duplicate.	Percentages	 shown	represent	the	proportion	of	apoptotic	cells	(early	and	late	combined),	which	is	the	proportion	of	cells	in	the	upper	and	lower	right	quadrants	combined.	Discernible	increases	in	the	proportion	of	apoptotic	cells	were	observed	following	treatment	with	IR	+	2-DG	compared	with	IR	alone	 in	mutant	but	not	wild-type	TP53	SCCHN	cells,	most	evident	at	either	24	or	48	hours	depending	on	individual	cell	line.			
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Figure	3.3.4.3:	Levels	of	apoptosis	in	isogenic	SCCHN	cells	following	treatment	with	IR	with	
and	 without	 2-DG.	 Following	 treatment	 with	 6Gy	 IR	 alone,	 25mM	 2-DG	 alone	 or	 combined	treatment,	cells	were	stained	with	annexin	V	and	PI	and	analysed	by	flow	cytometry	as	described	in	section	2.8.	at	24	and	48	hours.		Results	are	first	shown	for	UM-SCC-1	and	derivative	cell	lines	(A)	 and	 subsequently	 for	 UM-SCC-17A	 and	 derivative	 cell	 lines	 (B).	 Results	 shown	 are	representative	of	 typical	experiments,	which	were	performed	at	 least	 in	duplicate.	Percentages	shown	 represent	 the	 proportion	 of	 apoptotic	 cells	 (early	 and	 late	 combined),	 which	 is	 the	proportion	of	cells	in	the	upper	and	lower	right	quadrants	combined.	Discernible	increases	in	the	proportion	of	apoptotic	cells	were	observed	following	treatment	with	IR	+	2-DG	compared	with	IR	 alone	 in	UM-SCC-1	 and	 the	 empty	 vector	 control	 (pBABE),	while	 forced	 expression	of	wild-type	 p53	 in	 UM-SCC-1	 resulted	 in	 a	 loss	 of	 this	 effect.	 Similarly,	 UM-SCC-17A	 and	 the	 empty	vector	 control	 (lenti)	 displayed	 no	 difference	 in	 levels	 of	 apoptosis	 between	 IR	 and	 IR	 +	 2-DG	
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conditions,	while	in	the	stable	wild-type	p53	knockdown	cell	line	there	was	an	obvious	increase	in	apoptosis	following	treatment	with	IR	+	2-DG	compared	with	IR	alone.		Intriguingly,	a	clear	increase	in	the	proportion	of	apoptotic	cells	was	observed	following	IR	in	the	presence	of	glycolytic	inhibition	relative	to	IR	alone	exclusively	in	SCCHN	cells	harbouring	 TP53	 mutations	 or	 wild-type	 p53	 knock-down,	 and	 thus	 is	 the	 likely	mechanism	of	cell-death	correlating	with	the	potentiating	effects	of	2-DG	on	IR	observed	earlier.	Consistent	with	this,	a	previous	study	examining	the	effects	of	2-DG	on	several	cancer	 cell	 lines	 of	 diverse	 origin	 demonstrated	 that	 although	 response	 was	 variable	among	 cell	 lines,	moderate	 to	 high	 levels	 of	 apoptosis	were	 present,	 characterised	 by	morphological	 modifications,	 altered	 nuclear	 morphology,	 sub-G1	 peak	 occurrence,	caspase-3	 activation	 and	 PARP	 cleavage(357).	 Moreover,	 a	 similar	 study	 also	investigating	the	effects	of	glycolytic	inhibition	on	a	number	of	human	tumour	cell	lines,	demonstrated	 the	activation	of	death	 receptor-induced	apoptosis,	 related	 to	 increased	processing	of	 apical	 procaspase-8	 at	 the	DISC	upon	death	 receptor	 activation(415).	 In	terms	of	deciphering	a	link	between	glycolytic	inhibition	and	the	induction	of	apoptosis,	a	 role	 for	 hexokinase	 has	 been	 suggested.	 Danial	 et	 al	 reported	 that	 hexokinase	 IV	interacts	 with	 the	 pro-apoptotic	 protein	 Bad	 in	 a	 mitochondrial	 complex,	 where	 the	phosphorylation	status	of	Bad	is	regulated,	which	in	turn	regulates	both	apoptosis	and	glycolysis(422).	 Similarly,	 a	 subsequent	 study	 reported	 that	 inhibition	 of	 hexokinase	with	 3-BP	 resulted	 in	 dephosphorylation	 of	 Bad,	 leading	 to	 translocation	 of	 the	 pro-apoptotic	factor	Bax	to	the	mitochondria,	thereby	activating	the	release	of	cytochrome	c	and	the	caspase	cascade(423).	Alternatively,	and	in	line	with	our	ROS	data,	a	number	of	studies	 have	 implicated	 cellular	 redox	 state	 in	 coupling	 glycolytic	 inhibition	 and	apoptosis.	 In	 a	 study	 of	 c-Myc-transformed	 cells,	 potent	 induction	 of	 apoptosis	 was	observed	 following	glycolytic	 inhibition,	mediated	by	 induction	of	LDH-A	activity,	 that	led	to	constitutive	generation	of	NAD	and	lactate	and	a	decrease	in	the	regeneration	of	NADH,	 which	 the	 authors	 proposed	 to	 alter	 the	 cellular	 redox	 state	 increasing	susceptibility	 to	 apoptosis(424).	 Interestingly,	 these	 effects	 also	 appeared	 to	 be	independent	 of	 wild-type	 p53	 activity(424).	 Similarly,	 in	 a	 study	 of	 tumour	 necrosis	factor	(TNF)-induced	cytotoxicity	of	fibrosarcoma	cells,	the	absence	of	glucose	increased	production	 of	 ROS,	 sensitising	 the	 cells	 to	 death	 receptor-mediated	 apoptosis(425).	More	 recently,	 Vaughn	 and	 Deshmukh	 showed	 that	 the	 pro-apoptotic	 activity	 of	cytochrome	c	 is	 influenced	by	 its	 redox	 state:	 cytochrome	c	 is	held	 in	 its	 reduced	and	inactive	form	by	intracellular	GSH,	generated	as	a	result	of	glycolysis	and	the	PPP,	while	increases	in	ROS	lead	to	the	oxidation	and	activation	of	cytochrome	c(192).	
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3.4.	 Investigating	 the	 mechanisms	 underpinning	 the	 metabolic	 shift	 in	
mutant	TP53	SCCHN		
3.4.1.	Introduction	Having	established	in	section	3.1.	that	in	SCCHN	the	metabolic	profile	differs	markedly	on	the	basis	of	TP53	status,	with	the	loss	of	functional	wild-type	p53	conferring	loss	of	metabolic	 diversity	 and	 glycolytic	 dependence,	 and	 having	 correlated	 this	 with	 anti-metabolic	 therapeutic	potential	 in	sections	3.2.	and	3.3.,	we	next	sought	to	explore	the	mechanistic	basis	underpinning	this	TP53-dependent	metabolic	switch.			p53	 plays	 a	 fundamental	 role	 in	 regulating	 metabolic	 homeostasis,	 balancing	mitochondrial	respiration	and	glycolysis.	True	to	its	role	as	a	tumour	suppressor	and	in	keeping	 with	 our	 findings,	 p53	 is	 thought	 to	 counteract	 metabolic	 alterations	characteristically	 associated	 with	 cancer	 development,	 with	 loss	 of	 wild-type	 p53	function,	 therefore,	 leading	 to	 acquisition	 of	 a	 glycolytic	 phenotype	 at	 the	 expense	 of	mitochondrial	respiration(247,	267,	294).	As	discussed	in	depth	earlier	in	section	1.3.2.,	p53	 exerts	 influence	 over	 glycolysis	 through	 multiple	 mechanisms,	 which	 may	 also	modulate	 activity	 of	 related	 subsidiary	 pathways.	 p53	 is	 known	 to	 down-regulate	 the	expression	 of	 the	 glycolytic	 transporters,	 including	 GLUT1,	 GLUT4,	 and	 MCT-1(298,	299),	as	well	as	 influence	 the	activity	of	 the	 following	glycolytic	enzymes:	hexokinase-II(318);	PGAM(295);	PDK(297);	and	PFK-1	through	transcription	of	TIGAR,	which	acts	as	 a	 bisphosphatase	 that	 dephosphorylates	 fructose-2,6-bisphosphate	 –	 a	 potent	allosteric	activator	of	PFK-1(205).	Complementary	to	these	actions	to	restrict	glycolytic	flux,	 p53	 is	 also	 coupled	 to	 the	maintenance	 of	mitochondrial	 biomass,	 integrity,	 and	quality	 control(300-303),	 as	 well	 as	 the	 promotion	 of	 oxidative	 phosphorylation,	through	transcriptional	activation	of	Parkin(304)	and	genes	involved	in	the	assembly	of	the	ETC	complexes(286,	305-308),	as	well	as	transcription	independent	assembly	of	the	ATP	 synthase	 complex(309).	 Given	 the	 paucity	 of	 published	 data	 concerning	 the	mechanisms	by	which	TP53	status	may	influence	metabolism	in	SCCHN	specifically,	our	investigation	 into	 the	 mechanistic	 basis	 underpinning	 the	 TP53-dependent	 metabolic	switch	 was	 focused	 around	 the	 above	 evidence	 of	 the	 influence	 of	 p53	 on	 metabolic	homeostasis.		
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3.4.2.	Depressed	ETC	complex	activity	 is	 involved	 in	the	TP53-dependent	metabolic	
switch	in	SCCHN	cells	Although	contemporary	studies	have	revealed	that	mitochondrial	function	is	frequently	unimpaired	 in	 cancer	 cells	 and	 many	 tumours	 retain	 the	 capacity	 for	 oxidative	phosphorylation(249,	 258-261),	 as	 discussed	 previously	 p53	 is	 crucially	 involved	 in	maintenance	 of	mitochondrial	 function	 (see	 section	 1.3.2.),	 and	 thus	 loss	 of	wild-type	p53	 function	 could	 conceivably	 result	 in	 disruption	 to	 oxidative	 phosphorylation.	Furthermore,	our	earlier	 findings	 that	maximal	respiration	and	ATP-linked	respiration	is	consistently	reduced	in	SCCHN	cells	with	abrogated	wild-type	p53	function	compared	with	wild-type	TP53	cells	(section	3.1.3.)	is	suggestive	of	compromised	ETC	function	in	these	 cells.	 We,	 therefore,	 interrogated	 the	 activity	 of	 individual	 ETC	 complexes	 in	SCCHN	 cells	 using	 the	 Seahorse	 Bioscience	 microplate-based	 XF24	 experimental	platform	in	combination	with	a	selective	plasma	membrane	permeabiliser	(XF	PMP)	and	specific	oxidisable	substrates,	as	outlined	in	section	2.4.9.			Many	oxidisable	substrates	are	unable	to	cross	the	plasma	membrane	freely,	preventing	control	 over	 which	 substrates	 the	 mitochondria	 are	 oxidising(385,	 386)	 (see	 figure	2.3.9.1.).	 Recognising	 the	 fact	 that	 specific	 substrates	 feed	 differentially	 into	mitochondrial	 pathways,	 permeabilising	 cells	 using	 XF	 PMP	 and	 supplying	 specific	oxidisable	substrates	and	ETC	complex	inhibitors	affords	this	experimental	control,	and	enables	 identification	 of	 any	 defects	 in	 function	 of	 ETC	 complexes	 responsible	 for	 the	altered	OCR	originally	 observed	 in	 intact	 cells(385,	 386).	 As	 detailed	 in	 section	 2.4.9.,	cells	were	subjected	to	mitochondrial	stress	tests	(section	2.3.7.)	in	the	presence	of	1nM	XF	 PMP	 and	 various	 oxidisable	 substrates	 to	 assess	 the	 activity	 of	 individual	 ETC	complexes.	Substrates	bypassing	potentially	defective	ETC	complexes	were	sequentially	added,	 along	with	 relevant	 inhibitors,	 in	 each	new	experiment	 for	 each	 individual	 cell	line	to	determine	whether	any	OCR	defects	could	be	rescued.	In	initial	experiments,	the	NADH-linked	 complex	 I	 substrates	 pyruvate	 (10mM)	 and	 glutamate	 (10mM)	 were	added.	Subsequently,	 in	order	to	bypass	ETC	complexes	and	analyse	OCRs	attributable	to	the	remaining	ETC	complexes,	the	following	substrates	and	inhibitors	were	supplied:	succinate	 (10mM)	 with	 rotenone	 (2μM)	 to	 bypass	 and	 inhibit	 complex	 I;	 glycerol-3-phosphate	 (10mM)	 with	 malonate	 (20mM)	 to	 bypass	 and	 inhibit	 complex	 II;	 and	ascorbate	 (10mM)	 and	TMPD	 (100μM)	with	 antimycin	A	 (2μM)	 to	 bypass	 and	 inhibit	complex	 III.	 As	 these	 experiments	 were	 designed	 to	 attempt	 to	 rescue	 any	 originally	identified	defects	in	the	function	of	mitochondrial	respiration,	only	those	cell	lines	with	
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identified	 defects	 were	 included	 –	 i.e.	 cells	 lines	 with	 abrogation	 of	 wild-type	 p53	function.	Results	are	shown	in	figures	3.4.2.1.			
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Figure	 3.4.2.1:	 Metabolic	 profiles	 of	 SCCHN	 cell	 lines	 in	 mitochondrial	 stress	 tests	
following	 sequential	 addition	 of	 specific	 oxidisable	 substrates.	 Cells	 were	 permeabilised	with	1nM	XF	PMP	and	subjected	 to	mitochondrial	 stress	 tests	 in	 the	presence	of	 the	 following	substrates	and	inhibitors:	pyruvate	(10mM)	and	glutamate	(10mM)	(A);	succinate	(10mM)	with	rotenone	 (2μM)	 (B);	 glycerol-3-phosphate	 (G3P)	 (10mM)	 with	 malonate	 (20mM)	 (C);	 TMPD	(100μM)	and	ascorbate	(10mM)	with	antimycin	A	(2μM)	(D).	As	before,	points	A,	B,	and	C	on	the	graphs	refer	to	the	injections	of	oligomycin	1.25μM,	FCCP	1.5μM,	and	rotenone	and	antimycin-A	1μM	 respectively.	 Data	 is	 presented	 as	 percentage	 increases	 or	 decreases	 in	 OCR	 relative	 to	baseline	measurements.	The	baseline	is	shown	as	the	black	line	at	100%	on	the	graphs.	Although	results	 varied	 slightly	 between	 cell	 lines,	 the	 sequential	 addition	 of	 oxidisable	 substrates	 to	
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bypass	potentially	defective	ETC	complexes	 resulted	 in	a	marked	 increase	 in	 spare	 respiratory	capacity,	 with	 maximal	 effects	 generally	 seen	 with	 the	 addition	 of	 TMPD	 and	 ascorbate	 with	antimycin	A.	Error	bars	represent	SEM	for	each	measurement.		The	 sequential	 addition	 of	 oxidisable	 substrates	 with	 relevant	 inhibitors,	 which	systematically	 bypassed	 ETC	 complexes,	 rescued	 the	 profile	 of	 mitochondrial	respiration	 in	 all	 of	 these	 cell	 lines,	 restoring	 relative	maximal	 respiration	 and	 spare	respiratory	capacity	 to	 that	observed	earlier	 in	SCCHN	cell	 lines	harbouring	 functional	wild-type	 p53.	 As	 would	 be	 expected,	 results	 varied	 slightly	 between	 cell	 lines,	 with	differing	 degrees	 of	 rescue	 observed	when	 bypassing	 ETC	 complexes.	 For	 instance,	 in	UM-SCC-5	 there	 was	 minimal	 rescue	 of	 maximal	 respiration	 and	 spare	 respiratory	capacity	with	 the	 addition	 of	 succinate	with	 rotenone,	 and	 thus	 the	 bypassing	 of	 ETC	complex	 I,	while	 in	 the	other	 cell	 lines	partial	 rescue	was	 seen.	Nonetheless,	 the	most	marked	 effects	 were	 observed	 with	 the	 addition	 of	 either	 glycerol-3-phosphate	 with	malonate	 and/or	 TMPD	 and	 ascorbate	 with	 antimycin	 A	 in	 all	 cell	 lines.	 Having	established	 that	 the	 capacity	 for	 maximal	 respiration,	 and	 by	 association	 spare	respiratory	 capacity,	 could	 be	 rescued	 by	 bypassing	 potentially	 defective	 ETC	complexes,	we	next	examined	whether	this	had	resulted	in	any	effect	on	rates	of	basal	respiration	 by	 extracting	 absolute	 values.	 Results	 are	 depicted	 in	 figure	 3.4.2.2.	 In	accordance	with	the	above	results	demonstrating	rescue	of	the	profile	of	mitochondrial	respiration	 in	 all	 cell	 lines,	 the	 addition	 of	 oxidisable	 substrates	 and	 inhibitors	 also	resulted	in	discernible	increases	in	basal	respiration,	suggesting	not	only	restoration	of	mitochondrial	 capacity	 but	 a	 switch	 back	 towards	 a	 metabolic	 phenotype	 in	 which	oxidative	 phosphorylation	 predominates	 as	 a	 means	 of	 glucose	 catabolism	 and	utilisation.	Again,	results	varied	slightly	between	cell	lines,	tending	to	reflect	the	degrees	of	rescue	observed	with	maximal	respiration	and	spare	respiratory	capacity.			
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Figure	 3.4.2.2:	 Absolute	 basal	 respiration	 derived	 from	 mitochondrial	 stress	 tests	
following	 sequential	 addition	 of	 specific	 oxidisable	 substrates.	 Absolute	 values	 for	 basal	respiration	 for	 each	 cell	 line	were	 extracted	 from	 the	mitochondrial	 stress	 tests	 performed	on	permeabilised	cells	in	the	presence	of	specific	oxidisable	substrates	shown	in	figure	3.4.2.1.	The	histograms	 are	 labelled	 to	 indicate	 which	 substrates	 had	 been	 sequentially	 added.	 Error	 bars	represent	SEM	for	each	measurement.	Again,	although	results	varied	slightly	between	cell	lines,	the	 sequential	 addition	 of	 oxidisable	 substrates	 to	 bypass	 potentially	 defective	 ETC	 complexes	resulted	in	a	marked	increase	in	basal	respiration.		Although	bypassing	of	ETC	complexes	I,	II,	and	III	resulted	in	marked	increases	in	both	basal	mitochondrial	respiration	and	the	capacity	for	maximal	respiration,	the	inability	to	bypass	complex	IV	in	this	experimental	design	(figure	2.4.9.1.)	prevented	assessment	of	whether	 complex	 IV	 itself	 was	 also	 defective	 and	 partly	 attributable	 to	 the	 TP53-dependent	 metabolic	 shift.	 Whilst	 we	 thought	 it	 unlikely	 that	 complex	 IV	 would	 be	defective	given	 that	bypassing	of	ETC	complexes	 I,	 II,	 and	 III	had	resulted	 in	rescue	of	mitochondrial	 respiration	 to	 levels	 akin	 to	 those	 observed	 in	 intact	 SCCHN	 cells	harbouring	 functional	wild-type	p53,	 complex	 IV-linked	 respiration,	 as	 determined	by	supplying	 permeabilised	 cells	 with	 TMPD	 and	 ascorbate	 and	 inhibiting	 complex	 III-driven	respiration	with	antimycin	A,	was	compared	in	the	isogenic	cell	lines	to	ascertain	whether	 any	 differences	 existed	 in	 SCCHN	 cells	 with	 and	 without	 the	 presence	 of	functional	wild-type	p53.	Results	are	shown	in	figure	3.4.2.3.			
Results	
	 179	
	
Figure	3.4.2.3:	Complex	IV-linked	respiration	in	isogenic	SCCHN	cell	 lines.	Absolute	values	for	 basal	 respiration	 for	 each	 isogenic	 cell	 line	were	 extracted	 from	mitochondrial	 stress	 tests	performed	on	permeabilised	cells	in	the	presence	of	TMPD	(100μM)	and	ascorbate	(10mM)	with	antimycin	A	(2μM).	These	values	were	normalised	to	DNA	content	as	described	in	section	2.3.8.	Error	 bars	 represent	 SEM	 for	 each	 measurement.	 There	 were	 no	 consistent	 differences	 in	complex	IV-linked	respiration	between	SCCHN	cells	with	or	without	functional	wild-type	p53.		Consistent	 with	 our	 previous	 findings	 that	 bypassing	 of	 ETC	 complexes	 I,	 II,	 and	 III	resulted	 in	 rescue	 of	mitochondrial	 respiration	 to	 levels	 similar	 to	 those	 observed	 in	intact	SCCHN	cells	harbouring	functional	wild-type	p53,	there	were	no	clear	differences	in	complex	 IV-linked	respiration	between	SCCHN	cell	 lines	 irrespective	of	TP53	 status,	indicative	of	no	clear	defects	in	complex	IV	function.		Considering	 the	 above	 findings	 for	 individual	 ETC	 complexes	 in	 permeabilised	 cells	collectively,	these	results	suggest	that	in	SCCHN	loss	of	wild-type	p53	function	results	in	global	 defective	 functioning	 of	 ETC	 complexes,	most	marked	 for	 complexes	 II	 and	 III,	which	 is	 at	 least	 partly	 responsible	 for	 a	 metabolic	 shift	 away	 from	 oxidative	phosphorylation	 towards	 glycolysis.	 These	 findings	 are	 in	 keeping	 with	 evidence	demonstrating	p53	as	a	promoter	of	oxidative	phosphorylation,	which	as	discussed	 in	section	1.3.2.,	 has	 linked	p53	with	 the	general	maintenance	of	mitochondrial	biomass,	integrity,	 quality	 control,	 and	 fidelity	 of	 mitochondrial	 DNA	 replication	 (300-303),	 as	well	as	with	several	aspects	of	ETC	complex	 function(286,	305-309).	Furthermore,	 the	limited	data	specific	 to	SCCHN	on	TP53	 status	and	ETC	activity,	which	 is	derived	 from	one	previous	study(360),	is	broadly	consistent	with	our	findings.	In	that	study,	although	gene	array	analysis	of	all	nuclear	encoded	mitochondrial-related	genes	demonstrated	no	significant	differences	between	wild-type	and	mutant	TP53	SCCHN	cells,	the	comparison	of	a	pair	of	isogenic	cell	lines	divergent	on	TP53	status	revealed	significant	reductions	in	
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ETC	complex	activity	in	the	mutant	TP53	cell	line,	with	specific	defects	identified	in	the	activity	of	 complexes	 II,	 III,	 and	 IV(360).	Notably,	 citrate	 synthase	 activity	 levels	were	similar	in	both	cell	lines,	suggesting	similar	mitochondrial	biomass(360).			
3.4.3.	 Differential	 expression	 of	 glycolysis-related	 transporters	 and	 enzymes	 is	
involved	in	the	TP53-dependent	metabolic	switch	in	SCCHN	cells		Although	in	the	previous	section	we	demonstrated	that	in	SCCHN	cells	loss	of	wild-type	p53	 function	 results	 in	 defective	 ETC	 complex	 function,	 which	 is	 at	 least	 partly	responsible	 for	 a	 metabolic	 shift	 away	 from	 oxidative	 phosphorylation	 towards	glycolysis,	 we	 also	 sought	 to	 examine	 whether	 any	 TP53-dependent	 differential	expression	 of	 glycolytic	 transporters	 and/or	 enzymes	 may	 also	 contribute	 to	 the	metabolic	 re-programming.	 As	 outlined	 in	 section	 1.3.2.,	 wild-type	 p53	 is	 known	 to	down-regulate	 the	 expression	 of	 several	 glycolytic	 transporters,	 including	 GLUTs	 and	MCT-1(298,	299),	as	well	as	influence	the	activity	of	the	glycolytic	enzymes	hexokinase-II(318),	PGAM(295),	PDK(297),	and	PFK-1(205).	As	such,	our	investigation	was	centred	on	these	proteins.	Cells	were	harvested	and	lysed	for	each	SCCHN	cell	line,	and	samples	prepared	as	described	 in	 section	2.11.	Western	blot	analyses	were	 then	performed	on	cell	lysates,	again	as	described	in	section	2.11.,	with	the	appropriate	antibodies	used	for	protein	 detection	 as	 listed	 in	 section	 2.1.4..	 The	 resulting	western	 blots	 are	 shown	 in	figure	3.4.3.1.							
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Figure	3.4.3.1:	Western	blot	 analyses	of	 relative	 levels	of	 glycolysis-related	 transporters	
and	enzymes	known	to	be	controlled	by	p53	 in	SCCHN	cells. Cells	from	each	cell	line	were	harvested	and	lysed	as	described	in	section	2.11.	20μg	of	protein	was	analysed	in	each	lane	and	antibodies	used	for	detection	are	detailed	in	section	2.1.4.	Vinculin	or	actin	were	used	a	loading	controls,	dependent	on	the	molecular	weight	of	the	proteins	being	probed	for.	The	migration	of	protein	standards	of	 the	 indicated	approximate	molecular	weights	are	shown	in	kDa.	 	Blots	 for	the	panel	of	 SCCHN	cell	 lines	are	 shown	on	 the	 left	 and	 for	 the	 isogenic	 cell	 lines	on	 the	 right.	Analysis	of	GLUT-1	demonstrated	increased	protein	levels	in	SCCHN	cell	lines	with	abrogation	of	wild-type	 p53	 function	 compared	 with	 cells	 with	 functional	 wild-type	 p53.	 No	 clear	 patterns	were	observed	for	the	other	proteins	probed	for.		Although	 there	were	no	obvious	differences	between	SCCHN	cells	 in	 the	expression	of	the	glycolytic	enzymes	examined,	a	clear	pattern	was	identified	for	GLUT-1	expression.	
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Specifically,	SCCHN	cells	harbouring	mutant	TP53	expressed	GLUT-1	to	a	greater	extent	than	wild-type	TP53	 cells	 and	 this	 held	 true	when	 analysing	 the	 isogenic	 cell	 lines,	 in	which	greater	GLUT-1	expression	was	observed	 in	 cell	 lines	with	abrogated	wild-type	p53	function.	This	suggests	that	loss	of	wild-type	p53	function	in	SCCHN	cells	results	in	an	 increase	 in	 GLUT-1	 expression	 and	 is	 partly	 attributable	 to	 the	 observed	 TP53-dependent	switch	in	metabolism	towards	glycolysis.	This	finding	is	in	keeping	with	the	previous	report	that	wild-type	p53	acts	to	repress	GLUT-1	gene	transcription,	and	that	mutations	within	 the	DNA-binding	domain	 of	 p53	 impair	 this	 repressive	 effect	 on	 the	transcriptional	 activity	 of	 the	 GLUT1	 gene	 promoters,	 thereby	 resulting	 in	 increased	glucose	 metabolism(298).	 As	 discussed	 in	 section	 1.3.3.,	 several	 retrospective	pathological	 studies	 have	 investigated	 GLUT-1	 expression	 in	 SCCHN	 and	 have	consistently	shown	overexpression	relative	to	normal	mucosa	and/or	benign	squamous	lesions(324-328),	and	have	also	demonstrated	that	GLUT-1	expression	correlates	with	surrogates	of	disease	 severity(329).	Furthermore,	GLUT-1	expression	has	been	 shown	to	be	 an	 independent	negative	prognosticator	 in	both	oral	 cavity	 and	hypopharyngeal	SCC(330,	 331),	 and	 a	marker	 of	 radioresistance	 in	 oral	 cavity	 SCC(332),	 findings	 that	have	 been	 paralleled	 in	 18F-FDG-PET	 studies,	 the	 biochemical	 and	 clinically	 utilised	correlate	 of	 GLUT	 expression,	 which	 have	 shown	 18F-FDG	 avidity,	 as	 measured	 by	standard	 uptake	 value,	 as	 a	 reliable	 predictor	 of	 long-term	 survival	 in	 SCCHN(335).	Interestingly,	 despite	 these	 findings,	 the	 only	 other	 study	 to	 date	 examining	 GLUT-1	expression	in	SCCHN	relative	to	TP53	status	observed	equivalent	expression	of	GLUT-1	in	wild-type	and	mutant	TP53	cells(360).	The	reason	for	this	disparity	in	findings	is	not	clear,	 and	may	 simply	 relate	 to	 the	 specific	 cell	 lines	 investigated.	 Indeed,	 whilst	 our	findings	 were	 consistently	 demonstrated	 in	 a	 panel	 of	 SCCHN	 cell	 lines,	 including	isogenic	pairs	divergent	on	TP53	status,	the	earlier	study	examined	GLUT-1	expression	only	in	one	mutant	and	one	wild-type	TP53	SCCHN	cell	line.				
3.4.4.	Expression	of	TIGAR	becomes	uncoupled	from	p53	transcriptional	regulation	
in	the	context	of	loss	of	wild-type	p53	function	in	SCCHN	cells	Having	 examined	 the	 differential	 expression	 of	 glycolysis-related	 transporters	 and	enzymes	 that	 p53	 is	 known	 to	 regulate	 directly,	we	 then	 sought	 to	 investigate	 TIGAR	expression	given	its	close	relationship	with	regulation	of	glycolysis	and	the	fact	that	it	is	under	 the	 transcriptional	 control	 of	 p53(205).	 As	 discussed	 previously	 (see	 section	1.3.1.),	 TIGAR	 acts	 principally	 as	 a	 bisphosphatase	 that	 reduces	 the	 concentration	 of	intracellular	 fructose-2,6-bisphosphate,	 which	 is	 a	 potent	 allosteric	 activator	 of	 PFK-1(205).	PFK-1	is	an	essential	glycolytic	enzyme	that	catalyses	conversion	of	fructose-6-
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phosphate	to	fructose-1,6-bisphosphate,	which	represents	a	key	regulatory	point	in	the	glycolytic	 pathway,	 and	 p53	 regulates	 glycolysis	 at	 this	 critical	 point	 by	 inducing	 the	transcription	of	TIGAR(205).	Thus,	by	decreasing	PFK-1	activity	TIGAR	limits	glycolytic	flux	downstream	of	 this	 point.	 TIGAR	expression	 levels	were	 examined	using	western	blot	 analyses	 on	 cell	 lysates,	 again	 performed	 as	 described	 in	 section	 2.11.	 Resulting	western	blots	are	shown	in	figure	3.4.4.1.			
	
Figure	3.4.4.1:	Western	blot	analyses	of	baseline	TIGAR	expression	levels	 in	SCCHN	cells. Cells	from	each	cell	 line	were	harvested	and	lysed	as	described	in	section	2.11.	20μg	of	protein	was	 analysed	 in	 each	 lane	 and	 the	 α-TIGAR	 antibody	 used	 for	 detection	 is	 detailed	 in	 section	2.1.4.	Vinculin	was	used	as	a	loading	control.	The	migration	of	protein	standards	of	the	indicated	approximate	molecular	weights	 are	 shown	 in	 kDa.	 	 Blots	 for	 the	panel	 of	 SCCHN	 cell	 lines	 are	shown	 on	 the	 left	 and	 for	 the	 isogenic	 cell	 lines	 on	 the	 right.	 TIGAR	 expression	 levels	 were	observed	to	be	greater	in	SCCHN	cell	lines	with	abrogation	of	wild-type	p53	function	compared	with	cells	with	functional	wild-type	p53.		Curiously,	baseline	TIGAR	expression	levels	were	clearly	greater	in	mutant	TP53	SCCHN	cells	than	in	wild-type	TP53	cells	and	in	the	isogenic	cell	lines	expression	was	greater	in	those	 cell	 lines	 with	 abrogation	 of	 wild-type	 p53	 function.	 Considering	 that	 TIGAR	 is	involved	in	the	p53	tumour	suppressor	pathway,	with	p53	inducing	the	transcription	of	TIGAR	 to	 dampen	 glycolysis,	 these	 findings	 seem	 counter-intuitive.	 Similar	 findings,	however,	 have	 been	 reported	 in	 several	 models	 for	 other	 tumour	 types(286-288),	raising	 the	 possibility	 that	 TIGAR	 expression	 becomes	 de-regulated,	 or	 at	 least	uncoupled	 from	 p53	 regulation,	 in	 cancer	 cells.	 In	 order	 to	 investigate	 this	 further	 in	SCCHN,	we	examined	TIGAR	expression	relative	 to	expression	of	both	p53	and	known	downstream	targets	(p21	and	MDM2)	using	western	blot	analyses	of	lysates	of	selected	mutant	 and	wild-type	TP53	cell	 lines	 as	well	 as	 the	 isogenic	 cell	 lines.	 These	 analyses	
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were	performed	both	at	baseline	and	at	various	time	points	following	administration	of	6Gy	IR	to	induce	p53	stabilisation.	Results	are	shown	in	figures	3.4.4.2	and	3.4.4.3.	
		
	
	
Figure	3.4.4.2:	Western	blot	analyses	of	TIGAR,	p53,	p21,	and	MDM2	expression	levels	in	
selected	mutant	and	wild-type	TP53	SCCHN	cells. Cells	from	each	cell	line	were	harvested	and	
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lysed	as	described	in	section	2.11.	20μg	of	protein	was	analysed	in	each	lane	and	antibodies	used	for	detection	are	detailed	in	section	2.1.4.	Vinculin	was	used	as	a	loading	control.	The	migration	of	protein	standards	of	the	indicated	approximate	molecular	weights	are	shown	in	kDa.		Blots	for	the	mutant	TP53	 cell	 line	UM-SCC-11B	 are	 shown	 first	 (A)	 and	 subsequently	 for	 the	wild-type	
TP53	cell	line	UM-SCC-17AS	(B).	In	the	wild-type	TP53	cell	line,	6Gy	IR	induced	p53	stabilisation	and	consequent	increases	in	expression	of	MDM2,	p21,	and	TIGAR,	while	in	the	mutant	TP53	cell	line,	although	there	was	expression	of	p53,	this	was	unchanged	in	response	to	6Gy	IR,	and	there	was	no	observed	relationship	with	MDM2,	p21,	or	TIGAR	expression.	
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Figure	3.4.4.3:	Western	blot	analyses	of	TIGAR,	p53,	p21,	and	MDM2	expression	levels	in	
isogenic	SCCHN	cells. Cells	from	each	cell	line	were	harvested	and	lysed	as	described	in	section	2.11.	20μg	of	protein	was	analysed	in	each	lane	and	antibodies	used	for	detection	are	detailed	in	section	2.1.4.	Vinculin	was	used	as	a	 loading	control.	The	migration	of	protein	standards	of	 the	indicated	approximate	molecular	weights	are	shown	in	kDa.		Blots	for	UM-SCC-1	and	derivate	cell	lines	are	shown	first	(A)	and	subsequently	for	UM-SCC-17A	and	derivative	cell	lines	(B).	Blots	for	
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UM-SCC-1	 included	 two	derivative	 lines	 transduced	with	TP53	mutations	 to	provide	 a	positive	control	for	p53	expression,	and	in	blots	for	UM-SCC-17A	shp53	the	parental	cell	line	UM-SCC-17A	was	 included	as	 a	positive	 control	 for	p53	expression.	 In	 cell	 lines	harbouring	 functional	wild-type	p53	 (UM-SCC-1	wtp53,	UM-SCC-17A,	UM-SCC-17A	 lenti)	 6Gy	 IR	 induced	p53	 stabilisation	and	 consequent	 increases	 in	 expression	 of	 MDM2,	 p21,	 and	 TIGAR.	 In	 cell	 lines	 with	 loss	 of	functional	wild-type	p53	there	was	no	expression	of	p53	in	response	to	6Gy	IR,	and	no	observed	relationship	with	MDM2,	p21,	or	TIGAR	expression.		As	would	be	expected,	in	cell	 lines	harbouring	functional	wild-type	p53,	p53-activating	stress	 induced	p53	stabilisation,	which	resulted	 in	an	 increase	 in	expression	of	known	transcriptional	 targets	 MDM2	 and	 p21.	 Importantly,	 there	 was	 also	 a	 clear	 direct	relationship	 between	 p53	 expression	 and	 TIGAR	 expression,	 consistent	 with	 TIGAR	being	under	tight	p53-dependent	transcriptional	control.	 In	stark	contrast,	 in	the	TP53	mutant	cell	line,	UM-SCC-11B,	whilst	there	was	p53	expression,	there	was	no	change	to	expression	levels	in	response	to	IR,	nor	was	there	any	relationship	with	MDM2,	p21,	or	TIGAR	expression.	Similarly,	 in	the	p53	null	cell	 lines	UM-SCC-1	and	UM-SCC-1	pBABE,	as	 well	 as	 in	 the	 stable	 p53	 knock-down	 in	 UM-SCC-17A,	 p53	 expression	 was	 not	detectable	under	any	conditions	and	despite	this	high	levels	of	TIGAR	expression	were	observed,	 which	 were	 unaffected	 by	 treatment	 with	 IR.	 This	 corroborates	 the	hypothesis	 that	 in	 the	 absence	 of	 functional	 wild-type	 p53	 in	 SCCHN	 cells	 TIGAR	expression	 is	 increased	 and	 uncoupled	 from	 the	 transcriptional	 regulation	 of	 p53.	 As	alluded	to	earlier	in	this	section,	this	is	a	notion	supported	by	an	ever-increasing	body	of	evidence	and	will	be	discussed	in	greater	depth	subsequently	in	section	4.	Although	on	initial	consideration	TIGAR	overexpression	may	seem	counter-intuitive	as	glycolytic	flux	would	 be	 slowed	 secondary	 to	 reduction	 in	 PFK-1	 activity,	 this	would	 be	 expected	 to	facilitate	shunting	of	carbon	into	subsidiary	metabolic	pathways,	chiefly	the	PPP,	which	would	 generate	 NADPH,	 in	 turn	 enabling	 the	 upregulation	 of	 cellular	 antioxidant	systems	 to	 combat	 oxidative	 stress	 and	 promote	 survival(280).	 In	 support	 of	 this,	several	 studies	 have	 shown	 that	 the	 downregulation	 of	 TIGAR	 is	 associated	 with	decreased	 levels	 of	NADPH(426,	 427),	 lower	 levels	 of	GSH,	 and	 in	 turn	 an	 increase	 in	ROS	levels	and	cell	death(205,	288,	427).		
3.4.5.	Uncoupling	of	TIGAR	expression	from	p53	regulation	in	SCCHN	cells	with	loss	
of	wild-type	p53	function	results	in	increased	PPP	flux	In	 the	 previous	 section	 we	 established	 that	 in	 the	 context	 of	 loss	 of	 wild-type	 p53	function	 in	 SCCHN	 cells	 TIGAR	 is	 highly	 expressed	 and	 its	 expression	 becomes	uncoupled	 from	 the	 transcriptional	 regulation	 of	 p53.	 As	 discussed	 in	 the	 previous	
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section,	the	anticipated	outcome	of	this	is	that	PPP	flux	would	be	heightened,	resulting	in	 increased	 generation	 of	 NADPH	 allowing	 for	 upregulation	 of	 cellular	 antioxidant	defences.	In	this	section	we	sought	to	investigate	this	hypothesis.	In	order	to	do	so,	we	first	 examined	 the	 expression	 of	 two	 key	 PPP	 enzymes	 –	 G6PD	 and	 6-PGD.	 G6PD	catalyses	the	first	and	rate-limiting	step	 in	the	oxidative	branch	of	 the	PPP,	generating	the	 first	molecule	of	NADPH,	while	6-PGD	drives	the	second	NADPH	producing	step	 in	the	 oxidative	 phase	 of	 PPP(280).	 G6PD	 and	 6-PGD	 expression	 levels	 were	 examined	using	western	blot	analyses	on	cell	lysates,	again	performed	as	described	in	section	2.11.	Resulting	western	blots	are	shown	in	figure	3.4.5.1.	
		
Figure	3.4.5.1:	Western	blot	analyses	of	PPP	enzyme	expression	levels	in	SCCHN	cells. Cells	from	each	cell	 line	were	harvested	and	 lysed	as	described	 in	section	2.11.	20μg	of	protein	was	analysed	in	each	lane	and	the	antibodies	used	for	detection	are	detailed	in	section	2.1.4.	Vinculin	was	used	as	a	loading	control.	The	migration	of	protein	standards	of	the	indicated	approximate	molecular	weights	are	shown	in	kDa.		Blots	for	the	panel	of	SCCHN	cell	lines	are	shown	on	the	left	and	 for	 the	 isogenic	 cell	 lines	 on	 the	 right.	 Expression	 levels	 of	 both	 G6PD	 and	 6-PGD	 were	observed	to	be	higher	 in	SCCHN	cell	 lines	with	abrogation	of	wild-type	p53	 function	compared	with	cells	with	functional	wild-type	p53.		In	keeping	with	our	earlier	results	in	relation	to	TIGAR	expression,	expression	levels	of	both	PPP	oxidative	branch	enzymes	were	discernibly	higher	in	SCCHN	cells	harbouring	
TP53	mutations	 relative	 to	 those	 harbouring	 wild-type	 TP53,	 and	 in	 the	 isogenic	 cell	lines	higher	expression	levels	were	observed	in	cells	with	loss	of	wild-type	p53	function.	Whilst	 these	 findings	of	 increased	PPP	enzyme	expression	are	 suggestive	of	 increased	PPP	 activity	mediated	 through	 TIGAR-dependent	 shunting,	 other	 factors	may	 directly	
Results	
	 190	
influence	expression	of	these	enzymes.	For	instance,	wild-type	p53	can	interact	directly	with	G6PD	and	suppress	its	activity	by	inhibiting	the	assembly	of	G6PD	monomers	into	active	 dimers(428).	 In	 order	 to	 explore	 the	 relationship	with	 PPP	 activity	 further,	we	next	examined	intracellular	NADP	and	NADPH	levels.	Cells	were	either	left	untreated	or	were	treated	with	5μM	6-AN,	and	measurement	of	intracellular	NADP	and	NADPH	levels	performed	 using	 the NADP/NADPH	 quantification	 kit	 as	 described	 in	 section	 2.10.	Resulting	NADPH/NADP	ratios	are	depicted	in	figure	3.4.5.2.	
	
Figure	 3.4.5.2:	 NADPH/NADP	 ratios	 in	 SCCHN	 cells	 at	 baseline	 and	 following	 treatment	
with	 6-AN.	 Following	 either	 no	 treatment	 or	 treatment	 with	 5μM	 6-AN,	 measurement	 of	
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intracellular	NADP	 and	NADPH	 levels	 performed	using	 the	NADP/NADPH	quantification	 kit	 as	described	 in	 section	 2.10.	 Results	 are	 first	 shown	 for	 the	 panel	 of	 SCCHN	 cell	 lines	 (A)	 and	subsequently	 for	 the	 isogenic	 SCCHN	 cell	 lines	 (B).	 Experiments	 were	 performed	 in	 duplicate	with	mean	values	depicted	in	the	histograms	and	SEMs	represented	by	error	bars.	NADPH/NADP	ratios	were	consistently	higher	in	mutant	TP53	compared	with	wild-type	TP53	SCCHN	cells	(A).	Similarly,	in	the	isogenic	cell	lines	NADPH/NADP	ratios	were	higher	in	those	cell	lines	with	loss	of	wild-type	p53	function	(B).	In	all	cases	the	PPP	inhibitor	6-AN	reduced	NADPH/NADP	ratios,	with	greatest	effects	seen	in	cells	with	loss	of	wild-type	p53	function.		Again	 in	 keeping	 with	 our	 previous	 results	 in	 relation	 to	 TIGAR	 and	 PPP	 enzyme	expression,	 NADPH/NADP	 ratios	 were	 clearly	 higher	 in	 SCCHN	 cell	 lines	 with	abrogation	 of	wild-type	 p53	 function,	 indicating	 that	 NADPH	 production	 is	 greater	 in	these	cell	lines.	Importantly,	in	all	cases	the	PPP	inhibitor	6-AN	reduced	NADPH/NADP	ratios,	 with	 greatest	 effects	 seen	 in	 cells	 with	 abrogation	 of	 wild-type	 p53	 function,	supporting	 the	 fact	 that	 the	 NADPH	 production	 is	 principally	 derived	 from	 PPP	 flux.	Taken	together,	these	findings	suggest	that	higher	levels	of	TIGAR	expression,	resulting	from	uncoupling	from	p53	transcriptional	regulation,	do	indeed	translate	into	increased	diversion	 into	the	PPP,	which	 in	 turn	supports	 the	upregulation	of	cellular	antioxidant	systems	 through	NADPH	generation.	 Consistent	with	 this,	 several	 studies	 have	 shown	that	 the	 downregulation	 of	 TIGAR	 is	 associated	with	 decreased	 levels	 of	 NADPH(426,	427),	lower	levels	of	GSH,	and	in	turn	an	increase	in	ROS	levels	and	cell	death(205,	288,	427).	Specific	 to	SCCHN,	only	one	previous	study	has	examined	TIGAR	expression	and	its	 relationship	 with	 PPP	 activity.	 In	 that	 study,	 which	 sought	 to	 examine	 the	reprogramming	 of	 metabolism	 associated	 with	 the	 development	 of	 radioresistance	using	a	matched	model	of	radio-resistant	and	-sensitive	SCCHN	cells,	radioresistant	cells	were	 observed	 to	 exhibit	 increased	 levels	 of	 TIGAR	 and	 G6PD	 expression,	 as	 well	 as	increased	 production	 of	 NADPH(277).	 Unfortunately,	 as	 discussed	 previously	 in	reference	 to	 this	 study,	 information	on	 the	TP53	 status	of	 these	 cell	 lines	was	 lacking,	which	hinders	meaningful	comparison	with	our	findings.	However,	it	may	have	been	the	case	 that	sequential	 treatment	of	 the	parental	radiation-sensitive	cell	 line	with	several	fractions	of	IR	to	generate	the	radio-resistant	cell	line	would	have	resulted	in	acquisition	of	a	TP53	mutation,	in	which	case	the	reported	findings	would	be	highly	congruous	with	ours.	
Discussion	
	 192	
4.	Discussion	
	As	outlined	in	section	1.4.,	the	primary	aims	of	this	thesis	were	to	examine	the	metabolic	phenotype	 exhibited	 by	 SCCHNs,	 whether	 this	 was	 related	 to	 TP53	 status,	 and	 to	determine	whether	tailored	anti-metabolic	 treatment	might	have	potential	 therapeutic	value,	specifically	 in	enhancing	the	effects	of	radiation	treatment.	The	rationale	behind	these	research	aims	was	three-fold.	Firstly,	survival	outcomes	for	HPV-negative	SCCHN	have	 not	 improved	 significantly	 over	 the	 last	 20-30	 years,	 largely	 because	 currently	available	 treatment	 regimes	 fail	 to	 induce	 a	 response	 in	 those	with	 advanced	disease.	Approximately	 two-thirds	 of	 patients	 with	 SCCHN	 present	 with	 advanced	 disease(1),	and	overall	survival	rates	for	such	patients	remain	as	low	as	35%(128,	429).	Thus,	there	is	 a	 pressing	 need	 to	 develop	more	 effective	 and	 personalised	 treatment	 strategies.	 A	major	 focus	of	 this	 is	 to	 identify	ways	of	sensitising	 these	 tumours	 to	 the	effects	of	 IR,	particularly	given	the	fact	that	RT	is	 indicated	 in	almost	75%	of	all	SCCHN	cases(107),	resistance	 to	 RT	 remains	 a	 significant	 concern(369),	 and	 RT	 dosage	 escalation	 is	generally	 not	 a	 feasible	 option	 because	 of	 normal	 tissue	 toxicity(80,	 128,	 129,	 429).	Secondly,	 in	recent	years	cancer	cell	metabolism	has	come	into	the	 forefront	of	cancer	research	 because	 of	 increasing	 links	 between	 tumour	 metabolism	 and	 the	 causal	changes	 determining	 the	 cancer	 phenotype(247),	 yet	 has	 received	 relatively	 little	attention	in	the	context	of	SCCHN.	Renewed	interest	in	this	field	in	cancer	research	more	generally	has	 led	 to	 the	development	of	new	drugs	and	re-purposing	of	existing	drugs	that	target	cell	metabolism,	which,	when	combined	with	standard	therapies	can	offer	a	selective	 therapeutic	 gain(reviewed	 in	 (395,	 430)).	 Until	 now,	 the	 potential	 of	 this	approach	in	the	context	of	SCCHN	had	not	been	fully	realised.	Thirdly,	loss	of	wild-type	p53	is	fundamental	to	SCCHN	oncogenesis	(see	sections	1.1.3.	and	1.2.7.),	p53	is	known	to	 be	 an	 important	metabolic	mediator	 (see	 section	 1.3.2.),	 and	 two	 relatively	 recent	studies	 have	 implicated	 TP53	 status	 as	 a	 potential	 determinant	 of	 the	 metabolic	phenotype	in	SCCHN(359,	360).	Moreover,	it	is	widely	recognised	that	TP53	mutation	is	linked	to	particularly	poor	clinical	outcomes	and	treatment	resistance	in	SCCHN(56-58,	238,	239),	yet	to	date	there	are	no	clinically	available	treatment	strategies	that	stratify	on	this	basis.	The	proposed	therapeutic	paradigm	presented	here	specifically	addresses	these	issues,	and	this,	together	with	planned	future	work,	will	be	the	focus	of	discussion	in	this	section.			
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Data	 presented	 in	 section	 3.1.	 begins	 to	 address	 the	 primary	 aims	 of	 this	 study	 by	exploring	 the	 metabolic	 phenotype	 in	 a	 panel	 of	 SCCHN	 cell	 lines	 using	 real-time	microplate-based	XF	analysis	during	specifically	designed	mitochondrial	and	glycolytic	pharmacological	stress	tests.	The	results	presented	in	this	section	revealed	that	mutant	SCCHN	 cell	 lines	 reliably	 and	 consistently	 exhibited	 a	 distinct	metabolic	 phenotype	 to	that	 of	 wild-type	TP53	 cell	 lines,	 whereby	wild-type	TP53	 cells	maintained	metabolic	diversity,	 displaying	 robust	mitochondrial	 and	 glycolytic	 reserves,	while	mutant	TP53	cells	 exhibited	 markedly	 reduced	 mitochondrial	 and	 glycolytic	 reserves,	 functioning	near	or	at	capacity	under	basal	conditions.			Although	 in	 general	 metabolic	 studies	 in	 SCCHN	 have	 been	 somewhat	 lacking	 and	simplistic	 (discussed	 in	depth	 in	section	1.3.3.),	 two	relatively	recent	and	more	robust	studies	 from	 the	 same	 research	 group	 have	 observed	 a	 similar	 relationship	 between	
TP53	 status	and	metabolic	phenotype(359,	360).	Findings	 from	those	studies	revealed	that	 although	 SCCHN	 cells	 exhibited	 a	 general	 dependence	 on	 glycolysis	 over	glutaminolysis,	 there	was	significant	heterogeneity	among	cell	 lines,	which	was	shown	to	 relate	 to	TP53	 status(359).	 Specifically,	 initial	 studies	 showed	 that	 wild-type	TP53	cells	were	relatively	resistant	to	glucose	deprivation	and	glycolytic	inhibition	compared	with	mutant	TP53	cells(359),	and	follow-on	studies	demonstrated	that	mutant	TP53	cell	lines	displayed	markedly	reduced	spare	respiratory	capacity	relative	to	wild-type	TP53	cell	 lines,	using	the	same	microplate-based	XF	analysis	as	 in	this	thesis(360).	Although	both	of	 these	studies	were	 limited	 in	the	number	of	cell	 lines	analysed	with	respect	 to	the	 differences	 between	 mutant	 and	 wild-type	 TP53	 cells,	 the	 consistency	 with	 the	findings	presented	here	 in	 a	 larger	panel	 of	 SCCHN	cell	 lines	 is	 striking.	 Furthermore,	recapitulation	of	these	findings	using	isogenic	SCCHN	cell	lines	engineered	with	regards	to	 their	 expression	 of	 wild-type	 p53,	 both	 in	 the	 work	 presented	 here	 and	 in	 the	aforementioned	 studies,	 corroborates	 a	 functional	 dependence	 on	 p53.	 Additionally,	these	 studies	 utilising	 shRNA	 knock-down	 of	 wild-type	 p53	 demonstrate	 that	 the	observed	switch	in	metabolic	profile	is	the	result	of	loss	of	wild-type	p53	function	rather	than	any	oncogenic	GOF	properties	harboured	by	a	particular	TP53	mutation.		The	microplate-based	XF	data	demonstrating	that	loss	of	wild-type	p53	function	results	in	 reduced	 respiratory	 and	 glycolytic	 reserves	 in	 SCCHN	 cells	 was	 reported	 by	 the	authors	 of	 the	 previous	 study	 as	 globalised	 loss	 of	metabolic	 flexibility,	 but	 also	 as	 a	dependence	on	glycolysis(360).	However,	closer	scrutiny	reveals	that	these	data	can	be	interpreted	 in	 one	 of	 two	 ways.	 Firstly,	 in	 cells	 with	 loss	 of	 wild-type	 p53	 function	
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mitochondrial	 oxidative	 phosphorylation	 and/or	 glycolysis	 is	 compromised	 in	 some	way,	preventing	cells	 from	mounting	a	compensatory	response	 to	metabolic	stressors;	or	 alternatively,	 mutant	 TP53	 cells	 have	 significantly	 elevated	 rates	 of	 oxidative	phosphorylation	 and/or	 glycolysis	 at	 baseline	 that	 represent	 maximal	 cellular	 rates.	Further	work	presented	in	section	3.1	of	this	thesis	addressed	this	ambiguity,	providing	a	 clearer	 overall	 metabolic	 picture,	 which	 has	 important	 potential	 therapeutic	implications.	Unlike	 the	previous	 reports,	we	 conducted	 specific	 glycolytic	 stress	 tests	rather	 than	 extrapolating	 data	 from	 mitochondrial	 stress	 tests,	 and	 our	 XF	 data	 was	normalised	 to	DNA	 content	 to	 allow	 for	 calculation	 of	 absolute	 values	 for	 each	 of	 the	metabolic	 parameters	 derived	 during	 the	 stress	 test	 and	 enable	 more	 reliable	comparison	across	cell	lines.	These	data	revealed	that	under	basal	conditions	wild-type	p53	 SCCHN	 cells	 catabolise	 glucose	 primarily	 through	 oxidative	 phosphorylation	 and	maintain	 robust	mitochondrial	 function,	 thus	are	able	 to	mount	a	maximal	 increase	 in	ETC	activity	when	exposed	to	mitochondrial	stressors.	 In	contrast,	 in	SCCHN	cells	 that	have	 lost	wild-type	p53	 function	glycolysis	predominates	under	basal	 conditions,	with	levels	 elevated	 to	 maximal	 capacity	 leaving	 little	 or	 no	 reserve,	 while	 mitochondrial	activity	is	compromised,	with	reduced	oxidative	phosphorylation	under	basal	conditions	and	a	diminished	ability	 to	mount	an	 increase	 in	activity	 in	response	 to	mitochondrial	stressors.	Following	on	from	this,	additional	work	presented	in	section	3.1.	showed	that	this	p53-dependent	metabolic	re-programming	away	from	oxidative	phosphorylation	in	favour	of	glycolysis	does	indeed	represent	a	specific	survival	dependence	on	glycolysis,	which	again	has	attractive	therapeutic	implications.		It	 is	 widely	 acknowledged	 that	 there	 is	 a	 need	 for	 more	 selective	 and	 personalised	therapeutic	 approaches	 in	 the	 wider	 field	 of	 cancer	 research,	 and	 currently	 much	research	effort	is	focused	on	this	key	strategy.	Such	molecularly	targeted	therapies	have	as	yet	had	limited	translation	into	the	treatment	of	SCCHN	patients.	In	recent	years,	only	the	EGFR	 inhibitor	 cetuximab	has	been	approved	and	 introduced	 into	 clinical	practice	for	 the	 treatment	of	SCCHN(87)	 (see	section	1.1.3.),	 although	subsequent	 studies	have	raised	questions	over	clinical	applicability(431-433).	Thus,	it	remains	a	major	challenge	in	 SCCHN	 to	 develop	 such	 targeted	 treatments.	 Novel	 therapeutic	 approaches	 are	generally	 predicated	 on	 a	 discernible	 therapeutic	 index	 of	 the	 chosen	 agent,	 either	 in	isolation	or	 in	combination	with	other	treatment	regimes.	Considering	this,	 in	contrast	to	traditional	cytotoxic	agents,	which	largely	target	pathways	that	exist	in	normal	cells,	metabolic	 targeting	 can	 exploit	 the	 fact	 that	 tumour	 cells	 become	 predominantly	dependent	 on	 a	 particular	 metabolic	 pathway	 providing	 a	 selective	 therapeutic	 gain	
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while	 sparing	 most	 normal	 cells,	 which	 maintain	 metabolic	 diversity.	 Importantly,	subsequent	 work	 presented	 in	 section	 3.2.	 demonstrated	 that	 the	 observed	 glucose	“addiction”	of	mutant	TP53	SCCHN	cells	does	 indeed	correlate	with	radiation	response	after	glycolytic	inhibition.	Specifically,	2-DG	consistently	potentiated	radiation	effects	in	SCCHN	 cells	 harbouring	TP53	 mutations	 but	 not	 in	 those	 harbouring	wild-type	TP53.	These	 findings	 present	 the	 opportunity	 for	 a	 tailored	 anti-metabolic	 approach	 to	 the	treatment	of	SCCHN	that	takes	into	account	TP53	mutational	status,	whereby	2-DG	could	be	used	as	a	selective	radiosensitiser	specifically	to	treat	mutant	TP53	SCCHN.		Currently,	 therapeutic	decision-making	 for	 SCCHN	patients	 is	based	predominantly	on	TNM	classification	and	the	associated	UICC/AJCC	staging	system,	which	rely	 largely	on	clinical	and	radiological	findings,	although	as	outlined	in	section	1.1.4.	additional	factors	such	as	HPV	status	have	been	included	in	the	most	updated	versions(50).	Whilst	these	systems	have	fulfilled	their	original	mandate	remarkably	over	the	years,	owing	to	time-tested	 consistency	 and	 user-friendliness,	many	 have	 criticised	 their	 lack	 of	 predictive	power	 and	 failure	 to	 account	 for	 numerous	 potentially	 important	 prognostic	 and/or	predictive	 tumour	 factors(434).	 Fundamental	 to	 successful	 development	 of	 more	personalised	treatment	for	SCCHN	will	be	the	identification	of	these	tumour	factors	that	reliably	predict	which	patients	will	actually	derive	benefit	so	that	these	treatments	can	be	 effectively	 deployed.	 As	 such,	 the	 potential	 opportunity	 to	 utilise	 TP53	 status	 as	predictive	 biomarker	 to	 inform	 delivery	 of	 more	 personalised	 therapy,	 rather	 than	simply	a	prognostic	biomarker,	is	of	particular	interest.	Since	its	discovery,	p53	has	been	at	 the	 forefront	 of	 cancer	 research,	 is	 one	 of	 the	 most	 extensively	 studied	 genes	 in	biomedicine/life	 sciences	 (having	 been	 the	 subject	 of	 more	 than	 85,000	 published	articles	listed	on	PubMed),	and	is	recognised	as	the	most	common	molecular	alteration	found	 in	 human	 cancers(133).	 Despite	 this,	 therapeutic	 translation	 into	 the	 clinical	setting	 has	 been	 almost	 non-existent,	 with	 chronic	 lymphocytic	 leukemia	 the	 only	cancer	to	date	for	which	clinically	available	treatment	strategies	stratify	on	the	basis	of	
TP53	 status(435).	 The	 proposed	 therapeutic	 approach	 presented	 here	 would	 for	 the	first	time	stratify	SCCHN	patients	for	treatment	on	the	basis	of	TP53	mutational	status,	and	would	also	be	preferentially	effective	in	overcoming	cellular	resistance	to	radiation	treatment	 in	 patients	 with	 the	 treatment-resistant	 disease	 typically	 associated	 with	
TP53	mutation(56,	57).	Moreover,	this	approach	would	be	applicable	to	the	majority	of	SCCHN	patients	given	that	60-85%	of	SCCHNs	harbour	TP53	mutations(51-53).		
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This	 use	 of	 glycolytic	 inhibitor	 treatment	 in	 the	 context	 of	 SCCHN	has	 been	 examined	previously.	 A	 small	 number	 of	 in	 vitro	 studies	 generally	 focusing	 on	 2-DG	 and	 using	homotypic	 cell	 culture	 experiments	 have	 demonstrated	 a	 selective	 sensitivity	 to	glycolytic	 inhibition,	 particularly	 when	 combined	 with	 conventional	 treatments(354,	355,	 359,	 360).	 However,	 findings	 have	 not	 been	 universal(357)	 and	 few	 of	 these	previous	studies	have	accounted	for	TP53	status,	which	in	light	of	the	findings	presented	here	 seems	 highly	 relevant	 and	 conceivably	 could	 explain	 variability	 in	 results.	Consistent	 with	 this,	 and	 in	 keeping	 with	 our	 results,	 the	 study	 detailed	 above	examining	 effects	 of	TP53	 status	 on	metabolism	 and	 response	 to	 glycolytic	 inhibition	demonstrated	 potentiation	 of	 IR	 effects	 in	 the	 presence	 of	 2-DG	 exclusively	 in	 SCCHN	cells	 with	 loss	 of	 wild-type	 p53	 function(360).	 Moreover,	 a	 relatively	 recent	 study	specifically	 examining	 the	 differential	 cytotoxic	 effects	 of	 2-DG	 in	 isogenic	 cell	 lines	differing	in	TP53	status	also	reported	a	significantly	greater	sensitivity	in	mutant	TP53	cells(355).	Only	one	previous	study	has	examined	the	effects	of	glycolytic	 inhibition	 in	SCCHN	 in	 the	 in	 vivo	 setting,	 in	 which	 2-DG	 was	 observed	 to	 potentiate	 the	 anti-tumorigenic	 effects	 of	 cisplatin	 on	 cell	 proliferation	 and	 survival,	 inhibiting	 growth	 of	SCCHN	xenografts	both	in	isolation	and	in	a	combined-modality	approach	with	IR(356).	Interestingly,	 although	 this	 study	did	 not	 seek	 to	 examine	 any	 relationship	with	TP53	status,	both	xenografts	used	were	derived	from	SCCHN	cell	lines	documented	to	harbour	
TP53	mutations.		Following	 on	 from	 these	 pre-clinical	 studies,	 two	 clinical	 studies,	 both	 originating	 in	Italy	 in	 the	mid	 1990s,	 have	 evaluated	 the	 role	 of	 glycolytic	 inhibition	 in	 SCCHN(436,	437).	 These	 clinical	 trials	 both	 examined	 the	 effects	 of	 oral	 administration	 of	 the	glycolytic	inhibitor	lonidamine,	which	is	thought	to	inhibit	hexokinase	as	well	as	glucose	uptake	 and	 lactate	 efflux(395).	 One	 trial	 investigated	 lonidamine	 in	 combination	with	chemotherapy	 (methotrexate)	 in	 89	 patients	 with	 recurrent	 SCCHN	 using	 a	 phase	 II	randomised	design(437),	while	the	other	examined	lonidamine	in	combination	with	RT	in	96	patients	with	advanced	primary	SCCHN	as	a	phase	III,	double-blind,	randomised,	placebo-controlled	 trial(436).	 Intriguingly,	 results	 suggested	 that	 the	 addition	 of	lonidamine	in	either	instance	improved	clinical	outcomes,	and	was	seemingly	tolerable,	with	 only	 minor	 side	 effects	 and	 relatively	 low	 attrition	 rates	 reported(436,	 437).	Specifically,	 in	 the	 phase	 III	 study	 although	 there	 was	 negligible	 difference	 in	 initial	disease	control	rates	(66%	in	the	lonidamine	group	versus	65%	in	the	placebo	group),	the	 addition	 of	 lonidamine	 resulted	 in	 a	 lower	 subsequent	 treatment-failure	 rate	following	 initial	disease	clearance	(50%	versus	77%),	and	significantly	 improved	 loco-
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regional	 control	 and	 disease-free	 survival	 at	 three	 and	 five	 years(436).	 Considering	these	findings	in	light	of	those	presented	in	this	thesis,	it	is	perhaps	surprising	that	such	favourable	 outcomes	were	 observed	 given	 that	 neither	 trial	 utilised	TP53	 status	 as	 a	predictive	 biomarker.	 However,	 if	 rates	 of	 TP53	 mutation	 in	 SCCHN	 from	 recent	sequencing	studies	(65-80%)(51-53)	are	extrapolated	to	these	patient	groups	it	is	likely	that	 only	 a	 small	minority	 of	 tumours	would	 have	 harboured	wild-type	 p53,	 and	 that	any	 potential	 resistance	 to	 glycolytic	 inhibition	 in	 these	 tumours	 would	 have	 been	masked	 by	 the	 effects	 observed	 in	 mutant	 TP53	 disease.	 What	 is	 perhaps	 more	surprising	given	these	promising	 findings	 is	 the	absence	of	subsequent	clinical	studies	further	 investigating	 this	 issue.	 Findings	 from	 other	 solid	 tumour	 types,	 however,	highlight	 that	whilst	 in	many	 instances	 initial	 pre-clinical	 and/or	 clinical	 results	 have	been	therapeutically	promising,	responses	have	been	inconsistent,	even	when	combined	with	 conventional	 therapies(438).	 Whilst	 these	 discrepancies	 may	 simply	 reflect	differing	metabolic	 profiles	 in	 different	 tumour	 types,	 and	 thus	 variable	 responses	 to	glycolytic	 inhibition,	 another	 possible	 explanation	 relates	 to	 a	 lack	 of	 available	predictors	 to	 define	 patient	 populations	most	 likely	 to	 derive	 therapeutic	 benefit.	 For	instance,	 in	 keeping	 with	 our	 findings	 presented	 here,	 it	 is	 conceivable	 that	 tumours	harbouring	 TP53	mutations	 would	 be	 sensitive	 to	 glycolytic	 inhibition,	 while	 those	expressing	 wild-type	 p53	 may	 be	 resistant,	 requiring	 a	 broader	 anti-metabolic	approach,	and	thus	attributable	to	the	variable	results.		Based	 on	 the	 findings	 and	 proposed	 therapeutic	 paradigm	 presented	 in	 this	 thesis,	ultimately	we	 anticipate	 conducting	 a	 phase	 II/III	 clinical	 trial	 in	 SCCHN	patients	 that	would	 investigate	 the	 efficacy	 of	 a	 tailored	 anti-metabolic	 therapeutic	 approach	 in	mutant	TP53	 disease.	 Specifically,	we	envisage	 that	 SCCHN	patients	 for	whom	RT	was	indicated	 as	 part	 of	 their	 treatment	 regime	 would	 be	 first	 identified,	 and	 of	 these	patients	 those	 with	 mutant	 TP53	 disease	 would	 be	 further	 identified	 through	sequencing	of	pre-treatment	biopsy	specimens.	Following	selection	on	the	basis	of	these	inclusion	 criteria,	 the	 trial	 would	 take	 the	 form	 of	 a	 randomised,	 controlled,	 parallel-group,	superiority	study,	in	which	all	patients	would	receive	their	proposed	RT	regime	but	would	be	 randomised	 to	 receive	either	2-DG	or	placebo	prior	 to	each	RT	 fraction.	Oncological	outcome	measures	of	 interest	would	 include	 loco-regional	disease	control,	disease	 specific	 survival,	 and	 overall	 survival.	 Functional	 outcome	 measures	 with	regards	 to	 swallowing	 and	 voice	would	 also	 be	 included.	 In	 the	 first	 instance,	 for	 the	sake	of	 simplicity	and	 to	minimise	heterogeneity,	we	 suggest	 that	 recruitment	 include	only	 those	SCCHN	patients	planned	 to	have	 single-modality	RT	as	 their	 recommended	
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treatment.	 Recruitment	 could	 then	 be	 expanded	 to	 patients	 who	 were	 having	 multi-modality	treatment,	for	example	surgical	resection	with	adjuvant	RT	or	primary	CRT.		Although	 no	 previous	 clinical	 studies	 have	 been	 conducted	 using	 2-DG	 in	 SCCHN	patients,	2-DG	in	combination	with	RT	has	been	evaluated	more	extensively	in	patients	with	cerebral	gliomas.	Consequently,	these	data	could	be	extrapolated	to	inform	dosing	schedules	and	safety	profiles	in	SCCHN	patients,	potentially	obviating	the	need	for	phase	I/II	 trials	 before	 proceeding	 to	 the	 phase	 II/III	 trial	 design	 as	 described	 above.	 The	clinical	trials	and	dosage	escalation	studies	in	cerebral	glioma	patients	conducted	so	far	suggest	 that	 the	 oral	 administration	 of	 2-DG	 following	 overnight	 fasting	 and	immediately	prior	 to	RT	 in	doses	between	250	and	300mg/kg	body	weight	 is	 feasible,	efficacious,	and	safe.	The	clinical	side	effect	profile	reflects	that	of	hypoglycaemia	and	is	predictable	 on	 the	 basis	 of	 the	 cell	 types	 that	 depend	 most	 on	 glycolysis,	 such	 as	cerebral	and	cardiac	tissues.	Diaphoresis,	generalised	warmth,	flushing,	drowsiness,	and	hypothermia	have	been	observed	but	have	not	been	severe,	have	been	transient	lasting	approximately	90	minutes,	 and	 can	be	 reversed	by	 the	 administration	of	 glucose.	 The	predictability	 of	 the	 source	 of	 these	 adverse	 effects	 is	 favourable	 insofar	 as	 potential	toxicities	could	be	monitored	for	on	a	proactive	rather	than	reactive	basis.		Although	 the	 likely	 method	 of	 delivery	 of	 2-DG	 in	 SCCHN	 patients	 would	 be	 oral	administration,	in	line	with	previous	studies	in	cerebral	glioma,	topical	delivery	may	be	an	option	in	the	context	of	patients	receiving	adjuvant	RT	following	surgical	resection	of	their	disease,	and	may	further	minimise	any	systemic	toxicities.	In	this	paradigm,	topical	2-DG	could	be	applied	onto	the	tumour	bed	following	resection	in	order	to	maximise	the	efficacy	 of	 RT	 in	 eliminating	 any	 residual	 disease,	 although	 the	 temporal	 relationship	between	 surgical	 resection	 and	 administration	 of	 adjuvant	 RT	 may	 limit	 the	effectiveness	of	this	approach.		Prior	 to	 any	 translation	 into	 clinical	 practice,	 however,	 our	 findings,	 and	 in	 particular	our	proposed	therapeutic	approach,	would	require	validation	in	further	experiments	in	a	 pre-clinical	 environment.	 Indeed,	 one	 of	 the	 frailties	 of	 the	 work	 presented	 in	 this	thesis	is	that	experiments	have	been	conducted	exclusively	using	homotypic,	monolayer	cell	 culture	 of	 immortalised	 cell	 lines	 derived	 from	 SCCHN	 tumours.	 Although	 such	cultured	cancer	cell	lines	are	the	most	widely	used	model	systems	and	have	formed	the	basis	for	much	of	our	current	understanding	of	cancer	biology,	the	clinical	relevance	of	these	models	has	been	questioned(439).	One	of	 the	major	concerns	over	 immortalised	
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cell	 lines	 is	 that	of	clonal	evolution,	whereby	cells	adapt	 to	 the	culture	environment	 in	
vitro	as	they	grow	and	may	develop	genetic	and	phenotypic	differences	from	the	original	tumour(439).	Genetic	 and	molecular	 cytogenetic	data	 for	 SCCHN	cells	 lines	 in	 culture,	however,	 has	 shown	 a	 close	 resemblance	 to	 those	 in	 the	 primary	 tumours(371).	 In	addition,	 to	 counteract	 clonal	 evolution	 as	 best	 possible,	 our	 experiments	 were	performed	 with	 relatively	 low	 passage	 number	 cell	 lines.	 Nonetheless,	 to	 mitigate	against	 this	 issue	more	definitively	 future	pre-clinical	experiments	could	be	conducted	using	short-term,	fresh,	primary	cell	cultures	depending	on	availability	and	feasibility.		A	 further	 potential	 drawback	 of	 monolayer	 cell	 culture	 is	 failure	 to	 model	 potential	complex	 interactions	 between	 the	 tumour	 and	 surrounding	 stroma	 as	well	 as	 tumour	and	 its	host	because	monolayer	cultures	 lack	the	cell-to-cell	 interactions	characteristic	of	 tumours	 in	vivo(371).	A	possible	 solution	 to	 this	 in	 future	experiments	would	be	 to	utilise	a	three-dimensional	spheroidal	culture	system.	Such	systems	are	composed	of	an	outer	layer	of	proliferating	cells,	an	inside	layer	of	quiescent	cells,	and	an	inner	core	of	necrotic	 cells.	 This	 arrangement	 reflects	 the	 growth	 pattern	 and	 the	 irregular	distribution	 of	 oxygen	 and	 nutrients	 found	 in	 solid	 tumours,	 and	 may	 be	 a	 better	representation	 of	 the	 in	 vivo	 cellular	 complexity	 and	 heterogeneity	 than	 monolayer	culture(440,	441).	To	 this	end,	microplates	specifically	designed	 for	use	with	spheroid	cultures	in	the	XF	experimental	platform	we	utilised	for	our	metabolic	profiling	studies	have	 recently	 been	 developed,	 which	 would	 support	 this	 experimental	 design	 going	forward.	A	 limiting	 factor	 to	 the	use	of	spheroidal	culture,	however,	 is	 the	difficulty	of	establishing	 cell	 lines	 that	 can	 associate	 into	 spheroid	 clusters.	 Indeed,	 of	 almost	 300	well-characterised	 and	 widely	 utilised	 SCCHN	 cell	 lines,	 so	 far	 only	 11	 have	 been	reported	as	being	capable	of	associating	into	spheroidal	clusters(371).		The	 issue	 of	 oxygen	 supply	 is	 of	 particular	 relevance	 when	 considering	 cellular	metabolism.	In	monolayer	cell	culture	cells	are	usually	maintained	in	conditions	of	20%	oxygen,	whereas	the	in	vivo	tumour	microenvironment	is	typically	hypoxic	due	to	lack	of	oxygen	diffusion	to	the	centre	of	a	growing	tumour.	Hypoxia	can	regulate	the	metabolic	activity	 of	 cells	 and	 induce	 glycolysis	 through	 the	 activation	 of	 HIF-1α,	 which,	 as	 the	major	 transcription	 factor	 involved	 in	 regulating	 the	 adaption	 of	 cells	 to	 hypoxic	conditions,	 regulates	 the	expression	of	many	glycolytic	genes(442).	Nevertheless,	HIF-1α	can	be	activated	 in	cancers	even	under	normoxic	 (or	pseudohypoxic)	conditions	 in	response	 to	 oncogenic	 signalling	 pathways,	 including	TP53	 mutation(443).	 Indeed,	 as	
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discussed	in	section	1.3.3.,	normoxic	stabilisation	of	HIF-1α	has	been	reported	in	SCCHN	cells(338,	339).		An	alternative	pre-clinical	model	system	that	could	also	be	applied	 to	more	effectively	mimic	 tumour	 heterogeneity	 and	 the	 in	vivo	milieu	 is	 a	microfluidic	 system.	 Purpose-built	microfluidic	devices	allow	a	small	sample	of	tumour	to	be	maintained	alive	ex	vivo	in	a	pseudo–in	vivo	microenvironment(444).	Specifically,	biopsies	of	 tissue	can	remain	in	a	viable	state	for	periods	of	up	to	seven	days	in	a	heterogenic	and	dynamic	molecular	ecosystem,	in	which	variables	such	as	laminar	flow,	perfusion,	and	diffusion	rates	can	all	be	manipulated,	enabling	close	control	of	the	chemical	and	physical	environment(444).	Response	 of	 the	 tumour	 specimen	 to	 treatment	 regimens	 in	 this	 environment	 can	subsequently	 be	 assessed.	 Although	 to	 date	 use	 of	 microfluidic	 systems	 has	 been	relatively	 limited	 in	the	context	of	SCCHN,	recent	studies	have	successfully	maintained	both	 SCCHN	 primary	 tumour	 and	 regional	 lymph	 node	 metastases	 tissue	 in	 such	systems	 while	 assessing	 differential	 response	 to	 external	 beam	 IR	 to	 personalise	therapy(445).		Despite	the	potential	utility	of	 these	pre-clinical	 in	vitro	and	ex	vivo	model	systems,	 in-vivo	xenograft	animal	models	are	still	widely	regarded	as	 the	most	valid	and	clinically	relevant	experimental	platforms	 to	accurately	predict	 the	activity	of	 anti-cancer	drugs	or	demonstrate	 the	 oncogenic	 properties	 of	 solid	 tumours(371,	 446).	As	 such,	 further	pre-clinical	validation	of	 the	 findings	and	proposed	therapeutic	approach	presented	 in	this	 thesis	 would	 almost	 certainly	 be	 conducted	 in	 this	 setting.	 We	 envisage	 use	 of	athymic	nude	mice	with	xenografts	 established	 from	 the	SCCHN	cell	 lines	used	 in	 this	study.	 Indeed,	 a	 number	 of	 these	 cell	 lines	 have	 previously	 been	 used	 to	 successfully	establish	 xenografts	 in	 such	 mice(371),	 and	 athymic	 nude	 mice	 have	 been	 more	thoroughly	 characterised	 and	 used	 more	 widely	 than	 other	 immunodeficient	 mouse	models,	 such	 as	 the	 severe	 combined	 immunodeficiency	 (SCID)	 mouse.	 Furthermore,	athymic	 nude	 mice	 are	 logistically	 more	 favourable	 models	 insofar	 as	 they	 are	 less	susceptible	 to	 thymic	 lymphomas	 and	 life-threatening	 infection	 than	 SCID	 mice(371,	446).	We	would	also	foresee	using	an	orthotopic	xenograft	system,	in	which	the	SCCHN	cells	are	injected	into	the	mylohyoid	muscle	in	the	floor	of	the	mouse	oral	cavity,	rather	than	 the	 traditional	 xenograft	 technique	 of	 subcutaneous	 or	 tail	 vein	 injection.	 This	facilitates	tumour	development	from	the	natural	anatomical	site	and	thus	is	more	likely	to	mimic	the	in	vivo	pathology	and	microenvironment	of	SCCHN(447).	Once	tumour	cell	implantations	 became	 established	 and	 palpable,	 mice	 could	 be	 then	 given	 either	 oral	
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doses	or	intra-peritoneal	injections	of	2-DG	prior	to	exposure	to	fractionised	IR	given	in	2-Gy	 fractions.	 Changes	 in	 tumour	 volume	 to	 assess	 response	 could	 be	 then	 assessed	through	caliper	measurement	and	calculation	of	 tumour	volume,	direct	removal	of	 the	tumour,	or	 through	 imaging	techniques.	As	alluded	to	above,	one	potentially	attractive	application	 of	 2-DG	 would	 be	 topical	 delivery	 to	 the	 tumour	 bed	 following	 surgical	resection	with	 the	 goal	 of	 enhancing	 the	 efficacy	 of	 adjuvant	RT.	 This	 approach	 could	also	 be	 first	 explored	 in	 the	 mouse	 xenograft	 model	 by	 performing	 macroscopic	excisions	 of	 tumour	 xenografts	 with	 the	 intent	 of	 leaving	 a	 small	 burden	 of	 residual	disease.	2-DG	could	then	be	delivered	topically	to	these	tumour	margins,	in	conjunction	with	a	fractionated	IR	regime,	and	marginal	biopsies	could	subsequently	be	taken	from	these	areas	and	monitored	for	any	remaining	tumour	tissue	after	a	suitable	time	frame.	A	 comparison	 could	 then	 be	 made	 against	 administration	 of	 IR	 alone	 following	 the	tumour	xenograft	resection.		As	mentioned	 previously,	 one	 previous	 study	 has	 examined	 the	 potential	 therapeutic	effects	 of	 2-DG	 in	 SCCHN	 using	 a	 xenograft	 mouse	 model	 derived	 from	 SCCHN	 cell	lines(356).	 In	 that	 study,	2-DG	was	observed	 to	potentiate	 the	effects	of	 cisplatin	with	respect	 to	 inhibiting	growth	of	SCCHN	xenografts	both	 in	 isolation	and	 in	a	combined-modality	approach	with	IR(356).	However,	the	effect	of	2-DG	in	the	absence	of	cisplatin	was	 not	 examined,	 only	 two	 SCCHN	 cell	 lines	 were	 xenografted,	 both	 of	 which	 were	mutant	TP53	cell	lines,	and	the	xenograft	technique	used	was	subcutaneous	injection.		Whilst	the	findings	presented	here,	which	demonstrate	that	in	SCCHN	cells	loss	of	wild-type	p53	 function	 confers	 a	 loss	of	metabolic	 flexibility	 and	a	 survival	dependence	on	glycolysis,	 appear	 compelling	 and	 are	 consistent	 with	 other	 recent	 SCCHN	 metabolic	studies(359,	 360),	 as	 discussed	 in	 section	 1.3.3.	 one	 research	 group	 has	 offered	 an	alternative	 model	 of	 SCCHN	 metabolism.	 Based	 on	 functional	 biomarker	 analysis	 of	SCCHN	 resection	 specimens,	 a	model	 of	metabolic	 symbiosis	with	 three	metabolically	and	morphologically	distinct	cell	populations	was	proposed(366).	In	this	paradigm	non-proliferative	glycolytic	stromal	and	cancer	epithelial	cells	generate	catabolites	which	are	released	into	the	tumour	microenvironment	and	subsequently	taken	up	and	utilised	by	the	mitochondrial	rich	cancer	cells	to	drive	energy	production	and	proliferation	through	oxidative	 phosphorylation(366).	 Close	 examination	 of	 these	 findings,	 however,	 raises	questions	 over	 the	 conclusions	 drawn.	MCT-1,	which	was	 the	 biomarker	 employed	 to	indicate	catabolite	influx	in	support	of	mitochondrial	respiration,	is	capable	of	adapting	to	 facilitate	 both	 inward	 and	 outward	 lactate	 flux	 depending	 on	 glucose	
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availability(299),	while	LDH-B,	which	was	used	as	a	glycolytic	marker,	is	an	isoenzyme	of	LDH	that	drives	conversion	of	lactate	back	to	pyruvate,	and	is	thus	more	indicative	of	catabolite	 influx	 and	 reverse	 glycolysis.	 Moreover,	 only	 in	 a	 subset	 of	 specimens	examined	were	both	non-proliferative	compartments	noted	to	be	highly	glycolytic	and	observed	to	represent	a	significant	proportion	of	the	tumour(366).	Given	that	there	was	conspicuous	absence	of	TP53	characterisation,	it	is	possible	that	this	subset	of	tumours	displaying	 a	 significant	 glycolytic	 compartment	 were	 those	 harbouring	 mutant	 TP53.	Similar	 findings	of	metabolic	 coupling,	however,	have	been	reported	 for	other	 tumour	types(367,	 368),	 and	 further	 exploration	 in	 SCCHN	 using	 one	 of	 the	 aforementioned	experimental	 systems	 that	models	 for	 the	 tumour	microenvironment	 is	 warranted	 to	help	reconcile	these	discrepancies.	This	is	particularly	pertinent	given	that	our	findings	and	 those	 of	 others	 demonstrating	 a	 generalised	 glycolytic	 phenotype	 of	 SCCHN	cells(359,	360)	have	been	derived	from	experiments	using	monolayer	cell	 line	culture,	and	given	the	important	therapeutic	implications	of	these	discrepant	models	of	SCCHN	metabolism.	According	to	the	model	of	metabolic	symbiosis	therapeutic	targeting	would	focus	on	MCT-1	and	MCT-4	 inhibition,	while	with	 the	model	presented	here	upstream	glycolytic	inhibition	is	the	focus.		As	 touched	 on	 above,	 findings	 presented	 in	 sections	 3.1.	 and	 3.2.	 revealed	 that	 in	contrast	 to	mutant	TP53	 disease,	 in	SCCHN	cells	harbouring	wild-type	TP53	metabolic	diversity	 is	 maintained,	 and	 thus	 a	 broader	 anti-metabolic	 approach	 was	 required	 to	potentiate	 the	effects	of	 IR.	Specifically,	 administration	of	2-DG	alone	did	not	 sensitise	these	cells	 to	 the	effects	of	 IR	and	combined	administration	of	2-DG	and	metformin	(a	biguanide	 with	 demonstrated	 activity	 against	 ETC	 complex	 I(405))	 was	 required	 to	achieve	this	effect.	Similar	results	were	also	observed	for	HPV-positive	SCCHN	cell	lines.	This	was	perhaps	surprising	given	the	role	of	the	HPV	E6	oncoprotein	in	targeting	p53	for	 proteasomal	 degradation	 (detailed	 in	 section	 1.1.3.).	 However,	 these	 results	 are	consistent	with	 the	only	other	 study	 to	date	 investigating	metabolism	 in	HPV-positive	SCCHN,	which	reported	that	both	HPV-positive	SCCHN	resection	specimens	and	a	HPV-positive	 SCCHN	 cell	 line	 expressed	 increased	 levels	 of	 proteins	 indicative	 of	 oxidative	phosphorylation	and	a	relatively	lower	level	of	extracellular	lactate	accumulation(361).	It	may	be	the	case,	therefore,	that	E6-mediated	inactivation	of	p53	is	incomplete,	leaving	sufficient	 functional	 wild-type	 p53	 to	 maintain	 a	 balanced	 and	 diversified	 metabolic	phenotype.	In	accordance	with	this,	genome-wide	microarray	data	from	a	recent	study	examining	 radiation	 response	 in	 HPV-positive	 and	 HPV-negative	 SCCHN	 cell	 lines	suggested	 that	 low	 levels	 of	wild-type	 p53	 remain	 in	HPV-positive	 cell	 lines,	 that	 this	
Discussion	
	 203	
p53	 can	 be	 activated	 by	 exogenous	 stress	 such	 as	 IR,	 and	 that	 this	 effect	 can	 be	overcome	by	more	complete	knockdown	of	p53	using	shRNA(381).	This	also	raises	the	issue	 of	 the	 validity	 of	 HPV-positive	 SCCHN	 cell	 lines	 as	 clinically	 relevant	 model	systems,	 several	 of	 which	 have	 been	 derived	 from	 patients	 with	 backgrounds	 of	cigarette	 smoking	 and	 alcohol	 excess,	 and	 from	 SCCHN	 subsites	 outside	 the	oropharynx(371,	 378).	 Nonetheless,	 recent	 comprehensive	 characterisation	 of	 the	reportedly	 HPV-positive	 established	 cell	 lines	 revealed	 transcriptionally	 active	integrated	 and/or	 episomal	 viral	 DNA	 in	 seven	 cell	 lines,	 suggesting	 that	 these	 may	represent	 suitable	 model	 systems	 of	 HPV-positive	 SCCHN	 in	 the	 absence	 of	 feasible	alternatives(378).	However,	until	E6/7	manipulation	of	cells	is	accomplished	there	will	not	 be	 a	 truly	 reliable	 link	 to	HPV	 and	 functional	 studies,	 and	 this	 is	 part	 of	 on-going	work	by	other	researchers	in	our	laboratory.		From	 a	 therapeutic	 perspective,	 although	 the	 proposed	 combination	 of	 2-DG	 and	metformin	 to	 augment	 IR	 effects	 in	 wild-type	 TP53	 SCCHN	 is	 enticing,	 it	 has	 the	potential	to	carry	a	narrower	therapeutic	 index	than	the	strategy	proposed	for	mutant	
TP53	disease.	Because	wild-type	TP53	 SCCHN	cells	 (HPV-positive	disease	 included)	do	not	depend	so	heavily	on	one	 isolated	metabolic	pathway,	 and	 thus	 require	a	broader	anti-metabolic	approach,	sparing	of	normal	cells	is	less	likely.	Indeed,	in	this	instance	it	seems	 that	 the	 therapeutic	 gain	 largely	 stems	 from	 the	 fact	 that	 tumour	 cells	 have	 a	requirement	 for	 fluxing	 greater	 quantities	 of	 glucose	 through	 both	 glycolysis	 and	oxidative	 phosphorylation.	 Metformin,	 however,	 has	 been	 used	 widely	 in	 clinical	practice	 in	 the	 treatment	of	 type	 II	 diabetes	 for	 approximately	30	years	with	minimal	toxicity	and	there	has	been	an	ever-increasing	interest	 in	re-purposing	metformin	as	a	anti-cancer	 treatment(406),	 an	 interest	 which	 stems	 from	 several	 epidemiological	studies	 demonstrating	 a	 lower	 cancer	 incidence	 in	 diabetic	 patients	 taking	metformin	than	 in	 the	 general	 diabetic	 population(407).	Moreover,	metformin	 users	 have	 higher	rates	 of	 disease	 control	 when	 treated	 with	 neoadjuvant	 chemotherapy	 for	 breast	cancer(408).	 Regardless,	 given	 that	 our	 proposed	 radiosensitising	 approach	 of	 2-DG	combined	with	metformin	 has	 not	 been	 investigated	 previously	 in	 patients,	 extensive	further	 validation	 in	 the	pre-clinical	 setting	using	 the	 experimental	 systems	described	above	 would	 certainly	 be	 required.	 In	 particular,	 in	 vivo	 studies	 determining	 dose-limiting	toxicity	of	the	combination	of	compounds	would	be	required	initially,	followed	by	optimisation	of	the	dosing	schedule.	Factors	to	be	optimised	would	include	the	dose	of	 compounds,	 timing	 and	 frequency	 of	 administration	 of	 the	 drugs,	 and	 possibly	staggering	each	drug	as	a	way	of	limiting	toxicity.	Should	these	prove	successful,	similar	
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thorough	 safety	 testing	would	 be	 required	 in	 the	 setting	 of	 a	 phase	 I	 clinical	 trial.	 As	discussed	 in	sections	1.1.5.	and	3.2.5.,	 the	prospect	of	radiosensitisation	 is	particularly	attractive	 in	 HPV-positive	 oropharyngeal	 SCC,	 given	 the	 current	 interest	 in	 treatment	de-intensification	for	these	patients,	as	this	would	potentially	facilitate	reduction	in	total	RT	dose.	The	rationale	behind	this	concept	of	de-intensification	relates	to	reducing	the	impact	 of	 treatment	on	 long-term	 function,	which	 is	 key	 in	 these	patients	who	have	 a	favourable	prognosis(94-96,	102)	and	tend	to	be	younger	and	otherwise	medically	fit	at	presentation(30),	 and	 thus	 more	 likely	 to	 experience	 the	 functional	 ramifications	 of	their	treatment	long-term.	
	Following	on	from	characterising	the	TP53	mutation-induced	glycolytic	switch	in	SCCHN	cells,	 and	 demonstrating	 the	 associated	 anti-metabolic	 therapeutic	 implications,	secondary	aims	of	this	thesis	were	to	explore	the	mechanistic	basis	underlying	both	the	metabolic	re-programming	and	anti-metabolic	therapeutic	effects.	Findings	presented	in	section	3.3.	showed	that	the	mechanism	underlying	the	potentiating	effects	of	glycolytic	inhibition	 on	 IR	 in	 SCCHN	 cell	 lines	 with	 loss	 of	 wild-type	 p53	 function	 involves	oxidative	stress-mediated	activation	of	apoptosis.	Specifically,	the	addition	of	2-DG	to	IR	resulted	 in	 a	 marked	 increase	 in	 both	 intracellular	 ROS	 and	 levels	 of	 apoptosis	compared	to	IR	alone	in	such	cells,	effects	that	were	reversed	by	the	further	addition	of	NAC.	Accordingly,	the	addition	of	NAC	also	consistently	reversed	the	potentiating	effects	of	 2-DG	 on	 IR	 in	 terms	 of	 clonogenic	 survival.	 As	 discussed	 in	 section	 3.3.2.,	 these	findings	 are	 consistent	 with	 those	 of	 numerous	 studies	 of	 pharmacological	 glycolytic	inhibition	 in	 cancer	 cells	 of	 various	 origin(402,	 411,	 412),	 and	 also	with	 those	 of	 the	paucity	of	 studies	 in	SCCHN(354,	359,	360).	For	 instance,	 in	studies	specific	 to	SCCHN	glycolytic	inhibition	has	been	shown	to	cause	perturbations	in	parameters	indicative	of	oxidative	 stress,	 including	 decreased	 intracellular	 total	 glutathione	 with	 a	 reduced	proportion	 of	 GSH(354),	 lessened	 cellular	 reducing	 potential(359),	 and	 significantly	elevated	 ROS	 levels(360).	 Furthermore,	 simultaneous	 treatment	 with	 NAC	 has	 been	shown	 to	 inhibit	 such	 parameters	 and	 reverse	 the	 cytotoxic	 effects	 of	 glycolytic	inhibition(354,	359,	360).		These	 findings	 implicating	 induction	 of	 oxidative	 stress	 as	 the	mechanism	 underlying	glycolytic	 inhibition	 in	 SCCHN	 provide	 further	 support	 for	 a	 selective	 therapeutic	advantage	 in	 the	 context	 of	 potentiating	 the	 effects	 of	 IR.	 IR	 induces	 DNA	 damage	through	a	mechanism	that	relies	to	a	considerable	extent	on	free	radical	formation(369),	and	 consequently	 intracellular	 redox	 status	 is	 thought	 be	 a	 crucial	 determinant	 of	
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sensitivity	to	IR	and	may	alter	the	outcome	of	radiation	therapy(448).	Therefore,	normal	cells,	 which	 do	 not	 carry	 such	 a	 high	 burden	 of	 oxidative	 stress,	 are	 less	 likely	 to	 be	susceptible	to	the	potentiating	effects	of	glycolytic	inhibition	on	IR.	In	addition,	recovery	following	IR-induced	damage	requires	activation	of	DNA	damage	repair	pathways	and	is	energetically	demanding,	rendering	tumour	cells	yet	more	vulnerable	to	anti-metabolic	therapeutic	 strategies.	 Interestingly,	 cisplatin,	 which	 constitutes	 another	 mainstay	 of	non-surgical	management	of	advanced	SCCHN	(see	section	1.1.5.),	is	inactivated	by	GSH	and	other	 thiol-containing	proteins(449).	Thus,	glycolytic	 inhibitors	 such	as	2-DG	may	also	 potentiate	 its	 effects.	 Indeed,	 this	 has	 been	 observed	 in	 two	 previous	 studies	 in	SCCHN	 and	 presents	 another	 interesting	 area	 for	 further	 study	 and	 potential	 clinical	translation(354,	356).		Our	 findings	 implicating	 oxidative	 stress	 as	 the	 mechanism	 underlying	 glycolytic	inhibition	in	SCCHN	also	lend	support	to	the	hypothesis	that	the	impetus	driving	cancer	cells	 (in	 this	 case	 specifically	mutant	TP53	 SCCHN	 cells)	 towards	 glycolysis	 is	 at	 least	partly	 to	 regulate	 cellular	 redox	 status	 and	 evade	 excessive	 ROS	 accumulation	 (see	section	1.3.1.).	Moreover,	further	findings	presented	in	section	3.4.	also	support	this	by	demonstrating	 that	 the	 increase	 in	 glycolysis	 seen	 in	 mutant	 TP53	 SCCHN	 cells	 also	facilitates	increased	PPP	flux.	As	discussed	in	section	1.3.1.,	the	PPP	is	the	major	source	of	 intracellular	 NADPH,	 which	 is	 critical	 to	 cellular	 redox	 control,	 and	 our	 findings	demonstrate	 that	 PPP	 enzyme	 expression	 and	 associated	 intracellular	 NADPH/NADP	ratios	were	 greater	 in	mutant	TP53	 compared	 to	wild-type	 SCCHN	 cells,	 indicative	 of	increased	 PPP	 flux.	 Interestingly,	 in	 addition	 to	 heightening	 flux	 through	 subsidiary	carbohydrate	 metabolic	 pathways	 simply	 by	 virtue	 of	 increased	 glycolysis,	 we	 also	observed	 a	 potential	 mechanism	 that	 might	 lead	 to	 PPP	 diversion	 –	 specifically	overexpression	of	TIGAR.	Again	as	outlined	in	section	1.3.1.,	TIGAR	exerts	influence	at	a	key	 regulatory	 point	 in	 the	 glycolytic	 pathway	 by	 acting	 to	 indirectly	 reduce	 PFK-1	activity	 and	 slow	 glycolytic	 flux,	 thus	 facilitating	 PPP	diversion	with	 resultant	NADPH	generation	 and	 upregulation	 of	 cellular	 antioxidant	 systems	 to	 combat	 oxidative	stress(280).	 Overexpression	 of	 TIGAR,	 related	 to	 its	 role	 in	 balancing	 redox	 state	 in	cancer	cells,	has	been	implicated	in	a	number	of	tumour	types.	As	discussed	in	section	1.3.3.,	 one	 previous	 study	 in	 SCCHN,	which	 sought	 to	 examine	 the	 reprogramming	 of	metabolism	 associated	 with	 the	 development	 of	 radioresistance,	 demonstrated	 that	radioresistant	 SCCHN	 cells	 displayed	 higher	 levels	 of	 TIGAR	 expression,	 as	 well	 as	elevated	 expression	 of	 key	 PPP	 enzymes	 and	 increased	 production	 of	 NADPH(277).	Glioma	 cells	 have	 also	 been	 reported	 to	 display	 a	 higher	 level	 of	 TIGAR	 expression	
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compared	 to	 normal	 brain	 tissue(288),	 and	 knock-down	 of	 TIGAR	 resulted	 in	radiosensitisation	 via	 accumulation	 of	 ROS,	 leading	 to	 DNA	 damage	 and	 cellular	senescence(450).	Moreover,	TKTL1	inhibition	reversed	the	beneficial	effects	of	TIGAR	in	glioma	cells	(in	terms	of	GSH	generation,	preventing	ROS	accumulation,	and	limiting	cell	death	 during	 conditions	 of	 metabolic	 stress),	 further	 supporting	 the	 role	 of	 PPP	flux(288).	In	multiple	myeloma	cells	inhibition	of	the	key	oncoprotein	MUC1-C	resulted	in	downregulation	of	TIGAR,	lower	levels	of	NADPH,	and	in	turn	an	increase	in	ROS	and	cell	 death(427).	 Similarly,	 in	 nasopharyngeal	 cancer	 cells	 inhibition	 of	 c-Met	 tyrosine	kinase,	 the	overexpression	of	which	has	been	 linked	with	poor	 survival	outcomes	and	metastasis(451),	resulted	in	lower	TIGAR	expression,	decreased	NADPH,	and	increased	apoptosis(426).	Finally,	 in	an	 intestinal	adenoma/carcinoma	mouse	model,	TIGAR	was	found	 to	be	highly	expressed	when	compared	 to	 surrounding	normal	 tissue,	 and	mice	deficient	 in	 TIGAR	 exhibited	 a	 reduction	 in	 total	 tumour	 burden	 and	 average	 tumour	size,	associated	with	an	enhanced	survival,	compared	to	TIGAR-competent	mice(287).	In	
vitro,	this	defective	growth	could	be	rescued	with	antioxidants	and	nucleosides(287).			This	well-documented	role	of	TIGAR	overexpression	in	promoting	cancer	development	through	 the	 induction	 of	 metabolic	 changes	 to	 counteract	 oxidative	 stress	 seems	counterintuitive	 given	 that	TIGAR	 is	 a	p53-activated	 transcriptional	 target	 involved	 in	the	 p53	 tumour	 suppressor	 pathway(205,	 285).	 However,	 we	 observed	 unexpectedly	greater	 levels	 of	 baseline	 TIGAR	 expression	 in	 those	 SCCHN	 cells	with	 abrogated	 p53	function,	 suggestive	 of	 uncoupling	 of	 TIGAR	 expression	 from	 p53	 transcription	regulation.	Further	time	course	analyses	following	exposure	to	p53-activating	genotoxic	stress	also	supported	this	notion,	 in	that	there	was	a	clear	direct	relationship	between	p53	and	TIGAR	expression	in	wild-type	TP53	cells,	but	no	such	relationship	in	cells	with	abrogated	 p53	 function,	which	 displayed	 high	 levels	 of	 TIGAR	 expression	 at	 all	 times.	Although	not	anticipated,	this	notion	of	uncoupling	of	TIGAR	regulation	is	supported	by	an	ever-increasing	body	of	evidence:	for	instance,	p53-independent	expression	of	TIGAR	has	 been	 observed	 in	 several	 human	 cancer	 cell	 lines(287),	 while	 its	 expression	 in	human	breast	cancer	has	been	inversely	correlated	with	the	expression	of	p53(286).		Whilst	 little	 is	 known	 currently	 about	 p53-independent	 regulation	 of	 TIGAR,	 the	capacity	for	a	p53-target	protein	to	become	oncogenic	when	no	longer	tightly	controlled	has	also	been	described	 for	other	mediators	of	 the	p53	survival	 response.	Specifically,	p53-independent	overexpression	of	carnitine	palmitoyltransferase	1C	(CPT1C),	which	is	normally	 a	p53-activated	 transcript,	 has	been	 reported	 in	 lung	 cancers	 in	 response	 to	
Discussion	
	 207	
metabolic	stress	to	increase	fatty	acid	oxidation	and	ATP	production(452).	Interestingly,	regulation	 of	 CPT1C	 in	 this	 instance	 depends	 on	 a	mechanism	 that	 involves	 activated	AMPK(452),	which	as	a	key	metabolic	mediator	may	be	implicated	in	p53-independent	regulation	 of	 TIGAR.	 Notably,	 other	 members	 of	 the	 p53	 family,	 p63	 and	 p73,	 can	activate	 promoters	 of	 several	 p53	 target	 genes(453,	 454),	 and	 could	 conceivably,	therefore,	 also	 be	 capable	 of	 regulating	 TIGAR	 expression.	 Alternatively,	 other	transcription	 factors	may	 be	 involved:	 in	 particular	 another	 transcription	 factor,	 SP1,	has	also	been	found	to	regulate	the	basal	 level	of	TIGAR	expression	in	 liver	cancer	cell	lines(455).	Future	work	 investigating	TIGAR	expression	 in	this	context	may,	 therefore,	be	 centred	 on	 these	 possibilities.	 Additionally,	 mutant	 forms	 of	 p53	 can	 display	oncogenic	GOF	properties	that	can	also	involve	modulation	of	tumour	metabolism(319),	and	 it	 is	 plausible	 that	 certain	mutant	 forms	 of	 p53	 retain	 the	 ability	 to	 influence	 the	expression	of	TIGAR.	Our	findings,	however,	do	not	support	this	given	that	high	levels	of	TIGAR	expression	were	observed	in	p53	null	cell	lines	and	when	a	stable	wild-type	p53	knock-down	 was	 engineered	 in	 a	 TP53	 wild-type	 cell	 line.	 Nonetheless,	 p53-independent	regulation	of	TIGAR	may	be	transcriptional,	translational,	or	through	post-translational	modifications	of	the	protein	and	this	will	be	an	interesting	area	for	further	study.	 In	 the	 first	 instance	 this	 could	 take	 the	 form	 of	 co-immunoprecipitaion	 and	chromatin	 immunoprecipitaion	 to	 explore	 possible	 protein-protein	 and	 protein-DNA	interactions	 respectively.	 It	will	 also	 be	 important	 to	 explore	TIGAR	 expression	 levels	under	conditions	of	hypoxia	as	although	TIGAR	expression	is	not	controlled	by	hypoxia,	the	 activity	of	TIGAR	 is	modulated	under	 conditions	of	 low	oxygen.	 Specifically,	 it	 has	been	 reported	 that	 during	 hypoxia,	 a	 fraction	 of	 TIGAR	 relocates	 to	 the	mitochondria	and	associates	with	and	enhances	the	activity	of	hexokinase-II(289).	Perhaps	of	greater	priority	 in	 terms	of	 future	 study,	 however,	 is	 to	 examine	 further	 the	 contribution	 and	importance	of	TIGAR	overexpression	to	survival	in	mutant	TP53	SCCHN	cells	as	this	may	have	 therapeutic	 implications.	 To	 begin	 to	 address	 this,	 shRNAs	 designed	 to	 knock-down	TIGAR	could	be	developed	and	transfected	into	mutant	TP53	SCCHN	cell	lines,	and	the	 impact	on	proliferation	and	 sensitivity	 to	 IR	 assessed.	 Should	 this	have	 significant	effects	on	proliferation	and/or	radiosensitisation	it	would	suggest	that	development	of	an	inhibitor	of	TIGAR	would	be	a	promising	novel	therapeutic	avenue,	which	may	offer	yet	greater	selectivity	over	glycolytic	inhibition.		Importantly,	 identifying	 that	 a	major	 impetus	 for	metabolic	 re-programming	 towards	glycolysis	 in	 SCCHN	 cells	 with	 abrogated	 p53	 function	 was	 to	 upregulate	 cellular	antioxidant	 systems	 by	 heightening	 of	 PPP	 flux	 also	 revealed	 a	 further	 potential	
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therapeutic	gain.	The	addition	of	the	PPP	inhibitor	6-AN	significantly	augmented	effects	of	IR	in	these	cells	over	and	above	the	potentiating	effects	of	glycolytic	inhibition	alone.	As	discussed	in	section	3.2.4.,	although	investigation	of	6-AN	in	SCCHN	has	been	limited	to	 studies	 by	 only	 two	 research	 groups,	 findings	 are	 consistent	with	 those	 presented	here,	 in	 that	 combining	 2-DG	 with	 6-AN	 enhanced	 cytotoxicity	 over	 2-DG	 alone(277,	403,	456).	No	previous	studies,	however,	have	examined	this	effect	with	respect	to	TP53	status.	 Although	 6-AN	 is	 an	 inhibitor	 of	 the	 key	 PPP	 enzyme	 6-PGD,	 and	 thus	 would	inhibit	NADPH	production	and	upregulation	of	 cellular	anti-oxidant	 systems,	on	 initial	consideration	it	is	perhaps	surprising	that	6-AN	provided	further	therapeutic	gain	over	2-DG	 given	 that	 2-DG	 inhibits	 glycolysis	 upstream	 of	 PPP	 branching.	 However,	 it	 has	been	reported	that	2-deoxy-D-glucose-6-phosphate	(phosphorylated	product	of	2-DG	by	hexokinase)	can	be	oxidised	 to	2-deoxygluconate-6-phosphate	by	G6PD,	 leading	 to	 the	regeneration	 of	 one	 molecule	 of	 NADPH	 and	 subsequent	 regeneration	 of	 GSH	 from	glutathione	 disulfide(404).	 Additionally,	 the	 products	 of	 gluconeogenesis	 feeding	 into	the	PPP	may	still	occur	in	2-DG	treated	cells.	Thus,	inhibition	of	glycolysis	and	PPP	by	2-DG	alone	does	not	inhibit	NADPH	regeneration	maximally,	and	distinct	PPP	inhibition	is	required	 to	 restrict	 NADPH	 production	 and	 upregulation	 of	 cellular	 anti-oxidant	systems.	There	are	 concerns,	however,	over	potentially	 toxic	 side-effects,	 in	particular	neurotoxicity(457).	Yet,	in	studies	to	date	selective	cytotoxicity	for	cancer	cells	has	been	observed,	 with	 no	 significant	 loss	 of	 viability	 or	 clonogenicity	 in	 non-malignantly	transformed	 human	 embryonic	 kidney	 cells	 and	 human	 lung	 fibroblasts	 following	treatment	with	2-DG	+	6-AN	+	IR(456,	458).	Nonetheless,	6-AN	has	yet	to	be	subjected	to	clinical	evaluation.	As	such,	whilst	the	in	vitro	results	presented	here	are	compelling,	extensive	 further	 validation	 in	 the	 pre-clinical	 setting	 using	 the	 experimental	 systems	described	 above	 would	 again	 be	 required	 before	 contemplating	 clinical	 trials,	particularly	focusing	on	in	vivo	dose-escalation	and	dose-limiting	toxicity	studies.			In	 addition	 to	 identifying	 increased	 PPP	 flux	 mediated	 through	 de-regulated	 TIGAR	overexpression	as	mechanisms	underlying	 the	metabolic	 shift	 in	mutant	TP53	 SCCHN,	we	also	demonstrated	ETC	complex	dysfunction	and	GLUT-1	overexpression.	Analysis	of	individual	ETC	complexes	in	permeabilised	cells	presented	in	section	3.4.2.	suggests	that	in	SCCHN	cells	 loss	of	wild-type	p53	 function	results	 in	global	defective	 functioning	of	ETC	 complexes,	 most	 marked	 for	 complexes	 II	 and	 III.	 These	 findings	 are	 broadly	consistent	 with	 the	 only	 previous	 study	 in	 SCCHN	 examining	 ETC	 complex	 integrity,	which	reported	defects	in	the	activity	of	complexes	II,	III,	and	IV	in	mutant	TP53	SCCHN	cells(360).	However,	these	findings	are	at	odds	with	contemporary	opinion	that	tumour	
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metabolism	is	a	dynamic	process	adopted	by	cancer	cells	to	fit	the	requirements	of	rapid	cell	proliferation,	 rather	 than	a	self-correcting	secondary	consequence	 to,	 for	example,	energy	 deficiency	 resulting	 from	 defective	mitochondrial	 respiration.	 Indeed,	 findings	with	regards	to	ETC	function	in	the	wider	field	of	cancer	research	have	been	conflicting,	with	 some	reports	 suggesting	dysfunction	 in	oxidative	phosphorylation(459,	460)	and	others	indicating	that	the	capacity	for	oxidative	phosphorylation	is	retained	and	oxygen	is	 consumed	 at	 rates	 similar	 to	 those	 observed	 in	 normal	 tissues(249,	 259).	Notwithstanding,	because	ROS	are	natural	by-products	of	mitochondrial	 respiration,	 it	may	 be	 the	 case	 that	 dampening	 oxidative	 phosphorylation	 represents	 another	mechanism	 to	 protect	 cancer	 cells	 from	 excessive	 ROS	 accumulation	 and	 oxidative	stress(461).	Moreover,	our	 findings	 specific	 to	 loss	of	wild-type	p53	 function	and	ETC	dysfunction	are	in	keeping	with	evidence	demonstrating	p53	as	a	promoter	of	oxidative	phosphorylation.	 As	 discussed	 in	 greater	 depth	 in	 section	 1.3.2.,	 p53	 has	 been	 linked	with	 the	general	maintenance	of	mitochondrial	biomass,	 integrity,	quality	 control,	 and	fidelity	of	mitochondrial	DNA	replication	(300-303),	as	well	as	with	several	aspects	of	ETC	 complex	 function(286,	 305-309).	 The	 fact	 that	 in	 mutant	 TP53	 SCCHN	 there	 is	global	 dysfunction	 of	 ETC	 complexes	 is	 also	 an	 important	 consideration	 from	 a	therapeutic	 standpoint	 insofar	 as	 therapeutic	 strategies	 predicated	 on	 inhibition	 of	oxidative	phosphorylation,	such	as	metformin,	are	likely	to	have	limited	efficacy	in	these	tumours.	This	is	highly	relevant	given	the	current	interest	in	re-purposing	metformin	as	an	anti-cancer	agent,	as	discussed	above,	and	should	inform	any	future	work	to	this	end.		That	 levels	 of	 GLUT-1	 expression	were	 demonstrated	 to	 be	 partly	 attributable	 to	 the	observed	 p53-dependent	 switch	 in	 metabolism	 towards	 glycolysis,	 with	 loss	 of	 wild-type	p53	function	resulting	in	relative	GLUT-1	overexpression,	was	an	expected	finding	in	light	of	our	initial	metabolic	profiling	results.	Considering	that	SCCHN	cells	with	loss	of	 wild-type	 p53	 function	 adopted	 a	 glycolytic	 phenotype,	 and	 that	 glycolysis	 is	 a	relatively	 energetically	 inefficient	 process	 (yielding	 only	 two	 molecules	 of	 ATP	 per	molecule	of	glucose	consumed	as	opposed	to	up	to	36	with	oxidative	phosphorylation),	these	 cells	would	need	 to	drastically	 increase	 rates	of	 glycolysis	 to	maintain	 sufficient	ATP	 production,	 which	 would	 require	 a	 corresponding	 upregulation	 of	 glucose	transporters.	 Consistent	 with	 this,	 in	 addition	 to	 sustaining	 higher	 basal	 levels	 of	glycolysis,	these	cells	also	exhibited	higher	overall	glycolytic	capacities.	Furthermore,	as	discussed	previously	 in	section	3.4.3.,	 this	 finding	is	 in	keeping	with	the	fact	that	TP53	mutation	 diminishes	 the	 repressive	 effect	 of	 p53	 on	 GLUT-1	 transcription	 (298),	 and	with	several	previous	reports	of	GLUT-1	expression	in	SCCHN	relative	to	normal	tissues	
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(324-329).	 Curiously,	 however,	 in	 the	 only	 other	 study	 to	 date	 examining	 GLUT-1	expression	 in	 SCCHN	 relative	 to	TP53	 status	no	difference	 in	 expression	 of	GLUT-1	 in	wild-type	 and	mutant	TP53	 cells	 was	 observed(360).	 The	 reason	 for	 this	 disparity	 is	unclear,	and	most	likely	relates	to	the	specific	cell	lines	investigated.	Whilst	our	findings	were	 consistently	 demonstrated	 across	 a	 panel	 of	 SCCHN	 cell	 lines,	 the	 earlier	 study	examined	GLUT-1	 expression	 only	 in	 one	mutant	 and	 one	wild-type	TP53	 SCCHN	 cell	line.		By	 analogy	 to	 our	 expectation	 of	 differential	 GLUT-1	 expression,	 its	 was	 perhaps	surprising	 that	 no	 obvious	 differences	were	 observed	 between	mutant	 and	wild-type	
TP53	 SCCHN	 cells	 in	 the	 expression	 of	 the	 other	 glycolysis-related	 enzymes	 and	transporters	examined.	Our	 investigation	of	 this,	however,	was	 limited	to	western	blot	analyses	 of	 the	 glycolysis-related	 proteins	 previously	 reported	 to	 be	 under	 the	 direct	influence	 of	 p53,	 which	 may	 have	 been	 too	 narrow	 and	 simplistic	 an	 approach.	 For	instance,	p53	may	mediate	the	activity	and/or	expression	of	other	metabolic	proteins	in	the	context	of	SCCHN	that	have	yet	to	be	elucidated,	the	differential	expression	of	which	would	not	have	been	captured	using	our	approach.	Furthermore,	as	discussed	in	section	1.3.2.,	 there	 is	 also	 a	 substantial	 degree	 of	 cross-talk	 between	 the	 p53	 system	 and	several	other	key	metabolic	mediating	pathways	–	including	PI3K/Akt(310),	mTOR(310,	311),	 	 HIF-1α(315),	 and	 	NF-kβ(316)	 pathways	 –	 resulting	 in	 indirect	 p53	 regulation.	Again,	any	alterations	in	these	indirect	links	may	have	been	missed	in	our	analysis.	Our	decision	 to	 centre	 our	 investigation	 on	 glycolysis-related	 proteins	 known	 to	 be	 under	the	 influence	 of	 wild-type	 p53,	 however,	 was	 taken	 largely	 due	 to	 time	 and	 resource	constraints	on	the	project,	cognizant	of	the	anticipated	limitations.	Future	experiments	directed	 at	 more	 extensive	 profiling	 would	 be	 interesting	 to	 pursue	 to	 potentially	elucidate	 further	 mechanisms	 underpinning	 the	 p53-dependent	 metabolic	 switch	 in	SCCHN.	 These	 experiments	 could	 be	 conducted	 using	 either	 a	 gene	 array	 analysis	platform,	with	a	panel	reflecting	genes	involved	in	cellular	metabolism,	or	using	a	next-generation	 sequencing	 approach.	 Complementary	 examination	 of	 metabolite	 levels	using	NMR	spectroscopy	or	mass	spectrometry	could	also	be	utilised,	as	flux	is	not	only	a	reflection	of	steady	state	levels	of	gene	expression.		These	 experimental	 systems	 could	 also	 be	 utilised	 to	 examine	 metabolism	 in	 SCCHN	more	 globally.	 Indeed,	 the	 work	 in	 this	 thesis	 focused	 exclusively	 on	 carbohydrate	metabolism.	 Whilst	 this	 was	 predicated	 on	 the	 fact	 that	 alterations	 in	 carbohydrate	metabolism	 remain	 chief	 among	 the	 recognised	metabolic	 perturbations	of	 the	 cancer	
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phenotype	 and	 that	 glucose	 catabolism	 has	 been	 identified	 as	 the	 predominant	metabolic	 pathway	 on	 which	 SCCHN	 cells	 depend(359),	 future	 work	 exploring	 other	metabolic	 avenues	 may	 reveal	 other	 potential	 therapeutic	 windows	 to	 exploit.	 In	accordance	with	this,	the	aforementioned	study	aiming	to	identify	metabolic	alterations	related	 to	 the	 development	 of	 radioresistance	 in	 SCCHN	 reported	 alterations	 in	 lipid	metabolism	 with	 associated	 therapeutic	 implications(277).	 Specifically,	 increased	expression	and	activity	of	 fatty	 acid	 synthase	 (FASN)	was	 reported	 in	a	 radioresistant	SCCHN	cell	line,	suggestive	of	increased	utilisation	of	endogenous	fatty	acids	for	energy	production,	and	FASN	inhibition	with	orlistat	increased	cytotoxicity	and	radiosensitised	these	cells(277).	Furthermore,	a	recent	study	identified	a	subpopulation	of	cells	in	oral	cavity	 SCC	 implicated	 in	 initiating	 metastases	 that	 are	 predominantly	 defined	 by	 a	signature	of	 lipid	metabolism,	and	of	particular	 interest,	blocking	 lipid	uptake	resulted	in	almost	complete	inhibition	of	metastases	in	orthotopic	oral	SCC	mouse	models(462).		Ultimately,	the	work	presented	in	this	thesis	is	of	potential	interest	from	a	translational	research	 perspective	 because	 it	 explores	 the	 possibility	 of	 therapeutically	 targeting	 a	fundamental	 area	 of	 cancer	 cell	 biology	 to	 induce	 radiosensitisation,	 an	 area	 that	 for	SCCHN	 is	 relatively	 uncharted.	 Our	 initial	 studies	 demonstrated	 that	 the	 metabolic	phenotype	in	SCCHN	is	p53-dependent,	with	mutational	 loss	of	wild-type	p53	function	resulting	 in	 a	 loss	 of	 metabolic	 diversity	 and	 conferring	 a	 survival	 dependence	 on	glycolysis.	 Further	 work	 showed	 that	 upregulation	 of	 cellular	 antioxidant	 systems	 to	quench	excessive	ROS	accumulation	underlies	 this	glycolytic	switch,	which	 is	achieved	by	 heightening	 PPP	 flux	 to	 produce	 NADPH	 through	 GLUT-1	 overexpression	 and	uncoupling	 of	 TIGAR	 regulation	 with	 resultant	 overexpression.	 Critically,	 subsequent	therapeutic	studies	correlated	with	these	findings,	which	has	led	us	to	propound	a	novel,	tailored	 anti-metabolic	 therapeutic	 paradigm	 for	 SCCHN,	 which	 not	 only	 carries	 a	selective	 therapeutic	 index,	 but	 is	 also	 informed	 by	 TP53	 status	 as	 a	 predictive	biomarker.	 Specifically,	 we	 propose	 that	 in	mutant	 TP53	 SCCHNs	 glycolytic	 inhibition	with	2-DG,	possibly	 in	 combination	with	6-AN-induced	PPP	 inhibition,	would	 result	 in	significant	radiosensitisation	through	oxidative	stress-mediated	activation	of	apoptotic	signalling.	 This	 strategy	 would	 be	 applicable	 in	 upwards	 of	 60-85%	 of	 SCCHN	tumours(51-53)	 and	would	 be	 preferentially	 effective	 in	 patients	 with	 the	 aggressive	and	 treatment-resistant	 disease	 typically	 associated	 with	 TP53	 mutation(56-58,	 238,	239).	SCCHNs	harbouring	wild-type	TP53	 (HPV-positive	disease	 included)	are	 likely	 to	be	resistant	to	this	approach,	reflecting	their	more	metabolically	diverse	phenotype.	In	these	 cases,	 therefore,	 we	 suggest	 the	 combination	 of	 2-DG	 with	 mitochondrial	
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inhibition,	 using	metformin.	 This	 strategy	may	 also	 provide	 an	 attractive	 platform	 for	the	 treatment	de-intensification	of	 carefully	 selected	HPV-positive	 cases	by	 facilitating	RT	 dose	 reduction	 to	 minimise	 the	 impact	 of	 treatment	 on	 long-term	 function.	 The	efficacy	 and	 safety	 of	 these	 strategies	 will	 require	 further	 validation	 in	 pre-clinical	models	prior	to	translation	into	the	clinical	setting,	and	future	work	will	be	directed	in	this	 regard.	 Nevertheless,	 we	 have	 presented	 a	 novel	 approach	 to	 the	 treatment	 of	SCCHN,	 together	 with	 mechanistic	 insights,	 that	 takes	 into	 account	 TP53	 mutational	status	 in	 determining	 selection	 of	 radiosensitising	 anti-metabolic	 agents,	 and	 which	provides	a	rationale	for	initiating	clinical	trials.	
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5.	Appendix		
5.1.	Mycoplasma	contamination		As	part	of	an	effort	to	optimise	the	cell	lines	used	in	this	thesis,	all	cell	lines	were	tested	for	the	presence	of	mycoplasma	contamination	as	described	in	section	2.3.2.	During	the	course	of	this	testing	several	of	the	cell	lines	were	found	to	be	contaminated,	examples	of	which	are	shown	in	figure	5.1.1.	
		
Figure	 5.1.1:	 An	 example	 of	 mycoplasma	 contamination.	 The	 output	 from	 the	 e-MycoTM	mycoplasma	PCR	detection	kit	(ChemBio)	demonstrating	presence	of	mycoplasma-specific	DNA	sequences	 in	 UM-SCC-10A,	 UM-SCC-11A,	 and	 UM-SCC-11B.	 Mycoplasm	 positive	 sequences	 are	found	at	268-277	bp	as	sizes	of	the	PCR	product	depend	on	the	individual	species.	There	is	also	an	internal	control	band	at	160bp	to	confirm	quality	of	PCR.				
5.2.	Mycoplasma	eradication	If	no	negative	stocks	of	contaminated	cell	 lines	could	be	sourced	these	cells	were	then	treated	 to	 eradicate	 the	 contamination.	 Initially	 a	 decision	 was	 made	 to	 attempt	eradication	with	the	aminoglycoside	antibiotic	geneticin.	This	decision	was	based	on	the	findings	 that	 one	 of	 our	 cell	 lines	 (UM-SCC-12)	 was	 mycoplasma	 positive,	 while	genetically	 engineered	 cell	 lines	 derived	 from	 this	 line	 that	 were	 selected	 for	 with	
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geneticin	 were	 negative	 for	 mycoplasma.	 MTT	 assays	 (section	 2.5.2.)	 were	 used	 to	determine	 drug	 sensitivity	 to	 geneticin.	 Specifically,	 the	 concentration	 to	 be	 used	 for	treating	 the	 cell	 lines	 was	 the	maximal	 concentration	 that	minimally	 affected	 growth	and	 viability.	 Examples	 for	 three	 cell	 lines	 are	 depicted	 in	 figure	 5.2.1.	 The	 chosen	concentration	for	treatment	was	100μg/ml.		
	
	
Figure	 5.2.1:	 Examples	 of	 MTT	 assays	 used	 to	 determine	 treatment	 concentration	 of	
geneticin.	MTT	assays	were	performed	as	described	in	section	2.5.2.	and	are	shown	for	UM-SCC-
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10A,	 UM-SCC-11A,	 and	 UM-SCC-11B.	 All	 concentrations	 shown	 are	 in	 μg/ml.	 The	 optimal	concentration	chosen	to	treat	the	cell	lines	was	100μg/ml.		Following	 two	 weeks	 of	 treatment	 with	 100μg/ml	 geneticin	 all	 treated	 cell	 lines	remained	positive	for	mycoplasma	contamination.	Consequently,	it	was	then	decided	to	treat	 these	 lines	 with	 a	 commercially	 available	 and	 well-established	 mycoplasma	eradication	 reagent	 –	 PlasmocinTM	 (Invivogen)(463).	 Contaminated	 cell	 lines	 were	treated	for	two-three	weeks	at	a	concentration	of	25μg/ml.	This	successfully	eradicated	the	 mycoplasma	 contamination	 in	 all	 cell	 lines.	 All	 cell	 lines	 were	 continually	 tested	every	six-eight	weeks	to	ensure	no	further	contamination.	
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